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Abstract
Psychological interventions to improve self-management of
type 1 and type 2 diabetes: a systematic review
Kirsty Winkley,1* Rebecca Upsher,2 Daniel Stahl,3 Daniel Pollard,4
Architaa Kasera,2 Alan Brennan,4 Simon Heller5 and Khalida Ismail2
1Florence Nightingale Faculty of Nursing and Midwifery, King’s College London, London, UK
2Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London, UK
3Department of Biostatistics, Institute of Psychiatry, King’s College London, London, UK
4Health Economics and Decision Science, School of Health and Related Research (ScHARR),
University of Sheffield, Sheffield, UK
5Academic Unit of Diabetes, Endocrinology and Metabolism, Department of Oncology &
Metabolism, University of Sheffield, Sheffield, UK
*Corresponding author kirsty.winkley@kcl.ac.uk
Background: For people with diabetes mellitus to achieve optimal glycaemic control, motivation to
perform self-management is important. The research team wanted to determine whether or not
psychological interventions are clinically effective and cost-effective in increasing self-management and
improving glycaemic control.
Objectives: The first objective was to determine the clinical effectiveness of psychological interventions for
people with type 1 diabetes mellitus and people with type 2 diabetes mellitus so that they have improved
(1) glycated haemoglobin levels, (2) diabetes self-management and (3) quality of life, and fewer depressive
symptoms. The second objective was to determine the cost-effectiveness of psychological interventions.
Data sources: The following databases were accessed (searches took place between 2003 and 2016):
MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, PsycINFO,
EMBASE, Cochrane Controlled Trials Register, Web of Science, and Dissertation Abstracts International.
Diabetes conference abstracts, reference lists of included studies and Clinicaltrials.gov trial registry were
also searched.
Review methods: Systematic review, aggregate meta-analysis, network meta-analysis, individual patient
data meta-analysis and cost-effectiveness modelling were all used. Risk of bias of randomised and
non-randomised controlled trials was assessed using the Cochrane Handbook (Higgins JP, Altman DG,
Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of
bias in randomised trials. BMJ 2011;343:d5928).
Design: Systematic review, meta-analysis, cost-effectiveness analysis and patient and public consultation
were all used.
Setting: Settings in primary or secondary care were included.
Participants: Adolescents and children with type 1 diabetes mellitus and adults with types 1 and 2
diabetes mellitus were included.
Interventions: The interventions used were psychological treatments, including and not restricted to
cognitive–behavioural therapy, counselling, family therapy and psychotherapy.
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Main outcome measures: Glycated haemoglobin levels, self-management behaviours, body mass index,
blood pressure levels, depressive symptoms and quality of life were all used as outcome measures.
Results: A total of 96 studies were included in the systematic review (n = 18,659 participants). In random-
effects meta-analysis, data on glycated haemoglobin levels were available for seven studies conducted in
adults with type 1 diabetes mellitus (n = 851 participants) that demonstrated a pooled mean difference
of –0.13 (95% confidence interval –0.33 to 0.07), a non-significant decrease in favour of psychological
treatment; 18 studies conducted in adolescents/children with type 1 diabetes mellitus (n = 2583 participants)
that demonstrated a pooled mean difference of 0.00 (95% confidence interval –0.18 to 0.18), indicating
no change; and 49 studies conducted in adults with type 2 diabetes mellitus (n = 12,009 participants) that
demonstrated a pooled mean difference of –0.21 (95% confidence interval –0.31 to –0.10), equivalent to
reduction in glycated haemoglobin levels of –0.33% or ≈3.5 mmol/mol. For type 2 diabetes mellitus, there
was evidence that psychological interventions improved dietary behaviour and quality of life but not blood
pressure, body mass index or depressive symptoms. The results of the network meta-analysis, which
considers direct and indirect effects of multiple treatment comparisons, suggest that, for adults with type 1
diabetes mellitus (7 studies; 968 participants), attention control and cognitive–behavioural therapy are
clinically effective and cognitive–behavioural therapy is cost-effective. For adults with type 2 diabetes
mellitus (49 studies; 12,409 participants), cognitive–behavioural therapy and counselling are effective
and cognitive–behavioural therapy is potentially cost-effective. The results of the individual patient data
meta-analysis for adolescents/children with type 1 diabetes mellitus (9 studies; 1392 participants) suggest
that there were main effects for age and diabetes duration. For adults with type 2 diabetes mellitus
(19 studies; 3639 participants), baseline glycated haemoglobin levels moderated treatment outcome.
Limitations: Aggregate meta-analysis was limited to glycaemic control for type 1 diabetes mellitus.
It was not possible to model cost-effectiveness for adolescents/children with type 1 diabetes mellitus
and modelling for type 2 diabetes mellitus involved substantial uncertainty. The individual patient data
meta-analysis included only 40–50% of studies.
Conclusions: This review suggests that psychological treatments offer minimal clinical benefit in improving
glycated haemoglobin levels for adults with type 2 diabetes mellitus. However, there was no evidence of
benefit compared with control interventions in improving glycated haemoglobin levels for people with
type 1 diabetes mellitus.
Future work: Future work should consider the competency of the interventionists delivering a therapy and
psychological approaches that are matched to a person and their life course.
Study registration: This study is registered as PROSPERO CRD42016033619.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 28.
See the NIHR Journals Library website for further project information.
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Plain English summary
L iving with diabetes mellitus (hereafter referred to as diabetes) involves taking on new roles andresponsibilities and is key to success in achieving the best diabetes control. There are education
programmes that help people with diabetes to access the information and skills needed but managing
diabetes is hard and must be done 24/7, causing people to lose motivation. There are many emotional
reasons for this. This research team aimed to discover if talking therapies that are designed to help people
challenge their negative thoughts and feelings and be more motivated and confident could help improve
their self-management and blood glucose levels. The team also wanted to find out if talking therapies
could be good value for money and people with diabetes were asked for their views on the research.
To conduct the research, electronic databases were searched for studies that have used talking therapies
to support diabetes management.
It was found that:
l For adults with type 2 diabetes, talking therapies improved diabetes control by only a small amount,
although such therapies could represent value for money. People with type 2 diabetes who had talking
therapy reported improved diet and quality of life. For adults with type 1 diabetes, some types of
talking therapies could improve diabetes control, although this result was uncertain. Talking therapies
were not effective for children or adolescents in improving diabetes control but there was not enough
data to see if the therapies improved general health and well-being.
l When the results were presented to people with diabetes, they still wanted access to these treatments,
even though results of this research did not suggest, overall, that talking therapies help improve
diabetes control.
l Now that this research is complete, it is suggested that future studies look at whether or not more
sessions of talking therapies should be delivered over a longer time period and whether or not the
therapies should match the needs of the person with diabetes more closely.
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Scientific summary
Background
For people with diabetes mellitus (hereafter referred to as diabetes) to achieve optimal glycaemic control
and to avoid micro- and macrovascular disease, day-to-day self-management is essential. The nature of
self-management varies from person to person: for someone with type 1 diabetes, it would involve managing
multiple insulin injections or an insulin pump, together with frequent blood glucose testing, matching insulin
to carbohydrate intake, exercise, and managing intercurrent illness, whereas for someone with type 2
diabetes, it may involve dietary management, exercise, taking medication to prevent or treat cardiovascular
risk factors and taking medication or insulin to control their blood glucose levels. It is time-consuming; there
are no days off and there are often no immediate rewards of doing it. Therefore, it is no surprise that more
than one-third of people with type 2 diabetes and two-thirds of people with type 1 diabetes do not achieve
target blood glucose levels.
Adequate training is essential for optimal diabetes self-management so people have the knowledge and
skills to be effective at self-management, and the motivation to do it. Structured education programmes
are widely available, if underutilised; potential benefits include improved diabetes outcomes, such as
glycaemic control, psychological status, cardiovascular disease risk reduction and improved quality of life.
However, motivation for diabetes self-management is also required and this can be affected by emotional
issues, common with diabetes, such as depression, psychological distress and diabetes ’burn-out’.
Psychological interventions may help to improve motivation for self-management as they rely on the
therapeutic alliance between the client and interventionist, usually involve talking or communicating,
and may improve emotional and cognitive functioning. This research team previously conducted a
systematic review and meta-analysis of psychological interventions for people with diabetes, up to 2003;
overall, it was demonstrated that psychological interventions were effective in improving glycaemic control
to clinically significant levels for adolescents/children with type 1 diabetes and adults with type 2 diabetes,
but not adults with type 1 diabetes. However, since the last reviews were published, the types of
psychological treatments tested have changed, as have standards in trial reporting and meta-analytic
synthesis. In addition, it would also be important to determine whether or not psychological interventions
represent value for money. The aim was to update the previous systematic review and meta-analyses
to determine which psychological and psychotherapeutic interventions are most clinically effective and
cost-effective in improving glycaemic control.
Objectives
The overall aim was to conduct a systematic review and meta-analysis of controlled trials of psychological
treatments to:
1. assess the effectiveness of psychological interventions that aim to improve motivation for people with
type 1 diabetes and people with type 2 diabetes so that they have improved (1) glycaemic control
(2) diabetes self-management, (3) psychological distress and (4) health-related quality of life
2. examine the overall cost-effectiveness of psychological treatments in diabetes and to model the potential
predicted savings in reducing the risk of diabetes complications long term
3. assess the effectiveness of different types or techniques of psychological treatments for (1) better
self-management and (2) glycaemic control
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4. examine whether or not psychological treatments are effective for populations who experience health
inequalities, such as different ethnic groups, whose with severe mental illness and those experiencing
social deprivation
5. conduct subgroup analyses to identify the clinical characteristics of patients who have better or worse
diabetes self-management or glycaemic control, for example by age, gender, complication status
6. describe the development of new psychological theories and techniques and any advancements in
research methodologies, such as quality assurance of fidelity of intervention delivery or characteristics
of control groups
7. identify gaps in the literature to make recommendations for primary research
8. summarise the data for translation into the NHS via Health Improvement Networks, Diabetes Strategic
Networks, Diabetes UK and Clinical Commissioning Groups.
Methods
For children/adolescents and adults with type 1 diabetes and adults with type 2 diabetes, the main aim
was to test the clinical effectiveness and cost-effectiveness of psychological interventions to improve
glycaemic control by identifying randomised controlled trials and non-randomised controlled trials
published since 2003.
For the randomised controlled trials, a systematic review was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and electronic databases
were screened from 2003. The results of this screening were combined with a previous review (from inception
of electronic databases to 2003) of the literature to determine cohort effects.
Two studies were undertaken to examine the cost-effectiveness of psychological interventions versus usual
care: one for adults with type 1 diabetes and one for adults with type 2 diabetes.
For non-randomised controlled trials, a systematic review was conducted.
A public consultation with people with type 1 diabetes and type 2 diabetes was conducted in London and
Sheffield, along with a presentation of preliminary results of the systematic review and meta-analysis.
Data sources
For randomised controlled trials, an all-language search was performed from February 2003 to July 2016
in the following databases: MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL),
The Cochrane Library, PsycINFO, EMBASE, Cochrane Controlled Trials Register, Web of Science, Dissertation
Abstracts International and Clinicaltrials.gov. The abstracts of four diabetes conferences from 2012 to
2016 (Diabetes UK, American Diabetes Association, European Association for the Study of Diabetes and
International Diabetes Federation) were also searched for reports of trials using psychological therapies.
The following electronic databases were searched for non-randomised controlled trials: EMBASE (2003 to
January 2017), MEDLINE (2003 to January 2017) and PsycINFO (2003 to January 2017).
Study selection (inclusion criteria)
The following key search terms were used to search for randomised controlled trials in MEDLINE, and
adapted for each database: ’psychological therapies’ and ’mood disorders’ and ’diabetes mellitus’ and
’clinical trials’. An alternative strategy was used to identify non-randomised controlled trials.
Titles and abstracts of studies, identified by electronic searches, were independently inspected by two
researchers. Abstracts were selected if they described a controlled trial of a psychological or behavioural
intervention for people with type 1 diabetes or type 2 diabetes. If there was ambiguity in the description
of the study or intervention, then the study was included in the second stage. The second stage of study
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selection involved eligibility assessment of full-text papers by the same two researchers; differences over
inclusion of studies at this stage of study selection were resolved by consensus and discussion with a third
researcher.
Problems were encountered in relying on identifying psychological treatments using titles and abstracts
only, as some studies do not explicitly describe the psychological treatment in the abstract. Therefore,
previously rejected abstracts were screened a second time to reduce the risk of excluding potentially
eligible papers.
Participants
Participants included adolescents and children with type 1 diabetes aged 5–17 years, adults with type 1
diabetes and adults with type 2 diabetes.
Interventions
Studies of psychological interventions were identified using the following criteria and were included if they
met all of the following criteria: (1) they relied on communication, using the therapeutic alliance between
the patient and therapist; (2) the intervention was facilitated by psychologists, psychotherapists and
therapists in training, or facilitated by persons trained in a psychological method/supervised by a clinical
psychologist or therapist; (3) the intervention was based on a psychological model; and (4) the intervention
aimed to improve outcome changes in emotional, cognitive or behavioural functioning, including diabetes
self-management.
Control groups included usual care (generally usual diabetes care), waiting list control, attention control,
diabetes education or a less intensive psychological intervention.
Outcomes
The primary outcome was a change in glycaemic control glycated haemoglobin levels, measured as a
percentage or in mmol/mol, between baseline and 1-year follow-up.
Secondary outcomes of interest were changes in (1) self-management activities, (2) psychological functioning,
(3) clinical outcomes, (4) economic outcomes using unit costs or (5) adverse effects. For studies to be eligible,
they had to include the primary outcome with or without secondary outcomes.
Data extraction
Data were extracted on publication characteristics; participant baseline characteristics, such as type of
diabetes, age, gender, ethnicity, clinical subgroup, socioeconomic setting, duration of diabetes, complication
status, receipt of structured education and occupation; intervention characteristics, such as type of therapy,
number of sessions attended, duration of therapy sessions and overall duration of therapy, psychological
theoretical framework used, use of manual, specialty of therapist, training of therapist, fidelity assessment
of therapist, description of techniques used, format of delivery, mode of delivery, and use of booster or
maintenance sessions; control characteristics; and outcome characteristics.
Data synthesis
A systematic review, an aggregate meta-analysis, a network meta-analysis, an individual patient data
meta-analysis and cost-effectiveness modelling were all conducted.
Study level
Narrative synthesis was used to describe individual studies in terms of setting, participants, psychological
intervention, type of comparator and primary and secondary outcomes.
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Meta-analyses
An aggregate meta-analysis was conducted to determine the mean difference between baseline and
follow-up (closest to 12 months) scores between the psychological intervention and control groups,
standardised by calculating Cohen’s d, for each of the included studies.
For the main outcome, glycated haemoglobin levels, we conducted a network meta-analysis to allow for
simultaneous analysis of multiple treatments and incorporate direct and indirect treatment comparisons
and evidence. Cost-effectiveness modelling for the outcome of glycated haemoglobin levels was
conducted using network meta-analysis data.
For studies included in the aggregate meta-analysis, study teams were contacted for individual patient data
and a one-stage meta-analysis was conducted to explore predictors and moderators of response for
glycated haemoglobin levels.
Quality assessment
The quality of randomised controlled trials was assessed using Cochrane Handbook Tool for Risk of Bias
(Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s
tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928).
Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to determine
the quality of the evidence of the outcomes under investigation and the subsequent translational strength
of recommendations for clinical practice.
The quality of non-randomised controlled trials was assessed using the Risk Of Bias In Non-randomized
Studies – of Interventions (ROBINS-I) created by the Cochrane Methods Bias group and Cochrane
Non-Randomized Studies for Interventions Methods Group.
Results
Systematic review and meta-analyses of randomised controlled trials of psychological
treatments in diabetes
A total of 96 randomised controlled trials (18,659 participants) were included in the systematic review.
In random-effects meta-analysis, data on glycated haemoglobin levels were available for seven studies
conducted in adults with type 1 diabetes (851 participants) that demonstrated a pooled mean difference
of –0.13 (95% confidence interval CI –0.33 to 0.07), a non-statistically significant decrease in favour of
psychological treatment compared with control; 18 studies conducted in adolescents/children with type 1
diabetes (2583 participants) that demonstrated a pooled mean difference of 0.00 (95% confidence interval
–0.18 to 0.18), indicating no change; and 49 studies in adults with type 2 diabetes (12,009 participants)
that demonstrated a statistically significant pooled mean difference of –0.21 (95% confidence interval
–0.31 to –0.10), equivalent to a reduction in glycated haemoglobin levels of –0.33% or ≈3.5 mmol/mol for
psychological treatment compared with control interventions. A reduction of ≈4 mmol/mol is considered
clinically important as it reduces the incidence of microvascular disease. For type 2 diabetes, there was
evidence of psychological interventions improving dietary behaviour and quality of life compared with
control interventions, but not blood pressure, body mass index or depressive symptoms. It was not possible
to conduct meta-analyses for secondary outcomes in studies of people with type 1 diabetes.
Subgroup analyses were conducted to compare type of therapy and interventionist. The results
demonstrated that, for adults and adolescents/children with type 1 diabetes, there was no statistically
significant difference in clinical effectiveness for type of intervention (adult: cognitive–behavioural therapy
vs. counselling; adolescent/child: counselling vs. family therapy) or interventionist (psychology professional
vs. diabetes specialist), although study heterogeneity was high for counselling interventions and those
delivered by diabetes specialists to adolescents/children. For adults with type 2 diabetes, the results of
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subgroup analyses determined no statistically significant differences between cognitive–behavioural therapy
and counselling studies, as both were clinically effective, although study heterogeneity was high for
counselling. Nor were there statistically significant differences between interventionist, as both psychology
professionals and diabetes specialists were effective in delivering psychological treatments, but study
heterogeneity was high for diabetes specialists.
The results of the network meta-analysis for type 1 diabetes adults (seven studies; 908 participants) suggest
that attention control and cognitive–behavioural therapy are clinically effective and cognitive–behavioural
therapy is cost-effective in improving glycaemic control. For adults with type 2 diabetes (50 studies;
12,409 participants), the results suggested that cognitive–behavioural therapy and counselling are clinically
effective and that cognitive–behavioural therapy is potentially the most cost-effective intervention.
The results of the individual patient data meta-analysis for adolescents/children with type 1 diabetes
(9 studies; 1392 participants) suggest main effects for age and duration of diabetes; therefore, participants
who were younger at baseline and those with longer duration of diabetes at baseline improved their
glycated haemoglobin levels the most, independent of treatment arm. For type 2 diabetes (19 studies;
3639 participants), baseline glycated haemoglobin levels moderated the treatment outcome, with higher
baseline values associated with greater improvement in glycated haemoglobin levels. Individual patient
data were limited to 40–50% of included studies.
Systematic review of non-randomised controlled trials of psychological treatments
in diabetes
Fourteen studies (1791 participants) met the inclusion criteria and were included in the systematic review;
these comprised six studies conducted in adults with type 1 diabetes (n = 416), seven studies conducted
in adults with type 2 diabetes (n = 1317) and one study with a mixed type 1 diabetes and type 2 diabetes
population (n = 58). Only one of the five adult type 1 diabetes studies demonstrated a statistically
significant difference between intervention and control, with a greater reduction in glycated haemoglobin
level in the intervention group. For other outcomes, there were statistically significant between-group
differences in positive coping for stress management in favour of the psychological intervention group
compared with the control (usual care) group for one study.
For type 2 diabetes, two out of the six studies demonstrated a statistically significant difference between
the psychological intervention and control groups, with greater improvement in glycated haemoglobin
levels in the intervention group.
For secondary outcomes, three studies reported statistically significant between-group differences in favour
of the psychological intervention group compared with the control group for self-reported readiness to
change, self-efficacy, self-care, depression, anxiety and stress.
Public consultation
When the preliminary findings of the evidence synthesis were presented to people with diabetes, one of
the main themes generated from the focus groups was the lack of available psychological support and
treatment; this was something that they felt would benefit them.
Conclusions
Implications for health care
This review does not support the use of psychological treatments compared with control interventions to
improve diabetes self-management and glycaemic control for people with type 1 diabetes. For adults with
type 2 diabetes, there is weak evidence of borderline clinical significance, and psychological treatments are
potentially cost-effective, although there is much uncertainty in the cost-effectiveness models. There has
been a non-statistically significant reduction in the magnitude of the effect, since the previous review.
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Psychological interventions included in this review were typically cognitive–behavioural therapy or
counselling interventions and may not be sufficiently intensive to improve glycaemic control. Although
reporting of studies has improved, there are questions to be asked in terms of whether or not the
interventionists delivering the psychological treatments were competent to do so. Other issues include the
lack of description in the psychological ingredients reported in the abstracts of papers. Finally, there is also
the question of whether or not short-term interventions are appropriate for people with diabetes, as this a
lifelong condition.
Recommendations for research
Based on the findings of this evidence synthesis and gaps in the literature, the following research questions
or priorities are recommended:
l Promote the use of consolidated outcome sets in trials of psychological interventions to ensure that
treatment efficacy is not limited to glycaemic control, particularly for studies involving people with
type 1 diabetes.
l Encourage researchers to be more explicit in their description of psychological techniques/interventions
in titles and abstracts to enable future reviewers to identify studies.
l Determine long-term cost-effectiveness of psychological interventions.
l Develop different models of psychological care depending on what stage a person is at in their life
journey with diabetes.
l Determine whether or not psychological interventions are effective at improving motivation for diabetes
self-management when interventionists are competent to deliver the intervention.
l Develop a multifactorial intervention involving psychology and education to address psychological
distress, such as depressive symptoms, and diabetes self-management.
Study registration
This study is registered as PROSPERO CRD42016033619.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 28.
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
D iabetes mellitus (hereafter referred to as diabetes) is a common chronic, non-communicable disease,affecting an estimated 415 million people globally.1 Of these, 90% have type 2 diabetes mellitus
(T2DM),2 and the remainder have type 1 diabetes mellitus (T1DM).3 T1DM and T2DM differ in their
aetiology and pathophysiology but both exhibit altered glucose metabolism, specifically hyperglycaemia,
that can lead to microvascular complications. The difference in aetiology is significant because T1DM
generally results in complete dependence on exogenous insulin injection, as there is complete destruction
of beta cells owing to an autoimmune response, and this has implications for self-management and
psychological adaptation. What causes T1DM is not known although there is a genetic predisposition and
a complex interaction with environmental factors. It typically develops in younger people, usually before
40 years of age, and 1 in 300 children are affected by the age of 18 years in the USA.4 T2DM is associated
with insulin resistance and a more gradual destruction of pancreatic beta cells that may or may not lead
to complete insulin insufficiency. Obesity, ethnicity, old age and inactivity are associated with the onset
of T2DM and hypercholesterolaemia and hypertension often pre date diagnosis; therefore, T2DM is also
considered a cardiovascular disease. Self-management for T2DM often involves treatment for weight loss,
and management of blood pressure and lipids is essential.5,6 However, self-management of blood glucose
control to re-establish normoglycaemia, without significant hypoglycaemia (caused by over-treatment,
change in activity levels or intake of carbohydrates) is important for both T1DM and T2DM,7,8 although the
targets set are typically higher for T2DM because there is some evidence for an increased risk of cardiovascular
events and mortality in elderly people and those with comorbidity who experience hypoglycaemia.9,10 Diabetes
is costly to health services: in the UK it uses ≈10% of the annual NHS budget.11 Most of the cost relates to
treatment and management of complications that are often preventable.
Self-management and structured education
Self-management of diabetes, for people with a relatively new onset of T2DM, involves behaviour change
in terms of diet and exercise and attending diabetes appointments and eye screening. It is recommended
that someone with T2DM taking oral antidiabetic medication should spend 2 hours per day managing
their diabetes, for example taking tablets and organising tablets for the day or week; problem-solving
regarding blood glucose levels, snacks or medicine; shopping and reading labels on food products; exercise;
attending support groups or finding out information that can aid self-management; and scheduling
appointments.12 However, for people with T1DM who are dependent on exogenous insulin injection and for
people with T2DM that has progressed, self-management becomes more time-consuming and may involve
activities specified for T2DM and additional tasks, such as taking tablets, monitoring food and carbohydrate
consumption, testing blood glucose levels and acting on the results, managing exercise, sickness, travel and
administering insulin or another injectable therapy. People with T1DM have the additional pressures of
managing multiple daily injections or an insulin pump.
Diabetes self-management programmes for T1DM and T2DM aim to equip people with the knowledge
and skills they need to be confident in self-managing their diabetes, and there is evidence that these
are effective in terms of improved patient outcomes, including glycated haemoglobin (HbA1c) levels;
cardiovascular risk factors; quality of life (QoL); and measures of psychological health. However, these
improvements do not necessarily remain at long-term follow-up, although improvements in QoL, how
people think and feel about diabetes (illness cognitions) and satisfaction with treatment do.13,14 Despite
national roll-out in the UK, attendance rates are low, those most in need do not attend15–19 and attendance
per se does not guarantee effective diabetes self-management.
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The importance of motivation
When we talk about diabetes self-management, we are referring to health-related behaviour that we
know can improve an individual’s health; therefore, for many people, this can involve making changes to
what they are already doing. Knowledge, skills and confidence to manage diabetes are important but so is
motivation to put it into practice. Although the definition of motivation as intrinsic or extrinsic in relation to
diabetes self-management is up for debate,20 people with diabetes may or may not find performing the
behaviours personally rewarding. Others have considered motivation to be the likelihood or probability
that someone will make behavioural change.21 There are a number of health psychology models that have
been proposed to explain behaviour that have motivation at their core, such as the Health Belief Model,22
which considers ‘likelihood of taking action’; the theory of reasoned action23 and the theory of planned
behaviour,24 in which motivation either influences ‘behavioural intention’ or is similar in concept to
‘perceived behavioural control’; and Protection Motivation Theory,25,26 which was originally based on how
fear can motivate behaviour and coping appraisal, and now considers the efficacy of the behavioural
response and an individual’s perception that they can perform the behaviour, known as ‘self-efficacy’.
Motivation to perform effective self-management tasks for people with diabetes might be low as the
barriers to doing it are great. We know that < 30% of people with T1DM achieve national targets27 and
30% of people with T2DM in primary care do not achieve target HbA1c levels.15,28 Diabetes self-management
is complex and is not restricted to one target behaviour, such as smoking cessation. Furthermore, as there
are no ‘days off’, diabetes self-management is a 24/7 activity and the ‘rewards’ of good glycaemic control
or lowering of cardiovascular risk may not be immediate. Motivation to manage diabetes may be affected
by previous attempts and occasions in which things do not go according to plan. For example, when people
who are insulin treated are aiming for target blood glucose and HbA1c levels, they may find that increasing
insulin may put them at risk of hypoglycaemia; this may then dissuade them from future attempts to achieve
tight blood glucose control.
Psychological barriers are common and may also interfere with motivation for diabetes self-management.
For example, people who are depressed may find that they have little motivation to perform self-management
tasks such as testing their blood glucose levels, or eating healthy food; they may also rate their QoL as
poor.29,30 Other psychological barriers may include anxiety disorders,31 abnormal eating behaviours,32 fear
of hypoglycaemia,33 fear of complications,34 fear of self-testing or self-injecting,35 psychological insulin
resistance,36 diabetes burn-out37,38 and diabetes-specific distress.38,39 Therefore, psychological interventions
that aim to improve motivation and/or reduce psychological barriers to diabetes self-management may
improve glycaemic control and QoL, and are considered an important adjunct to support people with
diabetes self-management.
Psychological interventions
Psychological interventions differ from educational interventions that aim to improve self-management
by increasing diabetes knowledge. Psychological interventions rely on the therapeutic alliance, usually
talking or communicating, between a patient and the interventionist to not only improve motivation for
self-management, but also promote change in emotional and cognitive functioning.40,41 Although there
is still a lack of any consensus definition of psychological interventions that can be applied to increase
motivation for diabetes self-management, they can be categorised by their theoretical framework.42–44
These include psychoanalytical/psychodynamic therapies, often intensive and longer treatments, which
explore internal conflicts perhaps arising from early life experiences that affect personality development
and interpersonal functioning;45,46 cognitive–behavioural therapy (CBT) and it’s variations and techniques,
which is a brief therapy that targets the current cognitions and emotions associated with behaviours,
such as diabetes self-care, and is widely used to treat depression and a broad range of mental health
disorders with an underlying assumption that these disorders will remit;47 and counselling or person-
centred therapy,48 which can be focused, for example motivational interviewing (MI): a very brief therapy
BACKGROUND
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(usually four sessions) developed to strengthen motivation for behaviour change, particularly health-related
behaviours.49–51 Other psychotherapies52 include interpersonal therapy,53 family or systemic therapies54
and variations such as narrative and art therapy.52,55,56
How psychological interventions in diabetes have evolved
We previously conducted a systematic review and meta-analysis of psychological interventions for people
with diabetes up to 2003. In that meta-analysis, for adults with T1DM (11 studies), there was no statistically
significant improvement in glycaemic control for adults who received a psychological intervention compared
with those in a control group,57 but in children and adolescents (10 studies) there was a small clinically
significant improvement: a reduction in HbA1c levels equivalent to 6 mmol/mol. An improvement of
≈4 mmol/mol is considered effective at lowering the risk of microvascular complications.58 For T2DM
(12 studies), glycaemic control was also significantly improved for adults who received a psychological
intervention (e.g. counselling, CBT, psychodynamic therapy) compared with the control group, equivalent
to a reduction in HbA1c levels of 8 mmol/mol.40
Since the last review, the types of psychological interventions studied have changed. In the 1980s, stress
management and relaxation training interventions were popular, whereas since the late 1990s onwards
there has been an explosion of CBT and counselling techniques, and variations of MI interventions have
become the norm in clinical practice. Research and treatment for specific clinical groups have grown;
therefore, there have been systematic reviews with a specific clinical problem or subgroups of the diabetes
population, such as CBT for adults with depression and diabetes,59,60 people with eating disorders in T1DM,61
the effectiveness of MI for people with T2DM62 and family interventions for children and adolescents with
T1DM.63,64 In T1DM, a growth in psychological research for adults with hypoglycaemia unawareness has
resulted in clinical trials, currently under way in the UK, the USA and Europe.65,66
Another major change relates to the improved reporting of clinical trials and the introduction of Consolidated
Standards of Reporting Trials (CONSORT) in 2001.67 Similarly, there have been changes in treatment
comparison groups: fewer studies have used treatment as usual (TAU) and more have used an attention
control group, such as diabetes education or a different psychological intervention. Not offering treatment
for adolescents/children with diabetes could be considered unethical.
Therefore, limitations of the studies described in our early reviews include the poor methodological quality
of many of the included studies; insufficient studies to compare the relative effectiveness of specific
categories of psychological intervention, such as CBT versus counselling or MI; whether or not choice of
control groups had an impact on the overall findings; specialism of the therapist; and which clinical
subgroups benefit the most.
Recent systematic reviews and meta-analyses have focused on some of these elements. However, none to
date have considered the cost-effectiveness of psychological interventions or the relative effectiveness of
psychological interventions and attention controls, nor have they employed newer methods of synthesis
such as network and individual patient data (IPD) meta-analysis.
Current review
The aim of the current review was to update the systematic reviews of psychological interventions conducted
in 2003, using the same protocol, to assess whether or not the effectiveness of such interventions in improving
the primary outcome (i.e. glycaemic control for people with T1DM and T2DM) has changed. In addition, we
wanted to evaluate whether or not psychological interventions could be considered cost-effective based on
the primary outcome. We also wanted to detect whether or not these treatments could improve emotional
health, such as depressive symptoms and QoL, and diabetes self-management behaviours; therefore, these
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were included as secondary outcomes. We employed three methods of meta-analysis: (1) aggregate (same as
the 2003 review); (2) IPD, which allows the use of individual patient characteristics when data are available;
and (3) network meta-analysis (NMA) to perform indirect comparisons and simultaneous analysis of clinical
trials involving different treatments or control groups. IPD meta-analysis and NMA were not performed for
secondary outcomes. Finally, this review also reports on the cost-effectiveness of psychological interventions
in diabetes.
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Chapter 2 Research question
The overall aim was to summarise evidence from randomised controlled trials (RCTs) and conduct asystematic review, meta-analysis and cost-effectiveness analysis of controlled trials of psychological
interventions, specifically to:
l assess the effectiveness of psychological interventions that aim to improve motivation for patients
with T1DM and T2DM so that they have (1) improved glycaemic control, (2) improved diabetes
self-management, (3) reduced psychological distress and (4) improved health-related quality of life
l examine the overall cost-effectiveness analysis of psychological interventions in diabetes and to model
the potential predicted savings in reducing the risk of diabetes complications long term
l compare the clinical effectiveness of different types or techniques of psychological interventions for
improved glycaemic control and better self-management
l examine whether or not psychological interventions are effective in addressing populations who
experience health inequalities, such as different ethnic groups, those with severe mental illness and
those experiencing social deprivation
l conduct subgroup analyses to identify the clinical characteristics of patients who have better or worse
diabetes self-management or glycaemic control, for example by age, gender, complication status
l describe the development of new psychological theories and techniques, and of any advancements in
research methodologies, such as quality assurance of fidelity of intervention delivery or characteristics
of control groups
l identify gaps in the literature to make recommendations for primary research
l summarise the data for translation to the NHS via Health Improvement Networks, Diabetes Strategic
Networks, Diabetes UK and Clinical Commissioning Groups.
DOI: 10.3310/hta24280 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 28
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Winkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Chapter 3 Review methods
Protocol and registration
This systematic review and meta-analysis is registered with PROSPERO (registration number CRD42016033619).
The study protocol is available on the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/
1421310#/ (accessed 14 May 2019).
The methods are reported in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines and relevant extensions.68 We matched the methods reported here,
when possible, for the systematic reviews conducted from the inception of the electronic databases to
2003 by Ismail et al.40 and Winkley et al.57 This enabled us to pool data from the current review with an
older cohort of studies. Intervention methodologies and psychological technologies have improved, and
this method avoids contaminating the modern review with methodological biases and limitations of
under-reporting in older studies. We include a list of the additions to the original review, as well as changes
between the current protocol and review in Appendix 1.
Part A: systematic review, randomised controlled trial meta-analysis, network
meta-analysis and individual patient data meta-analysis methods
Eligibility criteria
Types of studies
Published and unpublished RCTs of interventions to improve self-management were included in the
systematic review; non-randomised controlled trials (nRCTs) were included in a separate review (see Part B:
non-randomised controlled trial systematic review methods and Chapter 7). Pre-and-post observational and
n-of-1 studies were excluded as there is no control group. If there were multiple publications of the same
study, the publication that reported the outcome of interest at the relevant time period was included,
and in some cases data were extracted from other publications, such as long-term follow-ups or study
protocols, for more detailed information regarding the intervention under investigation. There was no
restriction on language or the publication status of included studies. Non-English-language study reports
were screened and data extracted by a native speaker.
Types of participants
Participants of all ages diagnosed with T1DM or T2DM were included as the population under investigation.
People with T1DM and T2DM were considered separately as they are distinct clinical groups. T1DM was
stratified by age, adults (≥ 18 years) and adolescents/children (< 18 years). Participants with other medical
conditions were excluded, unless the separate analysis for people with diabetes was available or could be
provided. People with prediabetes, impaired glucose tolerance or gestational diabetes were excluded as,
again, these are distinct and separate clinical groups. If studies included participants with T1DM and T2DM,
authors were contacted for the data and separate analysis. If authors did not respond or were unable to
provide a separate analysis per diabetes type, studies were included in the systematic review but not the
meta-analysis.
Types of intervention (health technologies)
Interventions were described as psychological and were included if they met all of the following criteria:
l They relied on communication, using the therapeutic alliance between a patient and therapist.
l The intervention was facilitated by psychologists, psychotherapists and therapists in training, or facilitated
by persons trained in a psychological method/supervised by a clinical psychologist or therapist.
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l The intervention was based on a psychological model.
l The intervention aimed to improve outcome changes in emotional, cognitive or behavioural functioning,
including diabetes self-management.
If these criteria were unclear and the intervention could not be clearly described as psychological, then authors
were contacted for more information. The psychological interventions were classified into the following
categories: psychoanalytical/psychodynamic (including some that used elements of psychotherapy, such as in
collaborative care treatments), CBT; counselling (including MI); family therapy; and creative therapy (including
music, narrative, art therapy and psychodrama). Studies that used self-help (unless guided by a therapist) were
excluded, as were those for which there was no information on dose delivered.
Control groups included usual care (generally usual diabetes care), waiting list control, attention control,
diabetes education or a less intensive psychological intervention (i.e. fewer sessions/frequency/duration;
delivered by interventionists with less/no psychological training).
Types of outcome measures
The primary outcome of interest was change in glycaemic control, such as HbA1c, which refers to average
plasma glucose concentration over the previous 8–12 weeks. HbA1c is measured using percentage or
mmol/mol, between baseline and 1-year follow-up. The secondary outcomes of interest were (1) changes
in self-management activities [e.g. self-monitoring blood glucose, self-examination, diet, physical activity,
oral antidiabetes medication adherence, uptake of insulin therapy, increased clinic attendance], (2) change
in psychological functioning (e.g. depressive symptoms, diabetes distress, anxiety, QoL), (3) clinical outcomes
[body mass index (BMI)], blood pressure], (4) economic outcomes using unit costs and (5) adverse effects
[e.g. incidents of severe hypoglycaemia, diabetic ketoacidosis (DKA), diabetes complications]. For studies to
be eligible, they had to have included the primary outcome with or without secondary outcomes. Secondary
outcomes were used for meta-analysis when five or more studies provided data for that outcome.
Identification of studies
Information sources
The following electronic databases were searched from January 2003 to July 2016: MEDLINE (Ovid);
Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Cochrane Library, PsycINFO,
EMBASE (Ovid), Cochrane Controlled Trials Register and Web of Science. When protocols or conference
abstracts were identified through database searching, authors were contacted if full-text articles could not
be found. If authors did not respond or were unable to provide a full text, the studies were excluded.
In addition, national and international diabetes conference abstracts were searched from 2012 to July 2016
for reports of any trials using psychological therapies. These included Diabetes UK, the American Diabetes
Association, the European Association for the Study of Diabetes and the International Diabetes Federation
(IDF). The reference lists of included studies and reviews were searched for additional studies. The US
government clinical trials registry [https://clinicaltrials.gov (accessed 1 July 2016)] was searched for potential
relevant studies that were ‘active, not recruiting’ with an estimated completion of 2016. Authors were
contacted for full-text papers, if such papers were available.
Search
The following key search terms were used for MEDLINE and adapted for each database: ‘psychological
therapies’ and ‘mood disorders’ and ‘diabetes mellitus’ and ‘clinical trials’ (see Appendix 2). The Scottish
Intercollegiate Guidelines Network filter for RCTs was used for ‘clinical trials’ in MEDLINE, EMBASE and
CINAHL, and adapted for others.
Study selection
Titles and abstracts of studies, identified by electronic searches, were inspected independently by two
researchers (RU and KW). In the first stage, abstracts were selected if they described a controlled trial of a
REVIEW METHODS
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psychological or behavioural intervention for people with T1DM or T2DM. If there was ambiguity in the
description of the study or intervention, then the study was included into the second stage. The second
stage of study selection involved eligibility assessment of full-text papers by the same two researchers.
The inter-reliability for study selection was (Cohen’s kappa = 0.945) conducted on this second stage process.
Any differences over inclusion of studies at this stage of study selection were resolved by consensus and
discussion with a third researcher (KI).
We encountered problems relying on identifying psychological interventions using titles and abstracts only,
as some studies do not explicitly describe the psychological intervention in the abstract. Therefore, we
rescreened previously rejected abstracts for a second time to reduce the risk of excluding potentially
eligible papers.
Data collection process
Data extraction forms were developed in line with the protocol and piloted on five studies from the scoping
searches by two independent researchers (RU and KW) (see Appendix 3). If there was more than one
psychological intervention group (e.g. a three- or four-arm controlled trial), all arms were included in the
data extraction and NMA, but comparisons of the most intensive intervention arm versus the least intensive
arm were used for the aggregate meta-analysis. If data were not available in the study report, corresponding
authors were contacted and the missing data items were requested.
Authors of studies included in the aggregate meta-analysis were informed that their study had been
included in a systematic review and meta-analysis and were invited to participate in the IPD meta-analysis by
contributing IPD. A list of the required data items was provided. The corresponding author was contacted
via e-mail. If there was no response within 2–4 weeks, the lead, senior and other authors were contacted.
If this was unsuccessful, authors were contacted via ResearchGate (Berlin, Germany) or contacted in person
at conferences. If still unsuccessful, the head of the department at an author’s institution and/or the editor
of journals in which the paper was published was contacted.
In the first correspondence, a data use agreement (DUA) was sent to the author to be completed by the
corresponding institution before data transfer occurred. On some occasions, institutions had their own
ethics/legal procedures for sharing data. This was honoured by King’s College London (KCL) and a senior
contracts associate at KCL was involved to ensure that legal practices were adhered to. Once authors had
agreed to participate and completed the DUA, data transfer could occur.
Data were requested in any format convenient to the author, including Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA), SPSS [Statistical Product and Service Solutions; SPSS Inc., Chicago, IL,
USA (version 18 and below) or IBM Corporation, Armonk, NY, USA (IBM SPSS Statistics from version 19
onwards], SAS® (SAS Institute Inc., Cary, NC, USA), Stata® (StataCorp LP, College Station, TX, USA) or text.
Fewer data items were requested for the IPD than were extracted for the aggregate meta-analyses. If study
authors were unable to provide data, the reason given for not sharing data was recorded and authors
were informed that their study would still be included in the aggregate meta-analysis. When data were
received from study authors, they were checked against the study report and the data managed in SPSS
version 15.
Data items
Data were extracted for the characteristics listed below for the main aggregate meta-analysis; all data
items were considered to have the potential to influence efficacy and/or be potential effect modifiers in the
aggregated meta-analysis. For the IPD meta-analysis, the items in italics were requested from the study
research team for individual participants:
l Publication characteristics – year of publication, publication type (peer review or not), country of origin,
health-care setting, language, funding source.
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l Patient baseline characteristics – participant identification (ID) (IPD only), type of diabetes, mean age,
age in years (IPD only), gender, ethnicity, clinical subgroup (e.g. treatment type, smoking status, BMI),
socioeconomic setting (e.g. individual or family income, education), duration of diabetes (years) and
complication status, receipt of structured education and occupation status/type.
l Intervention characteristics – type of therapy; number of therapy sessions; average number of sessions
attended; duration of overall therapy; duration of therapy sessions; psychological theoretical framework
or model; use of manual; specialty of therapist; training of therapist; fidelity assessment of therapist;
description of techniques that aim to change emotional, cognitive and behavioural functioning
(including adherence); format of delivery (face to face, online, telephone, text messaging); mode of
delivery (one to one, group or family/couple); and use of booster or maintenance sessions.
l Control characteristics – the same data were extracted as for the intervention as applicable.
l Outcome characteristics –
¢ Type of outcome included the primary outcome [change in glycaemic control (HbA1c level in % or
mmol/mol)] and secondary outcomes (change in self-reported self-management behaviour, change
in self-reported psychological functioning, BMI).
¢ Method of assessing the outcomes. For the primary outcome of HbA1c level, this was an objective
laboratory measurement. For the secondary outcomes, change in self-reported self-management
behaviour was measured using validated measures [e.g. the Summary of Diabetes Self-Care Activities69
measure], as was psychological functioning [e.g. depression was measured using the Patient Health
Questionnaire-9 items (PHQ-9)70], the Center for Epidemiologic Studies Depression Scale (CES-D),71
the Montgomery–Åsberg Depression Rating Scale,72 the Beck Depression Inventory,73 the Hospital
Anxiety and Depression Scale74 or the Symptom Checklist Depression Scale-20 items75] and QoL
[measured using the World Health Organization (WHO) Quality of Life-BREF,76 the Diabetes-specific
QoL Measure,77 Ferrans and Powers QoL Index,78 the Short Form questionnaire-12 items or the
EuroQol-5 Dimensions79]. Scores were standardised prior to analysis.
¢ Time point of follow-up (post baseline or post treatment), baseline and follow-up data (or mean change).
For studies that were not reported in the English language, a restricted data extraction took place; for
example, not all publication and patient characteristics were extracted. An example of data extracted from
an Iranian study can be found in Appendix 4.
Individual patient data integrity
Data integrity was conducted. This involved an initial assessment of data completeness. Each data set
received from the study authors was checked to determine the consistency of the main analysis with that
in the published report.
Risk of bias in individual studies
The quality of RCTs was assessed using Cochrane Handbook Tool for Risk of Bias (RoB).80 RoB assessment
was carried out by two independent researchers (RU and KW); any disputes were resolved by a third
researcher (KI). Studies were assessed as having a high, low or unclear RoB for the following domains:
sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors,
incomplete outcome data (for glycaemic control HbA1c% or mmol/mol), selective outcome reporting and
other potential threats to validity. This was used to generate a graph for data synthesis (study reference
vs. RoB domain). Studies were not excluded from the meta-analyses based on RoB assessment; for example
those rated as having a high RoB were not excluded.
Synthesis methods
Systematic review
A standardised structured synthesis of all studies included in the systematic review was conducted.
If a study did not contain sufficient data to be pooled in the meta-analysis, it was summarised in a
narrative synthesis.
REVIEW METHODS
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Aggregate meta-analysis
The mean difference in change between baseline and follow-up (12 months or closest) scores between
the two groups (psychological intervention vs. control group or least psychological intervention) was
standardised by calculating Cohen’s d for each of the included studies. The effect size was calculated
from the raw published data or, if the necessary raw data were missing from publication, authors were
contacted to provide data.
The standardised effects were pooled using a random-effects model and meta-analysis was performed in
Stata 14 using the ‘metan’ command. The ‘metainf’ command was used to examine the influence of
individual studies whereby meta-analysis estimates are computed omitting one study at a time. Publication
bias was assessed using the Stata commands ‘metabias’ (Egger’s test), ‘metafunnel’ (funnel plot) and
‘metatrim’ (fill and trim method for estimating missing studies). Any meta-regression was performed using
the ‘metareg’ command. We conducted the meta-analyses only if there were five or more studies available
because of problems to reliably estimate the between-studies variance of random-effects models.81
The combined data from previous systematic reviews40,57 were aggregated with the current review to
determine an overall effect size for change in glycaemic control. The findings of the current review were
also reported separately.
Network meta-analysis
Organisations such as the NHS and the National Institute for Health and Care Excellence (NICE) need the
synthesis of evidence from existing studies to inform their decisions. Meta-analysis methods combine
evidence from related studies to produce results based on a whole body of research. However, relevant
studies may not provide direct evidence about all the treatments or outcomes of interest. Often treatments
are compared with different control treatments. NMA is a method to address this, using correlated or
indirect evidence from such studies, alongside any direct evidence.82
Unlike standard meta-analyses that are based on combining results from the same or similar sets of
treatments/and or controls, NMA allows simultaneous analysis of multiple treatments (and multiple outcomes)
and, thus, allows the inclusion of all available information towards each outcome and treatment comparison.
This is done by incorporating indirect evidence from related treatment comparisons (e.g. A–B and B–C allows
one to infer an A–C comparison), in addition to any standard direct evidence. A treatment effect, therefore,
can differ not only between studies (heterogeneity) but also by design (inconsistency). NMAs assume
‘transitivity’, which concerns mainly the validity of indirect comparisons. Transitivity refers to the assumption
that it was equally probable that any patient in the network could have been given any of the treatments in
the network. It is an assumption of balanced clinical and methodological study characteristics between the
direct comparisons that make up an indirect comparison.83
In the first step, network plots of direct comparisons of all available studies for the NMA were assessed.
Circles (nodes) represent the intervention type and lines that connect the interventions represent the direct
comparisons available in the literature (see Figures 18, 21 and 22). The width of the lines is proportional
to the number of trials comparing each pair of treatments and the size of each node is proportional to
the number of studies testing the specific treatment. The network pattern plot for all treatments was
conducted to show which treatments were used in which studies.
In the main step, we performed network multivariate random-effects meta-analyses to perform frequentist
estimation of meta-analyses models84, which allows for both heterogeneity (variation in the true treatment
effect between studies) and inconsistency (additional variation in the true treatment effect between
different sets of treatments compared in a study). Inconsistency is modelled as a fixed effect using the
design-by-treatment interaction model.84,85
Inconsistency in the contrasts between designs was assessed by comparing direct and indirect treatment
effects of a contrast between two treatments and an overall Wald test of inconsistency treatment.86
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If there was no evidence of inconsistency, a consistency model was fitted. Standardised mean differences
(SMDs), using treatment as usual as control group, are presented in Chapter 5. The formulae for Hedges’ g
in White and Thomas87 are used to estimate the SMD. These are unbiased estimators and involve corrections
for small numbers of degrees of freedom.
In the last step, the performance of different treatments was assessed by estimating relative treatment
rankings. Ranking probabilities for all treatments at each possible rank for each intervention are presented
in Chapter 5 as cumulative probability plots. The treatment hierarchy was established using the surface
under the cumulative ranking (SUCRA) curve and mean ranks. SUCRA accounts for the location as well as
the variance of all relative treatment effects. The larger the SUCRA value, the better the rank of the
treatment.
Individual patient data meta-analysis
For the IPD meta-analysis, baseline variables were described using mean and standard deviation (SD) for
continuous variables and frequencies and percentages for categorical variables.
For the outcome measure of HbA1c level, we performed an IPD ‘one-stage’ meta-analysis. The one-stage
was preferred to the ‘two-stage’ IPD meta-analysis because it is more suitable for exploring predictors and
moderators of response (for reviews, see Simmonds et al.88 and Debray et al.89). In addition, the one-stage
approach uses a more exact likelihood function and, thus, does not rely on assumptions of within-study
normality and known study variances.90 The one-stage model uses a random effects model to account for
the clustering of patients within studies.91,92
Data were analysed using the Stata commands ‘mixed’ and ‘ipdforest’, in accordance with the
recommendations of guidelines for performing IPD one-stage meta-analysis in Stata.93
Participants with T1DM and T2DM were analysed separately. Of participants with T1DM, adolescents/
children (< 18 years) and adults (≥ 18 years) were analysed separately.
We used linear regression models with HbA1c level as outcome, and treatment type and baseline values
of HbA1c as fixed independent variables, with a random intercept for study and random treatment effect,
and a random effect for baseline measures of HbA1c levels. For adolescents/children with T1DM, only a
random effect for treatment arm was included. The variance–covariance structure was considered to
be independent; this structure allows a distinct variance for each random effect within a random-effects
equation and assumes all covariances to be zero. The random effect structure was selected by model
comparisons using the Bayesian information criterion.94
To identify moderators of improvement in HbA1c levels, we ran several analyses, initially using only one
predictor variable and its interaction with treatment arm at a time to avoid reducing sample size. The
moderators considered included age, duration of diabetes and, for T2DM only, type of diabetes medication
and gender. Non–significant interactions were removed and main effects were reported. In the last step,
we assessed year of study as a potential confounder. Because not all variables were collected in all trials,
sample sizes change between different studies. However, it can be assumed that data missing by design
are missing completely at random, which does not produce any bias. Within studies, a complete-case
analyses was performed, assuming that missingness is completely at random, unless a predictor of
missingness is included as a covariate. In this case, missing at random is assumed.
The intraclass correlation for the random-effects study was presented as a measure of the correlation of
patients in a cluster study site. We also present the estimate I2 statistic to describe the percentage of
variation across studies that is caused by heterogeneity rather than chance.
REVIEW METHODS
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Risk of bias across studies
Publication bias was assessed by inspecting funnel plots and the effect of possible bias was assessed using
the ‘trim and fill’ method in sensitivity analyses.95 Meta-regression was used to investigate the possible
effects of age of study and study quality, and compared with the data pooled for the previous T1DM and
T2DM meta-analysis.40,57
Additional analyses
A meta-regression was conducted to determine whether or not factors such as country of study, number
of therapy sessions, duration of therapy session, overall duration of treatment, control group and RoB were
associated with changes in glycaemic control. Meta-regression was also performed to determine any
difference between previous reviews40,57 and the current review with regard to change in glycaemic
control.
A network analysis was also undertaken including all arms of studies with more than two intervention arms.
The NMAs allowed a comparison of results from two or more studies that have one treatment in common.
Confidence in synthesised evidence
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to
determine the quality of the evidence of the outcomes under investigation and subsequent translational
strength of recommendations for clinical practice.96 The GRADE criteria were used to assess the quality
of aggregate meta-analysis evidence for each outcome (primary and secondary) for T1DM and T2DM.
The quality for each outcome was rated according to the following: RoB, inconsistency, indirectiveness,
imprecision and publication bias. Each factor can be rated as not serious, serious or very serious. Overall
evidence for each outcome can be rated as high (no problems in any factors), moderate (problem in one
factor), low (problem in two factors or very serious problem in one factor) or very low (problem in three
or more factors).
Part B: non-randomised controlled trial systematic review methods
Eligibility criteria
Eligibility criteria for the nRCT systematic review follows the same method as the RCT review (see Part A:
systematic review, randomised controlled trial meta-analysis, network meta-analysis and individual patient
data meta-analysis methods) for type of participants, types of intervention (health technologies) and types
of outcome measures. Types of studies was also the same, except this review included published and
unpublished non-randomised controlled studies of interventions to improve motivation for self-management
rather than RCTs. Only reports of nRCTs written in English were selected.
Identification of studies
Information sources and search strategy
The following electronic databases were searched for nRCTs: EMBASE (2003 to January 2017), MEDLINE
(2003 to January 2017) and PsycINFO (2003 to 16 January 2017). The search strategy for nRCTs used in
EMBASE and MEDLINE were taken from Li et al.97 and MEDLINE’s nRCT search terms were used in PsycINFO
to generate results (see Appendix 6 for search terms for nRCTs).
Study selection and data collection process
Initially, one reviewer (AK) independently selected abstracts after running the searches in the electronic
databases. In the following step, two reviewers (AK and RU) screened the full texts and made a decision to
include studies that met the eligibility criteria. Any disagreement was resolved through discussion with a
third researcher (KW). The inter-rater reliability was calculated using the Cohen’s kappa. One reviewer (AK)
extracted data from the articles that met all the inclusion criteria using a data extraction form (see Appendix 7
for blank data extraction table for nRCTs).
DOI: 10.3310/hta24280 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 28
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Winkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Data items
Data were extracted for the characteristics listed below for the nRCT narrative synthesis:
l Publication characteristics – year of publication, country of origin, health-care setting, study design.
l Patient baseline characteristics – type of diabetes, number of participants screened/assessed for
eligibility, inclusion/exclusion criteria, number of participants assigned to psychological intervention,
number of participants assigned to control, number of participants lost to follow-up, reasons for loss to
follow-up, mean age (years at baseline), mean duration of diabetes (years at baseline) and gender.
l Intervention and control characteristics – same as RCT systematic review reported in Part A: systematic
review, randomised controlled trial meta-analysis, network meta-analysis and individual patient data
meta-analysis methods.
l Outcome characteristics – outcome measure, method of assessing outcome, type of outcome (e.g. HbA1c
levels, change in psychological functioning, change in self-management behaviours, other), time point
of follow-up, post-baseline or post-treatment findings, and other (e.g. any discussion points, notes about
the study).
Risk of bias assessment
To assess the quality of studies, we used the Risk of Bias in Non-randomized Studies – of Interventions
(ROBINS-I),98 created by the Cochrane Methods Bias Group and Cochrane Non-Randomized Studies for
Interventions Methods Group. The tool is designed to approximate the effectiveness of interventions that
do not use randomisation to assign treatment groups to subjects. The tool includes seven domains to
investigate bias in non-randomised studies. The first two domains are pre intervention and are used to
determine confounding at baseline (prognostic factors that predict the outcome and/or predict the
intervention received) and participant selection biases (exclusion of subjects who were eligible for the
study). The third domain concerns bias when classifying the intervention, such as observer or measurement
bias. The last four domains focus on the post-intervention period, addressing biases due to aberrations
from the planned intervention, missing data, measurement issues or problems with the reporting of data.
A study is said to have a low risk of bias when the study is similar to a well-conducted RCT across all the
domains. Moderate risk denotes that a study is comparable to a thorough nRCT but not as good as a RCT.
For serious risk, the study has some major issues and critical risk means that the study has too many
problems and cannot provide any valuable information. ‘No information’ (NI) is assigned to studies when
one or more domain is lacking information that makes decision-making regarding the risk difficult.
Synthesis methods
Systematic review
Structured narrative synthesis was used to evaluate the results of the review as the included studies were
heterogeneous in nature and design. Results are reported by diabetes type, T1DM (including both adult
and adolescent populations) and T2DM. The studies were systematically appraised by highlighting the
similarities/dissimilarities between texts. The current review focused on the study characteristics, type of
participants included, intervention and control designs, attendance and dropout rates, reporting of fidelity
assessments in studies, types of outcome measures, methods of their assessment, risk of bias in studies
and a summary of individual study results.
Part C: health economics methods
In this section, we report the methods for the literature reviews of health economic studies and an overview of
the methods used to develop and adapt two existing health economic individual-level simulation models {the
Sheffield Type 1 Diabetes Policy Model [Thokala P , Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, et al.
The Sheffield Type 1 Diabetes Policy Model. HEDS Discussion Paper 13/05. Sheffield; 2013 (unpublished)]
and the School for Public Health Research [SPHR] Type 2 Diabetes Prevention Model99}, which were utilised
in this study to address the research questions regarding the cost-effectiveness of psychological interventions.
Chapter 8 reports the detail of the health economic analyses undertaken.
REVIEW METHODS
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Literature searching for previous economic evaluations
Methods
We undertook a process that involved:
l Web of Science citation-searching on the found articles in the clinical effectiveness systematic review.
l The reference lists of the articles were read to identify protocol articles.
l If protocol articles existed, they were also citation-searched.
l Known literature sources of health economic literature were examined, including studies on T1DM
and T2DM.
l The Mount Hood website100 was also searched.
This process was adopted so that the search for economic studies could use the studies found in the
clinical review to find the articles that related to economic evaluations of psychological interventions.
The main inclusion criterion was an economic evaluation in which one arm was a psychological
intervention. We did not exclude within-trial analyses, as they could provide useful costing information.
Results
One study was found, the ADaPT (A Diabetes and Psychological Therapies study) within-trial health
economic analysis.101 This was used to inform costings for psychological therapies (see Chapter 8).
Conclusions
A new health economic modelling exercise would be required for both T1DM and T2DM.
Literature searching for long-term effectiveness studies
Methods
l Web of Science citation searching on the found articles in the clinical effectiveness systematic review.
l The reference lists of the articles were read to identify protocol articles.
Results
Only one relevant paper was found. The ADaPT long-term follow-up101 report. This has been used in
Chapter 8 to estimate longer-term HbA1c level trajectories after 12 months.
Overview of the health economic analyses undertaken
In this subsection, we summarise the new health economic modelling work undertaken for this report
using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist framework.102
The CHEERS checklist items are as follows.
Present the study question and its relevance for health policy or practice decisions
We undertook two main studies to examine the cost-effectiveness of psychological interventions versus
usual care: one for adults with T1DM and one for adults with T2DM. The interventions chosen were those
interventions identified in the NMA results for interventions with more than two studies. Attention control
was not included as a comparator arm, as this was not a psychological intervention. Psychotherapy was
not assessed for adults with T2DM, as the p-value was very close to 1 (p = 0.98).
l Cost-effectiveness of CBT versus counselling versus usual care in adults with T1DM.
l Cost-effectiveness of CBT versus counselling versus usual care in adults with T2DM.
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Target population and subgroups
The target populations were adults with T1DM and adults with T2DM. No further subgroup analyses were
undertaken because of limited evidence on subgroup effectiveness differences, that is the evidence was
too limited to enable NMAs by subgroups. We did not model cost-effectiveness for adolescents with T1DM
because the NMAs for adolescents (see Chapter 5) showed only non-significant differences, with p-values
typically ranging from 0.4 to 0.9.
Setting and location
The studies were set in the UK.
Study perspective
The perspectives used were the NHS and Personal Social Services (PSS).
Comparators
The comparators were CBT versus counselling versus usual care in adults with T1DM, and CBT versus
counselling versus usual care in adults with T2DM.
Time horizon
A lifetime time horizon was used.
Discount rate
A discount rate of 3.5% per annum was applied.
Choice of health outcomes
HbA1c effects in year 1 and HbA1c longer-term trajectories evidence were used as input to the individual-level
simulation models, which then analysed the numbers of clinical events. For T1DM, the clinical events included
were nephropathy, neuropathy, retinopathy, macular oedema, myocardial infarction, stroke, heart failure,
angina, severe hypoglycaemia and DKA. For T2DM, the clinical events included were kidney disease, ulcer,
amputation and blindness, cardiovascular disease (CVD), congestive heart failure, osteoarthritis, depression
and breast or colon cancer.
Measurement of effectiveness
Quality-adjusted life-years (QALYs) were used as the measure of effectiveness.
Measurement and valuation of preference-based outcomes
Quality-adjusted life-years were based on utility values for health states from published literature and
previous studies using the models and life expectancy (see Appendix 16 for the utilities used in the
T1DM analyses).
Estimating resources and costs
Resource use associated with model health states was estimated based on published literature and previous
studies using the economic models. Costing of psychological interventions was undertaken based on their
description in clinical studies and liaison with UK experts in the project team.
Currency, price date and conversion
Costs were inflated to 2015/16 Great British pound (GBP) values.
Choice of model
Two previously used individual-level simulation models were extended and adapted to incorporate
evidence on psychological interventions.
REVIEW METHODS
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Assumptions
Assumptions are reported in detail in Chapter 8 (for T1DM and T2DM populations). The key assumptions
in relation to this particular study relate to the evidence to be utilised for the long-term trajectory of HbA1c
levels for people who receive a psychological intervention versus those who do not.
Analytic methods
Analytic methods are reported in detail in Chapter 8 (for T1DM and T2DM populations).
Study parameters
Study parameters are reported in detail in Chapter 8 (for T1DM and T2DM populations).
Incremental costs and outcomes
Lifetime discounted costs and QALYs for each comparator are used to quantify incremental cost-effectiveness
ratios (ICERs) (incremental cost/incremental QALYs) and net monetary benefit (QALYs × £20,000 – costs).
Characterising uncertainty
A probabilistic sensitivity analysis (PSA) was undertaken using uncertainty on all parameters. A total of
500 samples of the parameters were used; for each sample, 5000 individual patients were simulated in each
arm of the model. We used the Sheffield Accelerated Value of Information (SAVI) online tool to calculate
the expected value of perfect information (EVPI) to quantify overall decision uncertainty. Expected value of
perfect parameter information (EVPPI) analysis was also used to identify key uncertainties to inform priorities
for further research in terms of reducing uncertainty about the quantitative effects of psychological
interventions.
Characterising heterogeneity (e.g. subgroup differences)
No further subgroup analyses were undertaken because of limited evidence on subgroup effectiveness
differences.
The reporting of both models in this report have been compared to the Palmer et al.103 checklist for the
reporting model inputs in diabetes simulation models. These checklists are provided separately for the
modelling of psychological interventions for people with T1DM and people with T2DM in Appendix 16.
Part D: patient and public involvement methods
We used qualitative methods to determine the views of people with diabetes with regard to the initial
findings of this systematic review and meta-analysis.
Aims
The aims of the focus groups were to:
l determine patient views on the preliminary findings of the RCT systematic review and meta-analysis
l discuss the best ways to inform patients and the public regarding the review findings.
Participants, recruitment and setting
People with T1DM and people with T2DM were identified from London and Sheffield and surrounding
areas to take part in a focus group. The focus groups were advertised via NHS England, Diabetes UK local
groups, Twitter (Twitter, Inc., San Francisco, CA, USA; www.twitter.com), Lay ADvice for Diabetes and
Endocrine Research (LADDER) patient and public involvement (PPI) panel in Sheffield, and patient
information boards in diabetes clinics.
The focus group in London was held in a conference room at KCL, and the Sheffield focus group was held
at the University of Sheffield. The focus groups were facilitated by the principal investigator (KW), PhD
student (RU), and a MSc Health Psychology student [Sophie Fawson (SF)].
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Focus group meetings were held in March 2017 for the London and Sheffield groups. Participants were
offered up to £50 in travel expenses and £75 for their time on the day. Lunch was also provided.
Procedure
Focus group participants were provided with a formal invite and information sheet prior to the focus group
meeting. The information sheet detailed what the review involved, a definition of a psychological
intervention and what we aimed to achieve through this research.
On the day of the focus groups, participants consented to the session being audio-taped and transcribed,
and consented to the use of unattributed quotations in the report.
Kirsty Winkley introduced the research team and initiated participant introductions and discussion.
Participants were first asked: ‘What three things do you feel would improve your diabetes care from
hospital/general practice?’ Each member of the focus group was given the opportunity to answer this
question, which prompted everyone in the group to speak.
Rebecca Upsher presented preliminary findings of the research using mini posters (see Appendix 8), which
also included characteristics of the studies included in the review, for example intervention facilitators,
mode of delivery, type of psychological intervention and format of delivery. Kirsty Winkley then asked the
group questions based on these findings. This was split into three phases, to present findings and ask
questions based on studies of adolescents/children with T1DM, adults with T1DM and T2DM. Following
this, participants were then asked questions regarding their views on how the findings of the research
should be disseminated.
Focus groups lasted ≈2 hours.
Focus group questions
These questions followed the presentation of findings:
l What are your impressions of these findings for T1DM/T2DM?
l What are your thoughts on the delivery of psychological interventions for T1DM/T2DM?
l Do you feel that psychological interventions can help better manage your diabetes? How/why not?
l In your opinion, what components of a psychological intervention are important to help improve
T1DM/T2DM management?
l What types of psychological support for T1DM/T2DM would you like to see offered?
l Do these findings convince you that psychological interventions are important in T1DM/T2DM?
How so/why not?
Dissemination
l How do you access information about diabetes-related research?
l Where would you like to see the results of our research published?
l If you were to see our research published, what pieces of information are most important to you to
inform you about the literature of psychological interventions in diabetes care?
Synthesis of focus group findings
Sophie Fawson took notes during the focus group sessions, listened to interview transcripts and summarised
findings detailing participant views of research findings and views of the best methods to disseminate findings.
REVIEW METHODS
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Chapter 4 Results
Study selection and individual patient data obtained
Literature searches identified 24,694 citations (Figure 1). There were 16,705 citations after removing
duplicates; titles/abstracts were screened for eligibility. A total of 259 articles were assessed for full-text
eligibility, conducted per protocol. A total of 182 studies were excluded based on the full-text screening.
No unpublished studies were identified. Fourteen studies were included in qualitative analysis for adults
with T1DM and seven were included in the aggregate meta-analysis (three studies104–106 were from papers
that included a T1DM and T2DM population, and separate analysis per diabetes type was provided by the
author). Eighteen studies were included in the qualitative analysis for adolescents/children with T1DM and
14 studies were included in the aggregate meta-analysis. Fifty-six studies were included in the qualitative
analysis for adults with T2DM and 40 studies were included in the aggregate meta-analysis (three
studies104–106 were from papers that included a T1DM and T2DM population, and separate analysis per
diabetes type was provided by the author). Eleven studies included in the qualitative analysis included
a T1DM and T2DM population; for eight of these studies, no separate analysis per diabetes type could be
provided for the aggregate meta-analysis.
In the re-screen, 19 new studies were identified: (see Figure 1) 11 adult T2DM studies (nine for the
aggregate meta-analysis) and four studies on T1DM in adolescents/children (all with sufficient data for the
aggregate meta-analysis) and four studies with an adult T1DM and T2DM population (all with sufficient
data for the qualitative synthesis).
For the IPD (Figure 2), 58 study authors included in the aggregate meta-analysis were contacted (from
studies identified prior to re-screening of study abstracts) and 41 responded (70.69%); 29 provided data
(50%), (adults with T1DM: n = 6 studies, 751 participants; adolescents/children with T1DM: n = 9 studies,
1392 participants; adults with T2DM: n = 19 studies, 3639 participants; note that five studies included
people with T1DM and people with T2DM). Twelve study authors responded but declined to forward data
for the following reasons: three authors and/or their research team had no access to data, two authors
were not interested in participating, two could not provide data, citing ethical reasons, and five did not
have time to find the data set within the given time frame. The total number of participants for the IPD
data set was 5823. Authors of studies identified when we re-screened study titles and abstracts were not
contacted because of insufficient time.
Type 1 diabetes mellitus adult study characteristics
For the qualitative synthesis for adults with T1DM, 18 studies were included; 13 studies had a mixed T1DM
and T2DM population. Studies are described qualitatively and a summary of study characteristics for each
is reported in Table 1. Details of psychological interventions, control groups and interventionist categories
are included in Appendix 5.
Study location
Twelve studies were conducted in Europe (Denmark, n = 3;165,166,178 Germany, n = 3;105,106,190 the Netherlands,
n = 3;104,164,197 Sweden, n = 1;162 the UK, n = 1;163 and Norway, n = 1188), one in Australia108 and five in
North America.187,192,193,195,196
Participant characteristics
The total sample size for all adult T1DM studies was 1457 (n = 13; five studies with a mixed T1DM and
T2DM population did not provide sample size per diabetes type). Across studies, the sample size ranged
from 11 to 315 participants.
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Records after duplicates
removed
(n = 16,705)
Records screened
(n = 16,705)
Records excluded
(n = 16,329)
Records identified through
database, conference abstract
and other sources
(n = 24,694)
Full-text articles
assessed for
eligibility
(n = 376)
• Protocols, n = 31
• Conference abstracts, n = 25
• Medical resource utilization/economic evaluation paper,
   main results reported elsewhere, n = 3
• Intervention not defined as psychological, n = 159
• Glycaemic control not measured, n = 28
• Not RCT, n = 9
• Unable to access study, n = 6
• Outcome of interest published in different paper, n = 18
• Not diabetes, n = 1
• T1DM adults: studies (n = 18, 13a studies included adults
   with a T1DM and T2DM population), participants,
   n = 1457
• T1DM adolescents/child: studies (n = 22, 2a studies
   included adolescents with T1DM and T2DM population),
   participants, n = 2876
• T2DM: studies (n = 71, 13a studies included adults with a
   T1DM and T2DM population, and 2a further studies
   included adolescents with T1DM and T2DM population),
   participants, n = 14,326
• T1DM adults: (n = 7), participants (n = 851), 3a of these
   studies were from T1DM+T2DM studies where separate
   analysis was provided per diabetes type
• T1DM adolescents/child: (n = 18), participants (n = 2583)
• T2DM: studies (n = 49), participants (n = 12,009), 3a of
   these studies were from T1DM+T2DM studies where
   separate analysis was provided per diabetes type
Full-text articles excluded, with reasons
(n = 280)
Studies included in quantitative synthesis
(aggregate meta-analysis) 
(n = 71)
Studies included in qualitative synthesis
(n = 96)
FIGURE 1 The PRISMA flow diagram for all studies (including re-screened studies) for the qualitative synthesis and
aggregate meta-analysis. a, Same studies.
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Intervention characteristics
Most studies tested a CBT intervention (n = 9),104–106,162–164,188,192,197 followed by counselling (n = 7)108,165,166,190,191,193,196
and collaborative care, including elements of psychotherapy (n = 2).188,195 Studies were delivered by non-diabetes
specialists, including psychologists, primary care physicians and peers (n = 8)104–106,164,191,195–197 and diabetes
specialists (i.e. diabetes nurses, diabetes educators) (n = 10).108,162,163,165,166,187,188,190,192,193 The mode of delivery was
mostly face to face (n = 15),104–106,162–166,187,188,190–192,195,197 with two intervention studies delivered via telephone.193,196
One study was delivered face to face and by telephone.108 Most studies were delivered in a group setting
(n = 9);104–106,162,164–166,188,192 the rest were delivered one to one (n = 9).108,163,187,190,191,193,195–197 The number of
psychological therapy sessions ranged from 5 to 14, and sessions lasted between 45 minutes and 2 hours.
The total duration of therapy ranged from 1.5 to 20 months.
Control characteristics
Control groups were categorised into two different types: usual care and attention control (matched with
the intervention in frequency and length). Fourteen studies104,106,108,162,163,165,166,187,188,191,193,195–197 delivered
usual diabetes care as a control, and four studies105,164,190,192 delivered attention control; this included blood
glucose awareness training (BGAT) (n = 1)164 and diabetes education (n = 2).105,192 One study190 delivered
peer support to the control participants; this was coded as attention control.
Primary outcome
The primary outcome was HbA1c level (measured as % or mmol/mol). The mean difference was calculated
from baseline to 12 months’ follow-up (or the closest measurement to 12 months) for the intervention and
control groups. The time between HbA1c level follow-up measurements between studies ranged from 2 to
18 months for adult T1DM studies.
Records identified through
database, conference abstract
and other sources
(n = 24,694)
Records after duplicates
removed
(n = 16,705)
Full-text articles
assessed for
eligibility
(n = 376)
Full-text articles excluded
(n = 280)
See Figure 1 for reasons
Eligible studies for which IPD not sought (n = 19), 
as not included in aggregate quantitative synthesis
(unable to obtain missing aggregate data from
authors)
Studies for which IPD were not provided (n = 29),
with reasons
• No response from author following multiple
   contact attempts, n = 17
• Author or research team has no access to data, n = 3
• Not interested in participating, n = 2
• Unable to share IPD due to ethics, n = 2
• Unable to provide data within time frame, n = 5
Studies for which
IPD sought
(n = 58 per
protocol studies)
Studies for which
IPD provided
(n = 29),
5378 participants
FIGURE 2 The IPD PRISMA flow diagram.
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
T2DM studies included in the meta-analysis
2004, the USA,
Whittemore107
49 All: 57.6 (10.9) T2DM, 30–70 years,
HbA1c level of > 7%
2.7 (3.0) Counselling 6 Nurse-coaching
intervention, nurses, face
to face, individual
Usual care 6 months
2012, the USA,
Williams108
293 l Intervention:
70.1 (6.9)
l Control: 70.3 (7.1)
T2DM, > 60 years NR Collaborative
care (including
psychotherapy)
6–8 Collaborative care
(depression treatment
including problem-solving
treatment); depression
clinical specialist plus GP;
face to face; individual
Usual care 12 months
2006, Germany,
Siebolds109
223 l Intervention:
58.7 (7.6)
l Control: 60.5 (6.6)
T2DM l Intervention:
65.5 (57.2)
l Control: 62.6 (47.3)
Counselling 4 Counselling, physician,
face to face, individual
Dietary counselling,
physician, face to
face, individual
6 months
2006, Thailand,
Keeratiyutawong110
90 27–60 T2DM for < 10 years;
OADs only; fasting blood
glucose of > 130mg/dl
on at least two occasions
NR CBT 5 Self-management group;
psychology researcher;
face to face; group
Diabetes education;
diabetes health-care
team; face to face;
individual
6 months
2007, the USA,
Gregg111
81 l Intervention: 51.9
l Control: 49.8
T2DM l Intervention: 5.3
l Control: 6.6
Counselling 1 ACT, psychologist, face to
face, group
Diabetes education,
psychology masters-
level students, face
to face, group
3 months
2007, the USA,
West112
217 l Intervention: 54 (10)
l Control: 52 (10)
T2DM, treated with
OADs, not insulin;
overweight
l Intervention:
5.8 (6.5)
l Control: 4.9 (5)
Counselling 5 MI; clinical psychologists;
face to face; individual
Diabetes education;
health educators;
face to face; individual
12 months
2009, the UK,
Dale113
231 n (%)
l Intervention 1:
< 50 years =6 (14.3);
51–69 years = 25
(59.5); > 70 years =
11 (26.2)
l Intervention 2:
< 50 years =17 (19.3);
51–69 years = 46
(52.3); > 70 years =
25 (28.4)
l Control: < 50 years =
12 (13.5);
51–69 years = 54
(60.7); > 70
years = 23 (25.8)
T2DM, not treated
with insulin, HbA1c
level of > 8%
l Intervention 1:
<1 year = 6 (14.3);
1–15 years = 30
(71.4); > 15 years
= 6 (14.3)
l Intervention 2:
< 1 year = 16 (18.2);
1–15 years = 65
(73.9); > 15 years =
7 (8.0)
l Control:
< 1 year = 12 (13.6);
1–15 years = 72
(18.8); > 15 years =
4 (4.6)
Counselling 6 l Telephone support (MI);
nurses; telephone;
individual
l Telephone support (MI);
peers; telephone;
individual
Usual care 6 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
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2
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2009, Iran,
Davazdah114
40 35–60 T2DM NR CBT 12 CBT, trained researcher,
face to face, group
Waiting list; see
intervention
description
3 months
2009, the USA,
Sacco115
62 52 (8.6) for all
participants
T2DM; HbA1c level of
> 6.5%
9.5 (7.2) for all
participants
Counselling 18 Telephone ‘coaching’
intervention;
undergraduates in
psychology; telephone;
individual
Usual care 6 months
2010, Australia,
Evans116
60 57.1 (22–84) for all
participants
T2DM 14.3 (1–45) for all
participants
CBT 7 CBT; face to face; group Waiting list (usual
care for 3 months,
then intervention)
3 months
2010, the USA,
Wolever117
56 l Intervention:
53.1 (8.29)
l Control: 52.8 (7.64)
T2DM for > 1 year, OADs
for > 1 year
l Intervention:
11.8 (8.5)
l Control:10.6 (6.43)
Counselling 14 Integrative health
coaching; coaches
(masters-level degrees in
social work or psychology);
telephone; individual
Usual care 6 months
2010, the USA,
D’Eramo Melkus118
109 l Intervention: 47 (9)
l Control: 45 (10)
T2DM; black women; did
not require insulin, BMI
of < 37 kg/m2
NR CBT 11 CBT+DSMT+CST; nurse;
face to face; group
Diabetes education;
nurse; face to face;
group
3 months
2010, Belgium,
De Greef119
41 l 35–54 years (n):
intervention – 6;
control – 3
l 55–75 years (n):
intervention – 35;
control – 18
T2DM for ≥ 6 months l 1–5 years (n):
intervention – 16;
control – 8
l > 5 years (n):
intervention – 25;
control – 13
CBT 5 cognitive–behavioural
pedometer-based group
intervention; coaches
(degree in PE, movement
sciences or clinical
psychology); face to face;
group
Usual care 52 weeks
2010, the USA,
Hawkins120
66 l Intervention: 64
l Control: 65.8 (10.4)
T2DM, ≥ 60 years l Intervention:
< 1 year – 7 (26.5);
1–5 years – 10
(29.4); 6–10 years
– 9 (26.5); > 10
years – 6 (17.6)
l Control: < 1 year
– 3 (9.3); 1–5 years
– 15 (46.9); 6–10
years – 6 (18.8);
> 10 years – 8 (25)
CBT 12 MI video call; nurses,
telephone, individual
Attention control
telephone support
(no MI); nurses;
telephone; individual
6 months
continued
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2010, the USA,
Osborn121
185 l Intervention:
56.9 (11.3)
l Control: 58.4 (10.1)
T2DM for > 1 year;
Puerto Rican ethnicity
l Intervention:
13.2 (12)
l Control: 12.3 (9.4)
Counselling 1 Culturally tailored
diabetes self-care
intervention; bilingual
medical assistant of
Puerto Rican heritage;
face to face; individual
Usual care 3 months
2011, Chile,
García-Huidobro122
167 l Intervention:
53.4 (8.1)
l Control: 53.5 (9.8)
T2DM, 18–70 years,
HbA1c level of ≥ 7%
NR Family therapy 4 Family intervention,
health-care team, face to
face, family
Usual care 6 months
2011, Ireland,
Keogh123
121 l Intervention:
59.96 (11.67)
l Control:
57.29 (11.34)
T2DM for > 1 year,
having at least two of
their last three HbA1C
readings at ≥ 8.0%
l Intervention:
9.17 (7.1)
l Control: 9.65 (6.45)
Counselling 3 Family-based intervention;
health psychologist; face
to face; family
Usual care 6 months
2011, Belgium,
De Greef124
67 l Intervention 1:
70 (6.3)
l Intervention 2:
66.6 (9.5)
l Control: 66 (11.1)
T2DM for ≥ 6 months,
aged ≤ 80 years, BMI
of 25–35 kg/m2, HbA1c
level of ≤ 12%,
pharmaceutically treated
for T2DM
< 5 years (%)
l Intervention 1:
68.5%
l Intervention 2:
66.7%
l Control: 59.1%
Counselling 3 l Group behavioural
intervention; clinical
psychologist; face to
face; group
l Individual consultation;
GP, face to face,
individual
Usual care 12 weeks
> 5 years:
l Intervention 1:
31.6%
l Intervention 2:
33.3%
l Control: 40.9%
2011, Iran,
Hamid125
46 32–65 T2DM NR CBT 12 CBT, trained researcher,
face to face, group
Waiting list, see
intervention
description
6 months
2011, the USA,
Piette126
291 l Intervention:
55.1 (9.4)
l Control: 56 (10.9)
T2DM, ≥ 21 years;
antihyperglycaemic
medication; depressed,
as measured by the
PHQ-9
NR CBT 12 Telephone-delivered CBT;
nurses; telephone;
individual
Enhanced usual care
(usual care+ copy
of self-help book
based on CBT for
depression)
12 months
2011, the
Netherlands,
Lamers127
70 l Intervention:
70.7 (6.6)
l Control: 69.7 (6.6)
T2DM; depressed,
as3 measured by the
PHQ-9; ≥ 60 years
l Intervention:
8.2 (8.8)
l Control: 9.8 (9.1)
CBT 4 Minimal psychological
intervention; nurses; face
to face; individual
Usual care 9 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
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Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2011, the USA,
Welch128
119 l Intervention 1:
56.1 (10.4)
l Intervention 2:
54.9 (9.3)
l Control 1: 57.2 (10.9)
l Control 2: 54.4 (10.3)
T2DM, 30–70 years,
(HbA1c levels of ≥ 7.5%)
l Intervention1:
9.8 (8)
l Intervention 2:
9 (7.3)
l Control 1: 7 (6.5)
l Control 2: 7.1 (5.8)
Counselling 4 l MI+ computerised self-
management: diabetes
educator; face to
face; individual
l MI alone; diabetes
educator; face to
face; individual
l Diabetes
education alone;
diabetes
educator; face to
face; individual
l Computer self-
management
alone;
computer;
individual
6 months
2011, the USA,
Ell129
229 All: 54 (8.7) T1DM or T2DM; ≥ 18
years; depressed, as
measured by the PHQ-9
NR Collaborative
care (elements
of
psychotherapy)
NR Socioculturally adapted
collaborative care: primary
care physicians/graduate
social workers/diabetes
depression clinical
specialists; face to face/
telephone; individual
Enhanced usual
care (usual care+
prescribed
antidepressant
medication and
provided counselling
or refer to
community mental
health care)
12 months
2012, the UK,
Farmer130
211 l Intervention: 62.5 (11)
l Control: 64.1 (10.3)
T2DM, ≥ 18 years, HbA1c
levels of ≥ 7.5%
l Intervention:
6.7 (4.8)
l Control: 6.9 (5.3)
Counselling 1 Consultation-based
intervention, clinical
nurses, face to face,
individual
Usual care 8 weeks
2012, the USA,
Penckofer131
74 l Intervention:
54.8 (8.8)
l Control: 54 (8.4)
T2DM for > 6 months;
≥ 18 years; depressed, as
measured by the CES-D
l Intervention:
10.5 (8.2)
l Control: 10 (6.5)
CBT 8 Psychoeducation: nurses;
face to face, group
Usual care 6 months
2012, Germany,
Hartmann132
110 l Intervention:
58.7 (7.4)
l Control: 59.3 (7.8)
T2DM, albuminuria l Intervention:
11 (7.5)
l Control: 12.2 (7.6)
Counselling 8 Mindfulness-based
intervention: psychologist
and a resident in internal
medicine; face to face;
group
Usual care 12 months
2012, Taiwan,
Chen133
215 l Intervention:
59.19 (10.24)
l Control:
58.67 (10.23)
T2DM for > 3 months,
aged > 18 years
l Intervention:
7.98 (7.57)
l Control: 7.91 (6.95)
Counselling NR MI: nurses; face to face;
individual
Diabetes education;
nurse/diabetes
educator; face to
face; group
3 months
continued
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2013, Canada,
Plotnikoff134
287 l Intervention:
62.3 (11.1)
l Control 1: 61 (11.7)
l Control 2: 61.4 (12.6)
T2DM, > 18 years l Intervention: 8.8 (7)
l Control 1: 11.7 (9.9)
l Control 2: 10.7 (9.9)
Counselling 22 Telephone counselling
(MI): five individuals
with relevant degree
qualifications related to
physical activity promotion
and/or counselling;
telephone; individual
1. Diabetes
education;
educational
materials
2. Printed materials
(relates to
transtheoretical
model)
12 months
2013, the
Netherlands,
Welschen135
154 l Intervention:
60.5 (9.4)
l Control: 61.2 (8.8)
T2DM, 18–75 years,
HbA1c level of
≥ 52mmol/mol (7.0%)
and/or BMI of 27.0 kg/m2
and/or smoking
l Intervention: 7.6 (5)
l Control: 7.8 (6.1)
CBT 3–6 CBT; diabetes nurse and
dietitian; face to face;
individual
Usual care; dietitian/
diabetes nurse; face
to face; individual
12 months
2013, the USA,
Mandel136
131 l Intervention:
58 (11.29)
l Control 1: 57.1 (9.67)
l Control 2:
58.9 (10.76)
T2DM, 30–85 years,
enrolled in diabetes
education programme
l Intervention:
3.22 (5.94)
l Control 1: 2.32 (6.1)
l Control 2:
3.78 (7.06)
Creative
therapy
4 Music therapy; music
therapy clinician; face to
face; group
1. Diabetes
education;
diabetes
educator/
dietitian; face to
face; group
2. Music
relaxation CD
3 months
2013, the
Netherlands,
Jansink137
521 l Intervention:
64.1 (8.9)
l Control: 63.9 (9.8)
T2DM, < 80 years, HbA1c
level of > 7%, BMI of
> 25 kg/m2
l Intervention:
7.5 (6.0)
l Control: 7.8 (5.8)
Counselling 5–8 MI; nurse; face to face;
individual
Usual care 14 months
2014, Denmark,
Juul138
3946 l Intervention:
60.2 (8.2)
l Control: 60.7 (8.6)
T2DM l Intervention: 8
l Control: 8
Counselling Variable Nurse-led diabetes
consultations, GP &
nurses, face to face,
individual
Usual care 18 months
2014, the UK,
Steed139
124 l Intervention:
59.2 (8.8)
l Control:60.3 (8.6)
T2DM, < 75 years l Intervention:
10.7 (7.5)
l Control: 10.9 (7.9)
Counselling 5 Self-management
intervention, diabetes
specialist nurse &
dietitian, face to face,
group
Usual care 3 months
2014, the USA,
Safren140
87 l Intervention:
55.44 (8.72)
l Control: 58.31 (7.41)
T2DM; 18–70 years;
HbA1c level of
> 52mmol/mol (7.0%);
depressed, as measured
by the DSM-IV
NR CBT 9–12 CBT-AD: therapist; face to
face; individual
Enhanced usual care;
nurse/dietitian; face
to face; individual
4 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
2
6
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2014, Portugal,
Gois141
22 l Intervention:
56.82 (4.25)
l Control: 53.81 (7.04)
T2DM for > 6 months,
aged 18–65 years
l Intervention:
13.12 (4.85)
l Control:
11.63 (6.68)
Psychotherapy 12 Interpersonal
psychotherapy, psychiatry,
face to face, individual
Medical care and
sertraline
6 months
2014, China, Li97 101 l Intervention: 58.5 (5)
l Control: 59.2 (5.2)
T2DM for 1–2 years,
aged 40–70 years,
HbA1c level of ≥ 9%
l Intervention:
1.3 (0.5)
l Control: 1.2 (0.4)
Counselling 4 MI; therapist; face to face;
individual
Diabetes education;
face to face;
individual
6 months
2014, the UK,
Griffin142
478 l Intervention:
59.5 (7.5)
l Control:59.8 (7.5)
T2DM clinical diagnosis
within previous 3 years,
aged 40–69 years
NR Counselling 8 Intensive plus behavioural
intervention: lifestyle
facilitators; face to face/
telephone; individual
Enhanced usual care;
GP; face to face;
individual
12 months
2014, Australia,
Eakin143
277 l Intervention:
57.7 (8.1)
l Control: 58.3 (9.0)
T2DM, 20–75 years,
inactive, BMI of
≥ 25 kg/m2
Median (quartiles):
l Intervention: 4 (2, 7)
l Control: 5 (2, 10)
Counselling 27 Telephone counselling
(MI): trained researchers
(degree nutrition or
dietetics); telephone;
individual
Usual care 6 months
2014, the
Netherlands,
van Son104
83 l Intervention: 56 (13)
l Control: 57 (13)
T1DM or T2DM, of
emotional well-being
(WHO-5)
NR CBT 8 Mindfulness cognitive-
based therapy;
psychologist; face to face;
group
Usual care 6 months
2015, the USA,
Kim144
209 l Intervention:
59.1 (8.4)
l Control: 58.3 (8.5)
T2DM, ≥ 35 years,
HbA1c level of ≥ 7.0%
In months:
l Intervention:
105.3 (87.6)
l Control: 99.3 (84.8)
Counselling 6 Self-management
intervention, nurses and
community health
workers, face to face,
group
Diabetes education,
face to face, group
12 months
2015, the USA,
Chlebowy145
62 l Intervention:
55.8 (2.1)
l Control: 53 (2.25)
T2DM, ≥ 18 years,
African American,
prescribed oral
antihyperglycaemic
agents and/or insulin
NR Counselling 4 MI: nurses; face to face;
individual
Usual care 3 months
2015, the USA,
Pladevall146
1692 l Intervention:
64.5 (10.5)
l Control 1: 64.9 (11.5)
l Control 2: 63.3 (10.9)
T2DM, ≥ 18 years,
HbA1c level of ≥ 7%,
LDL-C ≥ 100mg/dL
NR Counselling 6 MI and adherence
information: nurses and
pharmacists; face to face/
telephone; individual
l Usual care
l Adherence
information;
clinicians; face to
face; individual
12 months
2015, Germany,
Hermanns105
60 l Intervention:
34.2 (14.9)
l Control: 43.4 (13.8)
T1DM or T2DM;
depressed, as measured
by the CES-D; 18–70 years
l Intervention:
14.2 (10.3)
l Control: 14.2 (10.7)
CBT 5 DIAMOS: psychologists,
face to face; group
Diabetes education;
diabetes educators;
face to face; group
12 months
continued
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2015, Croatia,
Pibernik-
Okanovic´147
121 l Intervention:
57.7 (6.2)
l Control: 58.2 (5.6)
T2DM for at least 1 year,
aged 18–65 years
l Intervention:
11.4 (9.1)
l Control: 10.5 (6.9)
CBT 6 Psychoeducation:
psychologist; face to face;
group
Diabetes education;
diabetologist; face to
face; group
12 months
2015, Germany,
Petrak106
53 l Intervention: 49 (10.6)
l Control: 47.9 (12.8)
T1DM or T2DM, insulin
treated, 21–69 years,
major depression DSM-IV,
HbA1c level of > 7.5%
(58mmol/mol)
l Intervention:
15.7 (10.4)
l Control: 15.0 (10.6)
CBT 10 CBT, clinical psychologists,
face to face, group
Usual care and
antidepressants
12 months
2016, Taiwan,
Huang148
61 l Intervention:
55.06 (10.44)
l Control:
57.83 (10.38)
T2DM; ≥ 20 years;
depressed, as measured
by the CES-D
Months:
l Intervention:
44.32 (21.59)
l Control:
45.7 (18.06)
CBT 12 MET+CBT:
psychotherapist/clinical
nurse; face to face; group
Usual care 90 days
2016, China,
Browning149
682 l Intervention:
63.7 (7.6)
l Control: 64 (9)
T2DM, ≥ 50 years l Intervention: 10 (6.5)
l Control: 9.6 (6.6)
Counselling 9 Health coaching: clinicians
(doctors, nurses and
psychologists; face to
face/telephone; individual
Usual care 12 months
2016, the
Netherlands,
Kasteleyn150
161 l Intervention: 66 (9.3)
l Control: 65.6 (9.4)
T2DM for > 1 year,
aged > 35 years
Mean (IQR):
l Intervention:
7 (2.8–16)
l Control: 8.5 (5–15)
Counselling 3 MI: nurses; face to face;
individual
Less intensive
psychological
intervention; nurse,
telephone; individual
5 months
2016, Taiwan,
Chiu151
174 l Intervention:
64.78 (0.3)
l Control: 64.59 (0.4)
T2DM, ≥ 50 years, minor
depressive symptoms
l Intervention: 10 (0.6)
l Control: 10.58 (0.2)
Counselling 4 Minimal psychological
intervention: psychology
assistants; telephone;
individual
Usual care 10 weeks
Studies in systematic review only (not included in meta-analysis) of T2DM
2004, the UK,
Clark152
100 All: 59.5 (NR) T2DM, 40–70 years,
BMI of > 25 kg/m2
NR Counselling 1 Self-management
intervention:
interventionist (trained
in MI); face to face;
individual
Usual care 12 months
2006, the USA,
Hokanson153
114 l Intervention: 54 (9)
l Control: 53 (9)
T2DM, smokers NR Counselling 4–7 Smoking cessation MI,
research staff, telephone,
individual
Usual care 6 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
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Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2010, the
Netherlands,
Heinrich154
537 All: 59 (5.27) T2DM for ≤ 5 years,
aged 40–70 years
26.4% were diagnosed
with diabetes ≤ 1 year
previously; 47.0% were
diagnosed 2–3 years
previously; and 26.6%
were diagnosed
4–5 years previously
Counselling 8 MI; nurses; face to face;
individual
Usual care 12 months
2010, Iran,
Pourisharif155
41 NR T2DM, 30–75 years,
diagnosed in the
preceding 12 months
NR Counselling 4 1. CBT; face to face;
group
2. MI; face to face; group
Usual care 9 weeks
2011, Italy,
Castelnuovo156
34 l Intervention:
59.19 (10.24)
l Control:
58.67 (10.23)
T2DM l Intervention:
7.98 (7.57)
l Control: 7.91 (6.95)
CBT Variable TECNOB: clinical
psychologist; face to face/
telephone/online and text
messaging; individual/
group
Usual care 12 months
2012, the USA,
Waker157
154 l Intervention:
60.35 (NR)
l Control: 58.67 (NR)
T2DM, HbA1c level of
≥ 6.5%
l Intervention:
13.1 (NR)
l Control: 13.28 (NR)
Counselling 2 MI: researcher; face to face;
individual
Usual care 3 months
2013, the USA,
Gabbay158
545 l Intervention: 58 (11)
l Control: 58 (11)
T2DM, HbA1c level of
> 8.5%
NR Counselling 8 MI: nurses; face to face;
individual
Usual care 12 months
Jiang 2014159 52 Cannot access paper for
this information
T2DM Cannot access paper
for this information
Psychotherapy Cannot
access paper
for this
information
Psychotherapy, face to
face, group
Usual care plus
paroxetine
6 months
2015, the USA,
Inouye160
207 l Intervention: 57 (11.1)
l Control: 57.8 (10.8)
T2DM, 18–76 years,
received diabetes
education
NR CBT 6 CBT: research assistants;
face to face; group
Diabetes education;
research assistants;
face to face; group
12 months
2016, the USA,
Fitzpatrick161
182 l Intervention 1:
58.72 (11.21)
l Intervention
2:54.82 (9.31)
l Control 1:
54.51 (10.34)
l Control 2:
60.57 (10.27)
T2DM, ≥ 25 years,
black/African American
NR Counselling 9 1. DECIDE group,
graduate assistant, face
to face, group
2. DECIDE individual,
graduate assistant, face
to face, individual
1. Enhanced usual
care (usual
care+ education
materials), face to
face/mail,
individual
2. DECIDE self-study;
mail; individual
20 weeks
continued
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
Studies included in meta-analysis of adults with T1DM
2009, Sweden,
Amsberg162
74 l Intervention:
41.1 (11.7)
l Control: 41.4 (12.9)
T1DM for ≥ 2 years,
aged 18–65 years,
BMI of < 30 kg/m2,
HbA1c level of > 7.5%
l Intervention:
19.9 (9.4)
l Control: 23.2 (11.8)
CBT 8 CBT-based intervention;
diabetes specialist nurse
and psychologist; face to
face; group
Waiting list 48 weeks
2008, the UK,
Ismail163
344 l Intervention 1:
37.2 (9.9)
l Intervention 2:
35.6 (9.6)
l Control: 36.4 (11.3)
T1DM for ≥ 2 years, two
records of HbA1c levels of
between 8.2% and 15%
(within 12 months), aged
18–65 years
l Intervention 1:
18.7 (9.2)
l Intervention 2:
17.3 (9.6)
l Control: 19.5 (10.4)
CBT 1. 12
2. 4
1. MET+CBT; nurse; face
to face; individual
2. MET; nurse; face to
face; individual
Usual care 12 months
2008, the
Netherlands,
Snoek164
86 All: 37.8 (10.6) T1DM for ≥ 1 year,
HbA1c level of ≥ 8.0% on
two occasions, multiple
daily insulin injections
(≥ 2) or continuous
subcutaneous insulin
infusion
All: 18 (10.4) CBT 6 Cognitive–behavioural
group training;
psychologist; face to face;
group
BGAT; psychologist;
face to face; group
12 months
2015, Germany,
Hermanns105
114 l Intervention:
34.2 (14.9)
l Control: 43.4 (13.8)
T1DM and T2DM;
depressed, as measured
by the CES-D; 18–70 years
l Intervention:
14.2 (10.3)
l Control: 14.2 (10.7)
CBT 5 DIAMOS: psychologists,
face to face; group
Diabetes education;
diabetes educators;
face to face; group
12 months
2015, Denmark,
Zoffmann165
200 l Intervention: 25.9 (5)
l Control: 25.3 (5.2)
T1DM for ≥ 1 year, aged
18–35 years, HbA1c level
of ≥ 64mmol/mol
l Intervention:
13.8 (6.9)
l Control: 13.7 (6.8)
Counselling 14 Flexible GSD; nurses; face
to face; group
Waiting list 12 months
2014, the
Netherlands,
Van Son104
83 l Intervention: 56 (13)
l Control: 57 (13)
T1DM and T2DM, low
level of emotional
well-being (WHO-5)
NR CBT 8 Mindfulness cognitive-
based therapy;
psychologist; face to face;
group
Usual care 6 months
2015, Germany,
Petrak106
53 l Intervention: 49 (10.6)
l Control: 47.9 (12.8)
T1DM and T2DM, insulin
treated, 21–69 years,
major depression DSM-IV,
HbA1c level of 7.5%
(58mmol/mol)
l Intervention:
15.7 (10.4)
l Control: 15.0 (10.6)
CBT 10 CBT, clinical psychologists,
face to face, group
Usual care and
antidepressants
12 months
Studies in systematic review only (not included in meta-analysis) of adults with T1DM
2006, Denmark,
Zoffmann166
50 l Intervention:
36.8 (1.7)
l Control: 35.7 (2.1)
T1DM, 18–49 years,
HbA1C level of ≥ 8.0%
NR Counselling 8 GSD; nurses; face to face;
group
Waiting list 12 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
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0
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
Studies included in meta-analysis of adolescents/children with T1DM
2005, Norway,
Graue167
83 l Intervention:
14.5 (1.6)
l Control: 14.3 (1.6)
T1DM, 11–17 years l Intervention:
6.7 (3.3)
l Control: 6.9 (4.3)
Counselling 3 Structured educational
and counselling
programme, physician/
diabetes specialist nurse/
clinical psychologist/
dietitian/social worker,
face to face, group
Usual care 15 months
2007, the UK,
Channon168
66 l Intervention:
15.3 (0.97)
l Control: 15.4 (1.19)
T1DM for ≥ 1 year;
aged 14–17 years
l Intervention:
9.2 (1.96)
l Control: 9.1 (1.47)
Counselling 4 MI; nurse; face to face;
individual
Non-directive
psychological
support; nurse; face
to face; individual
12 months
2007, the USA,
Ellis169
127 l Intervention:
13.4 (1.9)
l Control: 13.1 (2)
T1DM for ≥ 1 year;
HbA1c level of ≥ 8%,
10–17 years
l Intervention:
5.3 (3.9)
l Control: 5.2 (4.8)
Family therapy NR MST; therapist; face to
face; family
Usual care 6 months
2007, the USA,
Nansel170
81 l Intervention:
13.6 (1.9)
l Control: 13.9 (1.6)
T1DM for ≥ 1 year;
aged 11–16 years
l Intervention:
7.5 (3.4)
l Control: 7.8 (4)
Counselling 6 Diabetes personal trainer
intervention; trained non-
professional (MI training);
face to face/telephone;
family/individual
Diabetes education;
educational booklet;
family
12 months
2009, the USA,
Grey171
82 l Intervention:
9.91 (1.48)
l Control: 9.91 (1.4)
T1DM for ≥ 6 months;
8–12 years; treated with
insulin
l Intervention:
3.66 (2.75)
l Control: 3.8 (3.2)
CBT 6 CST; mental health
professional; face to face;
group
Diabetes education;
nurse; face to face;
group
12 months
2010, the USA,
Wang172
44 l Intervention:
15.3 (1.4)
l Control: 15.6 (1.7)
T1DM for > 1 year; aged
12–18 years; HbA1c level
of ≥ 9%
l Intervention:
6.7 (3.4)
l Control: 7.6 (4.7)
Counselling 2 MI; diabetes educators;
face to face; group
Diabetes education;
diabetes educator;
face to face; group
9 months
2010, the USA,
Lehmkuhl173
32 l Intervention:
13.72 (2.67)
l Control: 13.43 (2.17)
T1DM for ≥ 6 months;
HbA1c level of > 9%
NR Family therapy 36 Telehealth behaviour
therapy; clinical
psychologists or clinical
psychology interns;
telephone; family
Waiting list control 12 weeks
2012, the UK,
Robling174
689 l Intervention:
10.4 (2.8)
l Control: 10.7 (2.8)
T1DM for ≥ 12 months,
aged 4–15 years
l Intervention:
5.2 (2.8)
l Control: 5.0 (2.7)
Counselling Variable DEPICTED, health-care
professionals, face to face,
individual
Usual care 12 months
2012, Germany,
Sassmann175
33 l Intervention: 6.4 (2.3)
l Control: 5.8 (1.9)
T1DM, aged 2–10 years l Intervention:
2.6 (1.6)
l Control: 2.6 (1.9)
CBT 5 DELFIN, psychologist,
face to face, group
Waiting list 3 months
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
4
2
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
2
0
V
O
L
.
2
4
N
O
.
2
8
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2020.
This
w
ork
w
as
produced
by
W
inkley
e
t
a
l.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
3
1
TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2012, the USA,
Nansel176
390 l Intervention:
12.5 (1.8)
l Control: 12.4 (1.7)
T1DM for ≥ 3 months,
with at least two or more
daily injections or use of
an insulin pump; aged
9–14.9 years; HbA1c level
of > 6%
l Intervention:
4.8 (3.3)
l Control: 4.9 (3.2)
Family therapy 9 Family behavioural
intervention; health
advisors; face to face/
telephone; family
Usual care 12 months
2013, Iran,
Najmi177
85 l Intervention 1:
15.1 (1.9)
l Intervention 2:
15.3 (1.8)
l Intervention 3:
14.1 (1.8)
l Control: 15.2 (1.7)
T1DM for > 1 year; aged
12–18 years
NR CBT 8 1. CBT+CST; psychiatrist;
face to face; family
2. CBT; psychiatrist; face
to face; family
3. CST; psychiatrist; face
to face; family
Usual care 3 months
2014, Denmark,
Husted178
71 l Intervention:
14.9 (1.5)
l Control: 14.6 (1.3)
T1DM for > 1 year, aged
13–18 years,
l Intervention:
6.1 (3.0)
l Control: 5.3 (3.4)
Counselling 8 GSD, physicians/diabetes
nurses/dietitian, face to
face, individual
Usual care 12 months
2014, the USA,
Jaser179
40 l Intervention:
15.3 (1.4)
l Control: 15 (1.6)
T1DM for ≥ 6 months;
aged 13–17 years
l Intervention:
7.3 (4.3)
l Control: 6.5 (3.5)
Counselling 4 Positive affect; trained
research assistant;
telephone; family
Diabetes education;
education materials;
mail; individual
6 months
2014, the USA,
Katz180
153 l Intervention 1:
12.7 (2.2)
l Intervention 2:
12.5 (2.3)
l Control: 13.4 (2.4)
T1DM for ≥ 6 months;
aged 8–16 years
l Intervention 1:
6.5 (3.8)
l Intervention 2:
6.8 (3.2)
l Control: 5.7 (3.5)
Family therapy Variable 1. Care ambassador ultra;
research assistant; face
to face; family
2. Care ambassador;
research assistant;
telephone or
e-mail; family
Usual care 12 months
2014, the UK,
Christie181
315 l Intervention:
13.1 (2.1)
l Control: 13.2 (2.1)
T1DM for ≥ 12 months;
aged 8–16 years; mean
12-month HbA1c value of
≥ 8.5%
l Intervention:
5.7 (3.2)
l Control: 6.1 (3.3)
Counselling 4 CASCADE
(psychoeducation);
paediatric diabetes
specialist nurse and
another health-care
professional; face to face;
group
Usual care 12 months
2015, the USA,
Harris182
90 l Intervention:
15.04 (1.79)
l Control: 14.94 (1.77)
T1DM for ≥ 1 year; aged
12–19 years; HbA1c level
of ≥ 9.0%
l Intervention:
6.51 (3.24)
l Control: 6.56 (3.77)
Family therapy 10 BFST-D via clinic;
therapist; face to face;
family
BFST-D via Skype™
(Microsoft
Corporation,
Redmond, WA,
USA); therapist;
Skype; family
3 months
R
E
S
U
L
T
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
3
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Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2015, the USA,
Nansel183
136 l Intervention:
12.6 (2.7)
l Control: 13 (2.5)
T1DM for ≥ 1 year;
aged 8–16.9 years;
most recent HbA1c level
of between 6.5% and
10.0%
l Intervention:
5.6 (2.5)
l Control: 6.3 (3.6)
Family therapy 6 Family intervention;
research assistant;
face to face; family
Care ambassador;
research assistant;
face to face; family
18 months
2016, Australia,
Serlachius184
147 l Intervention:
14.36 (1.07)
l Control: 14.31 (1.12)
T1DM; aged 13–16 years l Intervention:
5.63 (3.33)
l Control: 6.12 (3.8)
CBT 5 The BOC; health
psychologist; face to face;
group
Usual care 12 months
Studies in systematic review only (not included in meta-analysis) of adolescents/children with T1DM
2014, the USA,
Holmes185
40 l Intervention:
12.95 (1.24)
l Control: 12.73 (1.23)
T1DM for > 1 year;
aged 11–14 years
l Intervention:
4.93 (2.95)
l Control: 5.15 (3.16)
Family therapy 4 CST; interventionist;
face to face; family
Diabetes education;
BA-level facilitators;
face to face; family
3 months
2008, the USA,
Wysocki186
104 l Intervention:
13.9 (1.9)
l Control 1: 14.4 (1.9)
l Control 2: 14.2 (1.9)
T1DM or insulin-treated
T2DM for ≥ 2 years;
aged 11–16 years;
HbA1c level of ≥ 8%
l Intervention: 5.1 (3)
l Control 1: 5.5 (3.2)
l Control 2: 5.9 (4)
Family therapy 12 BFST-D; therapist; face to
face; family
1. Usual care
2. Educational
support; face to
face; family
12 months
Studies of people with T1DM and T2DM (included in systematic review only, as separate analysis T2DM not available)
2004, the USA,
Katon187
329 l Intervention:
58.6 (11.8)
l Control: 58.1 (12)
T2DM or T1DM l Intervention:
9.6 (8.8)
l Control: 10.2 (10.1)
Collaborative
care (including
psychotherapy)
Variable Pathways study, nurses/
psychiatrists/primary care
physician, face to face/
telephone, individual
Usual care 12 months
2004, Norway,
Karlsen188
63 l Intervention:
49.2 (24.7)
l Control: 48.6 (10.3)
T1DM or T2DM NR CBT 9 Group-based counselling;
nurse; face to face; group
Waiting list 6 months
2006, the USA,
Wysocki189
104 l Intervention:
13.9 (1.9)
l Control 1: 14.2 (1.9)
l Control 2: 14.4 (1.9)
T1DM or T2DM for
≥ 2 years; aged
11–16 years; HbA1c
level of ≥ 8%
l Intervention:
5.1 (3.0)
l Control 1: 5.9 (4.0)
l Control 2: 5.5 (3.2)
Family 12 Behavioural family systems
therapy; psychologists;
face to face; family
1. Usual care
2. Educational
support; nurses;
face to
face; family
6 months
2010, Germany,
Heisler190
244 l Intervention:
62.3 (6.6)
l Control: 61.8 (6.1)
T2DM or T1DM NR Counselling Variable Nurse case management,
nurses, face to face and
telephone, individual
Reciprocal peer
support, care
manager, face to
face, group
6 months
2011, Denmark,
Rosenbek Minet191
349 l Intervention:
57.1 (12.6)
l Control: 55.8 (11.6)
T1DM or T2DM,
aged > 18 years
l Intervention:
4.7 (6.9)
l Control: 4.7 (6.5)
Counselling 5 MI; health-care
professionals (nurse,
dietitian, physiotherapist
or psychologist); face to
face; individual
Usual care 12 months
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TABLE 1 Summary of characteristics for RCTs in the systematic review and meta-analysis for all studies (continued )
Year, country,
first author
Total number
of participants
Mean age (SD or
range) (years)
Clinical subgroup
(inclusion criteria for
individual studies)
Mean (SD or
range) duration of
diabetes, years in
intervention/control
Type of
psychological
intervention
Number of
sessions in
intervention
Intervention description
(intervention name,
facilitator, format,
individual/group)
Control description
(control category,
facilitator, format,
individual/group)
Follow-up,
up to 12 months
2011, the USA,
Weinger192
222 Median (range)
l Intervention:
51.8 (23.7–74.2)
l Control 1:
54.7 (25–75.1)
l Control 2:
56.2 (21.6–74.8)
T1DM or T2DM for
≥ 2 years, aged
18–70 years, HbA1c
levels of > 7.5%
Median (range)
l Intervention:
14.9 (1.3–66.1)
l Control 1:
15 (2.6–48.5)
l Control 2:
16.8 (2.2–45.7)
CBT 5 Structured behavioural
group; diabetes
educators; face to face,
group
1. Group attention
control; diabetes
educators; face to
face, group
2. Individual control;
diabetes educators;
face to face;
individual
12 months
2012, Australia,
Williams108
80 l Intervention: 68 (8.3)
l Control: 66 (10.8)
T2DM or T1DM NR Counselling Variable Self-management
intervention, nurse, face
to face and telephone,
individual
Usual care 9 months
2012, the USA,
Fischer193
762 l Intervention:
58.5 (12.4)
l Control: 58.3 (12.1)
T2DM or T1DM,
aged > 17 years
NR Counselling Variable Telephone-based
outreach, nurses,
telephone, individual
Usual care 18 months
2012, the USA,
Ellis194
146 l Intervention:
14.2 (2.2)
l Control: 14.1 (2.4)
T1DM or T2DM for
≥ 1 year; aged
10–18 years; HbA1c
level of ≥ 8%
l Intervention:
4.7 (3.2)
l Control: 4.6 (2.9)
Family Variable MST; therapist; face to
face; family
Telephone support;
therapist; telephone;
individual
12 months
2014, the USA,
Lin195
NR l Intervention:
57.4 (10.5)
l Control: 56.3 (12.1)
T1DM or T2DM,
depression (score of
> 10 points on the PHQ-9)
NR Collaborative
care (including
psychotherapy)
Variable Collaborative care;
primary care physician
and nurse and psychiatrist
and psychologist; face to
face; individual
Usual care 12 months
2015, the USA,
Safford196
NR l Intervention:
59.2 (11.8)
l Control: 61.1 (12.4)
T1DM or T2DM NR Counselling Variable MI; peers, telephone;
individual
Diabetes education;
face to face;
individual
12 months
2015, the
Netherlands,
Schroevers197
24 l Intervention:
54.9 (10.3)
l Control: 55.9 (8.2)
T1DM or T2DM,
18–70 years
l Intervention:
16.6 (14.4)
l Control: 20.5 (13.7)
CBT 8 Mindfulness-based
cognitive therapy; clinical
psychologist; face to face;
individual
Waiting list 8 weeks
ACT, acceptance and commitment therapy; BA, Bachelor of Arts; BFST-D, Behavioural Family Systems Therapy for Diabetes; BGAT, blood glucose awareness training; BOC, Best of Coping; CASCADE, Child and Adolescent
Structured Competencies Approach to Diabetes Education; CBT-AD, cognitive–behavioural therapy for adherence and depression; CST, coping skills training; DECIDE, Decision-making Education for Choices In Diabetes Everyday;
DELFIN, Das Elterntraining für Eltern von Kindern mit Diabetes Typ 1 (The parenting programme for parents of children with diabetes type 1); DEPICTED, Development and Evaluation of a Psychosocial Intervention in Children and
Teenagers Experiencing Diabetes; DIAMOS, Diabetes Motivational Strengthening; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSMT, diabetes self-management training; GP, general practitioner;
GSD, guided self-determination; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; MET, motivational enhancement therapy; MST, multisystemic therapy; NR, not reported; PE, physical education; TECNOB,
TEChnology for Obesity; WHO-5, the World Health Organization – Five Well-Being Index.
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Secondary outcomes
There were insufficient data (i.e. fewer than five studies) to conduct meta-analyses on secondary outcomes for
changes in psychological functioning (n = 4 studies) or change in self-management behaviour (n = 2 studies).
Results of individual studies of adults with type 1 diabetes mellitus
All studies included in the systematic review are listed in Table 1.
Synthesis of results
Primary outcome: glycated haemoglobin level
Seven adult T1DM studies104–106,162–165 (total participants, n = 851) had HbA1c level data available to
conduct a meta-analysis. A random-effects meta-analysis demonstrated a pooled mean difference of
–0.13 [95% confidence interval (CI) –0.33 to 0.07], a non-significant decrease in HbA1c level in favour of
psychological intervention (Figure 3). This was a small effect size and equates to –0.18 change in % of HbA1c
level (a reduction of ≈2 mmol/mol). There was low heterogeneity (I2 = 43.8%; p = 0.099). Egger’s test
demonstrated little evidence of publication bias (p = 0.889) (see Appendix 9, Figure 30). The trim-and-fill
method for correcting publication bias found no missing studies.
When the main outlier, Hermanns et al.,105 was removed from the meta-analysis, there was a statistically
significant (but not a clinically significant) decrease in HbA1c level in favour of psychological intervention
(SMD –0.20, 95% CI –0.37 to –0.02, equivalent to a –0.25 change in % HbA1c level or a reduction of
≈3 mmol/mol). There was little influence when any other single study was removed. Hermanns et al.’s48
study is one of two studies that compared an intervention with an attention control group (diabetes
education); the other, Snoek et al.,164 used BGAT. When both studies were removed, there was a
statistically significant (but not clinically significant) decrease in HbA1c level in favour of the psychological
intervention groups (SMD –0.25, 95% CI –0.41 to –0.09, equivalent to a –0.31 change in % HbA1c level,
or a reduction of ≈3–4 mmol/mol).
In a meta-regression, there was no statistically significant difference between different group of psychological
interventions (CBT vs. counselling, p = 0.985) and HbA1c level, or between type of interventionists delivering
Overall (I 2 = 43.8%; p = 0.099)
van Son et al.104
Petrak et al.106
Hermanns et al.105
Snoek et al.164
Amsberg et al.162
Zoffmann et al.165
Ismail et al.163
Study
– 0.13 (– 0.33 to 0.07)
– 0.29 (– 0.86 to 0.27)
– 0.08 (– 0.58 to 0.42)
0.23 (– 0.14 to 0.60)
SMD (95% CI)
0.17 (– 0.26 to 0.59)
– 0.58 (– 1.04 to – 0.11)
– 0.14 (– 0.43 to 0.16)
– 0.28 (– 0.53 to – 0.02)
100.00
8.83
10.47
15.33
Weight (%)
13.08
11.61
19.16
21.52
– 1.25
Favours psychological intervention Favours control
– 1.00 – 0.75 – 0.50 – 0.25 0.00 0.25 0.50 0.75 1.00
FIGURE 3 A meta-analysis of SMD in HbA1c level in the psychological intervention group compared with the control
group for adults with T1DM.
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the psychological intervention (nurses vs. psychologists, p = 0.074) and HbA1c level. There was no association
between the number of therapy sessions (p = 2.98), therapy session duration (p = 0.894) or duration of
therapy (p = 0.643) and HbA1c level. There was a statistically significant difference between the type of
control group (p = 0.04) and HbA1c level, with a larger treatment effect (coefficient of 0.45) for the attention
control group than the usual care group.
Combining the results with those of the previous review of studies of adults with
type 1 diabetes mellitus
For adults with T1DM, data from this review (n = 7 trials) and our previous review57 (n = 11 trials with a
total of 516 participants) were combined (Figure 4). For these 18 trials (a total of 1367 participants), a
random-effects meta-analysis demonstrated a non-statistically significant decrease in HbA1c level in favour
of psychological intervention versus control (SMD –0.12, 95% CI –0.29 to 0.04). Both the current review
(SMD –0.13, 95% CI –0.33 to 0.07) and the previous review (SMD –0.17, 95% CI –0.45 to 0.10) reported
a non-statistically significant decrease in HbA1c levels; a meta-regression demonstrated a non-statistically
significant difference in HbA1c change between both reviews (p = 0.927).
Risk of bias within studies
Overall, the RoB for the studies of adults with T1DM was rated as ‘unclear’ to ‘low’. All domains of RoB
were also rated as ‘unclear’ to ‘low’. Of the studies included in the meta-analysis, four104,106,163,164 were
rated as being at a ‘low’ RoB and three105,162,165 were rated as being at an ‘unclear’ RoB (see Appendix 9,
Figure 29). There were not enough studies to perform a subgroup analysis of HbA1c level by RoB rating.
Risk of bias across studies
For ‘selective reporting’ and ‘other bias’ domains, 100% of bias was rated as being at a ‘low’ RoB across
studies (Figure 5). For studies rated as having an ‘unclear’ RoB, this was usually in the ‘random sequence
generation’ and ‘blinding of participants and personnel’ domains.
Overall (I 2 = 42.9%; p = 0.035)
Halford et al.202
Snoek et al.164
van Son et al.104
Didjurgeit et al.203
Amsberg et al.162
Manning et al.199
Ismail et al.163
Zoffmann et al.165
van der Ven et al.206
Spiess et al.200
Petrak et al.106
Stenström et al.205
Feinglos et al.198
Weinger et al.204
Hermanns et al.105
Fosbury et al.201
– 0.12 (– 0.29 to 0.04)
0.57 (– 0.15 to 1.29)
0.17 (– 0.26 to 0.59)
– 0.29 (– 0.86 to 0.27)
– 0.38 (– 0.97 to 0.22)
– 0.58 (– 1.04 to – 0.11)
– 0.49 (– 1.41 to 0.42)
– 0.28 (– 0.53 to – 0.02)
– 0.14 (– 0.43 to 0.16)
– 0.48 (– 0.91 to – 0.06)
0.41 (– 0.43 to 1.24)
– 0.08 (– 0.58 to 0.42)
– 0.14 (– 0.85 to 0.57)
0.93 ( 0.00 to 1.85)
– 0.11 (– 0.57 to 0.34)
0.23 (– 0.14 to 0.60)
– 0.64 (– 1.46 to 0.17)
100.00
4.05
7.96
5.68
5.29
7.20
2.76
11.82
10.82
7.95
3.22
6.59
4.15
2.71
7.35
9.07
3.37
0.0– 1.5
Favours psychological intervention Favours control
– 0.5 0.51.0 2.0 3.0 4.0 5.0 6.0
Study SMD (95% CI) Weight (%)
FIGURE 4 A meta-analysis of SMD in HbA1c level in psychological intervention groups compared with control
groups for adults with T1DM, combined studies from current and previous review.
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Characteristics of studies on adolescents/children with type 1
diabetes mellitus
A total of 22 studies involving adolescents/children with T1DM were included in the qualitative synthesis;
two of these studies had a mixed T1DM and T2DM adolescent/child population. A summary of study
characteristics for each study is reported in Table 1.
Study location
Most studies of adolescents/children with T1DM were conducted in the USA (n = 14);169–173,176,179,180,182,183,185,
186,189,194 the remaining studies were conducted in the UK (n = 3, including re-screening),168,174,181 Europe
(non-UK, n = 3),167,175,178 Asia (n = 1)177 and Australia (n = 1).184
Participant characteristics
The total sample size for all studies of adolescents/children with T1DM was 2876 participants (n = 22
studies; two studies included a T1DM and T2DM population and did not report the sample size per
diabetes type). Sample sizes ranged from 32 to 390 participants.
Intervention characteristics
Psychological interventions were categorised into three types: CBT (n = 4),171,175,177,184 counselling (n = 10)167,168,
170,172–174,178,179,181,185 and family therapy (n = 8).169,176,180,182,183,186,189,194 The interventions were delivered by
diabetes specialists [N = 5; made up of diabetes nurses (n = 4)167,168,178,181 and diabetes educators (n = 1)172],
psychology professionals [N = 10; made up of clinical psychologists (n = 4),173,175,186,189 therapists (n = 3),169,182,194
mental health professionals (n = 1),171 psychiatrists (n = 1)177 and health psychologists (n = 1)184] and other
[N = 7; made up of a health advisor (n = 1),176 a health-care professional (n = 1),174 a trained non-professional
(n = 1)170 and research assistants (n = 4)179,180,183,185].
Most psychological interventions were delivered face to face (n = 18);167–169,171,172,174,175,177,178,180–186,189,194
the others were delivered via telephone (n = 2)173,179 or via a combination of face to face and telephone
(n = 2).170,176 Therapy sessions were administered to individuals (n = 3),168,174,178 groups (n = 6),167,171,172,175,181,184
families (n = 12)169,173,176,177,179,180,182,183,185,186,189,194 or families and individuals (n = 1).170 The number of therapy
sessions ranged from 2 to 36. The duration of therapy sessions ranged from 5 minutes to 2 hours. The total
duration of therapy ranged from 5 weeks to 2 years.
Control characteristics
The control groups were categorised as follows: usual care (n = 13),167,169,173–178,180,181,184,186,189 attention control
[N = 7, made up of diabetes education (n = 5),170–172,179,185,194 care ambassador case management (n = 1)183 and
telephone support (n = 1)194] and less intensive psychological intervention [n = 2; made up of Behavioral Family
Systems Therapy for Diabetes (BFST-D) via Skype (n = 1)182 and non-directive psychological support (n = 1)168].
0 25 50
%
75 100
Other bias
Selective reporting
(reporting bias)
Incomplete outcome data
(attrition bias)
Blinding of participants and personnel
(performance bias)
Allocation concealment
(selection bias)
Random sequence generation
(selection bias)
Low risk of bias
Unclear risk of bias
High risk of bias
FIGURE 5 Risk of bias across studies of adults with T1DM.
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Primary outcome
The primary outcome was HbA1c level. The mean difference was calculated from baseline to 12-month
follow-up (or closest measurement to 12 months) for the intervention and control groups. The follow-up
period for HbA1c level ranged from 3 months to 18 months.
Secondary outcomes
There were insufficient data (i.e. secondary outcomes in five or more studies) to conduct a meta-analysis on
secondary outcomes for changes in psychological functioning (n = 4) or in self-management behaviour (n = 2).
Results of individual studies of adolescents/children with type 1
diabetes mellitus
All studies included in the systematic review are listed in Table 1.
Synthesis of results
Eighteen studies (with a total of 2583 participants) were identified that had enough data to include in a
meta-analysis. A random-effects meta-analysis demonstrated a pooled mean difference of 0.00 (95% CI
–0.18 to 0.18) (Figure 6), equating to no change in HbA1c level (% or mmol/mol). Study heterogeneity was
high (I2 = 77.3%; p < 0.001), and may reflect the variation in the categories of interventions tested. There
was little influence on the removal of any individual study. There was little evidence of publication bias
according to Egger’s test (p = 0.45). No studies were estimated as missing according to the trim-and-fill
method for correcting publication bias.
Overall (I 2 = 77.3%; p = 0.001)
Ellis et al.169
Nansel et al.176
Robling et al.174
Nansel et al.170
Wang et al.172
Christie et al.181
Channon et al.168
Harris et al.182
Husted et al.178
Nansel et al.183
Katz et al.180
Serlachius et al.184
Najmi et al.177
Lehmkuhl et al.173
Grey et al.171
Sassmann et al.175
Jaser et al.179
Graue et al.167
0.00 (– 0.18 to 0.18)
– 0.12 (– 0.47 to 0.23)
– 0.05 (– 0.25 to 0.15)
0.00 (– 0.15 to 0.15)
– 0.23 (– 0.67 to 0.21)
4.56 (3.42 to 5.70)
0.13 (– 0.09 to 0.35)
– 0.42 (– 0.92 to 0.07)
– 0.13 (– 0.54 to 0.28)
– 0.09 (– 0.55 to 0.38)
– 0.02 (– 0.35 to 0.32)
0.07 (– 0.32 to 0.46)
– 0.20 (– 0.53 to 0.12)
– 0.06 (– 0.59 to 0.46)
– 0.33 (– 1.03 to 0.37)
0.18 (– 0.28 to 0.63)
– 0.49 (– 1.18 to 0.21)
0.23 (– 0.39 to 0.85)
– 0.29 (– 0.73 to 0.14)
100.00
6.37
7.55
7.85
5.63
1.96
7.39
5.17
5.82
5.39
6.47
6.02
6.58
4.92
3.72
5.49
3.77
4.23
5.65
– 1.5
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Study SMD (95% CI) Weight (%)
FIGURE 6 A meta-analysis of the SMD in HbA1c level in the psychological intervention group compared with the
control group for adolescents/children with T1DM.
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Subgroup analysis of glycated haemoglobin levels by psychological
intervention category
A subgroup analysis was conducted for the psychological intervention categories of counselling (n = 8)167,168,
170,172,174,178,179,181 and family therapy (n = 6)169,173,176,180,182,183 [there were too few CBT studies (n = 4) to include
in the analysis]. There was no statistically significant difference in HbA1c level for counselling studies (SMD
0.23, 95% CI –0.17 to 0.63) or family therapy studies (SMD –0.06, 95% CI –0.19 to 0.07); see Appendix 10,
Figure 33. Study heterogeneity was high and statistically significant for counselling studies (I2 = 89.8%;
p < 0.001), but low for family therapy studies (I2 = 0%; p = 9.4). There was no evidence of publication bias
(p = 0.39) for counselling studies or family therapy studies (p = 0.40), and no studies were estimated as
missing according to the trim-and-fill method.
Subgroup analysis of glycated haemoglobin levels by interventionist category
A subgroup analysis by interventionist revealed no statistically significant difference in HbA1c levels for
psychological interventions delivered by psychology professionals (SMD –0.13, 95% CI –0.3 to 0.06),
diabetes specialists (SMD 0.57, 95% CI –0.24 to 1.38) or ‘other’ interventionists (SMD –0.02, 95% CI
–0.12 to –0.03). There was no statistically significant difference (p = 0.47) between interventionist groups;
see Appendix 10, Figure 34. Study heterogeneity was high for diabetes specialists (I2 = 94%; p < 0.001),
but low for psychology professionals (I2 = 0%; p = 0.76) and ‘other’ interventionists (I2 = 0%; p = 0.86).
There was no evidence of publication bias for interventions delivered by psychology professionals (p = 0.55)
or diabetes specialists (p = 0.41), and no studies were estimated as missing according to the trim-and-fill
method. There was little evidence of publication bias according to Egger’s test (p = 0.84) for interventions
delivered by ‘other’ interventionists; however, one study was estimated to be missing according to the
trim-and-fill method.
Meta-regression
There was no association between the number of therapy sessions (p = 0.44), therapy session duration
(p = 0.60) or duration of overall therapy (p = 0.92) and HbA1c levels. There was no statistically significant
difference between types of control groups (p = 0.13) and HbA1c levels.
Combining the results with the previous review of studies on adolescents/children
with type 1 diabetes mellitus
For adolescents/children with T1DM, data from this review (n = 18) and the previous review were
combined57 (n = 8 studies with a total of 543 participants) (Figure 7). For the combined 26 trials (with a
total of 3126 participants), a random-effects meta-analysis demonstrated a non-statistically significant
decrease in HbA1c levels for psychological intervention groups versus control groups (SMD –0.07, 95% CI
–0.25 to 0.10). The current review reported no change in HbA1c levels (SMD 0.00, 95% CI –0.18 to 0.18),
whereas the previous review reported a statistically significant decrease in HbA1c levels (SMD –0.35,
95% CI –0.66 to –0.48; change in % HbA1c level: a reduction of ≈5 mmol/mol). The difference in the
change in HbA1c levels between reviews was non-statistically significant (p = 0.38).
Risk of bias in studies
Overall, the risk of bias in studies of adolescents/children with T1DM was rated as being unclear to low
(see Appendix 10, Figure 32). For studies included in the meta-analysis, 10 studies167–170,173,174,178,181,183,184
were rated as having a ‘low’ risk of bias and eight studies171,172,175–177,179,180,182 were rated having an
‘unclear’ risk of bias. In a subgroup analysis of HbA1c levels by risk of bias (see Appendix 10, Figure 31),
HbA1c levels reduced non-statistically significantly in studies rated as having a ‘low’ risk of bias (SMD –0.05,
95% CI –0.15 to 0.04) and increased non-statistically significantly for studies rated as having an ‘unclear’
risk of bias (SMD 0.35, 95% CI –0.14 to 0.83), although the difference between these risk-of-bias
categories was not statistically significant (p = 0.245).
Risk of bias across studies
The risk of bias for the ‘other’ bias domains was rated as being 100% low across studies (Figure 8). Risk of
bias was rated as being most unclear for the ‘blinding of participants and personnel’ domain.
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Characteristics of the studies of adults with type 2 diabetes mellitus
For the T2DM qualitative synthesis, 71 T2DM studies were included; 13 of these had a mixed T1DM and
T2DM population. A summary of the study characteristics for each study is reported in Table 1.
Overall (I 2 = 77.7%; p = 0.000)
Nansel et al.170
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Husted et al.178
Wysocki et al. 212
Wysocki et al. 213
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FIGURE 7 A meta-analysis of the SMD in HbA1c levels in psychological intervention groups compared with control
groups in studies of adolescents/children with T1DM, combining the current and previous reviews.
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FIGURE 8 Risk of bias across studies of adolescents/children with T1DM.
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Study location
These studies were published in Europe [Belgium (n = 2),119,124 Ireland (n = 1),123 the Netherlands (n = 7),104,
127,135,137,150,154,197 Germany (n = 5),105,106,109,132,190 Croatia (n = 1),147 Italy (n = 1),156 Norway (n = 1),188 Denmark
(n = 2),138,191 Portugal (n = 1)141 and the UK (n = 5)113,130,139,142,152], North America (n = 31),107,111,112,115,117,118,120,
121,126,128,129,131,134,136,140,144–146,153,157,158,160,161,187,189,192–196,214 Asia (n = 10),59,110,114,125,133,148,149,151,155,159 Australia
(n = 3)108,116,143 and Chile (n = 1).122
Participant characteristics
The total number of adults with T2DM included in the qualitative synthesis was 14,326 (n = 71 studies;
two studies195,196 did not report number of participants per diabetes type). The sample size per study
ranged from 13 to 3946 participants. Two studies189,194 included adolescent populations with T2DM.
Fifteen studies included a mixed T1DM and T2DM population. In three of these studies,104–106 a separate
analysis per diabetes type was provided, so T2DM data were included in the meta-analysis. For eight
studies,12,188,189,191,192,194,195,197 a separate analysis per diabetes type was not available; these studies were
included in the qualitative synthesis only.
Studies stipulated various inclusion criteria to study subgroups of people with T2DM. For example, some
studies included people with T2DM with suboptimal glycaemic control, which was defined as HbA1c levels of
> 6.5%,115,157 > 7%,135,140,146 > 7.5%,106,128,192 > 8%,113,123,189,194 > 8.5%158 and > 9%.97 One study required
patients to have glycaemic control of < 12.5%.124 Studies focused on populations with differing duration
of T2DM, for example having T2DM for < 10 years,110 ≤ 5 years,154 ≤ 3 years,142 < 1 year,155 > 3months,133
≥ 6 months,119,124,131 > 1 year117,121,123,147,150,194 and ≥ 2 years.192 Other studies defined a particular age group for
participants: ≥ 20 years,148 ≥ 25 years,161 > 35 years,150 40–70 years,152,154 ≥ 60 years,120,126,214 ≥ 50 years,149,151
≤ 70 years105,192,197 and < 80 years.124,137 Some studies included only people of a particular ethnicity, for example
black women,118 Puerto Rican121 and African American.145,161 There were criteria for BMI values for some RCTs,
for example > 25 kg/m2.124,135,137,143,152 Ten studies defined the population as depressed.105,106,126,127,129,131,140,148,151,195
Intervention characteristics
Psychological interventions were categorised into five therapy types according to which psychological
model underpinned treatment: CBT (n = 21),104–106,110,114,116,118,119,125–127,131,135,140,147,148,156,160,188,192,197 counselling
(n = 40),59,107–109,111–113,115,117,120,121,123,124,128,130,132–134,137–139,142–146,149–155,157,158,161,190,191,193,196 collaborative care
(including elements of psychotherapy; n = 6),129,141,159,187,195,214 creative therapy (i.e. music therapy, n = 1)136
and family therapy (n = 3).122,189,194
Control conditions were categorised into three main types: usual care [N = 51 – waiting list (n = 5),114,116,125,188,197
usual care (n = 41)104,106–108,113,115,117,119,121,122,124,126,127,129–132,135,137–139,142,143,145–149,151–159,187,189,191,193,195,214 and
enhanced usual care (n = 5)110,134,141,150,161], attention control [N = 16 – dietary counselling (n = 1),109 diabetes
education (n = 11),59,105,111,112,118,128,133,136,144,160,196 attention control (n = 2),120,192 peer support (n = 1)190 and
telephone support (n = 1);194 these matched the intervention in duration and frequency] and a less intensive
psychological intervention (n = 1).140
Interventionists who delivered the psychological therapies were categorised as follows: diabetes specialists
(n = 32),107–110,113,118,120,126–131,133,135,137–139,144–146,149,150,154,158,187,188,190–193,195 psychology professionals (n = 20)59,104–106,
111,112,123,124,132,140,141,147,148,151,156,157,189,194,197,214 and other (n = 16).114,115,117,119,121,122,125,134,136,142,143,152,153,160,161,196
Psychological interventions were delivered face to face (n = 56),59,104–107,109–112,114,116–119,121–125,127,128,130–133,135–141,144,
145,147,148,150,152,154–161,187–192,194,195,197,214 by telephone (n = 10),113,115,120,126,134,143,151,153,193,196 or by telephone and face
to face (n = 5).108,129,142,146,149 Most studies delivered psychological interventions in an individual (n = 42)59,107–109,
112,113,115,117,120,121,126–130,133–135,137,138,140–143,145,146,149–154,157,158,187,190,191,193,195–197,214 or group format (n = 25);104–106,110,111,
114,116,118,119,124,125,131,132,136,139,144,147,148,155,156,159–161,188,192 four interventions were delivered to families.122,123,189,194
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The mean number of psychological sessions was 7.40 (range 1–27 sessions). The mean overall duration
of interventions was 6.67 months (range 30 minutes to 2 years). The mean duration of a psychological
intervention session was 1.22 hours (range 15 minutes to 3 hours per session).
Primary outcome
In all studies, HbA1c level (in % or mmol/mol) was assessed at baseline and follow-up. In the meta-analysis,
data on HbA1c levels were extracted for 12 months or closest to 12 months. The mean length of follow-up
was 7.78 months (range 2–18 months).
Secondary outcomes
The following secondary outcomes were assessed: change in psychological outcomes (i.e. depression and
quality of life), change in self-management behaviour (i.e. dietary behaviour), BMI (in kg/m2) and blood
pressure (in mmHg).
Results of individual studies of adults with type 2 diabetes mellitus
All studies included in the systematic review are listed and described in Table 1.
Synthesis of results
Data on HbA1c levels for adults with T2DM were available for 49 studies (with a total of 12,009
participants). In a pooled random-effects meta-analysis, the SMD in HbA1c levels was statistically
significantly lower for adults with T2DM who received a psychological intervention than for those who
received a control condition (SMD –0.21, 95% CI –0.31 to –0.10) (Figure 9), equivalent to –0.33 change in
% HbA1c level (a reduction of ≈3.5 mmol/mol). Study heterogeneity was large: I2 = 93.9%; p < 0.001.
Removal of any of the individual studies from the meta-analysis had little or no impact on HbA1c levels.
There was little evidence of publication bias according to Egger’s test (p = 0.80); see Appendix 11, Figure 37.
The trim-and-fill method for correcting publication bias did not estimate any missing studies.
Subgroup analysis of glycated haemoglobin levels by psychological
intervention category
A subgroup analysis of HbA1c levels by psychological intervention category was conducted (see Appendix 11,
Figure 38) for CBT (n = 16)104–106,110,114,116,118,119,125–127,131,135,140,147,148 and counselling (n = 28) studies.59,107,109,111–113,
115,117,120,121,123,124,128,130,132–134,137–139,142–146,149–151 There were too few psychotherapy (n = 3),129,141,214 creative therapy
(n = 1)136 and family therapy (n = 1)122 studies to conduct subgroup analyses. CBT studies (SMD –0.25, 95% CI
–0.42 to –0.09; –0.44 change in % HbA1c levels, a reduction of ≈4 mmol/mol) and counselling studies (SMD
–0.24, 95% CI –0.39 to 0.00; –0.33 change in % HbA1c levels, a reduction of ≈3–4 mmol/mol) demonstrated
statistically significant reductions in HbA1c levels compared with controls, although the difference in effect size
between psychological intervention categories was not statistically significant (p = 088). The heterogeneity in
CBT studies was moderate and statistically significant (I2 = 54%; p = 0.005). There was some evidence of
publication bias for CBT studies (p = 0.03), although, the trim-and-fill method for correcting publication
bias did not estimate any missing studies. The heterogeneity in counselling studies was high (I2 = 89.1%;
p < 0.001). There was no evidence of publication bias for counselling studies (p = 0.12), and the trim-and-fill
method revealed no missing studies.
Subgroup analysis of glycated haemoglobin levels by interventionist category for
counselling studies only
In a non-prespecified subgroup analysis of counselling studies by interventionist, heterogeneity remained
high for counselling interventions delivered by diabetes specialists (I2 = 94.1%; p < 0.001), with a significant
reduction in HbA1c levels in favour of counselling (SMD –0.35, 95% CI –0.59 to –0.11; 0.49 change in
% HbA1c levels, a reduction of ≈5 mmol/mol). Study heterogeneity was low for counselling interventions
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delivered by psychological professionals (I2 = 11%; p = 0.35) and ‘other’ interventionists (I2 = 0%; p = 0.75),
and there was a non-statistically significant decrease in HbA1c levels for both categories of interventionists
(psychology professionals, SMD –0.08, 95% CI –0.23 to 0.02; ‘other’ interventionists, SMD –0.10, 95% CI
–0.22 to 0.01).
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FIGURE 9 A meta-analysis of the SMD in HbA levels in the psychological intervention groups compared with the1c
control groups for studies of adults with T2DM.
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Subgroup analysis of glycated haemoglobin levels by interventionist category
A subgroup analysis of HbA1c levels by interventionist category (see Appendix 11, Figure 39) for all psychological
intervention categories demonstrated that HbA1c levels were significantly lower in intervention than control
groups for psychological interventions delivered by psychology professionals (n = 15,59,104–106,111,112,123,124,132,140,141,
147,148,151,214 SMD –0.15, 95% CI –0.26 to –0.03; –0.26 change in % HbA1c levels, a reduction of ≈3mmol/mol)
and diabetes specialists (n = 22,107,109,110,113,118,120,126–131,133,135,137–139,144–146,149,150 SMD –0.30, 95% CI –0.48 to –0.11;
–0.47 change in % HbA1c levels, a reduction of ≈5mmol/mol). HbA1c levels were non-statistically significantly
lower in intervention than control groups for psychological interventions delivered by ‘other’ interventionists
(n = 11,114,115,117,119,121,122,125,134,136,142,143 SMD –0.06, 95% CI –0.22 to 0.11; –0.10 change in % HbA1c levels, a
reduction of ≈1mmol/mol), although there were no statistically significant differences between interventionist
groups (p = 0.49). In studies for which the intervention was delivered by a diabetes specialist, heterogeneity was
high and statistically significant (I2 = 91.8%; p < 0.001). There is no evidence of publication bias in studies in
which the intervention was delivered by a diabetes specialist (p = 0.19); in addition, the-trim and-fill method for
correcting publication bias did not estimate any missing studies. In studies for which the intervention was
delivered by a psychology professional, heterogeneity was low but non-significant (I2 = 27.3%; p = 0.156).
There was some evidence of publication bias in these studies (p = 0.02); however, the trim-and-fill method for
correcting publication bias did not estimate any missing studies. Heterogeneity was moderate and statistically
significant in studies for which the intervention was delivered by ‘other’ interventionists (I2 = 56.2%; p = 0.01).
There was no evidence of publication bias in study interventions delivered by ‘other’ interventionists (p = 0.60),
supported by the trim-and-fill method, which did not estimate any missing studies.
Subgroup analysis of glycated haemoglobin levels by the primary outcome of
individual studies
A subgroup analysis of HbA1c levels by primary outcome variable was conducted (see Appendix 11, Figure 40).
The primary outcome per study could be categorised into three groups:
1. glycaemic control (n = 24)106,107,109–112,114,116,118,120,122,123,125,126,128,133,136–138,144,146,148,149
2. self-management [N = 1359,115,117,119,121,124,130,134,139,140,142,143,145 – adherence (n = 3); medication use, glucose
monitoring and physical activity (n = 1); physical activity (n = 5); self-management behaviours (n = 2);
diet adherence (n = 1); and medication adherence (n = 1)]
3. psychological [N = 12104,105,113,127,129,131,132,141,147,150,151,214 – depression (n = 8), distress (n = 2), self-efficacy
(n = 1) and stress (n = 1)].
When glycaemic control was the main outcome of the study, there was a statistically significant improvement
in HbA1c levels (SMD –0.28, 95% CI –0.46 to –0.10). For studies in which self-management was the main
outcome, there was a statistically significant improvement in HbA1c levels (SMD –0.11, 95% CI –0.21 to
–0.01). When psychological outcomes were the main outcome of the study, there was a non-statistically
significant improvement in HbA1c levels (SMD –0.12, 95% CI –0.24 to 0.01). There were no statistically
significant differences between these groups (p = 0.63). Study heterogeneity was high and statistically
significant for studies in which glycaemic control was the primary outcome (I2 = 91.5%; p < 0.001), but low
and not statistically significant for studies in which the primary outcomes were psychological (I2 = 25.6%;
p = 0.19) or self-management (I2 = 12.0%; p = 0.33). There is no evidence of publication bias in studies for
which the primary outcome was glycaemic control (p = 0.13), self-management (p = 0.47) or psychological
outcome (p = 0.06); in addition, the trim-and-fill method for correcting publication bias did not estimate any
missing studies for any of these groups.
Meta-regression
Studies conducted in Asia compared with those conducted in the Western world (i.e. Europe, the UK,
North America, Australia) demonstrated a greater reduction in HbA1c levels (p = 0.05). There was no
association between HbA1c levels and the number of therapy sessions (p = 0.81), the length of therapy
sessions (p = 0.23) or the type of control group (p = 0.14).
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Secondary outcomes
Depression
Fourteen studies109,115,126,131,132,135,140,141,144,147,148,150,160,214 of T2DM (with a total of 2075 participants) had
outcome data for depression (see Appendix 12, Figure 41). There was a non-statistically significant decrease
in depression for psychological intervention groups compared with control groups (SMD –0.28, 95% CI
–0.63 to 0.06) (Figure 10). Study heterogeneity was high: I2 = 93.1%; p < 0.001). If the Kim et al.144 study
was removed from the analysis, there was a statistically significant decrease in depression in favour of
psychological interventions (SMD –042, 95% CI –0.61 to –0.23). Removal of any other individual studies
from the meta-analysis had little or no impact on HbA1c levels. There was little evidence of publication bias,
demonstrated by the Egger test (p = 0.72), as displayed in Appendix 12, Figure 41. The trim-and-fill method
for correcting publication bias did not estimate any missing studies.
Quality of life
A random-effects meta-analysis was conducted on 13 studies59,109,110,117,131,134,135,137,139,141,144,147,149 (with a
total of 2354 participants) reporting QoL measures (Figure 11). Psychological therapies were associated
with statistically significant improved QoL compared with control groups (SMD 0.66, 95% CI –0.08 to
0.24). Heterogeneity was high: I2 = 96.9%; p = < 0.001). Removal of the Kim et al.144 study did not affect
QoL. Removal of any other individual studies from the meta-analysis had little or no impact on QoL.
Egger’s test indicated some evidence of publication bias (p = 0.048). The trim-and-fill method estimated
five missing studies.
Body mass index
Twelve studies107,119,123,124,134,136,137,142,145,148,149,152 (with a total of 2254 participants) provided BMI outcome data
(Figure 12). The pooled mean difference was –0.08 (95% CI –0.16 to 0.00), indicating a non-statistically
Overall (I 2 = 93.1%; p = 0.001)
Favours psychological intervention Favours control
Penckofer et al.131
Piette et al.126
Siebolds et al.109
Sacco et al.115
Safren et al.140
Welschen et al.135
Williams et al.214
Kasteleyn et al.150
Kim et al.144
Gois et al.141
Pibernik-Okanović et al.147
Huang et al.148
Inouye et al.160
Hartmann et al.132
– 0.28 (– 0.63 to 0.06)
– 0.82 (– 1.29 to – 0.34)
– 0.52 (– 0.75 to – 0.28)
– 0.21 (– 0.47 to 0.05)
– 0.30 (– 0.80 to 0.20)
– 0.58 (– 1.01 to – 0.16)
– 0.15 (– 0.46 to 0.17)
– 0.60 (– 0.84 to – 0.37)
– 0.03 (– 0.34 to 0.28)
1.60 (1.29 to 1.91)
0.22 (– 0.62 to 1.06)
– 0.16 (– 0.52 to 0.20)
– 1.76 (– 2.36 to – 1.17)
– 0.20 (– 0.47 to 0.07)
– 0.59 (– 0.97 to – 0.21)
100.00
6.90
7.66
7.59
6.81
7.07
7.44
7.65
7.46
7.45
5.42
7.32
6.43
7.56
7.24
– 2.5 – 2.0 – 1.5 – 1.0 – 0.5 0.0 0.5 1.0 1.5 2.0
Study SMD (95% CI) Weight (%)
FIGURE 10 A meta-analysis of the SMD in depression in psychological intervention groups compared with control
groups for studies of adults with T2DM.
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significant decrease in BMI. Removal of the Griffin et al.142 study reveals a significant reduction in BMI
(SMD –0.09, 95% CI –1.19 to –0.001; equivalent to a change in BMI of –0.80 kg/m2). Heterogeneity was
low but not statistically significant (I2 = 0%; p = 0.678). There is little evidence of publication bias (Egger’s
test, p = 0.68); see Appendix 12, Figure 43. The trim-and-fill method for correcting publication bias did not
estimate any missing studies.
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FIGURE 11 A meta-analysis of the SMD in QoL in psychological intervention groups compared with control groups
for studies of adults with T2DM.
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FIGURE 12 A meta-analysis of the SMD in BMI in psychological intervention groups compared with control groups
for studies of adults with T2DM.
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Blood pressure per protocol
Blood pressure outcomes were available for six studies.119,123,136,137,142,149 In a pooled random-effects meta-
analysis, the mean systolic blood pressure (SBP) (Figure 13) and diastolic blood pressure (DBP) (Figure 14)
values were non-statistically significantly lower in psychological intervention groups than control groups.
Pooled mean differences were –0.11 for SBP (95% CI –0.26 to 0.04; a reduction of 1.97 mmHg) and –0.04
for DBP (95% CI –0.16 to 0.08; a reduction of 0.39 mmHg). Heterogeneity was high for SBP (I2 = 51.5%;
p = 0.067) and low for DBP (I2 = 27.6%; p = 0.228). There was little influence of omission of individual
studies from the random-effects meta-analysis: the pooled mean difference remained non-statistically
significantly lower for SBP and DBP. There was no evidence of publication bias for SBP (p = 0.33) or DBP
(p = 0.92); see Appendix 12, Figures 44 and 45, respectively. The trim-and-fill method for correcting
publication bias did not estimate any missing studies for SBP. However, for DBP, the trim-and-fill method
estimated two missing studies.
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FIGURE 13 A meta-analysis of the SMD in SBP in psychological intervention groups compared with control groups
for studies of adults with T2DM.
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FIGURE 14 A meta-analysis of the SMD in DBP in psychological intervention groups compared with control groups
for studies of adults with T2DM.
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Changes in self-management behaviours
Eight studies111,115,123,139,149,152,157,214 (with a total of 1608 participants) had data available to conduct a meta-analysis
for dietary self-management (Figure 15), measured by the SDSCA. A random-effects meta-analysis
demonstrated no improvement in general dietary behaviour (SMD 0.47, 95% CI –0.28 to 1.23). High
significant heterogeneity was found: I2 = 97.8%; p < 0.001. There was little change on effect size following
removal of individual studies. There was little evidence of publication bias (p = 0.18); see Appendix 12,
Figure 46. The trim-and-fill method for correcting publication bias did not estimate any missing studies.
Combining the results with those of the previous review of studies of adults with
type 2 diabetes mellitus
In our previous review,40 data on HbA1c levels for 12 trials (with a total of 510 participants) were available
for meta-analysis (studies from 1991–2003). Combining data from both reviews (n = 61 studies, with a
total of 12,519 participants), a random-effects meta-analysis demonstrated that the SMD in HbA1c levels
was statistically significantly lower for people with T2DM in receipt of a psychological intervention than
those in a control condition (SMD –0.22, 95% CI –0.32 to –0.12; equivalent to a –0.35 change in %
HbA1c levels, a reduction of ≈4 mmol/mol) (Figure 16). The effect size was larger in the previous review
(SMD –0.32, 95% CI –0.57 to –0.07; equivalent to a –0.76 change in % HbA1c levels, a reduction of
≈8 mmol/mol) than the current review (SMD –0.21, 95% CI –0.31 to –0.10; equivalent to a –0.33 change
in % HbA1c levels, a reduction of ≈3.5 mmol/mol), although the difference between reviews was not
statistically significant (p = 0.53).
Risk of bias in studies
Of the studies included in the meta-analysis, 23 studies104,106,111,119,120,123,124,126,127,129–131,134,136,138,140–143,147,149,214
were rated as having a ‘low’ RoB, 25studies59,105,107,109,110,112–118,121,125,128,132,133,137,139,144–146,148,150,151 were rated
as having an ‘unclear’ RoB and one study122 was rated as having a ‘high’ RoB (see Appendix 11, Figure 35).
In a subgroup analysis of HbA1c levels by risk of bias (see Appendix 11, Figure 36), HbA1c levels reduced
more in studies rated as having an ‘unclear’ RoB (SMD –0.32, 95% CI –0.53, –0.11) than those rated as
having a ‘low’ RoB (SMD –0.08, 95% CI –0.16 to –0.01), although the difference between these RoB
categories was not statistically significant (p = 0.178).
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FIGURE 15 A meta-analysis of the SMD in general diet behaviour in psychological intervention groups compared
with control groups for studies of adults with T2DM.
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FIGURE 16 A meta-analysis of the SMD in HbA1c levels in psychological intervention groups compared with control
groups for studies of adults with T2DM, combining the current and previous reviews.
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Risk of bias across studies
For RoB across studies, the RoB was lowest for the ‘other bias’ domain. The RoB was most unclear in the
‘blinding of outcome assessment domain’; Figure 17.
GRADE assessment
The primary outcome, HbA1c levels, was rated as being of ‘high quality’ for studies of adults with T1DM
and studies of adolescents/children with T1DM, as there were no problems with any factors (Table 2).
Heterogeneity for the outcome of HbA1c levels in studies of adolescents/children with T1DM was high;
however, a prespecified subgroup analysis by interventionist revealed low heterogeneity in interventionist
groups (i.e. psychology professionals and ‘other’). This meant that a ‘no serious inconsistency’ rating could
be allocated to HbA1c levels for this analysis. A ‘high-quality’ rating indicates confidence that the effect size
found is close to the true effect.
For studies of adults with T2DM, the outcomes of HbA1c levels was rated as being at a moderate risk of
bias, as the inconsistency factors were graded ‘serious’ because heterogeneity was large for this outcome
(I2 ≥ 50%).
Meta-analyses were conducted for secondary outcomes in T2DM only. Secondary outcomes assessed as
being of ‘high quality’ included BMI and blood pressure, with no problems in either factor.
Depression, QoL and general dietary behaviour (measured by the SDSCA scale) outcomes were rated as
being of ‘low quality’, as the inconsistency factor was rated as ‘very serious’; heterogeneity was very large
for these outcomes (I2 ≥ 75%). In addition, for the QoL outcome, publication bias was rated as ‘serious’
because the trim-and-fill method estimated five missing studies. Subanalyses were not conducted for
secondary outcomes, and could account for high heterogeneity.
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Unclear risk of bias
High risk of bias
FIGURE 17 The RoB across studies of adults with T2DM.
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TABLE 2 The GRADE evidence profile for the impact of psychological interventions for T1DM and T2DM from systematic review and meta-analysis of RCTs of psychological
interventions to improve motivation for self-management in diabetes
Quality assessment Summary of findings
Type of diabetes
Number of
studies
(design)
Risk of
bias Inconsistency Indirectiveness Imprecision
Publication
bias Quality
Total number
of participants SMD (95% CI)
Primary outcome
HbA1c levels
T1DM in adults 7 (RCTs) No serious
risk of bias
No serious
inconsistency
No serious
indirectness
No serious
imprecision
No serious
publication bias
High 851 –0.13 (–0.33 to 0.07)
T1DM in adolescents/
children
18 (RCTs) No serious
risk of bias
No serious
inconsistency
No serious
indirectness
No serious
imprecision
No serious
publication bias
High 2583 0.00 (–0.18 to 0.18)
T2DM 49 (RCTs) No serious
risk of bias
Serious No serious
indirectness
No serious
imprecision
No serious
publication bias
Moderate 12,009 –0.21 (–0.31 to –0.10)
Secondary outcomes
Depression
T2DM 14 (RCTs) No serious
risk of bias
Very serious No serious
indirectness
No serious
imprecision
No serious
publication bias
Low 1390 –0.28 (–0.63 to 0.06)
QoL
T2DM 13 (RCTs) No serious
risk of bias
Very serious No serious
indirectness
No serious
imprecision
Serious
publication bias
Low 2354 0.66 (–0.08 to 0.24)
BMI
T2DM 12 (RCTs) No serious
risk of bias
No serious
inconsistency
No serious
indirectness
No serious
imprecision
No serious
publication bias
High 2254 –0.08 (–0.16 to 0.00)
Blood pressure
T2DM 6 (RCTs) No serious
risk of bias
No serious
inconsistency
No serious
indirectness
No serious
imprecision
No serious
publication bias
High 1768 l SBP: –0.11
(–0.26 to 0.04)
l DBP: –0.04
(–0.16 to 0.08)
General diet behaviour
T2DM 8 (RCTs) No serious
risk of bias
Very serious No serious
indirectness
No serious
imprecision
No serious
publication bias
Low 1608 0.47 (–0.28 to 1.23)
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Chapter 5 Network meta-analysis results
Network meta-analysis of studies of adults with type 1 diabetes mellitus
Descriptives
In our meta-analyses, we retrieved data from seven studies with two different psychological intervention
types and two types of control groups. In addition, one of these studies, Ismail et al.,163 had two treatment
arms (CBT and counselling).
A total of seven studies with 15 treatment or control arms were included in the meta-analyses, with a total
sample size of 968 participants (Table 3). CBT (n = 6)104–106,162–164 and counselling (n = 2)163,165 were offered
as interventions, and usual care (n = 5)104,106,162,163,165 and attention control (n = 2)105,164 were the control
groups. The sample size and the number of studies using counselling and attention control are, thus,
limited.
Given that we had four conditions, six contrasts were possible. Figure 18 shows the network plots of
evidence for all studies. The plots reflect the number of patients for each arm (size of circles), the observed
contrasts (lines) and the amount of evidence for a contrast (width of line). The plot shows that five contrasts
were investigated. The two control arms, attention control and usual care, were not directly assessed.
Table 4 shows that the estimated direct and indirect effects between interventions did not differ
significantly. The non-significant chi-squared test for inconsistency [χ2(2) = 0.05; p = 0.98, I2 = 0] supports
the conclusion of model consistency. Table 5 shows the results of the consistency NMAs comparing
treatments with usual care. Only CBT and attention control showed significant reduction in treatment
outcome compared with usual care. Effect sizes were moderate (for CBT) or medium (for attention
control). A summary of pairwise comparisons of treatment effect can be found in Appendix 13, Table 28.
The rankogram graph (Figure 19) shows that attention control has an 88.9% probability of being the best
treatment whereas CBT has only a 7.6% probability of being the best treatment; the probabilities of the
other two interventions being best are negligible. An assessment of the rescaled mean rank (SUCRA) showed
that attention control is certain to be the best treatment, followed by CBT (SUCRA = 0.7) and counselling (0.3),
with usual care (0.0) most likely to be the worst therapy (see Appendix 13, Table 26).
TABLE 3 Number of studies and arms included in the NMAs of studies of adults with T1DM
Treatment Studies (n) Studies (%) Arm Sample size (n)
CBT 6 40.0 T 292
Counselling 2 13.3 T 251
Usual care 5 33.3 C 322
Attention control 2 13.3 C 103
Total 15 100 968
C, arm was defined as control group in original study; T, arm was defined as treatment arm.
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CBT
Counselling
Usual care
Attention control
FIGURE 18 Network plots of direct comparisons for the NMA of studies of adults with T1DM. The width of the
lines is proportional to the number of trials comparing each pair of treatments and the size of each node is
proportional to the number of studies testing the specific treatment. It shows, roughly, how much information is
available for each treatment and for each treatment comparison.
TABLE 5 A summary of the treatment effects compared with TAU, assuming a common heterogeneity estimate for
all treatment design comparisons, for studies of adults with T1DM
Treatment b 95% CI SE z-value p-value
Usual care 0
CBT –0.312 (–0.499 to –0.126) 0.095 –3.29 0.001
Counselling –0.121 (–0.307 to 0.066) 0.095 –1.27 0.21
Attention control –0.513 (–0.848 to –0.177) 0.1701 –3.00 0.003
SE, standard error.
Note
Supported by the non-significant test for inconsistency (χ2 = 0.05; p = 0.98) and non-significant differences between direct
and indirect treatment effects. ‘b’ is the SMD using TAU as the control group. The formulas for Hedges’ g in White and
Thomas87 are used.
TABLE 4 Direct and indirect treatment effects (where indirect treatment effects were available) and the difference
between them, including significance test for difference, in studies of adults with T1DM
Treatment
comparison Side
Direct Indirect Difference
p> zCoefficient SE Coefficient SE Coefficient SE
CBT Usual care 0.309 0.098 0.356 0.376 –0.047 0.388 0.90
CBT Counselling 0.191 0.131 0.195 0.212 –0.004 0.249 0.99
CBT Attention control –0.200 0.142 0.629 44.652 –0.829 44.652 0.99
Counselling Usual care 0.117 0.098 0.173 0.375 –0.056 0.387 0.88
SE, standard error.
Note
The large SE of 44.6 for the comparison between CBT and attention control suggests an unidentified model; therefore, the
conclusion about homogeneity should be treated with care.
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Network meta-analysis results for studies of adolescents/children with
type 1 diabetes mellitus
Descriptives
We retrieved data from a total of 18 studies of adolescents/children with T1DM. Two studies had more
than one treatment arm (main arm: CBT, extra arm: CBT2;177 main arm: family therapy, extra arm: family
therapy via telephone180). However, because the two treatments in each study shared the same category of
treatment, one treatment needed to be excluded (i.e. the least intensive).
All studies included
A total of 18 studies with 18 treatment and 18 control arms were included in the meta-analyses, with a
total sample size of 2583 participants (see Appendix 13, Table 29). Family therapy (n = 6)169,173,176,180,182,183
and counselling (n = 8)167,168,170,172,174,178,179,181 were offered most often as interventions; usual care (n = 11)167,
169,173–178,180,181,184 and attention control (n = 5)170–172,179,183 were mainly offered as control groups.
Given that we had six conditions, 15 contrasts were possible. Appendix 13, Figure 47, shows the network
plots of evidence for all studies. The plot shows that eight contrasts were investigated.
Table 6 shows that the estimated direct and indirect effects between interventions did not differ significantly.
The non-significant chi-squared test for inconsistency [χ2(3) = 1.19; p = 0.76, I2 = 0] supports the conclusion
of model consistency. Table 7 shows the results of the consistency NMAs comparing treatments with usual
care. No treatment showed a statistically significant reduction of treatment outcome compared with usual
care. The observed effect sizes of the two arms with small sample sizes, coping skills training and attention
control, were medium to large. Appendix 13, Table 32, reports pairwise comparisons of treatment effect.
Best Worst
Rank
(a)
C
u
m
u
la
ti
v
e
p
ro
b
a
b
il
it
y
 (
%
)
100
50
0
Best Worst
Rank
(b)
C
u
m
u
la
ti
v
e
p
ro
b
a
b
il
it
y
 (
%
)
100
50
0
Best Worst
Rank
(c)
C
u
m
u
la
ti
v
e
p
ro
b
a
b
il
it
y
 (
%
)
100
50
0
Best Worst
Rank
(d)
C
u
m
u
la
ti
v
e
p
ro
b
a
b
il
it
y
 (
%
)
100
50
0
FIGURE 19 Rankogram for all treatments in studies of adults with T1DM. (a) Usual care; (b) CBT; (c) counselling;
and (d) attention control. The plot shows the surface under the cumulative ranking curves for all treatments. For
example, usual care has a very low probability of being among the best treatments, but a very high probability of
being one of the worst.
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The rankogram graph (Figure 20) shows that attention control has a 66.6% probability of being the best
treatment, followed by CBT with an 18.5% probability of being the best; all others have a probability
of < 8% of being the best treatment. An assessment of the rescaled mean rank (SUCRA) shows that
attention control is most likely to be the best treatment (SUCRA = 0.9), followed by CBT and family therapy
(SUCRA = 0.6 and 0.5, respectively), and that less intensive psychological intervention and counselling are
least likely to be the best ones (SUCRA = 0.3) (see Appendix 13, Table 27).
Analyses of studies with more than two sites
Only less intensive psychological intervention was studied fewer than three times. A total of 16 studies
with treatment and control arms with five types of treatment (CBT, counselling, family therapy, attention
control and usual care) were included in the meta-analyses, with a total sample size of 2427 participants
(Table 8).
Given that we had five conditions, 10 contrasts were possible. Figure 21 shows the network plots of
evidence for all studies. The plot shows that six contrasts were investigated.
TABLE 7 Summary of treatment effects compared with TAU, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adolescents/children with T1DM
Treatment b 95% CI SE z-value p-value
Usual care 0
CBT –0.33 –1.248 to 0.589 0.469 –0.7 0.59
Counselling 0.141 –0.635 to 0.917 0.396 0.36 0.92
Family therapy –0.24 –1.045 to 0.565 0.411 –0.58 0.57
Attention control –0.767 –1.757 to 0.222 0.505 –1.52 0.22
SE, standard error.
Note
‘b’ is the SMD using TAU as the control group. The formulas for Hedges’ g in White and Thomas87 are used.
TABLE 6 Direct and indirect treatment effects (where indirect treatment effects were available) and the difference
between them, including the significance test for difference, for studies of adolescents/children with T1DM
Side comparison Direct Indirect Difference
p-valueIntervention Control SMD SE SMD SE SMD SE
CBT Usual care 0.241 0.557 0.718 1.136 –0.477 1.265 0.71
CBT Attention control –0.177 0.955 –0.654 0.830 0.478 1.265 0.71
Counselling Usual care 0.058 0.453 –0.984 0.928 1.042 1.033 0.31
Counselling Attention control –1.227 0.571 –0.184 0.862 –1.043 1.033 0.31
Family therapy Usual care 0.100 0.465 1.033 1.102 –0.932 1.196 0.44
Family therapy Attention control 0.017 0.918 –0.916 0.766 0.933 1.196 0.44
SE, standard error.
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FIGURE 20 Rankogram for all treatments in studies of adolescents/children with T1DM. (a) Usual care; (b) CBT;
(c) counselling; (d) family therapy; and (e) attention control. The plot shows the SUCRA curves for all treatments.
For example, usual care has a very low probability of being among the best treatments, but a very high probability
of being one of the worst.
TABLE 8 Number of studies and arms included in the NMAs for studies of adolescents/children with T1DM
Treatment Studies (n) Studies (%) Arm Sample size (n)
CBT 4 11.8 T 167
Counselling 7 23.5 T 676
Family therapy 5 17.6 T 399
Usual care 11 32.4 C 1002
Attention control 5 14.7 C 183
Total 32 100 2427
C, arm was defined as control group in original study; T, arm was defined as treatment arm.
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Table 9 shows that the estimated direct and indirect effects between interventions did not differ
significantly. The non-significant chi-squared test for inconsistency [χ2(2) = 0.98; p = 0.61, I2 = 0] supports
the conclusion of model consistency. Table 10 shows the results of the consistency NMAs comparing
treatments with usual care. No treatment showed a statistically significant reduction of treatment outcome
compared with usual care. Appendix 13, Table 33, reports pairwise comparisons of treatment effect.
CBT
Counselling
Family therapy
Usual care
Attention control
FIGURE 21 Network plots for all studies. Network plots of direct comparisons for the NMA for studies of adolescents/
children with T1DM. The width of the lines is proportional to the number of trials comparing each pair of treatments
and the size of each node is proportional to the number of studies testing the specific treatment. It shows, roughly,
how much information is available for each treatment and for each treatment comparison.
TABLE 9 Direct and indirect treatment effects (if indirect treatment effects were available) and the difference
between them for studies of adolescents/children with T1DM
Side comparison Direct Indirect Difference
p-valueTreatment Control Coefficient SE Coefficient SE Coefficient SE
CBT Usual care 0.241 0.526 0.721 1.072 –0.480 1.194 0.69
CBT Attention control –0.177 0.901 –0.657 0.784 0.481 1.194 0.69
Counselling Usual care 0.058 0.438 –0.559 0.775 0.617 0.890 0.49
Counselling Attention control –1.198 0.541 –0.129 0.780 –1.069 0.949 0.26
Counselling Less intensive
psychological
intervention
0.416 0.899 –0.253 1.036 0.670 1.372 0.63
Family therapy Usual care 0.100 0.448 0.513 0.868 –0.412 0.977 0.67
Family therapy Attention control 0.017 0.857 –0.969 0.682 0.986 1.095 0.37
Family therapy Less intensive
psychological
intervention
0.128 0.888 0.797 1.045 –0.670 1.372 0.63
SE, standard error.
Note
Includes significance test for difference.
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Network meta-analysis results for studies of adults with type 2
diabetes mellitus
Descriptives
In our meta-analyses, we retrieved data from 49 studies of adults with T2DM that had five different
psychological intervention types and five main types of control groups. In addition, four studies128,134,136,146
had two control groups and three studies had two treatment groups. However, two of those had the same
treatment arm (counselling) and only one control group. We had to remove one of the two counselling
groups as the network analyses algorithms did not allow the inclusion of two treatment arms of the same
type in a study. One study128 had two treatment and control substudies. These were separated into two
separate studies in the NMAs.
A total of 50 studies with 103 treatment or control arms were thus included in the meta-analyses, with a
total sample size of 12,409 participants (Table 11). Four studies128,134,136,146 provided more than two arms to
the NMAs.128,134,136,146 CBT (used in 53.7% of studies ) and counselling (used in 39% of studies) were the
TABLE 10 Summary of treatment effects compared with TAU, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adolescents/children with T1DM
Treatment b 95% CI SE z-value p-value
Usual care 0
CBT –0.329 –1.198 to 0.539 0.443 –0.74 0.54
Counselling 0.088 –0.621 to 0.797 0.362 0.24 0.8
Family therapy –0.184 –0.917 to 0.549 0.374 –0.49 0.55
Attention control –0.768 –1.704 to 0.169 0.478 –1.61 0.17
Less intensive psychological intervention 0.22 –1.076 to 1.516 0.661 0.33 1.52
SE, standard error.
Note
b is the SMD using TAU as the control group. The formulas for Hedges’ g in White and Thomas87 are used. These are
unbiased estimators and involve corrections for small numbers of degrees of freedom.
TABLE 11 Number of studies and arms included in the NMAs for studies of adults with T2DM
Arm Studies (n) % Arm Sample size (n)
CBT 16 15.53 T 717
Counselling 29 28.16 T 4636
Psychotherapy 3 2.91 T 268
Creative therapy 1 0.97 T 67
Usual care 37 35.92 T 5050
Attention control 12 11.65 C 796
Computerised material 2 1.94 C 666
Printed material 1 0.97 C 68
Music relaxation CD 1 0.97 C 58
Family therapy 1 0.97 T 83
Total 103 100 12,409
C, arm was defined as control group in original study; CD, compact disc; T, arm was defined as treatment arm.
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interventions most often studied. Usual care (used in 70.4% of studies) was used most often as control
arm, followed by attention control (used in 20.4% of studies). Other intervention and control arms were
offered only once or twice.
Descriptive information and the coding of variables for each of the studies are provided earlier in the
report (see Chapter 3 and Table 1).
Given that we had 10 conditions, 45 contrasts were possible. Figure 49 shows the network plots of
evidence for all studies. The plot shows that only 12 contrasts were investigated and only five conditions
had at least moderate sample size, based on more than two studies.
To reduce the overestimation of treatment effects due to publication bias and to obtain robust findings,
we performed two NMAs. First, all available studies were analysed. Second, we then restricted our main
analyses to five conditions (CBT, counselling, attention control, psychotherapy and usual care).
Results of all available studies
Table 12 shows that the estimated direct and indirect effects between interventions did not differ
significantly. The non-significant chi-squared test for inconsistency [χ2(2) = 2.55; p = 0.28, I2 = 0] supports
the conclusion of model consistency. Although there was no significant difference between direct and
indirect treatment effects, it should be noted that some direct and indirect effects show opposite
treatment effects, that is CBT shows a significant positive treatment effect in direct comparison with usual
care (–0.292, 95% CI –0.56 to –0.024) but a (non-significant) worsening effect when looking at the
indirect evidence (0.277, 95% CI –0.389 to 0.943).
Table 13 shows the results of the consistency NMAs comparing treatments with usual care. No therapy
shows a significant reduction of treatment outcome compared with usual care. Only music therapy
showed a moderate treatment standardised effect size. Appendix 13, Table 35, presents pairwise
comparisons of treatment effect.
The rankogram graph (see Appendix 13, Figure 50) shows that music therapy has a 62.5% probability of
being the best treatment, whereas computerised material treatment has only a 14.9% probability of being
the best treatment; the probabilities for all other studies are < 10%. An assessment of the rescaled mean
rank (SUCRA) shows that music therapy [music relaxation compact disc (CD)] is potentially the best
TABLE 12 Direct and indirect treatment effects (where indirect treatment effects were available) and the
difference between them for adults with T2DM, including significance test for difference
Comparison Direct Indirect Difference
p-valueTreatment Control SMD SE SMD SE SMD SE
Usual care Computerised material –0.087 0.314 –0.395 0.583 0.309 0.662 0.64
CBT Usual care 0.292 0.134 –0.277 0.333 0.569 0.359 0.11
CBT Family therapy 0.153 0.274 0.722 0.233 –0.569 0.359 0.11
Counselling Usual care 0.121 0.101 0.690 0.345 –0.569 0.359 0.11
Counselling Family therapy 0.551 0.161 –0.019 0.321 0.569 0.359 0.11
Counselling Computerised material –0.059 0.314 0.250 0.583 –0.309 0.662 0.64
Counselling Music relaxation CD –0.395 0.464 0.336 63.250 –0.731 63.252 0.99
Creative therapy Family therapy –0.221 0.459 0.538 63.247 –0.759 63.249 0.99
Family therapy Printed material 0.103 0.459 –0.656 63.256 0.759 63.258 0.99
CD, compact disc; SE, standard error.
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treatment (SUCRA = 0.9), followed by CBT (SUCRA = 0.8), counselling and computerised material
(SUCRA = 0.7 for both), psychotherapy and usual care (SUCRA = 0.5 for both) and printed material and
family therapy (both SUCRA = 0.3 for both). Creative therapy and attention control (SUCRA = 0.1 for both)
are most likely to be the two worst therapies (see Appendix 13, Table 34).
Music therapy (music relaxation CD) was assessed in only one study, with a sample size of 58 participants.
To reduce overestimation of effects and test the robustness of the findings, we conducted further analyses
restricted to treatments with more than two studies.
Results of reduced number of treatments (more than two studies per treatment)
A total of 37 studies with 48 treatment and 49 control arms were included in the meta-analyses, with a
total sample size of 11,467 participants (Table 14) in the reduced data set.
Given that we had five conditions, 10 contrasts were possible. Figure 22 shows the network plots of
evidence for all studies. The plot shows that five contrasts were investigated. Psychotherapy was connected
only with usual care. Rerunning a sensitivity analyses without psychotherapy did not alter conclusions
regarding the four main arms (this is not shown).
TABLE 14 Number of studies and arms included in the NMAs of studies of adults with T2DM
Arm Studies (n) Studies (%) Arm Cases (n)
CBT 16 16.5 T 717
Counselling 29 29.9 T 4636
Psychotherapy 3 3.1 T 268
Usual care 37 38.1 C 5050
Attention control 12 12.4 C 796
Total 97 100 100 11,467
C, arm was defined as control group in original study; T, arm was defined as treatment arm.
TABLE 13 Summary of treatment effects compared with TAU, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adults with T2DM
Treatment b (95% CI) SE z-value p-value
Usual care 0
CBT –0.213 –0.461 to 0.035 0.126 –1.68 0.09
Counselling –0.166 –0.36 to 0.027 0.099 –1.68 0.09
Psychotherapy 0.009 –0.535 to 0.553 0.277 0.03 0.97
Creative therapy 0.491 –0.464 to 1.446 0.487 1.01 0.31
Attention control 0.27 –0.051 to 0.591 0.164 1.65 0.1
Computerised material –0.156 –0.69 to 0.379 0.273 –0.57 0.57
Printed material 0.373 –0.581 to 1.328 0.487 0.77 0.44
Music relaxation CD –0.562 –1.492 to 0.369 0.475 –1.18 0.24
Family therapy 0.379 –0.507 to 1.265 0.452 0.84 0.4
CD, compact disc; SE, standard error.
Notes
‘b’ is the SMD using TAU as the control group. The formulas for Hedges’ g in White and Thomas87 are used.
Supported by the non-significant test for inconsistency (χ2 = 0.79, p = 0.67, I2 = 0) and non-significant differences between
direct and indirect treatment effects.
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Table 15 shows that the estimated direct and indirect effects between interventions did not differ
significantly. The non-significant chi-squared test for inconsistency [χ2(1) = 2.45; p = 0.12, I2 = 18.4%]
supports the conclusion of model consistency. Table 16 shows the results of the consistency NMAs
comparing treatments with usual care. Similar to the analyses using all studies, it should be noted that
some direct and indirect effects again show opposite treatment effects, that is CBT shows a significant
positive treatment effect in direct comparison with usual care (–0.292, 95% CI –0.564 to –0.02), but a
(non-significant) worsening effect when looking at the indirect evidence (0.278, 95% CI –0.804 to 1.48).
Assuming inconsistency, no treatment demonstrates statistically significant reduction of treatment outcome
compared with usual care. Observed effect sizes ranged between negligible and small. Appendix 13, Table 36,
reports pairwise comparisons of treatment effect.
The rankogram graph (Figure 23) shows that CBT has a 48.4% probability of being the best treatment,
followed by counselling (30.5%) and psychotherapy (21%). The probabilities of attention control (< 0.1%)
and usual care (0.1%) are negligible. An assessment of the rescaled mean rank (SUCRA) shows that CBT
and counselling are estimated to be the best treatments (SUCRA = 0.8), followed by psychotherapy
(SUCRA = 0.5); usual care (SUCRA = 0.3) and attention control (SUCRA = 0.1) are most likely to be the
worst therapies.
CBT
Counselling
Psychotherapy
Usual care
Attention control
FIGURE 22 Network plots for reduced number of studies. Network plots of direct comparisons for the NMA of
studies of adults with T2DM. The width of the lines is proportional to the number of trials comparing each pair
of treatments and the size of each node is proportional to the number of studies testing the specific treatment.
It shows, roughly, how much information is available for each treatment and for each treatment comparison.
TABLE 15 Direct and indirect treatment effects (where indirect treatment effects were available) and the
difference between them for studies of adults with T2DM, including significance test for difference
Comparison Direct Indirect Difference
p-valueTreatment Control SMD SE SMD SE SMD SE
CBT Usual care 0.292 0.136 –0.278 0.338 0.571 0.364 0.117
CBT Attention control 0.153 0.277 0.723 0.236 –0.571 0.364 0.117
Counselling Usual care 0.120 0.103 0.690 0.350 –0.570 0.364 0.118
Counselling Attention control 0.551 0.164 –0.020 0.326 0.571 0.364 0.117
SE, standard error.
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FIGURE 23 Rankogram for all treatments in studies of adults with T2DM. (a) Usual care; (b) CBT; (c) counselling;
(d) psychotherapy; and (e) attention control. The plot shows the SUCRA curves for all treatments. For example,
usual care has a very low probability of being the best or second-best treatment.
TABLE 16 Summary of treatment effects compared with TAU (usual care), assuming a common heterogeneity
estimate for all treatment comparisons, for studies of adults with T2DM
Treatment b 95% CI SE z-value p-value
Usual care 0
CBT –0.213 –0.464 to 0.038 0.128 –1.66 0.10
Counselling –0.166 –0.362 to 0.03 0.1 –1.66 0.10
Psychotherapy 0.009 –0.543 to 0.56 0.281 0.03 0.98
Attention control 0.27 –0.056 to 0.596 0.166 1.63 0.10
Note
Supported by the non-significant test for inconsistency [χ2(1) = 2.45; p = 0.12, I2 = 18.4%] and non-significant differences
between direct and indirect treatment effects (see Table 5).
‘b’ is the SMD using TAU as the control group. The formulas for Hedges’ g in White and Thomas87 are used.
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Chapter 6 Individual patient data meta-analysis
results
The IPD meta-analyses consisted of 29 studies published between 2007 and 2016, with a total sample sizeof 5823 participants. The type of diabetes was not known for two people. Fifteen studies104–106,129,163,164,
168–171,176,179,181,183,184 included a total of 2182 people with T1DM (range 8–390) and 19 studies104–106,113,118,123,129,
132,135–137,140,142,143,145,147,150,151,169 included a total number of 3639 (range 15–521) patients with a diagnosis of
T2DM. Of the 29 studies (study IDs listed in Appendix 14, Table 37), five studies104–106,129,169 included a mixed
population of T1DM and T2DM cases.104–106,129,169 There were no issues with IPD integrity. There were no
statistically significant differences between studies that provided data and those that did not with regard to
sample size, country, year of publication, type of psychological intervention or risk of bias (see Appendix 14,
Table 38).
Studies of T1DM were divided into adolescents and children (i.e. those aged < 18 years at recruitment; there
were nine such studies, including one with a mixed T1DM and T2DM population) and adult participants
(i.e. those aged ≥ 18 years; there were six such studies, including four with a mixed T1DM and T2DM
population). People with T1DM were, therefore, typically younger [1392 were adolescents or children
(< 18 years); 751 were adults (aged ≥ 18 years)] and typically had higher HbA1c levels at baseline and lower
BMI values (Table 17). Adults with T1DM had higher HbA1c level baseline values [9.26% (SD 1.47%);
n = 726] and lower BMI values [25.92 kg/m2 (SD 4.62 kg/m2); n = 374) than participants with T2DM.
Diabetes duration was, on average, similar in both groups. Only one study145 provided the gender of the
participants. Baseline recordings for HbA1c levels were above 95% for both types of diabetes groups, and
follow-up rates were 85% and 81% for T1DM and T2DM populations, respectively. Participants with T1DM
received mainly insulin treatment whereas only one-quarter of people with T2DM were treated with insulin.
TABLE 17 Clinical and demographic variables for participants with T1DM or T2DM
Variable
T2DM (N= 3639) T1DM (N= 2182)
n (%) Mean (SD) or n [%] Range n (%) Mean (SD) Range
Age (years) 3117 (85.6) 58.9 (10.16) 11.47–90 2143 (98.2) 21.9 (13.95) 8–78
HbA1c at baseline 3471 (95.4) 7.9 (1.69) 2.7–19 2100 (96.2) 9.1 (1.76) 4.6–19.5
HbA1c at follow-up 2797 (80.6) 7.5 (1.5) 2–20.8 1846 (84.6) 9.2 (1.81) 5.4–18.3
Gender (Male = 1) 57 (1.6) 25 [43.9] N/A 0 (0) N/A N/A
Duration (years) 2060 (59.3) 7.1 (6.73) 0.08–44 1695 (77.7) 7.9 (7.56) 0.08–52.7
BMI (kg/m2) 2909 (83.8) 32.1 (6.26) 13.9–63.2 1098 (50.3) 22.9 (5.65) 0.08–119.1
Treatment 1988 (91.1) – – 481 (13.2) – –
Insulin 535 (26.9) – – 480 (99.8) – –
Diabetic medication 154 (7.8) – – 0 (0) – –
Diet/exercise 1299 (65.3) – – 1 (0.2) – –
N/A, not available.
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We conducted linear regression models with HbA1c level as outcome and treatment type and baseline
values of HbA1c level as fixed independent variables, with a random intercept for study, random treatment
effect and a random effect for baseline measures of HbA1c levels. To identify moderators of improvement
in HbA1c levels, we ran several analyses, initially using only one predictor variable and its interaction with
treatment arm at a time to avoid reducing sample size. For adolescents/children with T1DM, only a random
effect for treatment arm was included.
Individual patient data meta-analysis for studies of adults with type 1
diabetes mellitus
Two studies168,169 had one and two participants, respectively, aged 18 years with T1DM; therefore, they
were not included in the analyses.
Step 1
In step 1, we investigated the effect of treatment and baseline values for HbA1c levels only.
Glycated haemoglobin levels at baseline did not moderate the treatment outcome [interaction HbA1c level
and arm: b = –0.053 (95% CI –0.20 to 0.094; p = 0.480), n = 455 participants, nstudies = 6]. After removing
the interaction, there was a small but non-significant decrease in HbA1c level at follow-up, after controlling
for baseline values in the treatment compared with the control group [mean difference –0.084 (95% CI
–0.412 to 0.244; p = 0.615)]. There was no within-study correlation [intracluster correlation coefficient
(ICC) = 0]. The forest plot of the meta-analyses is shown in Appendix 14, Figure 51. Between-study
heterogeneity was small (I2 = 0.05).
Step 2
In step 2, we explored age and duration of illness as potential moderators of treatment effect, in addition
to treatment arm and baseline HbA1c level.
There were only two studies with diabetes duration information; therefore, we included ‘study’ as a fixed
effect in the model. No combined analyses with age were performed.
Including age and the interaction between age and treatment arm did not reveal a significant moderating
effect of age [arm × age = –0.002 (95% CI –0.018 to 0.021; p = 0.844, n = 455 participants, nstudies = 6)].
After removing the interactions from the model, age did not predict HbA1c level at follow-up: [age: = –0.008
(95%. CI –0.018 to 0.002; p = 0.112)] and there was a non-significant treatment effect (b = –0.095, 95% CI
–0.414 to 0.224; p = 0.561). The ICC for ‘study’ site remained 0. Appendix 14, Figure 52, shows the
forest plot of estimated treatment effects after controlling for age and duration of study. There was little
between-group variance (I2 = 0.047).
Step 3
The year of publication was not significant (p = 0.520) and did not alter the conclusion of the results.
The analyses of duration of illness with two studies did not reveal a significant moderating treatment effect
(arm × duration: 0.002, 95% CI –0.023 to 0.027; p = 0.878, n = 261 participants, nstudies = 2). There was
no main effect for duration of treatment after removing the interaction with treatment arm (b = –0.009,
95% CI –0.026 to 0.007; p = 0.262). However, after controlling for duration of outcome, a significant
treatment effect was observed. Participants receiving treatment improved, on average, more after
treatment (b = –0.38, 95% CI –0.661 to 0.099; p = 0.008, n = 261 participants, nstudies = 2).
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Individual patient data meta-analysis for studies of adolescents/children
with type 1 diabetes mellitus
Step 1
In step 1, we investigated the effect of treatment and baseline values for HbA1c levels only.
Glycated haemoglobin levels at baseline did not moderate the treatment outcome (interaction HbA1c level and
arm: b = –0.022, 95% CI –0.101 to 0.0581; p = 0.595, n = 1257, nstudies = 9). After removing the interaction,
there was a small but non-significant decrease in HbA1c levels at follow-up, after controlling for baseline values
in the treatment group compared with the control group (mean difference –0.127, 95% CI –0.282 to 0.030;
p = 0.112). Within-study correlation was small (ICC 0.039, 95% CI 0.012 to 0.12). The forest plot of the
meta-analyses is shown in Appendix 14, Figure 53. Between-study heterogeneity was moderate (I2 = 0.28).
Models included a random study intercept and random treatment HbA1c at baseline effects.
Step 2
In step 2, we explored age and duration of illness as potential moderators of treatment effect, in addition
to treatment arm and baseline values for HbA1c levels.
Including age and the interaction between age and treatment arm did not reveal a significant moderating
effect of age (arm × age = –0.048, 95% CI –0.115 to 0.019; p = 0.160, n = 1234 participants, nstudies = 9).
Similarly, there was no moderating effect of duration of diabetes in years with treatment arm
(arm × duration: –0.028, 95% CI –0.017 to 0.073; p = 0.224, n = 1125 participants, nstudies = 8).
Including age and duration together as moderators in the model resulted in similar non-significant
moderating effects (arm × age: – 0.068, 95% CI – 0.14 to 0.009; p = 0.07) (arm × duration: 0.039, 95% CI
–0.008 to 0.085; p = 0.10, n = 1122 participants, nstudies = 8).
After removing the interactions from the model, age and duration of treatment were significant as main
effects: independent of treatment arm, younger patients improved more (age: 0.046, 95% CI 0.005 to
0.086; p = 0.03) and patients with longer duration of diabetes improved more (b = –0.038, 95% CI –0.062
to –0.014; p = 0.002). The treatment effect remained non-significant after including age and duration
(–0.149, 95% CI –0.306 to 0.016; p = 0.08). The ICC for ‘study’ site remained small (0.035). Appendix 14,
Figure 54, shows the forest plot of estimated treatment effects after controlling for age and duration of
study. There was a small amount of between-group variance (I2 = 0.24).
Step 3
The year of publication was not significant (p = 0.273) and did not alter the conclusion of the results.
Individual patient data meta-analysis for studies of adults with type 2
diabetes mellitus
Step 1
In step 1, we investigated the effect of treatment and baseline values for HbA1c levels only.
The models included a random study intercept and random treatment HbA1c level baseline effects.
Glycated haemoglobin level at baseline significantly moderates treatment outcome (interaction HbA1c level
and arm: b = –0.077, 95% CI –0.127 to –0.027; p = 0.003, n = 2541 participants, nstudies = 19) (Figure 24).
Appendix 14, Figures 24 and 55, show the predicted mean differences in HbA1c levels at follow-up at varying
HbA1c baseline levels. At about 6.5% HbA1c (48 mmol/mol) at baseline, there were no treatment differences
between the intervention and control groups predicted. There was an increasing advantage of intervention
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with increasing HbA1c baseline levels. At the mean baseline level of HbA1c of 7.8% (62 mmol/mol), patients
in the intervention group had, on average, 0.107% (1 mmol/mol) (95% CI –0.190% to –0.023%;
p = 0.013%) lower levels of HbA1c at follow-up than patients in the control group. The random effect of
baseline HbA1c level suggests considerable variation between study sites (SD 0.124%, 95% CI –0.081% to
0.190%) and considerable within-study correlation (ICC 0.329, 95% CI 0.147 to 0.582). The forest plot of
the meta-analyses with centred baseline HbA1c levels [equivalent to holding baseline values constant at 7.8%
(62 mmol/mol)] is shown in Appendix 14, Figure 56. No between-study heterogeneity was estimated (I2 = 0).
Step 2
In step 2, we explored age and duration of illness as potential moderators of treatment effect, in addition
to treatment arm and baseline values of HbA1c, and the interaction between arm and HbA1c baseline values.
Including age and the interaction between age and treatment arm did not reveal a significant moderating
effect of age (arm × age = –0.003, 95% CI –0.012 to 0.006; p = 0.580, n = 2336, nstudies = 13). After removing
the interactions from the model, age predicted HbA1c level at follow-up (b = –0.009 (95% CI –0.014 to
–0.004; p < 0.001). The interaction between baseline HbA1c levels and treatment arm and treatment
difference at mean baseline values remained significant. The ICC for study site remained large (0.187).
Including duration of diabetes and the interaction between duration and treatment arm did not reveal a
significant moderating effect of duration (arm × duration = 0.012, 95% CI –0.027 to 0.003; p = 0.11,
n = 1457 participants, nstudies = 11). After removing the interaction from the model, duration of diabetes
predicted HbA1c level at follow-up: participants with a longer duration of illness had lower HbA1c values at
follow-up (b = –0.011, 95% CI –0.002 to –0.019; p = 0.011). The interaction between baseline HbA1c level
and treatment arm and treatment difference at mean baseline values remained significant. The ICC for
study site remained large (0.265).
Including type of treatment and the interaction between type of treatment and treatment arm did not
reveal a significant moderating effect of type of treatment (p = 0.211, n = 1415 participants, nstudies = 11).
After removing the interaction from the model, type of treatment predicted HbA1c level at follow-up
(χ2(2) = 14.83; p < 0.0001): participants treated with diet and exercise improved by 0.47% (5 mmol/mol)
HbA1c at follow-up compared with participants treated with insulin (b = –0.471, 95% CI –0.728 to –0.214;
p < 0.001). Participants treated with medication also improved compared with those treated with insulin
(b = –0.223, 95% CI –0.373 to –0.074; p = 0.003), but significantly less so than those treated with diet
and exercise (b = 0.247 95% CI 0.02 to 0.475; p = 0.033).
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FIGURE 24 The IPD meta-analysis comparing treatment with control in terms of HbA1c levels at follow-up for
studies of adults with T2DM. The plot shows the differences in predicted mean treatment outcome together with
95% CIs follow-up between intervention and control groups in dependency of the moderator HbA1c level at
baseline. Effect sizes are unstandardized differences in % HbA1c.
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The interaction between baseline HbA1c level and treatment arm (b = –0.042, 95% CI –0.113 to 0.030;
p = 0.251) and treatment difference at mean baseline values (b = –0.042, 95% CI > –0.187 to 0.048;
p = 0.245) were not significant. The ICC for study site remained large (0.265).
Including age and duration of illness in the model resulted in a similar conclusion. Independent of treatment
type, older people improved more than younger people (b = –0.008, 95% CI –0.013 to –0.002; p = 0.011)
and the longer the duration of diabetes, the less the improvement at follow-up (b = 0.013, 95% CI 0042
to 0.021; p = 0.003). The interaction between treatment and HbA1c level remained significant (b = –0.09,
95% CI –0.013 to –0.002; p = 0.008): participants in the intervention group improved more with increasing
HbA1c baseline values than participants in the control group. At average HbA1c baseline levels, participants in
the intervention group had 0.0134% lower HbA1c levels at follow-up than participants in the control arm
(b = –0.0134, 95% CI = –0.232 to –0.035; p = 0.008). The large ICC of 0.236 shows that study site was a
factor in the degree to which participants’ HbA1c levels changed.
The forest plot of the meta-analyses with centred baseline HbA1c levels [equivalent to holding baseline
values constant at 7.8% (62 mmol/mol)] and controlling for age and duration of illness is shown in
Appendix 14, Figure 57. No between-study heterogeneity was estimated (I2 = 0).
Removing the study169 with the small sample size (n = 15) did not alter the results or conclusion in any of
the analyses. Appendix 14, Figure 58, shows the forest plot of the previous meta-analyses repeated but
excluding this study.169
Including all three potentials in the model reduced the sample size to six study sites with 873 participants.
There were no significant interactions of age, duration of illness or treatment type with treatment. Main
effects of age, duration and type of treatment were also not significant. There was no significant
treatment effect.
Step 3
The year of publication did not have any significant influence on treatment outcome (p-values of > 0.19)
and did not alter conclusions of the meta-analyses.
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Chapter 7 Non-randomised controlled trial results
Study selection
A total of 16,900 citations were identified; 1794 duplicates were removed and 15,054 citations were
excluded following title/abstract screening. The full texts of 52 citations were screened; 38 were excluded
for the following reasons: unable to access published paper (n = 2), not nRCTs (n = 11), did not include a
psychological intervention (n = 16), interventionists not trained in psychological therapy (n = 4), HbA1c level
was not an outcome (n = 3) and was not limited to a T1DM/T2DM population (and did not report separate
analysis for diabetes; n = 2). The remaining 14 studies met the inclusion criteria for review (T1DM, 6 studies;
T2DM, 7 studies; and T1DM and T2DM, 1 study). Inter-reliability for full-text inclusion was calculated;
58.8% (Cohen’s kappa 0.588) agreement was found between the two raters (AK and RU). Higher
agreement (Cohen’s kappa 0.910) was found after initial discussion. All the included studies were nRCTs
(comprising prospective/retrospective cohort studies, quasi-experimental studies, pre-/post-test control
designs and observational controlled pre/post studies) published in English.
Characteristics of studies of people with type 1 diabetes mellitus
Six studies226–231 had a T1DM population. People with T1DM and people with T2DM were included in the
Harris et al.232 study, in which 55 patients had T1DM. These 55 patients were included in the T1DM
qualitative synthesis. Study characteristics are summarised in Table 18.
Study location
The studies originated from the following places: the USA (n = 3),229,231,232 Asia [Japan (n = 1)226 and Iran
(n = 1)227] and Europe [Germany (n = 1)228 and Spain (n = 1)230].
Participant characteristics
The seven studies investigating people with T1DM included a total of 419 participants (ranging from 4 to
117 people with T1DM per study). Studies included adult (n = 3)226–228 or adolescent populations
(n = 4).229–232
Studies of T1DM stipulated various inclusion criteria for participants, for example a HbA1c level of ≥ 9%;232
or ≥ 14%.229 Age criteria were also outlined: 12–16 years,229 16–30 years227 and 11–18 years.230 Other
inclusion criteria included being at a high risk of developing hypoglycaemia;228 no impaired vison, cognitive
impairment or psychiatric comorbidity;228 binge-eating behaviours;226 missed more than two clinic
appointments;232 and non-adherence to pharmacological treatment and/or mental state of concern to
medical providers.231
Intervention characteristics
Psychological interventions were underpinned by various psychological models or principles: family-based
interventions,229,232 inpatient therapy,226 stress management,227 a self-management intervention,228
psychoeducation230 and psychotherapy.231 The number of therapy sessions per study ranged from 6 to 56
(2 or 3 times a week over a 7-month period).229 The following facilitators delivered the psychological
interventions: therapists (n = 2),226,229 psychiatrists/psychologist (n = 4)227,228,230,231 and social worker/trainee
psychologist (n = 1).232
Control characteristics
The nRCTs delivered the following control groups: usual care (n = 5);227,229–232 counselling (n = 1);226 and
hypoglycaemia education (n = 1).228 Details regarding the components and delivery of usual care were limited.
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TABLE 18 Summary of all included studies in the nRCT systematic review
Year, country,
first author
Number of
participants
with T2DM
Mean (SD) age
(years)
(intervention
and control)
Inclusion criteria
for individual
studies
Mean
duration of
diabetes
(intervention
and control)
Type of
psychological
intervention
Number of
sessions
Intervention name;
facilitator; format;
individual/group
Control category,
facilitator, format,
individual/group Follow-up
T2DM nRCT studies
2004, South
Korea, Kim233
45 l Intervention:
53.82 (07.42)
l Control:
52.78 (12.46)
T2DM for < 20 years;
HbA1c level of
< 10.0%; no chronic
complications;
no insulin
l Intervention:
7.45 (7.32)
l Control:
7.32 (6.37)
Transtheoretical
model
NR Staged-matched
intervention;
researcher; face to
face and telephone;
individual
Usual educational
advice; NR
Post intervention
2007, South
Korea, Song234
59 l Intervention:
51 (11.3)
l Control:
49.5 (10.6)
T2DM; HbA1c level of
> 7.0%; no mental
illness; no diabetic
complications
l Intervention:
4.9 (5.3)
l Control:
5.0 (5.7)
Counselling and
multidisciplinary
diabetes education
NR Counselling and
education;
psychologist; face to
face and telephone;
individual and group
Usual care; diabetes
education; NR
3 months
2009, Italy,
Forlani235
822 l Intervention:
56.7 (8.5)
l Control:
64.8 (10.3)
T2DM NR CBT 12–15 CBT; psychologist;
face to face; group
Usual care
(prescriptive diet);
dietitian; face to
face; individual
Up to 48 months
2009, the USA,
Harris232
3 l Intervention:
16.0 (0.9)
l Control:
15.2 (1.5)
T1DM or T2DM;
HbA1c level of
≥ 9.0%; missed
more than two clinic
appointments
l Intervention:
16.0 (0.9)
l Control:
15.2 (1.5)
BFST-D 10 Family therapy;
Master’s level social
worker/trainee
psychologist; face to
face; group
Usual care; NR Post intervention
2011, South
Korea, Lee236
83 l Intervention:
61.14 (6.01)
l Control:
63.18 (5.11)
T2DM; aged
> 50 years;
no exercise for
> 3 days per week
for 1 month;
no microvascular
complications
NR Cognitive
psychology,
educational
theory, social
problem-solving
12 Chronic disease
self-care using heart
rate monitor; research
assistant; face to face;
group
See intervention
description; without
heart rate monitor
3 and 6 months
2013, Spain,
Cervantes
Cuesta237
72 l Intervention:
66.37 (11.96)
l Control:
61.04 (09.54)
T2DM; aged
30–75 years; HbA1c
level of ≥ 6.5%
NR Psychoeducation 11 Psychoeducative
group; NR; face to
face; group
Usual diabetes
education; NR
3 months
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Year, country,
first author
Number of
participants
with T2DM
Mean (SD) age
(years)
(intervention
and control)
Inclusion criteria
for individual
studies
Mean
duration of
diabetes
(intervention
and control)
Type of
psychological
intervention
Number of
sessions
Intervention name;
facilitator; format;
individual/group
Control category,
facilitator, format,
individual/group Follow-up
2014,
Thailand,
Ounnapiruk238
60 l Intervention:
66.97 (1.54)
l Control:
69.20 (1.29)
T2DM for
> 6 months;
aged 60–79 years;
no complications
l Intervention:
9.35 (1.53)
l Control:
11.27 (1.74)
Bandura’s
concept of
self-efficacy239
4 Behavioural
modification
programme;
researcher; face to
face; individual and
group
Usual care; NR 3–4 months
2014, Taiwan,
Wu240
228 60.83 (12.48)
for all
participants
T2DM; aged
> 20 years; language:
Mandarin or
Taiwanese; home
telephone
10.27 (8.34) for
all participants
Diabetes
self-management
programme
4 Self-management;
trained nurses;
face to face and
telephone, individual
and group
Usual care, diabetes
education
consultant; face to
face; individual
1 month
T1DM nRCT studies
2003, the USA,
Ellis229
4 14–15 T1DM for ≥ 1 year;
HbA1c levels of
≥ 14%; aged
12–16 years
5 –10 Multisystemic
therapy
2 or 3
times a
week
Multisystemic
therapy; trained
therapist; face to
face; group
Usual care; NR 3 months
2003, Japan,
Takii226
19 l Intervention:
23.8 (5)
l Control:
21.3 (4)
T1DM for ≥ 1 year;
female; 3 years post
treatment or no
treatment for
≥ 2 years after first
visit; binge-eating
> 500 calories in
one sitting and
compensatory
behaviour two or
more times a week
for 3 months
l Intervention:
7.6 (5.1)
l Control:
8.8 (4.9)
Integrated
inpatient therapy
NR Integrated inpatient
therapy; therapist;
face to face;
individual and group
Counselling;
physician; face to
face; individual
l Intervention:
up to
36 months
from discharge
l Control: up to
24 months
from discharge
2006, Iran,
Attari227
60 l Intervention:
19.7 (3.29)
l Control:
20.8 (9.52)
T1DM for ≥ 1 year;
aged 16–30 years
l Intervention:
2.10 (0.6)
l Control:
2.14 (2.3)
Stress
management
8 Stress management
training; experienced
psychiatrist; face to
face; group
Usual care; NR Post intervention
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D
O
I:
1
0
.3
3
1
0
/h
ta
2
4
2
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
2
0
V
O
L
.
2
4
N
O
.
2
8
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2020.
This
w
ork
w
as
produced
by
W
inkley
e
t
a
l.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
7
3
TABLE 18 Summary of all included studies in the nRCT systematic review (continued )
Year, country,
first author
Number of
participants
with T2DM
Mean (SD) age
(years)
(intervention
and control)
Inclusion criteria
for individual
studies
Mean
duration of
diabetes
(intervention
and control)
Type of
psychological
intervention
Number of
sessions
Intervention name;
facilitator; format;
individual/group
Control category,
facilitator, format,
individual/group Follow-up
2006,
Germany,
Kubiak228
107 l Intervention:
37 (14.1)
l Control:
34.3 (12.9)
T1DM; at a high risk
of developing
hypoglycaemia;
no impaired vision,
cognitive impairment
or psychiatric
comorbidity
l Intervention:
16.4 (10.6)
l Control:
16.2 (9.3)
Self-management
intervention
6 Self-management
treatment;
psychologist; face
to face; group
Education on
hypoglycaemia;
psychologist; face
to face; group
6 months
2009, the USA,
Harris232
55 l Intervention:
16.0 (0.9)
l Control:
15.2 (1.5)
T1DM or T2DM;
HbA1c level of
≥ 9.0%; missed
more than two clinic
appointments
l Intervention:
16.0 (0.9)
l Control:
15.2 (1.5)
BFST-D 10 Family therapy;
Master’s level social
worker/trainee
psychologist; face
to face; group
Usual care; NR Post intervention
2010, Spain,
García-Pérez230
57 l Intervention:
13.79 (2.16)
l Control:13.61
(1.44)
T1DM; aged
11–18 years
l Intervention:
5.74 (3.39)
l Control:
6.20 (4.1)
Psychoeducation NR Summer camp for
T1DM; psychologist;
face to face; group
and individual
Usual care; NR 3 and
12 months
2013, the USA,
Bitsko231
117 l Intervention:
15.24 (0.49)
l Control:
15.19 (0.43)
T1DM; non-
adherence to
pharmacological
treatment/mental
state of concern by
medical providers
l Intervention:
4.59 (0.52)
l Control:
6.23 (0.57)
Psychotherapy 9 Talk therapy; licensed
doctoral-level
psychologist; face to
face; individual and
group
Usual care; NR 12 months
NR, not reported.
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The control counselling intervention226 was delivered on a one-to-one basis by a physician. The education on
hypoglycaemia control intervention228 was delivered in a group environment by a psychologist.
Primary outcome
In all studies, HbA1c level (in % or mmol/mol) was assessed at baseline and follow-up. Follow-up periods
ranged from immediately post intervention to 12 months post intervention.
Secondary outcomes
The types of measures for secondary outcomes are outlined in Appendix 15. The following outcomes
were assessed for T1DM studies: presence of eating disorders,226 depression,228 control beliefs,228 fear
of hypoglycaemia,228 fear of diabetes complications,228 stress management227 and anxiety.228,230
Risk of bias in studies of type 1 diabetes mellitus
The quality assessment for each study is reported in Appendix 15, Table 39. Four studies226–228,230 had
information missing for more than one domain, which made the assessment of quality difficult; therefore,
no decision was made regarding the RoB for these studies. The domains that had missing information
included bias arising from deviations from intended interventions and missing data. The remaining three
studies229,231,232 also had no information for the bias arising from missing data, but an assessment could
be made based on other domains. One study231 was considered to be at a ‘serious’ RoB because of
confounding issues with inclusion of participants, non-adjustment of baseline characteristics and possible
selection bias. Two studies were rated as being at a critical RoB169,232 because of problems with participant
recruitment for the control group and absence of separate information for each group regarding
demographic characteristics.
Results of individual studies of type 1 diabetes mellitus
Five studies with a T1DM population reported mean HbA1c levels at baseline and follow-up for intervention
groups; two studies226,229 did not report these values (see Appendix 15, Table 40). Of the five studies, only
one demonstrated a significant difference between the intervention and control groups, with a greater
reduction in HbA1c levels in the intervention group.227 Three studies did not provide a test for significance
for the difference in HbA1c levels between baseline and follow-up, or between groups.226,229,232
For other outcomes, Takii et al.226 reported that, in the intervention group, 78% participants no longer met
the clinical criteria for eating disorders at follow-up. Attari et al.227 demonstrated statistically significant
between-group differences in positive coping for stress management in favour of the psychological
intervention group (stress management) compared with the control (usual care). García-Pérez et al.230
reported that there were no statistically significant between-group differences in anxiety outcomes.
Harris et al.232 observed a statistically significant group difference at follow-up and improvement in diabetes
responsibility and conflict for adolescents and their mothers, but not their fathers. However, for conflict
behaviour, Harris et al.232 did find statistically significant group difference and improvement at follow-up for
adolescents and both parents (mothers and fathers). Note that this was not limited to a T1DM population
(three people with T2DM were included in this analysis).
Kubaik et al.’s228 study did not demonstrate any statistically significant between-group differences for
depression, anxiety, control beliefs, fear of hypoglycaemia or fear of diabetic complications.
Characteristics of studies of people with type 2 diabetes mellitus
Seven studies included a T2DM population. In addition, one study (Harris et al.232) included a mixed T1DM
and T2DM population, of which three participants had T2DM; these three participants were included in
the T2DM qualitative synthesis when possible. Study characteristics are summarised in Table 18.
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Study location
The studies originated from Asia (South Korea, n = 3; Thailand n = 1; and Taiwan n = 1), Europe (Italy, n = 1;
and Spain n = 1) and the USA (n = 1).
Participant characteristics
The eight studies investigating people with T2DM represented a total of 1372 participants (ranging from 3
to 822 people with T2DM per study). Studies included adult (n = 7)233–238,240 or adolescent populations
(n = 1).97
Studies stipulated various inclusion criteria for people with T2DM to participate, for example a HbA1c level
of < 10%,233 ≥ 6.5%,237 > 7%,234 or ≥ 9%.232 Some studies specified no complication status,233,234,236,238 no
mental health illness,234 treatment type (no insulin233) and duration of diabetes (< 20 years233). Age criteria
were also outlined: > 20 years,240 30–75 years,237 > 50 years236 and 60–79 years.238
Intervention characteristics
Psychological interventions were underpinned by various psychological models or principles: trans-theoretical
model,233 counselling,234,240 cognitive–behavioural approach,235,236 BFST-D,232 psychoeducation237 and
Bandura’s concept of self-efficacy.238 Two studies reported the use of manuals.232,235 The number of therapy
sessions per study ranged from 4 to 15.
Psychological interventions were delivered by the following facilitators: researcher or research assistant
(n = 3),233,236,238 psychologist (n = 2),234,235 trainee psychologist (n = 1)232 and nurses (n = 1);240 one study did
not report the type of facilitator.237 The level of training received by the facilitators was reported in two
studies: one provided intensive training232 and the other reported that the facilitator was provided with
reading material regarding the intervention.240
Control characteristics
Control groups consisted of usual care (n = 7)232–235,237,238,240 and chronic disease self-care (n = 1).236 In some
cases, usual care included diabetes education or dietary advice. Details regarding delivery and components
of control groups was limited.
Primary outcome
In all studies, HbA1c level (% or mmol/mol) was assessed at baseline and follow-up. The follow-up period
ranged from post intervention to 48 months.
Secondary outcomes
The type of measures used are outlined in Appendix 15, Table 41. The following outcomes were assessed:
readiness to exercise;233 diabetes responsibility and conflict;232 coping;236 diabetes self-management
self-efficacy;238 depression, anxiety and stress;240 perceived treatment efficacy;240 and well-being.240
Risk of bias in studies of people with type 2 diabetes mellitus
The quality assessment for each study is reported in Appendix 15, Table 39. Four studies had information
missing for more than one domain, which made the assessment of quality difficult; no decision was made
regarding the RoB for this study. The domains that had missing information included bias owing to deviations
from intended interventions and missing data. The remaining four studies also had no information for the
bias arising from missing data, but an assessment could be made based on other domains. One study was
considered to be at a ‘serious’ RoB,235 mainly because of confounding issues with inclusion of participants,
non-adjustment of baseline characteristics and possible selection bias. Two studies were rated as being
at a ‘critical’ RoB232,240 and one as was rated as being at a ‘moderate’ RoB236 because of major problems
with participant recruitment for the control group and absence of information regarding demographic
characteristics for both groups separately.
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Results of individual studies of people with type 2 diabetes mellitus
The following paragraphs present a summary of individual studies. Appendix 15, Table 40, reports HbA1c
values (primary outcome) and Appendix 15, Table 41, presents secondary outcomes for all individual studies.
Only two of the eight studies demonstrated a significant difference between the psychological intervention
group and the control group, with a greater improvement in HbA1c level in the intervention group.234,240
Harris et al.232 and Lee et al.236 did not provide a significance test for the difference in HbA1c levels between
baseline and follow-up, or between groups.
For secondary outcomes, Kim et al.233 reported a statistically significant increase in the participants’
readiness to change and participate in physical activities in the psychological intervention group, but not
the control group. Lee et al.236 demonstrated no between-group differences in coping strategies post
intervention. In one study,238 self-efficacy regarding diabetes management did significantly improve in the
intervention group compared with control group at 3 months.
In the study by Wu et al.,240 statistically significant group differences and improved perceived self-efficacy
and self-care, and levels of depression, anxiety and stress were demonstrated in favour of the psychological
intervention.
Limitations of the type 1 and type 2 diabetes mellitus studies
Most studies reported the method of non-randomisation as a potential limitation that hindered the validity
and reliability of the test results. Other limitations that were reported included small sample size;229,231,233,238
possible selection bias in recruiting participants;144,229,230,235 study design, such as retrospective or lack of
participant blinding;231,240 duration of the follow-up;231,234,238,240 difference between the recruiting sites;228,230,238
psychological assessments lacking validity and reliability;234,236 absence of standardisation of measures to
gauge clinical significance;232 effect of media or self-study;234,236 and non-adjustment of baseline data for
psychological characteristics.230,235
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Chapter 8 Health economic analyses
Overview
In this chapter, we cover the methods and results of two cost-effectiveness modelling exercises:
1. the cost-effectiveness of CBT versus counselling versus usual care in adults with T1DM using an
adapted health economic individual-level simulation model – the Sheffield Type 1 Diabetes Policy Model
2. the cost-effectiveness of CBT versus counselling versus usual care in adults with T2DM using an adapted
health economic individual-level simulation model – the SPHR Type 2 Diabetes Prevention Model.
Detailed methods on the Sheffield Type 1 Diabetes Policy Model
Sheffield Type 1 Diabetes Policy Model framework
The Sheffield Type 1 Diabetes Policy Model, version 1.4, henceforth ‘the model’, is an individual-level
simulation model used to estimate the lifetime costs and QALYs for adults with T1DM. An individual’s
HbA1c level determines their risk of progression for all diabetic complications in the model, which include
nephropathy, neuropathy, retinopathy, macular oedema, myocardial infarction, stroke, heart failure, angina,
severe hypoglycaemia and DKA (see Appendix 16, Tables 48 and 50). A higher HbA1c level increases the
risk of progression for all complications in the model, except severe hypoglycaemia, for which a lower HbA1c
level increases the risk of experiencing an event. Individuals in the model are at risk of death from the
incidence of nephropathy, myocardial infarction, stroke, heart failure, angina and all-cause mortality. HbA1c
level indirectly affects mortality in the model, as the probability of death does not differ by HbA1c level;
however, the risk of experiencing these events is higher for someone with a higher HbA1c level.
The model has previously been used to assess the cost-effectiveness of various versions of the Dose
Adjustment For Normal Eating (DAFNE) course241,242 (see Appendix 16, Table 49), stratification of DAFNE
by psychological factors,243 structured education for children with T1DM and extending the use of insulin
pumps244,245 to all adults with T1DM who are eligible to receive a structured education course.
Complete details of how the model calculates the incidents of diabetes complications is provided in
Heller et al.245 and Thokala et al.246
The model attaches costs to clinical events and health states allowing the calculation of costs over a
lifetime. Full details are given in Appendix 16, Tables 42–45.
The model attaches utilities to health states, allowing the calculation of QALYs over a lifetime.247–250 Utility
decrements are applied additively; if an individual experiences decrements in two different submodels
(e.g. end-stage renal disease in the nephropathy submodel and myocardial infarction), then both decrements
are applied. If an individual progresses in a submodel (e.g. in the retinopathy submodel, an individual can
progress from proliferative retinopathy to blindness), then only the decrement associated with the more
severe health state is applied. Full details are given in Appendix 16, Table 48.
Baseline characteristics for the people with type 1 diabetes mellitus modelled in
this study
Individual baseline characteristics were sourced from the NICE T1DM guidelines27 (see table 69 in
the appendices of the NICE guideline NG1727) and our previous work on the cost-effectiveness of
DAFNE-structured education. Most characteristics and their SDs were sourced from the NICE T1DM
guidelines. If SDs were not available from the NICE guidelines27 (because of transformation of variables),
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the correlation between the variables was sourced from the DAFNE research database. Two variables
(the baseline cost of insulin used and the baseline cost of diabetes-related contacts with health-care
professionals) were sourced from the Relative Effectiveness of Pumps over Structured Education (REPOSE)
trial data set.245 The samples of these variables were conditional on the other samples. Full details are given
in Appendix 16, Table 47.
Incorporating short-term (1 year) clinical effectiveness evidence for people with type 1
diabetes mellitus modelled in this study
In the main economic analysis, the effectiveness of the different psychological interventions was sourced
from the NMA shown Table 6. The main estimates are presented in Appendix 16, Table 46. The estimate
for the effect of CBT versus usual care was –0.312 (95% CI –0.499 to –0.126). The estimate for the effect
of counselling versus usual care was –0.121 (95% CI –0.307 to 0.066). The full variance–covariance matrices
used for the PSA on mean effects are presented in Appendix 16, Tables 43–45.
For each individual, the psychological intervention effect and the individual’s baseline HbA1c level were
used to generate the HbA1c level at 1 year. In the model, we capture heterogeneity of response to the
psychological intervention by allowing individuals’ HbA1c levels at year 1 to vary, but ensuring that, when
aggregated, they would have the mean effect from the NMA. The statistical method to incorporate this
heterogeneity uses evidence on the dispersion of HbA1c from the REPOSE trial of T1DM244 (see Appendix 16,
Tables 47–50, and table 22 of supplementary B material in Pollard et al.244). The impact of including
heterogeneity in HbA1c response is that the modelled HbA1c profile for an individual is more likely to reflect
clinical practice, in which some people’s HbA1c level is likely to rise after 1 year and others’ levels are likely to
fall, with the average across all the individuals being that from the meta-analysis. Another consequence of
using this technique is that the use of the dispersion parameter involves using a beta regression framework,
which means that people with a low baseline HbA1c level cannot receive an implausibly low HbA1c value
(< 4.8%, based on clinical expert opinion) in the simulation.
Incorporating longer-term clinical effectiveness evidence for type 1 diabetes mellitus
The key study found was Ridge et al.251 This study used a RCT of adults with T1DM and suboptimal glycaemic
control who received motivational enhancement therapy (i.e. counselling) alone or motivational enhancement
therapy CBT. The participants in the group that received motivational enhancement therapy CBT showed a
greater reduction in their 12-month HbA1c levels than those who received usual care. Whether or not
improvements in glycaemic control persisted up to 4 years after randomisation was tested. Statistical analysis
was undertaken on 260 (75.6%) people who consented to take part in this post-trial study.
We used the information from this study251 and its supplementary material to examine the duration of
treatment effects over 2, 3 and 4 years. We calculated the implied trajectory using the sample size
weighted average of the 2-, 3- and 4-year follow-ups. This was calculated as:
½(weighted average of the year 2-, 3- and 4-year follow-ups) – (average HbA1c level at year 1)
/ (mean follow-up time – 1). (1)
This calculation was done separately for the CBT and counselling arms.
We developed to a method to analyse the uncertainty in this trajectory. This was based on the CI for the
HbA1c fall at year 1 and the CI for the weighted average HbA1c level in the follow-up years, assuming
normal distribution for each. The implied trajectory was calculated for each sample from these distributions.
We then calculated the correlation between the trajectory and the fall in HbA1c level at 1 year. We used this
to estimate a normal conditional probability distribution for the trajectory, conditional on the 1-year fall in
HbA1c level from the NMA. Again, the uncertainty in the trajectory was analysed separately for the CBT and
counselling arms.
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Appendix 16 (see Tables 70–72) shows the resulting parameters for the conditional distributions for CBT
and for counselling.
When a PSA run samples a negative trajectory versus usual care (i.e. a persistently widening gap over the
long term), we have modelled maintenance of the initial treatment gap, rather than assuming that a
psychological intervention can generate a wider gap at year 10 or 20 than it has at year 4. This was
partially because the psychological intervention in the Ridge et al.251 study was just a 1-year intervention
(i.e. no further active psychological intervention was provided after year 1).
Costing psychological interventions for adults with type 1 diabetes
The cost of psychological interventions was calculated, based on the information from the trials and
studies from the systematic reviews. The references104,105,162–166 were examined in detail to extract
information on the main elements of cost, which are as follows:
l costs of staff time to deliver the intervention
l session-related non-contact staff time
l cost of consumables per session
l costs associated with training the staff who will deliver the psychological interventions
l costs associated with supervision of staff
l proportion of sessions that are individual based versus group based
l number of course participants in group sessions.
These are broadly split into two categories: those types of resource use/cost that are assumed to be the
same across interventions and those that are different (Table 19). The following categories are assumed
to be the same across interventions: the interventionists, the session-related non-contact time (either as
a ratio of contact time or an absolute value), the cost of consumables and the training costs. In addition,
the following categories are assumed to be different: the split between individual and group sessions, the
average number of people in a group session, the number of sessions and the duration of each session.
TABLE 19 Key model parameters for Sheffield type 1 Diabetes Policy Model applied to psychological interventions
for adults with T1DM
Parameter Value(s) (95% CI) Source/calculation
Cost of CBT per participant £657.22 This study (see Appendix 16, Table 75)
Cost of counselling per participant £580.42 This study (see Appendix 16, Table 75)
Mean reduction in HbA1c level in first year, CBT
versus usual care (%)
–0.312 (–0.499 to –0.126) Chapter 5 of this study. See Appendix 16,
Table 66, for variance–covariance matrix
Mean reduction in HbA1c level in first year,
counselling versus usual care (%)
–0.121 (–0.307 to 0.066) Chapter 5 of this study
Long-term trajectory of HbA1c levels 12 months
after CBT: annual change in % HbA1c level
versus usual care (%)
–0.009 (–0.176 to 0.158)a Ridge et al.251 and further analysis in
Appendix 16, Table 66
Long-term trajectory of HbA1c levels 12 months
after counselling: annual change in % HbA1c
level versus usual care (%)
–0.062 (–0.341 to 0.216)a Ridge et al.251 and further analysis in
Appendix 16, Table 66
a When a PSA run samples a negative trajectory versus usual care (i.e. a persistently widening gap over the long term),
we have modelled maintenance of the initial treatment gap, rather than assuming that a psychological intervention can
generate a wider gap at year 10 or 20 than it has at year 4. This was partially because the psychological intervention in
the Ridge et al.251 study was just a 1-year intervention (i.e. no further active psychological intervention was provided after
year 1).
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For T1DM, the estimated cost per participant of delivering the interventions is as follows:
l cost of CBT intervention – £657.22 per participant
l cost of counselling intervention – £580.42 per participant.
When examined in terms of cost per participant per session, these costs are £82.34 for CBT and £72.72
for counselling, which are of a similar order of magnitude to the costs (£81.12 for CBT and £49.14 at
2005/6 prices) reported in the 2010 Health Technology Assessment study by Ismail et al.252
All costs were adjusted to 2015/6 GBP prices using the hospital and community health services pay and
prices index.253 A summary of the costs is given in Table 19 and details of the methods and costs can be
seen in Appendix 16.
Usual care costs presented in the studies included in the systematic review were either in the context of
the intervention being an enhancement to usual care or the usual care contacts when related to protocol
requirements (e.g. collection blood samples at baseline). Therefore, it was assumed that there were no
additional costs associated with usual care.
Main analysis of cost-effectiveness
The analysis conducted 500 model runs, with each PSA iteration sampling every uncertain parameter from
its associated probability distribution, and each PSA run modelling 5000 individuals in each arm of the
comparison.
The average of these 500 PSA runs is used to estimate expected discounted lifetime costs and expected
discounted QALYs associated with each strategy being compared.
Methods to analyse decision uncertainty in type 1 diabetes model using expected value
of perfect parameter information
Uncertainty is analysed using expected value of information statistics. The first is the overall EVPI, which
calculates how valuable it would be to a decision-maker (e.g. NICE) to eliminate all uncertainty on all the
model parameters (i.e. CIs do not exist, as every parameter is certainly known). The second is the EVPPI,
which is the same idea but focused only on particular model parameters (i.e. only a defined subset of
model parameters are certainly known, the rest are still uncertain).
The expected value of information calculations were estimated efficiently using a recently developed
online tool called SAVI254 at a maximum acceptable ICER of £20,000 per QALY gained, in line with NICE
decision-making thresholds.
Two subsets of parameters were explored in the EVPPI calculations: the parameters that would be generated
directly by trial information (i.e. 1-year change in HbA1c level for psychological intervention vs. usual care)
and the parameters that would be generated directly by the trial and a long-term follow-up study (1-year
HbA1c level effects, the long-term trends in HbA1c level post usual care, and the long-term trends in HbA1c
level post psychological intervention).
To quantify the overall scale of this uncertainty for the country, we need to consider the number of people
affected. We assumed that every adult currently living with T1DM in the UK could potentially be affected
by the decision as to whether or not they might benefit from a psychological intervention over a 10-year
decision relevance time horizon. This means that ≈370,000 people255 could be affected by the decision to
have or not have a psychological intervention over the next 10 years in the UK.
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Detailed methods on the School for Public Health Research Type 2
Diabetes Prevention Model
School for Public Health Research Type 2 Diabetes Prevention Model framework
The SPHR Diabetes Prevention Model was developed to forecast long-term health and health-care costs
under alternative scenarios for diabetes prevention. A wide range of stakeholders were involved in its
development, including clinicians, public health commissioners, diabetes and health economic researchers
and members of the public with diabetes. A detailed description of the methodology and assumptions
used in the model can be found elsewhere.99,256 Here we present a summary of the model.
The model is an individual patient simulation model based on the evolution of personalised trajectories for
metabolic factors including BMI, SBP, cholesterol and measures of blood glucose (including HbA1c).
The usual baseline population consists of a representative sample of the English population obtained from
the Health Survey for England, an annual survey that is designed to provide a snapshot of the nation’s
health.257 Note that we discuss in a later section of this report how the population has been adapted to
focus on a population of people already diagnosed with T2DM and treated (see Baseline characteristics for
people with type 2 diabetes mellitus modelled in this study).
The model runs in annual cycles over a lifetime horizon. Individuals’ BMI, cholesterol levels, SBP and HbA1c
level fluctuate from year to year, representing natural changes as they age and depending on personal
characteristics such as gender, ethnicity and smoking status.
The evolution of these individual-level trajectories, apart from HbA1c level, is based on a statistical analysis
of the Whitehall II cohort258,259 (see Appendix 16, Tables 51–53), a longitudinal data set of civil servants.
Every year in the model, an individual may visit their general practitioner or undergo an opportunistic
health check, and be diagnosed with and treated for hypertension, high cardiovascular risk or diabetes,
depending on their personal characteristics.
The model simulates a three-stage treatment regimen for people with T2DM:
1. First-line treatment assumes the use of low-cost treatments such as metformin (Glucophage®; Bristol-Myers
Squibb, Uxbridge, UK).
2. A second treatment [assumed to be sitagliptin (Januvia®; Merck, Sharp & Dohme Inc., Kenilworth, NJ, USA)
for the costings] is added if HbA1c levels rise above 8.48%, based on a recent study by Bennet et al.260
3. Initiation of insulin or triple therapy (third-stage treatment) occurs if HbA1c level rises above 9.5%,
which is the weighted average of the mean HbA1c level when people switched to insulin (9.78%) and
triple oral therapy (8.71%), from the same Bennett et al.260 study.
Individuals with HbA1c levels of ≥ 6.5% are at a risk of microvascular complications of diabetes, whether or
not they are diagnosed with diabetes (see Appendix 16, Tables 54 and 55). The UK Prospective Diabetes
Study (UKPDS)261,262 outcomes model risk equations are used to model the annual risk of kidney disease,
ulcer, amputation and blindness (see Appendix 16, Table 56).
For this diabetes treatment version of the model, we have updated the risk of cardiovascular events for
people with diabetes to be based on UKPDS CVD risk equations.
All-cause mortality is based on life tables for England and Wales.263
Appendix 16 contains a detailed list of parameters and sources used in the model. These include cancer
(see Appendix 16, Tables 57 and 58), osteoarthritis (see Appendix 16, Table 59), depression (see Appendix 16,
Table 60) and associated utilities (see Appendix 16, Table 61) and unit health-care costs (see Appendix 16,
Table 62).
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Each condition is associated with a utility decrement and a cost.
The utility of each individual in each year of the model is dependent on their age, gender and medical
conditions.
Costs are derived from published literature and inflated to 2015/16 GBP values using the hospital and
community health services pay and prices index.264 Costs for medications were obtained from the British
National Formulary265 and costs for health-care resource use were obtained from the Personal Social
Services Research Unit (PSSRU) unit costs.266
The model perspective is that of the NHS and PSS.
Baseline characteristics for people with type 2 diabetes mellitus modelled in this study
The baseline characteristics are taken from recently published NICE guidelines (NG28)267 for T2DM, in which
the full health economics report (see appendix F of the guidelines267) undertook simulation modelling for
groups of people who are at the first line, second line and third line of diabetes therapy. In appendix F of
the NICE guideline,267 section 3.3.3 (tables 20–28) sets out the methods for generating sampled patients in
each of the three groups, which we have simply replicated for this study.
Some of the variables needed for the UKPDS outcomes model 2 risk equations were not present in these
tables, such as triglycerides,7 haemoglobin262 and sets of other variables268 (low-density lipoprotein,
estimated glomerular filtration rate, heart rate, presence of micro- and macro-albuminuria and white blood
cell count); therefore, we generated procedures to sample or impute these, based on NICE guidance.267
Incorporating short-term (1-year) clinical effectiveness evidence for patients with
type 2 diabetes mellitus modelled in this study
In the main economic analysis, the effectiveness of the different psychological interventions was sourced
from the NMA shown Table 15. The main estimates are presented in Appendix 16, Table 64.
The estimate for the effect of CBT versus usual care is –0.234 (95% CI –0.372 to –0.096). The estimate
for the effect of counselling versus usual care is –0.132 (95% CI –0.23 to –0.033). These effects are
somewhat smaller than the equivalents for T1DM. The full variance–covariance matrices used for the
PSA on mean effects are presented in Appendix 16, Table 63.
For each individual, the mean psychological intervention effect and their baseline HbA1c level were used to
generate the HbA1c levels at 1 year (see Appendix 16, Table 65). In the T2DM model, we do not capture
heterogeneity of response to the psychological intervention because there was an absence of evidence
available from the NMA or other sources regarding this.
Incorporating longer-term clinical effectiveness evidence for type 2
diabetes mellitus
There is an absence of any T2DM long-term psychological intervention follow-up studies analogous to
the Ridge et al.251 study we used for T1DM. Therefore, we used the same conditional distribution for
the trajectory, conditional on the initial fall that we obtained from Ridge et al.251 (see Appendix 16,
Tables 66 and 67).
This enabled us to sample trajectories for CBT and for counselling in T2DM. The resulting mean trajectories
are shown in Appendix 16, Tables 66 and 67.
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Costing psychological interventions for adults with type 2 diabetes mellitus
The cost of psychological interventions was calculated, based on the information from the trials and
studies from the systematic reviews (see Chapter 4 for included studies). The references were examined
in detail to extract information on the main elements of cost, which are:
l costs of staff time to deliver the intervention
l session-related non-contact staff time
l cost of consumables per session
l costs associated with training the staff who will deliver psychological interventions
l costs associated with supervision of staff
l proportion of sessions that are individual based versus group based
l number of course participants in group sessions.
These are broadly split into two categories: those types of resource use/cost that are assumed to be the
same across interventions and those that are different. The following categories are assumed to be the
same across interventions: the interventionists, the session-related non-contact time (either as a ratio of
contact time or as an absolute value), the cost of consumables and the training costs (see Appendix 16,
Tables 73 and 74). The following categories are assumed to be different: the split between individual and
group sessions, the average number of people in a group session, the number of sessions and the duration
of each session.
For T2DM, the estimated cost per participant of delivering the interventions is estimated to be as follows:
l The cost of the CBT intervention is £633.20 per participant.
l The cost of counselling intervention is £940.02 per participant.
Note that the cost of counselling for T2DM is somewhat higher than the equivalent cost of counselling for
T1DM (see Appendix 16, Tables 71 and 72); the main reason for that is a larger number of sessions per
participant (≈11 for T2DM compared with ≈7 for T1DM, in the studies from the systematic review) (Table 20).
TABLE 20 Key model parameters for SPHR Type 2 Diabetes Prevention Model applied to psychological
interventions for adults with T2DM
Parameter Value(s) (95% CI) Source/calculation
Cost of CBT per participant £633.20 This study (see Appendix 16, Table 75)
Cost of counselling per participant £940.02 This study (see Appendix 16, Table 75)
Mean reduction in HbA1c level in first year,
CBT versus usual care (%)
–0.234 (–0.372 to –0.096) Chapter 5 of this study. See Appendix 16,
Figure 28, for variance–covariance matrix
Mean reduction in HbA1c level in first year,
counselling versus usual care (%)
–0.132 (–0.23 to –0.033) Chapter 5 of this study
Long-term trajectory of HbA1c levels post
12 months after CBT: annual change in % HbA1c
level versus usual care (%)
–0.063 (–0.257 to 0.130)a Ridge et al.251 and further analysis based
on distribution for trajectory, conditional
on initial fall
Long-term trajectory of HbA1c levels post
12 months after counselling: annual change in %
HbA1c level versus usual care (%)
–0.043 (–0.299 to 0.213)a Ridge et al.251 and further analysis based
on distribution for trajectory, conditional
on initial fall
a When a PSA run samples a negative trajectory versus usual care (i.e. a persistently widening gap over the long term),
we have modelled maintenance of the initial treatment gap, rather than assuming that a psychological intervention can
generate a wider gap at year 10 or 20 than it has at year 4. This was partially because the psychological intervention in
Ridge et al.251 was just a 1-year intervention (i.e. no further active psychological intervention was provided after year 1).
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All costs were adjusted to 2015/6 prices using the hospital and community health services pay and prices
index.264 A summary of the costs is given in Appendix 16, Tables 68–70, and details of the methods and
costs can be found in Appendix 16, Tables 76 and 77.
Usual care costs presented in the studies included in the systematic review were in the context of either
the intervention being an enhancement to usual care or the usual care contacts being related to protocol
requirements (e.g. collection of blood samples at baseline). Therefore, it was assumed that there were no
additional costs associated with usual care.
Methods to analyse decision uncertainty in the type 2 diabetes mellitus model using
expected value of perfect parameter information
The methods for this are broadly the same as those described for T1DM in Methods to analyse decision
uncertainty in type 1 diabetes model using expected value of perfect parameter information.
Uncertainty is analysed using expected value of information statistics. The first is the overall EVPI, which
calculates how valuable it would be to a decision-maker (e.g. NICE) to eliminate all uncertainty on all the
model parameters (i.e. CIs do not exist, as every parameter is certainly known). The second is the EVPPI,
which is the same idea but focused on particular model parameters only (i.e. only a defined subset of
model parameters are certainly known; the rest are still uncertain).
The expected value of information calculations were estimated efficiently using a recently developed
online tool called SAVI254 at a maximum acceptable ICER of £20,000 per QALY gained, in line with NICE
decision-making thresholds.
Two subsets of parameters were explored in the EVPPI calculations: the parameters that would be
generated directly by trial information (i.e. 1-year change in HbA1c levels for psychological intervention vs.
usual care) and the parameters that would be generated directly by the trial and a long-term follow-up
study (1-year HbA1c level effects, the long-term trends in HbA1c levels post usual care and the long-term
trends in HbA1c levels post psychological intervention).
To quantify the overall scale of this uncertainty for the country, we need to consider the number of people
affected. In the NICE guidelines,267 appendix F reported the number of people at first intensification as
17,871, those at second intensification as 14,069 and those at third intensification as 4462, from the The
Health Improvement Network (THIN) database. In 2016, Public Health England reported269 that 3.8 million
people in England have diabetes, of whom 90% are estimated to have T2DM, that is 3,420,000 people.
It is estimated that 1 in 4 people are unaware of their condition. This means that approximately 2,565,000
people are aware and undergoing treatment.
We used the above information to estimate that:
l The number of adults with T2DM who are currently at the first-line therapy stage (i.e. people treated
with diet and lifestyle advice plus metformin) is 1,259,000.
l The number of adults with T2DM who are currently at the second-line therapy stage (i.e. people treated
with metformin plus another oral agent) is 991,000.
l The number of adults with T2DM who are currently at the third-line therapy stage (i.e. people on
combination triple oral therapy or insulin) is 314,000.
We have assumed that all of these adults could potentially be affected by the decision as to whether or
not they might benefit from a psychological intervention over a 10-year decision relevance time horizon.
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Main health economic analysis results for adults with type 1 diabetes mellitus
Table 21 shows the mean cost-effectiveness of psychological interventions for adults with T1DM. The main
findings are as follows:
l The CBT strategy is marginally less costly over a lifetime than both the counselling strategy and the
usual care strategy. Counselling is marginally more costly than the usual care strategy.
l The CBT strategy is estimated to provide more QALYs over a lifetime than the counselling strategy,
which in turn is estimated to provide more QALYs than the usual care strategy.
l The CBT strategy is, therefore, the most cost-effective of the three strategies.
l The counselling strategy is estimated to be more cost-effective than usual care, with an ICER of £3800
per QALY gained, below the typical thresholds of £20,000 per QALY used by NICE.
Analysis of uncertainty for adults with T1DM
All of these results are subject to substantial uncertainty (shown in the next section) because there is
uncertainty about both the 1-year HbA1c level reduction effectiveness of each of the strategies, and
because there is uncertainty about the long-term maintenance of the effects.
Figure 25 shows the results of the PSA. The results in Figure 25a show that, although the average of the
PSA runs shows that we expect CBT to be more cost-effective than usual care (because the central dark
blue dot is below the diagonal line that indicates the cost-effectiveness threshold of £20,000 per QALY
gained), there is substantial uncertainty and CBT could be less cost-effective. Similar pictures are shown
for Figure 25b and c. The cost-effectiveness acceptability curve (CEAC) shown in Figure 25d demonstrates
that the probability that CBT is the most cost-effective of the three strategies is 64.6%.
TABLE 21 The mean health economic results for adults with T1DM based on 500 PSA runs: per person lifetime
discounted
Outcomes Usual care Counselling CBT
Lifetime discounted cost of strategy (£) 70,258 70,365 68,505
Incremental cost versus usual care (£) 106 –1754
Lifetime discounted QALYs 12.268 12.2959 12.3735
Incremental QALY versus usual care – 0.0279 0.1055
Net monetary benefit of strategy (QALYs × £20,000 –
cost) (£)
175,102 175,553 178,307
Incremental net monetary benefit versus usual care (£) – 452 3205
Net benefit on QALY scale (QALYs – cost/£20,000) 8.7551 8.7777 8.9154
Incremental net benefit on QALY scale versus usual care – 0.022591 0.1602725
ICER Dominated by CBT Dominated by CBT Dominant
Stability of model results Average Standard error Probability negativea
Incremental net monetary benefit of CBT versus the most cost-effective option out of counselling or usual care
in each PSA run at
£20,000 per QALY gained £911 £269 0.0004
£30,000 per QALY gained £1249 £342 0.0001
a A negative value implies that a different strategy would be the most cost-effective strategy, on average.
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FIGURE 25 Analysis of the uncertainty in cost-effectiveness for adults with T1DM. (a) CBT vs. usual care; (b) counselling
vs. usual care; (c) CBT vs. counselling; and (d) the cost-effectiveness acceptability curve for CBT vs. usual care. (continued )
HEALTH ECONOMIC ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
The overall EVPI is estimated at £1989 per person, which is equivalent to 0.0995-worth of uncertainty
per person affected by the decision between CBT, counselling and usual care. We can multiply this up by
the estimated 370,000 people with T1DM in the UK, and assuming that, say, 10% of these people might
be affected by the decision per year over a decision relevance horizon of 10 years, the decision uncertainty
is estimated to be valued at £73.6M per annum or £735.9M over the 10 years. This would be equivalent
to 36,790 QALYs-worth of uncertainty.
Figure 26 shows a new way of visualising the decision uncertainty called the HTA risk analysis chart,270
which is generated automatically from the PSA results by the online SAVI tool. The HTA risk analysis chart
is a method for conveying the uncertainty associated with the decision problem (the green element) as well
as the differences in cost-effectiveness measured using the net monetary benefit between the strategies
(the blue element) in a single, simple plot. The green bars represent the overall EVPI (also known as the payer
uncertainty burden in the risk analysis chart method). They are the same height for each intervention because
the payer uncertainty burden is the risk relating to uncertainty associated with the whole decision problem
rather than any specific decision strategy. The overall EVPI is £1989 per person affected by the decision, which,
at a maximum acceptable ICER of £20,000, is equivalent to 0.0995 QALYs-worth of decision uncertainty per
person (Table 22). The payer strategy-specific burden (PSB) is represented by the blue bars stacked on top of
the payer uncertainty burden. The PSB is the difference in cost-effectiveness measured using the net monetary
benefit between each strategy and the most cost-effective strategy. The most cost-effective intervention,
CBT, has a PSB of zero (a blue element of zero).
Given current costs and evidence, both usual care and counselling are less cost-effective than CBT, which
is indicated by their respective PSBs of £3862 and £2831 per person (equivalent to 0.1931 QALYs for usual
care and 0.1416 QALYs for counselling). The sum of the uncertainty burden and the payer strategy-specific
risk burden is shown on the cost scale on the y-axis (£5851 and £4820 respectively) and on the QALY scale above
each bar (0.293 and 0.241 QALYs, respectively). Shown below the graph, for the affected patient population per
annum, are the overall EVPI (£73.6M) and the PSBs for usual care (£142.9M) and for counselling (£104.8M). This
enables cross-comparison between decision problems in terms of the national scale of risk involved. Interpretation
of the implications of the HTA risk analysis chart is straightforward. If there is a substantial PSB (a large blue
component for an intervention), this suggests that the intervention would need to be cheaper, more cost-saving
or more effective for it to be considered cost-effective. If there is a large payer uncertainty burden (a large
green component to each bar), this means that there is substantial uncertainty in model parameters based
on current evidence, and suggests further evidence collection could help reduce decision uncertainty.
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FIGURE 25 Analysis of the uncertainty in cost-effectiveness for adults with T1DM. (a) CBT vs. usual care; (b) counselling
vs. usual care; (c) CBT vs. counselling; and (d) the cost-effectiveness acceptability curve for CBT vs. usual care.
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The EVPPI analysis allows us to understand which are the most uncertain parameters driving decision
uncertainty and, therefore, which might be the highest priorities for further evidence collection. The results
show that four main parameters are the key drivers of uncertainty. It is partly the 1-year effectiveness that
is a key driver – for both CBT and counselling. The single most uncertain and important parameter is the
long-term effectiveness of CBT. The long-term effectiveness of counselling is also important to decision
uncertainty. Together, these four parameters represent 88% of the overall decision uncertainty
(EVPPI = 0.88 when overall EVPI is indexed to 1.00).
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Population-level burdens: 37,000 people affected by decision per annum in jurisdiction
Population PSBs for each strategy:
Population PSB = £142.90M (7144.85 QALYs) for usual care
Population PSB = £0.00M (0.00 QALYs) for CBT
Population PSB = £104.76M (5237.94 QALYs) for counselling
Population payer uncertainty burden per annum (EVPI) = £73.59M 
(3679.46 QALYs-worth of uncertainty per annum)
FIGURE 26 The HTA risk analysis chart for the health technology assessment of CBT, counselling and usual care for
adults with T1DM in the UK.
TABLE 22 For adults with T1DM, which parameters most affect the decision uncertainty and are, therefore, the
highest priorities for further evidence collection?
Parameter(s)
EVPPI per
person (£)
SE of EVPPI
estimate
EVPPI indexed to
EVPI (EVPI= 1.00)
All parameters 1989 – 1.00
110. CBT 1-year HbA1c effect (HbA1c_drop_CBT) 53 29 0.03
111. Counselling 1-year HbA1c effect (HbA1c_drop_Cou) 184 63 0.09
112. CBT longer-term HbA1c effect (Traj_CBT) 1143 114 0.57
113. Counselling longer-term HbA1c effect (Traj_COU) 145 101 0.07
110 and 112 1149 99 0.58
111 and 113 566 93 0.28
110, 111, 112 and 113 1752 56 0.88
SE, standard error.
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Conclusions on the cost-effectiveness of cognitive–behavioural therapy versus
counselling versus usual care in adults with type 1 diabetes mellitus
The results of these analyses suggest the following conclusions:
l CBT could be considered a cost-effective psychological intervention compared with usual care and
compared with counselling.
l Counselling appears to be more cost-effective than usual care but less cost-effective than CBT.
l There is substantial decision uncertainty around these conclusions and priorities for further evidence
collection would, in particular, focus on the longer-term (i.e. beyond 12 months) maintenance of
effectiveness compared with usual care. In other words, is the HbA1c level gap between CBT and usual
care maintained beyond year 1, and, if not, how quickly does the effect wane and the HbA1c level
return to what it would have been without the psychological intervention?
l We have not been able to analyse subgroups of patients, either by baseline HbA1c level or by those who
might respond more or less well than average to psychological interventions, because the NMA could
not provide effectiveness evidence on such subgroups.
Results for the cost-effectiveness of cognitive–behavioural therapy
versus counselling versus psychotherapy versus usual care in adults with
type 2 diabetes mellitus
Main health economic analysis results for adults with type 2 diabetes mellitus
Table 23 shows the mean cost-effectiveness results for adults with T2DM. It is split into three parts:
(1) patients receiving first-line treatment (i.e. people treated with diet and lifestyle advice plus metformin),
(2) patients receiving second-line treatment (i.e. people treated with metformin plus another oral agent) and
(3) patients receiving third-line treatment (i.e. people treated with combination triple oral therapy or on insulin).
The main findings for patients receiving first-line treatment are as follows:
l The CBT strategy is marginally less costly over a lifetime than the counselling strategy, which in turn is
marginally more costly than the usual care strategy.
l The CBT strategy is estimated to provide more QALYs over a lifetime than the counselling strategy,
which in turn is estimated to provide more QALYs than the usual care strategy.
l The CBT strategy is the most cost-effective of the three strategies as it has an ICER of £11,135 per
QALY gained, compared with usual care.
l The counselling strategy is estimated to be more cost-effective than usual care.
The main findings for patients receiving second-line treatment are as follows:
l The CBT strategy is marginally less costly over a lifetime than the counselling strategy, which in turn is
marginally more costly than the usual care strategy.
l The CBT strategy is estimated to provide more QALYs over a lifetime than the counselling strategy,
which in turn is estimated to provide more QALYs than the usual care strategy.
l The CBT strategy is the most cost-effective of the three strategies.
l The counselling strategy is estimated to be more cost-effective than usual care.
The main findings for patients receiving third-line treatment are as follows:
l The CBT strategy is marginally less costly over a lifetime than the counselling strategy, which in turn is
marginally more costly than the usual care strategy.
l The CBT strategy is estimated to provide more QALYs over a lifetime than the counselling strategy,
which in turn is estimated to provide more QALYs than the usual care strategy.
l The CBT strategy is, therefore, the most cost-effective of the three strategies using a maximum
acceptable ICER of £30,000 per QALY gained, but not at £20,000 per QALY gained.
l The counselling strategy is estimated to be less cost-effective than usual care at both maximum acceptable
ICER values.
DOI: 10.3310/hta24280 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 28
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Winkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
All of these results are subject to substantial uncertainty (shown in the next section) because there is
uncertainty about both the 1-year HbA1c reduction effectiveness of each of the strategies, and because
there is uncertainty about the long-term maintenance of the effects.
Analysis of uncertainty of the results for adults with type 2 diabetes mellitus
Figure 27 shows the results of the PSA.
The results for people on first-line therapies (see Figure 27a–d) show that, although the average of the
PSA runs shows in Figure 27a that we expect CBT to be more cost-effective than usual care (because the
central dark blue dot is below the diagonal line that indicates the cost-effectiveness threshold of £20,000
per QALY gained), there is substantial uncertainty, and CBT could be less cost-effective. Similar pictures are
shown for Figure 27b and c. The CEAC shown in Figure 27d demonstrates that the probability that CBT is
the most cost-effective of the three strategies is 43%.
TABLE 23 Mean health economic analysis results for adults with T2DM based on 100 PSA runs, per person lifetime
discounted
Outcomes Usual care Counselling CBT
(Part 1) Patients receiving first-line treatment (i.e. people treated with diet and lifestyle advice plus metformin)
Lifetime discounted cost (£) 36,857 37,581 37,013
Lifetime discounted QALYs 8.7002 8.7059 8.7142
Incremental cost (£) – – 156
Incremental QALYs – – 0.0140
ICER Dominated by CBT £11,135
Net monetary benefit (£) 137,147 136,538 137,271
Net benefit on QALY scale 6.8574 6.8269 6.8635
(Part 2) Patients receiving second-line treatment (i.e. people treated with metformin plus another oral agent)
Lifetime discounted cost (£) 31,582 32,353 31,861
Lifetime discounted QALYs 8.9253 8.9304 8.9398
Incremental cost (£) – – 279
Incremental QALYs – – 0.0145
ICER – Dominated by CBT £19,246
Net monetary benefit (£) 146,923 146,255 146,935
Net benefit on QALY scale 7.3462 7.3127 7.3468
(Part 3) Patients receiving third-line treatment (i.e. people on combination triple oral therapy or insulin)
Lifetime discounted cost (£) 43,526 44,479 44,195
Lifetime discounted QALYs 7.6199 7.6344 7.6531
Incremental cost (£) – – £669
Incremental QALYs – – 0.0332
ICER – Dominated by CBT £20,163
Net monetary benefit (£) 108,873 108,210 108,868
Net benefit on QALY scale 5.4437 5.4105 5.4434
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FIGURE 27 Analysis of uncertainty in cost-effectiveness results for adults with T2DM. (a) CBT vs. usual care (first line);
(b) counselling vs. usual care (first line); (c) CBT vs. counselling (first line); (d) CEAC (first line); (e) CBT vs. usual care
(second line); (f) counselling vs. usual care (second line); (g) CBT vs. counselling (second line); (h) CEAC (second line);
(i) CBT vs. usual care (third line); (j) counselling vs. usual care (third line); (k) CBT vs. counselling (third line); and
(l) CEAC (third line). (continued )
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FIGURE 27 Analysis of uncertainty in cost-effectiveness results for adults with T2DM. (a) CBT vs. usual care (first line);
(b) counselling vs. usual care (first line); (c) CBT vs. counselling (first line); (d) CEAC (first line); (e) CBT vs. usual care
(second line); (f) counselling vs. usual care (second line); (g) CBT vs. counselling (second line); (h) CEAC (second line);
(i) CBT vs. usual care (third line); (j) counselling vs. usual care (third line); (k) CBT vs. counselling (third line); and
(l) CEAC (third line). (continued )
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FIGURE 27 Analysis of uncertainty in cost-effectiveness results for adults with T2DM. (a) CBT vs. usual care (first line);
(b) counselling vs. usual care (first line); (c) CBT vs. counselling (first line); (d) CEAC (first line); (e) CBT vs. usual care
(second line); (f) counselling vs. usual care (second line); (g) CBT vs. counselling (second line); (h) CEAC (second line);
(i) CBT vs. usual care (third line); (j) counselling vs. usual care (third line); (k) CBT vs. counselling (third line); and
(l) CEAC (third line). (continued )
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FIGURE 27 Analysis of uncertainty in cost-effectiveness results for adults with T2DM. (a) CBT vs. usual care (first line);
(b) counselling vs. usual care (first line); (c) CBT vs. counselling (first line); (d) CEAC (first line); (e) CBT vs. usual care
(second line); (f) counselling vs. usual care (second line); (g) CBT vs. counselling (second line); (h) CEAC (second line);
(i) CBT vs. usual care (third line); (j) counselling vs. usual care (third line); (k) CBT vs. counselling (third line); and
(l) CEAC (third line).
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The results for people on second-line therapies show (see Figure 27e–h) that, although the average of the
PSA runs shows in Figure 27e that we expect CBT to be more cost-effective than usual care (because the
central dark blue dot is just below the diagonal line that indicates the cost-effectiveness threshold of
£20,000 per QALY gained), there is substantial uncertainty, and CBT could be less cost-effective. Similar
pictures are shown for Figure 27f and g. The CEAC shown in Figure 27h demonstrates that the probability
that CBT is the most cost-effective of the three strategies is 41%.
The results for people on third-line therapies show (see Figure 27i–l) that, although the average of the PSA
runs shows in Figure 27i that we expect CBT to be just less cost-effective than usual care (because the
central dark blue dot is just above the diagonal line that indicates the cost-effectiveness threshold of
£20,000 per QALY gained), there is substantial uncertainty, and CBT could be more cost-effective. Similar
pictures are shown for Figure 27j and k. The CEAC shown in Figure 27l demonstrates that the probability
that CBT is the most cost-effective of the three strategies is 37%.
Figure 28 shows the HTA risk analysis charts270 for patients on first-, second- and third-line therapies,
separately. The green bars represent the overall EVPI (also known as the payer uncertainty burden in
the risk analysis chart method). The PSB is represented by the blue bars stacked on top of the payer
uncertainty burden. The PSB is the difference in cost-effectiveness measured using net monetary benefit
between each strategy and the most cost-effective strategy. Interpretation of the implications of the
HTA risk analysis chart are straightforward. If there is a substantial PSB (a large red component for an
intervention), this suggests that the intervention would need to be cheaper or more cost saving or more
effective for it to be considered cost-effective. If there is a large payer uncertainty burden (a large blue
component to each bar), then this means that there is substantial uncertainty in model parameters based
on current evidence, and suggests further evidence collection could help reduce decision uncertainty.
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FIGURE 28 The HTA risk analysis charts for health technology assessment of CBT, counselling and usual care for
adults with T2DM in the UK. (a) First line; (b) second line; and (c) third line. (continued )
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FIGURE 28 The HTA risk analysis charts for health technology assessment of CBT, counselling and usual care for
adults with T2DM in the UK. (a) First line; (b) second line; and (c) third line.
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In Figure 28a, results for people on first-line therapies show that the overall EVPI is estimated to be
£189.60 per person, which is equivalent to 0.01 QALYs-worth of uncertainty per person affected by the
decision between CBT, counselling and usual care. When multiplied by the estimated 1,259,000 people
with T2DM in the UK who are receiving first-line therapy, decision uncertainty is estimated to be valued
at £23.9M per annum or £238.7M over 10 years (equivalent to 11,930 QALYs-worth of uncertainty).
Given current costs and evidence, both usual care and counselling are less cost-effective than CBT, which
is indicated by their respective PSBs of £124 and £733 per person (equivalent to 0.0062 QALYs for usual
care and 0.0366 QALYs for counselling). Shown at the bottom of Figure 28, for the affected patient
population per annum, are the PSBs for usual care (£15.6M) and for counselling (£92.3M).
In Figure 28b, results for people on second-line therapies show that the overall EVPI is estimated to be
£226 per person, which is equivalent to 0.01 QALYs-worth of uncertainty per person affected by the
decision between CBT, counselling and usual care. When multiplied by the estimated 991,000 people with
T2DM in the UK who are receiving second-line therapy, decision uncertainty is estimated to be valued at
£22.4M per annum or £224M over 10 years (equivalent to 11,200 QALYs-worth of uncertainty). Given
current costs and evidence, both usual care and counselling are less cost-effective than CBT, which is
indicated by their respective PSBs of £12 and £681 per person (equivalent to 0.0006 QALYs for usual care
and 0.0340 QALYs for counselling). Shown at the bottom of Figure 28, for the affected patient population
per annum, are the PSBs for usual care (£1.2M) and for counselling (£67.5M).
In Figure 28c, results for people on third-line therapies show that the overall EVPI is estimated to be
£234.60 per person, which is equivalent to 0.01 QALYs-worth of uncertainty per person affected by the
decision between CBT, counselling and usual care. When multiplied by the estimated 314,000 people
with T2DM in the UK who are receiving third-line therapy, decision uncertainty is estimated to be valued
at £7.4M per annum or £74M over 10 years (equivalent to 3683 QALYs-worth of uncertainty). Given
current costs and evidence, usual care is just slightly more cost-effective than CBT, and both are much
more cost-effective than counselling, which is indicated by the PSBs of £5 and £663 per person for CBT
and counselling, respectively (equivalent to 0.0003 QALYs for CBT and 0.0332 QALYs for counselling).
Shown at the bottom of Figure 28, for the affected patient population per annum, are the PSBs for CBT
(£0.2M) and for counselling (£20.8M).
The EVPPI analysis allows us to understand which are the most uncertain parameters driving decision
uncertainty and, therefore, which might be the highest priorities for further evidence collection. The results
for each of the first-, second- and third-line therapy analyses show that four main parameters are the key
drivers of uncertainty (Table 24). It is partly the 1-year effectiveness that is a key driver, for both CBT and
counselling. The single most uncertain and important parameter is the long-term effectiveness of CBT.
The long-term effectiveness of counselling is also important to decision uncertainty.
The results for people on first-line therapies show that it is the 1-year effectiveness that is a key driver,
for both CBT (indexed EVPPI = 0.75) and counselling, with counselling much less important to decision
uncertainty (indexed EVPPI = 0). The long-term effectiveness of CBT has an indexed EVPPI of 0.25.
The long-term effectiveness of counselling is also important (indexed EVPPI = 0).
The results for people on second-line therapies show that it is the 1-year effectiveness that is a key
driver – for both CBT (indexed EVPPI = 0.64) and counselling, with counselling much less important to
decision uncertainty (indexed EVPPI = 0). The long-term effectiveness of CBT has an indexed EVPPI of
0.25. The long-term effectiveness of counselling is also important (indexed EVPPI = 0.06).
The results for people on third-line therapies show that it is the 1-year effectiveness that is a key driver,
for both CBT (indexed EVPPI = 0.64) and counselling, with counselling somewhat important to decision
uncertainty (indexed EVPPI = 0.11). The long-term effectiveness of CBT has an indexed EVPPI of 0.26.
The long-term effectiveness of counselling is also important (indexed EVPPI = 0.06).
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TABLE 24 Which parameters most affect the decision uncertainty and are, therefore, the highest priorities for
further evidence collection?
Parameter EVPPI per person (£) SE of EVPPI estimate
Indexed to overall
EVPI= 1.00
(Part 1) Patients receiving first-line treatment (i.e. people treated with diet and lifestyle advice plus metformin)
All parameters 189.60 – 1.00
743. CBT, 1-year HbA1c effect
(HbA1c_drop_CBT)
141.97 22.87 0.75
745. Counselling, 1-year HbA1c effect
(HbA1c_drop_Cou)
0.16 11.02 0.00
744. CBT, longer-term HbA1c effect
(Traj_CBT)
47.04 20.40 0.25
746. Counselling, longer-term HbA1c
effect (Traj_COU)
0.26 11.26 0.00
743 and 744 147.63 18.41 0.78
745 and 746 3.00 15.62 0.02
(Part 2) Patients receiving second-line treatment (i.e. people treated with metformin plus another oral agent)
All parameters 226.00 – 1.00
743. CBT, 1-year HbA1c effect
(HbA1c_drop_CBT)
145.28 23.66 0.64
745. Counselling, 1-year HbA1c effect
(HbA1c_drop_Cou)
0.00 11.56 0.00
744. CBT, longer-term HbA1c effect
(Traj_CBT)
58.47 23.50 0.26
746. Counselling, longer-term HbA1c
effect (Traj_COU)
14.12 15.51 0.06
743 and 744 150.13 20.27 0.66
745 and 746 27.43 18.90 0.12
(Part 3) Patients receiving third-line treatment (i.e. people on combination triple oral therapy or insulin)
All parameters 234.60 – 1.00
743. CBT, 1-year HbA1c effect
(HbA1c_drop_CBT)
150.29 18.76 0.64
745. Counselling, 1-year HbA1c effect
(HbA1c_drop_Cou)
25.77 17.32 0.11
744. CBT, longer-term HbA1c effect
(Traj_CBT)
61.01 25.81 0.26
746. Counselling, longer-term HbA1c
effect (Traj_COU)
3.42 13.81 0.01
743 and 744 164.43 17.00 0.70
745 and 746 28.80 19.79 0.12
SE, standard error.
Note
Adults with T2DM (first-, second- and third-line therapies shown separately).
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Conclusions on the cost-effectiveness of cognitive–behavioural therapy versus
counselling versus usual care in adults with type 2 diabetes mellitus
The results of these analyses suggest the following conclusions for patients receiving:
l first-line therapy –
¢ CBT could be considered a cost-effective psychological intervention compared with usual care
(ICER ≈£11,000 per QALY gained) and compared with counselling (CBT dominates counselling).
¢ Counselling would appear not to be cost-effective compared with usual care (ICER ≈£127,000 per
QALY gained).
¢ There is considerable decision uncertainty around these conclusions (although less so than for T1DM).
Priorities for further evidence collection would focus on the CBT versus usual care short-term
effectiveness, and longer-term (i.e. beyond 12 months) maintenance of effectiveness compared with
usual care.
l second-line therapy –
¢ CBT could be considered a borderline cost-effective psychological intervention compared with usual
care (ICER ≈£19,000 per QALY gained) and very cost-effective compared with counselling.
¢ Counselling would appear not to be cost-effective compared with usual care (ICER ≈£151,000 per
QALY gained).
¢ There is considerable decision uncertainty around these conclusions (although less so than for T1DM).
Priorities for further evidence collection would focus on the CBT versus usual care short-term
effectiveness, and longer-term (i.e. beyond 12 months) maintenance of effectiveness compared with
usual care.
l third-line therapy –
¢ CBT could be considered a borderline cost-effective psychological intervention compared with usual
care (ICER ≈£20,000 per QALY gained) and very cost-effective compared with counselling.
¢ Counselling would appear not to be cost-effective compared with usual care (ICER ≈£65,000 per
QALY gained).
¢ Once again, there is considerable decision uncertainty around these conclusions (although less so
than for T1DM). Priorities for further evidence collection would, again, focus on the CBT versus
usual care short-term effectiveness, and longer-term (i.e. beyond 12 months) maintenance of
effectiveness compared with usual care.
For all therapy lines, a confirmatory trial with a long-term follow-up is necessary to establish the long-term
treatment effect of psychological interventions for people with T2DM, as the only available long-term
evidence is from a population with T1DM.
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Chapter 9 Patient and public involvement focus
groups
Participants
Ten people with diabetes participated in the focus groups (five from Sheffield and five from London)
(Table 25). Four participants had T1DM and six had T2DM. Three males and seven females participated.
Results of focus groups
Five main themes of discussion were prevalent in both focus groups: (1) the need for psychological support
in practice, (2) views on psychological intervention delivery, (3) views on diabetes research outcomes,
(4) the importance of diabetes and psychology research and (5) dissemination of diabetes research.
Need for psychological support in practice
Several participants in both locations identified psychological interventions as a missing aspect of their care,
and that it should, at least, be offered. The Sheffield group seemed in agreement that if clinicians were more
psychologically aware, then some of their diabetes-related issues might be more likely to be addressed:
. . . that psychology behind it and that’s never, that kind of stuff isn’t brought up in those consultant
meetings . . .
Male Participant (MP), London
. . . quite a lot of it is emotional, managing your emotions with it, you know, when you have a bad
day . . .
Female participant (FP), London
. . . they have something in place for that person, and that is a choice, you’re not saying you have to
do it, but give the person the choice . . .
FP, Sheffield
Views on psychological intervention delivery
Participants identified that interventions could be particularly important for children and adolescents, but it
can depend on how they are delivered. Their views were in line with the studies, as most studies looked at
TABLE 25 Patient characteristics of peoples with diabetes participating in focus groups
Characteristic London focus group (n) Sheffield focus group (n) Total (n)
Type of diabetes
T1DM 3 1 4
T2DM 2 4 6
Gender
Male 1 2 3
Female 4 3 7
Total 10 10
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family interventions, and this was highlighted as important. They also identified peer support groups as
being potentially effective for them.
In relation to who should facilitate psychological therapy, psychologists with diabetes knowledge or
psychologically trained diabetes nurses were identified as suitable interventionists:
I think that the dream would be a psychologist who had some, even just background knowledge of
diabetes . . . if the diabetes nurse had been psychology trained then that should really be the ideal
scenario . . .
MP, London
Others expressed a need for a differentiation between a clinician who takes care of medical health, and a
clinician addressing mental health:
. . . I think the psychologist is good because you’ve kind of got your consultant and your nurse looking
after your medical side of it and I think if you’ve got a psychologist looking after your, you know,
perhaps I think I would probably prefer that and not necessarily to mix the two as much.
FP, London
One participant explained that, no matter what illness or condition you have, you need the nurse and
psychological input.
. . . you need both for any patient, I don’t care what illness you got, you need that . . .
FP, Sheffield
Views on diabetes research outcomes
In regards to views on components of psychological interventions and how they are explored in research,
the London group appeared surprised that follow-up points were not longer and they emphasised that
psychological problems are not easily resolved:
Because I would think, you know, if you’re having, like, psychological intervention, that might take
longer . . .
FP, London
I would think, if you were having psychological support, that’s going to take a couple of months
to get ingrained in you and then to change and then for you to start to change your behaviour,
so I wouldn’t imagine that a year is quite a short time . . .
FP, London
There appeared to be a consensus that psychological outcomes were more important to group members
than HbA1c level. It was suggested that HbA1c level is of more importance to clinicians and researchers than
the patients. Several participants reiterated the fact that only HbA1c level was commented on in clinical
appointments:
. . . they are looking only at the HbA1c and not at the whole approach.
FP, London
In the Sheffield group, there was some disagreement about who psychological interventions for people
with diabetes should target. For example, some believed interventions should be focused only on people
with suboptimal glycaemic control:
It’s a waste of resources going after someone who is already in control of it.
MP, Sheffield
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In contrast, a couple of other participants felt psychological interventions should be ‘part of the preventative
programme’ (FP, Sheffield) and that patients should be offered this support before glycaemic control worsens.
Both groups emphasised the importance of spending money and investing in psychological support to save
money in the long term from complications caused by poor self-management and psychological issues:
. . . what we’re saying is, it’s going to cost a lot of money to put these things into place, but if it
means people stay healthier both physically and mentally, in the long run it will save them.
FP, London
Importance of diabetes and psychology research
The participants also emphasised the importance of research being undertaken, in terms of linking diabetes and
psychology. The participants identified frequently that there is a psychological impact of living with diabetes:
. . . there is no health without mental health.
MP, London
It’s diabetes forever . . . is that we don’t have a holidays, we have diabetes, even when you go on
holiday you still have it to control, we still have it to care, so it’s life without a holiday . . .
FP, London
I think that’s one of the things that’s so difficult is that you don’t get a weekend off or a day off or a
minute off, it’s relentless in that way . . .
MP, London
The focus group itself seemed to have a positive impact on participants:
Yeah it’s really marvellous that we can come here and give our own view, I think that that’s so
important, as it’s psychological, you needed to talk to diabetics themselves, don’t you?
FP, London
Dissemination of diabetes research
There were a number of points raised that addressed how the research should be disseminated.
Some participants belonged to a variety of different research groups and charities, such as Diabetes UK.
They expressed interest in seeing updates of the research in Diabetes UK newsletters and magazines:
I always look at the Diabetes UK! In the Diabetes UK website, there is quite a lot.
FP, London
In addition, the knowledge of this research project itself was positively commented on. The participants
wanted to be informed about the research and to have copies of the outcomes:
. . . is so important and it’s nice to see that this is actually . . . I’d never heard about any research being
done into this side of it until now . . .
MP, London
Some participants expressed concern about whether or not the outcomes of the research could positively
and directly influence practice and provide access to psychological support. The group expressed a desire
to have this support available and accessible. One member explained that there was no point in being
informed about psychological interventions if there was no chance of having access to this support:
. . . if we can’t access it, it’s not much use us knowing about it.
FP, Sheffield
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Chapter 10 Discussion
Summary of main results
This systematic review and meta-analysis of psychological interventions to improve self-management in
people with T1DM and people with T2DM demonstrates that this is an active area of research; using our
original protocol, we identified 96 new RCTs from the literature that were reported between 2003 and
2016. This included five RCTs of adults with T1DM, 20 RCTs of adolescents/children with T1DM, 56 RCTs
of adults with T2DM and 13 RCTs with a mixed adult T1DM and T2DM population; there were also two
studies that used a mixed adolescent T1DM and T2DM population.189,194 Only adult studies were included
in the meta-analysis of T2DM. Most of the increased level of activity in this field has been in the
development and testing of psychological interventions for adults with T2DM.
The main results of the aggregate meta-analysis indicate that, for adults and adolescents/children with T1DM
in receipt of a psychological treatment, there is no significant improvement in glycaemic control. Overall,
psychological interventions have a statistically significant improvement in glycaemic control for adults with
T2DM, but the effect size is small and of borderline clinical significance. Results are discussed in more depth
for T1DM and T2DM and refer to the outcome of additional NMAs and IPD meta-analyses.
Adults with type 1 diabetes mellitus
In the aggregate meta-analysis, there was no statistically significant improvement in glycaemic control
for adults with T1DM in receipt of psychological treatment compared with those in the control group
(i.e. receiving usual care or attention control). These findings are consistent with our previous review of
adults with T1DM, which demonstrated a non-significant improvement in glycaemic control compared
with controls.57 However, when one of the outlier adult studies (a study aiming to improve depressive
symptoms in which glycaemic control was a secondary outcome)105 was removed from the meta-analysis
in the current review, there was a statistically significant improvement in glycaemic control, although it is
likely to be a clinically non-significant effect size (SMD –0.20, 95% CI –0.37 to –0.02, equivalent to a
–0.25 change in % HbA1c level or a reduction of ≈3 mmol/mol). It is important to consider the problems of
ignoring outliers in meta-analysis, especially when removal results in a change to the overall conclusion.271
Therefore, considering that this remains a small effect size and of limited clinical benefit for adults with
T1DM, a reduction of 0.4% in HbA1c level (≈4 mmol/mol) is considered beneficial.58 Our overall conclusion
remains the same: that, based on the available evidence, psychological interventions do not improve
glycaemic control in adults with T1DM. To underscore this, when data from the previous review and the
current review were combined, there was no change to this conclusion, although the evidence from the
current review is of high quality according to GRADE.
Which psychological treatment is the most effective for adults with type 1
diabetes mellitus?
According to the results of the aggregate meta-regression, it was not possible to determine which
psychological treatment was more effective, as CBT and counselling studies were not significantly different.
However, we also conducted a NMA and, as this uses the same aggregate data, although drawing on
direct and indirect comparisons, this does suggest that some treatments may be more effective than others
and that treatments can be ranked based on the probability of effectiveness. Therefore, the treatment arm
suggested by the NMA to be most effective was not a psychological intervention but ‘attention control’;
this was used in two out of seven studies in which ‘BGAT’ and ‘diabetes education’ were compared with
a psychological intervention. The fact that the ‘attention control’ groups here are probably most effective
is not surprising as, essentially, both are diabetes education interventions predicated on supporting individuals
to develop their knowledge and skills to improve self-management and achieve optimal glycaemic control,
and they parallel the success of the DAFNE-structured education programme272 and BGAT, which is a
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treatment to improve blood glucose awareness and glycaemic control.273 The next most successful treatment
identified by the NMA was CBT. Other meta-analyses60,274,275 focusing specifically on CBT interventions have
established these as effective in improving depressive symptoms for people with T1DM and T2DM, and one
study274 has established short-term improvement in glycaemic control (3–6 months) but not longer-term,
namely 12 months, which was the follow-up we used. Longer-term evaluation from the ADaPT study163
suggests that, even when CBT based treatment is effective in improving HbA1c levels for adults with T1DM
at 12 months, without ongoing treatment the benefits completely disappear by 24 months.251
Who should deliver psychological treatments to adults with type 1 diabetes mellitus?
According to the results of the aggregate meta-regression, there was no statistically significant difference
in outcome according to who delivered the psychological treatment, for example psychology professionals
compared with diabetes specialists. This contrasts with a pilot study of MI for adolescents with T1DM
delivered by a psychologist, which was effective,276 but not when diabetes specialists were trained in the
intervention for a RCT.174
Who benefits the most from psychological treatments for adults with type 1
diabetes mellitus?
For the IPD meta-analysis, we had data for six of the seven studies included in the aggregate meta-analysis
but data were limited in terms of potential independent or moderating variables, that is only age of
participants was available for all studies, and age was not found to be a moderator of treatment outcome
or a main effect. Therefore, more and comparable IPD across trials would be required to improve our
understanding of which individuals benefit most from psychological interventions.
Interpretation
Explanations for the lack of effectiveness of psychological interventions for adults may be summarised
as follows:
l Improved quality of RCT design and reporting, and, therefore, less potential for biased treatment effect.
In our previous review,57 we established that overall quality of the reporting of the included studies
was poor. In the current review, we were able to establish that most included trials were at a low risk
of bias, albeit the methods used differed between reviews; therefore, it was not possible to directly
compare the quality of the cohorts. However, given that studies included in the current review were
more likely to report intention-to-treat analyses, and CONSORT criteria67 and reporting are prerequisites
to publishing in most peer-reviewed journals, there is now less potential for overestimation of treatment
effects.
l Use of attention control focused on diabetes education.
As discussed in Chapter 5. The attention control groups used in two of the seven studies were identified
by the NMA as having the highest probability of being the best treatment. Therefore, educational
interventions that have a direct focus on diabetes self-management are likely to be as effective as,
if not more effective than, a psychological treatment that may focus more on improving motivation for
diabetes self-management; we did not have data on the secondary outcomes that could be pooled.
Furthermore, it may be a consequence that individuals who participated in these trials had not received
educational training in self-management prior to participation in the studies.
l Timing of psychological interventions in adults with T1DM.
Delivering psychological treatments to adults with T1DM at the right time for each individual may
influence their effectiveness. It has been suggested by a range of researchers that psychological support
should come before, during or after structured education. Poor psychological adaptation to T1DM may
occur in childhood-onset277 or adult-onset T1DM; around half of people with T1DM are diagnosed in
adulthood.278 In a meta-synthesis of qualitative research on adjustment to diagnosis in adults with
T1DM, Due-Christensen et al.279 conclude that the physical and social stress of adapting to T1DM
causes psychological distress and, without support to minimise the distress, may increase the likelihood
of developing beliefs and behaviours that have a detrimental impact on motivation for diabetes self-
management and optimisation of glycaemic control. The average duration of diabetes for participants
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included in the IPD meta-analysis was ≈8 years; therefore, most of the interventions in the current
review were not focused on people with new-onset T1DM. This suggests that we need to determine
whether we need to address skills training in diabetes self-management first and psychological distress
later or both together. We should also consider what is the best outcome, as measuring change in
diabetes distress and depressive symptoms may be more appropriate than glycaemic control. We may
also need to consider whether or not existing interventions, such as CBT, are in fact the best approach,
as many are derived from mental health models to improve depression and do not necessarily provide
the best fit for someone trying to cope with a long-term chronic condition such as diabetes.280,281
Health economics
Cognitive–behavioural therapy interventions are potentially cost-effective, because of the potential for a
larger improvement in glycaemic control compared with counselling therapies or usual care; this is supported
by the NMA. However, there was a substantial uncertainty with the economic modelling; long-term studies
are required to determine the maintenance of benefits and to eliminate decision uncertainty.
Adolescents/children with type 1 diabetes mellitus
In the aggregate meta-analysis, there was no statistically significant improvement in glycaemic control for
adolescents/children with T1DM in receipt of a psychological treatment compared with those in receipt of a
control (i.e. usual care, attention control or a less intensive psychological intervention). The current findings
are inconsistent with the previous review for adolescents/children with T1DM, which demonstrated a
significant improvement in glycaemic control for people in receipt of a psychological therapy.57 However,
the evidence from the current review is rated as being of high quality according to GRADE and, therefore,
is likely to contain more reliable estimates.
Which psychological treatment is the most effective for adolescents/children with type 1
diabetes mellitus?
It was not possible to determine from the meta-regression which type of psychological therapy
(i.e. counselling, family therapy or CBT) had the most potential for effectiveness in improving glycaemic
control. However, one of the reasons why the results of this review are in contrast to the earlier review
could be because of the increased use of attention control groups, used in 27% of included studies. In
addition, although the NMA suggests that none of the treatments was effective overall, attention control
had the highest probability of being the best treatment in terms of improving glycaemic control for young
people, followed by CBT and family therapy. A recent systematic review and meta-analysis282 of UK-based
psychoeducational interventions for adolescents with T1DM achieved a similar non-significant improvement
in glycaemic control; the authors did not compare types of psychological therapy,282 but were able to
determine a moderate effect on improving self-efficacy. However, a systematic review283 of educational
interventions that aimed to improve skill development reported improved QoL for young people when
interventions incorporated psychological components such as stress reduction and coping skills training.
Who should deliver psychological treatments to adolescents/children with type 1
diabetes mellitus?
We compared interventionist type in the aggregate meta-regression; there were no statistically significant
differences in effectiveness for interventions delivered by psychology professionals compared with those
delivered by diabetes specialists. Therefore, we can say the challenge now is to make diabetes health
professionals more effective in delivering psychological interventions to young people with T1DM;
although other recent reviews282,283 have mainly included studies delivered by nurses, these have not
conducted a comparative analysis.
Who benefits the most from psychological treatments for adolescents/children with
type 1 diabetes mellitus?
Our IPD meta-analysis was based on 50% of the studies included in the aggregate meta-analysis and
suggested that participation in research was beneficial for young people. There were main effects
demonstrating that younger participants had improved glycaemic control over the intervention period,
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as did participants with a longer duration of diabetes. However, we were not able to determine whether
particular subgroups of young people, such as those with behaviour problems or depression,284 benefited
more as these data were not requested from study authors given that it would have been difficult to
request comparable information across studies.
Interpretation
Explanations for the lack of effectiveness of psychological interventions for adolescents/children may be
summarised as follows:
1. Improved quality of trial reporting, as noted for adults with T1DM.
2. Increased use of attention control groups.
This highlights the ethical dilemma faced by researchers who may want to ensure ‘therapeutic
equipoise’: the need to establish genuine doubt regarding the superiority of the treatments being
compared.285 This means that offering ‘something’ rather than nothing, that is standard or usual care
alone, is considered important and may encourage participation in a RCT, and that participation can
provide benefit. Therefore, on the one hand, this makes it more difficult to derive an overall effect and,
on the other hand, attention control is a good comparator if the psychological intervention is more
intense and process evaluation is conducted to identify key ingredients that may be common to
both groups.
3. Relatively varied psychological interventions tested in combination with varied control groups.
Under the umbrella of psychological treatments for adolescents/children with T1DM, there are now
multiple treatment comparisons, and not only is there heterogeneity in terms of the type of intervention,
the mode of intervention delivery and the recipients, be they individual, family, parents or a combination
of all three, but also there are numerous control groups to consider. Related to points 2 and 3 is that,
for adolescents/children, it was not possible to conduct meta-analysis on secondary outcomes, such as
psychological status, DKA admission rates or self-management activities such as blood glucose testing.
There were too few studies using secondary outcome measures that could be pooled.
Health economics
It was not possible to determine the cost-effectiveness of psychological interventions for adolescents/
children with T1DM as there was no evidence of any improvement in HbA1c levels from the meta-analyses.
Type 2 diabetes mellitus
In an aggregate meta-analysis of 49 trials, there was a statistically significant improvement in glycaemic
control for adults with T2DM in receipt of a psychological treatment compared with those in receipt of a
control (usual care or attention control). This was a small effect at –0.21 (95% CI –0.31 to –0.10) or –0.33
change in % HbA1c level (a reduction of ≈3.5 mmol/mol) and, therefore, of borderline clinical significance,58
usually a 0.4% (4–5 mmol/mol) reduction in HbA1c level, as this is associated with a reduction in the
development of microvascular disease. Our previous review40 to determine the effectiveness of psychological
interventions for T2DM included in the meta-analysis 12 studies published from 1983 to January 2003,
whereas this review compared studies from February 2003 to 2016. The previous review40 reported a
clinically relevant moderate effect size in terms of improved glycaemic control, whereas the current review
reported a smaller effect size. When combined (n = 61), there remained a small effect, but the combined
effect was at the level of clinical significance (SMD –0.22, 95% CI –0.32 to –0.12, equivalent to a –0.35
change in % HbA1c level, or a reduction of ≈4 mmol/mol). However, it is difficult to determine which cohort
is most reliable as the moderate GRADE assessment indicates that there was significant heterogeneity
across studies for glycaemic control and other outcomes. Other systematic reviews from 2015–1762,286,287 of
psychological interventions for people with T2DM have reported variable improvement in glycaemic control.
In other words, the effectiveness of psychological treatments is getting smaller over time.
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Which psychological treatment is the most effective for adults with type 2
diabetes mellitus?
The aggregate meta-regression demonstrated that both CBT- and counselling-based interventions were
effective in improving glycaemic control, but there was no significant difference between the two. Results
of the NMA suggested that, when direct and indirect evidence was combined, there was no psychological
treatment that demonstrated an overall effect, although some power is lost to support model consistency
and effect sizes were similar to aggregate results (CBT –0.213, p = 0.09 and counselling –0.166, p = 0.09).
The NMA ranking of CBT and counselling suggested that each shared the probability of being the best
treatment. A recent systematic review62 of MI (therefore counselling interventions) reported that three62,286,287
of the 13 included studies demonstrated a significant reduction in HbA1c levels compared with a control
group. In contrast, a systematic review and meta-analysis287 of CBT for people with depression and T2DM
reported moderate to large effect sizes for glycaemic control and improvement in depressive symptoms,
respectively.
For secondary outcomes, there was no evidence for psychological therapies improving depression over
controls. Previous reviews focusing on distinct populations of people with depression and diabetes find
that psychological treatments are effective.59,60,275 However, the current review included different clinical
subgroups, suboptimal glycaemic control, specific age groups and ethnicities and specific diabetes duration,
and few were depressed populations. Our earlier reviews40,288 also demonstrated that psychological
interventions significantly reduced psychological distress over controls. QoL and dietary behaviour, a
potential moderator of glycaemic control, for participants in receipt of psychological interventions improved
significantly compared with controls. However, there was no statistically significant improvement in BMI or
blood pressure. Our previous review40 also found no effect of psychological therapies in improving weight
control. However, weight loss, if successful, may take longer than improvement in glycaemic control,
and behavioural or lifestyle interventions that specifically target BMI as an outcome are likely to be more
effective.286
Who should deliver psychological treatments to adults with type 2 diabetes mellitus?
It was not possible to determine whether psychology professionals or diabetes specialists were more
effective as interventionists. Both were effective according to aggregate meta-regression; however, there
was a high level of heterogeneity for interventions delivered by diabetes specialists. An explanation for
these results could be twofold: (1) there may be less variability in psychological interventions delivered by
psychologists across studies as the techniques and training is likely to be more in-depth and (2) there is
also qualitative evidence that psychological techniques are difficult for non-psychologists to deliver and
they may not want to be trained in psychological techniques.289
Who benefits the most from psychological treatments for adults with type 2
diabetes mellitus?
Our IPD meta-analysis was based on 50% of the included studies and demonstrated a significant interaction
effect between baseline HbA1c level and treatment, suggesting that psychological interventions are most
effective when the baseline HbA1c level is ≥ 8% (≥ 64 mmol/mol). This finding has previously been
established in a systematic review and NMA of behavioural and lifestyle self-management programmes for
people with T2DM.286 Therefore, it would make sense to target interventions for people who are struggling
with glycaemic control rather than for people with relatively good HbA1c levels, who are probably motivated
to self-manage their diabetes effectively. This finding may also, in part, explain why there was such
heterogeneity of effect across studies in the aggregate meta-analyses. There were main effects for age and
diabetes duration, and older participants and people with a shorter duration of diabetes improved over the
intervention period. It is concerning that younger people with T2DM are less likely to improve and younger
adults with T2DM are less likely to attend for diabetes monitoring such as annual checks (National Diabetes
Audit 2016/17). The reasons for this are likely to be multifactorial, reflecting the difficulties faced by people
of working age in managing a chronic illness16 and perhaps also approaches to lifestyle that have led to
diagnosis of T2DM when young that may be more resistant to change.
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Considering the high level of heterogeneity across trials in terms of their effectiveness in improving
glycaemic control, it is helpful to consider whether or not there could be a ‘blueprint’ for a successful
psychological treatment for adults with T2DM. A crude method for doing this is to summarise the main
characteristics of trials that demonstrated the largest effect. The five studies with the largest effect size
from this meta-analysis suggest that the most effective treatments are counselling, usually MI, and
CBT-based interventions. The interventionists were nurses or psychologists/therapists, although most did
not adequately describe the training the interventionists received. However, some were pre-trained, such
as fully trained therapists, or were in receipt of training delivered by clinical psychologists and psychiatrists.
The dose of therapy received by participants was 4 to 12 group or individual face-to-face sessions.
Interpretation
Explanations for the small effect of psychological interventions on improving glycaemic control for adults
with T2DM may be summarised as follows:
1. Improved quality of trial reporting, as previously described for T1DM.
2. Improved ‘usual’ care in control groups and/or availability of attention control groups, both of which
may include diabetes education together with a lack of an effect of psychological treatment –
the standards of diabetes care for people with T2DM in the UK has improved markedly since the
introduction of the primary care targets and Quality and Outcomes Framework.290
3. Including diverse populations in the meta-analyses and including interventions for which glycaemic
control was a secondary outcome –
this includes interventions that recruited participants with optimal glycaemic control, who therefore had
little room for improvement and determination of effect of treatment.
4. potential lack of fidelity and quality assurance of psychological treatment –
although most studies reported on the training interventionists received, few reported whether or not
interventionists actually achieved competency in the techniques prior to the start of the intervention,
or quality assurance of ongoing performance was not described. These aspects are inherent to the
successful delivery of psychological interventions and, over time, this may become a marker of quality
for this type of non-pharmacological intervention.
5. reducing the intensity of the psychological interventions –
there is increased pressure on NHS resources and research funders seek the most cost-effective
interventions. Researchers are perhaps more likely to get research funding for a low-intensity
intervention as it is cheaper to run and, if effective, cheaper to deliver.
Health economics
Cognitive–behavioural therapy was found to be less costly than counselling interventions, mainly because
there were fewer sessions involved across studies. CBT was also potentially more cost-effective than
counselling interventions or usual care, although this varied according to whether or not participants were
in receipt of treatment for T2DM. Therefore, CBT was the most cost-effective when participants were
treated with diet and exercise plus or minus metformin, rather than two or more oral antidiabetic agents
and/or insulin treatment. However, larger studies are required to reduce decision uncertainty; as for adults
with T1DM, more long-term data on effectiveness are required. This is particularly the case for people with
T2DM, as no long-term studies were found in a population of people with T2DM that could inform how
long the effects of psychological interventions were maintained.
Other evidence
Evidence from the patient and public involvement focus groups
When we presented preliminary findings of our evidence synthesis to people with diabetes, one of the
main themes generated from the focus groups was the fact that psychological support and treatment
is one aspect of diabetes care that is currently missing. This is interesting, as some of the participants
attended King’s College Hospital NHS Foundation Trust and others attended Sheffield Teaching Hospitals
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NHS Foundation Trust, both of which provide some psychological treatment and much more than smaller
hospitals or primary care clinics. All participants spoke about the day-to-day psychological struggle of
managing diabetes and they believed that this approach might really help them. Although they understood
why we were focusing on glycaemic control for this review, they felt that psychological outcomes were just
as important, if not more so, but unfortunately these were not measured in most of the included studies.
Despite the fact that psychological treatments, overall, were not effective in improving glycaemic control in
adolescents/children and adults with T1DM and of limited effect for adults with T2DM, they believed that
these treatments would be cost-effective in the long term.
The importance of psychological support among people with diabetes was recently highlighted by a report
generated by Diabetes UK called The Future of Diabetes.291 This report is the result of conversations with
9000 people with diabetes who identified psychological support as the most important area that could
make it easier to live with diabetes in the future. Therefore, even though psychological interventions were
not, on the whole, effective in terms of glycaemic control, they may have discrete benefits, but we were
not able to analyse other outcomes, such as diabetes distress, because of the heterogeneity of outcome
measures used across studies.
Evidence from non-randomised controlled trials
We conducted a systematic review of nRCTs comparing the effectiveness of a psychological treatment versus
a control group. Fourteen studies were identified (T1DM, n = 6;226–231 T2DM, n = 7;233–238,240 and mixed T1DM
and T2DM, n = 1232); only three demonstrated statistically significant improvement for those receiving
psychological treatment versus usual care control203,234,240 (one study of people with T1DM in receipt of stress
management intervention and two studies of people with T2DM in receipt of counselling240). Few studies
demonstrated significant results for different reasons. The RoB assessment suggested that most studies were
of poor quality or did not provide adequate information; sample sizes were small and exhibited selection
bias; and the competency of the interventionists was questionable. As studies were generally of poor quality,
we did not consider adding them to aggregate meta-analyses or NMAs.
Strengths and limitations of this evidence synthesis
The strengths of this review included our choice of a defined research question and conducting a systematic
review according to PRISMA guidance.292 We did not limit the research to English language publications and
we attempted to identify published and unpublished studies, including hand-searching conference abstracts
from the main national and international diabetes conferences. We used a detailed protocolised approach
to identify studies for inclusion in terms of the definition of the health technology (i.e. psychological
intervention) and main and secondary outcomes. We contacted authors when information was missing for
inclusion in meta-analyses and also performed network analyses to maximise data from studies comparing
multiple interventions. We also conducted an IPD meta-analysis for the main outcome of interest, namely
glycaemic control. A further strength is our inclusion of the same protocol we used approximately 10 years
ago, to allow us to pool results and so determine cohort effects.
Limitations of the review include that we were unable to determine whether or not psychological
interventions worked best among different cultures, as most were conducted in western Europe and
North America and few studies adequately described the specific cultural setting. There are also potential
difficulties applying psychological interventions developed in one country to another with a different health
system, such as the difference between UK and non-UK studies. We did determine that studies conducted
in Asian countries were more likely to be effective, but they also had a higher RoB. Although we know
that there are periods on a person’s journey with diabetes that might be particularly psychologically
stressful, such as diagnosis, starting insulin for T2DM or the onset of diabetes complications, we were
not able to find studies that had been specifically developed for these subgroups. Other factors that may
affect the results of this review include the rising numbers of people diagnosed with T2DM, meaning there
may be an increased awareness of diabetes among the general public and an associated awareness of
psychological distress,291 which may make people more aware of the need to seek psychological help.
Treatment for depression and anxiety is widespread in the UK since the Improving Access to Psychological
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Therapies programme, which provides low-intensity psychological treatments, was introduced in 2008.293
Prior access to psychological support was not adequately measured in the included studies.
Limitations at the protocol level include our reliance on using title and abstract to screen for relevant
studies. In our previous reviews, this was an adequate strategy as the terminology used to describe
psychological interventions was explicit. However, in the current work, we identified that this approach
was not adequate to detect all studies as the detail of psychological interventions was sometimes
described only in the main text rather than the abstract and suggests that there is a dilution and infusion
of psychological theory into complex interventions without specifying directly what the components are.
We tried to address this by conducting a re-screen of abstracts previously rejected and undertaking
sensitivity analyses. Other limitations reflect the concentration of psychological interventions in particular
countries; most were from the USA and western Europe. We assume that our search strategy was robust
enough to identify trials in other regions as some were identified and included, although these were
relatively few. We also restricted our analyses to those reporting follow-up to 12 months from baseline.
In terms of the searches, we restricted our grey literature search to conference proceedings for the main
diabetes conferences and did not include behavioural medicine or other conferences; this was based on
the assumption that diabetes RCTs were more likely to be presented at these. However, we may have
missed some eligible studies using this method. For the systematic review of nRCTs, only one researcher
screened titles and abstracts although two researchers screened the full-text articles; therefore, there is the
potential for some studies to have been missed in error.
Limitations at the study level may relate to publication bias. Our ability to assess this was limited because of
the small number of studies in some analyses (e.g. subgroup analyses and secondary outcomes). We tried to
address this by using the Egger test, funnel plots and the trim-and-fill method in combination. We found little
evidence of publication bias for adolescent/children and adult T1DM studies. We did not limit the systematic
review to studies that combined psychological treatment with diabetes self-management strategies.
However, we were able to subsequently address this in a meta-regression for the adult T2DM studies.
At the outcome level, our main analyses were limited to glycaemic control; in some studies included in the
evidence synthesis, this was not the primary outcome. However, we were unable to conduct meta-analysis
for psychological outcomes in studies of people with T1DM. This underlines the need to establish consolidated
outcome sets.294 CONSORT criteria were introduced in 200167 and our RoB assessment demonstrated a low
to unclear RoB. This is an improvement on the quality of studies included in our previous review, as many
of the studies were conducted prior to the introduction of CONSORT criteria. A further limitation at the
outcome level is that we used data closest to the 12-month follow-up, but this meant including outcome
data at varying time points, such as at the 3- or 6-month follow-ups, and, although we did conduct
meta-regression on overall duration of therapy, we did not specifically address this; therefore our analyses
may overestimate the effectiveness of psychological treatments.
Our IPD meta-analysis was limited to 40–50% of the included studies from the aggregate meta-analysis.
Therefore, the finding from this analysis are subject to response bias. However, there were no significant
differences between studies that provided data and those that did not according to date of publication,
type of psychological treatment tested and country of origin.
The overall heterogeneity for studies involving adults with T2DM and adults with T1DM was low to
moderate for the primary outcome (i.e. glycaemic control) according to GRADE, which may be surprising
considering the range of different psychological therapies pooled for analysis. We decided to pool a
range of psychological therapies used in diabetes care to address the research question. All psychological
therapies met the predefined criteria described in Chapter 3, Types of intervention (health technologies)
which may account for lower heterogeneity than expected. When heterogeneity existed, we conducted
meta-regression and sensitivity analyses. Because of the relatively small number of studies, negative
results of meta-regressions need to be treated with care because of a lack of power, and estimations
of regressions may not be robust.295
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The key limitation regarding the health economic analysis was the lack of available data on how long any
changes in biomarkers would be maintained. Consequently, how long the treatment effects found in the
systematic review and meta-analyses would last was highly uncertain and was identified as key driver of
decision uncertainty around the cost-effectiveness of psychological interventions for both people with T1DM
and people with T2DM. It should be noted that this parameter was more uncertain for people with T2DM,
as no evidence on the long-term effects of psychological interventions was available in this population.
The GRADE assessment of certainty of evidence
The evidence for adults with T1DM, and adolescents/children with T1DM was rated as being of high
quality, increasing our confidence that the result reflects a true effect for the primary outcome, HbA1c level.
The quality of evidence in studies involving adults with T2DM was rated as being of moderate quality,
indicating only moderate confidence in the estimate. Further research may improve the quality of evidence
in terms of HbA1c level. This moderate rating reflects inconsistency and considerable heterogeneity, which
remained moderate to high in most subgroups of psychological interventions (i.e. CBT, counselling) and
interventionist subgroups (i.e. diabetes specialists, other).
Secondary outcomes were assessed only for adults with T2DM, when outcomes such as BMI and blood
pressure were of high quality. Other outcomes including depression, QoL and general diet behaviour were
considered to be of low quality, due to major heterogeneity. The true effect may significantly differ from
these estimates. Subgroup analyses were not conducted on these outcomes; therefore, heterogeneity may
be less in certain subgroups, for example for different psychological intervention types (i.e. counselling,
CBT) or for interventionist type (e.g. diabetes specialists, diabetes professionals).
The NMAs results rely on the assumptions of homogeneity and transitivity. However, the small number of
comparisons for most treatments limit the interpretation of the heterogeneity assumptions using inferential
statistics. The indirect comparisons are not protected by randomisation and may be confounded by
differences between the trials. Unlike homogeneity, transitivity cannot be evaluated quantitatively and is
difficult to assess.
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Chapter 11 Conclusions
The aim of this evidence synthesis was to determine whether or not psychological interventions areclinically effective and cost-effective in improving self-management for adults and adolescents/children
with T1DM and adults with T2DM. The evidence was generally considered to be of good quality according
to GRADE96 and suggests that, overall, psychological interventions to improve motivation for diabetes
self-management, specifically glycaemic control, are not clinically effective for adults and adolescents/
children with T1DM. For adults with T2DM, there was evidence of a borderline clinically significant effect.
Although results for adults with T1DM suggest that there is no effect of psychological interventions on
glycaemic control, there was some evidence that CBT is potentially a cost-effective treatment. Likewise, for
adults with T2DM, CBT was considered potentially cost-effective for people in receipt of first-line diabetes
treatment, namely diet, exercise and metformin (i.e. biguanide). For both adults with T1DM and adults
with T2DM, there was substantial uncertainty in the economic modelling, particularly around how long any
differences in effectiveness would be maintained.
Implications for clinical practice
Policy-makers and service providers generally recognise the benefits of providing psychological support for
people with diabetes, yet there are few services available for adults;296 however, service provision for children
and young people is improving.297 This review does not support the use of psychological interventions over
control interventions (such as diabetes education) to improve glycaemic control for adults and adolescents/
children with T1DM;298 for adults with T2DM there is only weak evidence of borderline clinical significance.298
However, for adults with T2DM, psychological interventions may be effective in people with suboptimal
glycaemic control. There are also additional benefits in terms of healthy eating and improved QoL. Nevertheless,
despite the lack of evidence, people with diabetes want access to psychological support;291 in our focus groups,
patients were less concerned regarding the degree of clinical effectiveness in terms of HbA1c levels. A lack of
psychological support when indicated may lead to a vicious cycle of maladaptive coping behaviours and poor
diabetes self-management.279
Implications for future research
In adolescents/children with diabetes, there are challenges in using a RCT to test the effectiveness of
psychological interventions, as it may be unethical to withhold potentially effective treatment. In this
group, non-randomised designs may be more appropriate.299 We were unable to determine if psychological
treatments improved self-management using outcome variables other than glycaemic control for
adolescents/children and adults with T1DM as there were typically fewer available studies; therefore,
common outcome sets may be useful.
In the current review, we found it difficult to identify psychological interventions from titles and abstracts
and had to re-screen rejected abstracts because of the lack of ‘psychological language’ used in them.
Although most of the included studies in this review were deemed to be at a low or unclear risk of bias
according to the metrics commonly used, it was generally unclear whether or not individuals who were
delivering the psychological interventions were competent to do so. Few studies reported this level of
detail. A 2018 study300 highlights this problem: in a pragmatic trial, community practice nurses were
trained in psychological techniques to support people with T2DM, but none achieved competency prior to
the study starting. In the current review, we were able to demonstrate that psychology professionals and
diabetes specialists can deliver psychological treatments, although, perhaps unsurprisingly, there was more
heterogeneity between studies when interventions were delivered by diabetes specialists than when they
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were delivered by psychology professionals. Further research is required to determine who can be trained
to deliver psychological interventions at a competent level.
In summary, based on the findings of this evidence synthesis and the gaps in the literature, we would
recommend the following research questions or priorities:
l Promote the use of consolidated outcome sets in trials of psychological interventions to ensure that
treatment efficacy is not limited to glycaemic control, particularly for studies involving adolescents/
children and adults with T1DM.
l Encourage researchers to be more explicit in their description of psychological techniques/interventions
in titles and abstracts to enable future reviewers to identify studies.
l Determine the long-term clinical effectiveness and cost-effectiveness of psychological interventions.
l Develop different models of psychological care depending on where the person is in their life journey
with diabetes.
l Determine whether or not psychological interventions are effective at improving motivation for diabetes
self-management when interventionists are competent to deliver the intervention.
l Develop a multifactorial intervention involving both psychology and education to address psychological
distress, such as depressive symptoms, and diabetes self-management.
CONCLUSIONS
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Appendix 1 List of the additions to the
original review
List of additions to original review
l Network meta-analysis.
l Individual patient data meta-analysis.
l Cost-effectiveness analysis.
l Non-randomised controlled trials systematic review.
l Patient and public involvement input.
List of changes between current protocol and review
The following amendments were made to version 1.3 of the protocol:
l We were more explicit in the exclusion criteria, by saying that patients who had other medical conditions
would be excluded unless the data on patients with diabetes have been summarised and are extractable
as a subgroup, or a separate analysis can be provided by the author.
l We updated our definition of a psychological intervention. We defined an intervention as psychological
if it: (1) had a reliance on communication, using a therapeutic alliance between patient and the therapist;
(2) was facilitated by psychologists, psychotherapists and therapists in training, or facilitated by persons
trained/supervised by a clinical psychologist or therapist; (3) was based on a psychological model; and
(4) aimed to improve outcome changes in emotional, cognitive or behavioural functioning including
adherence. If these criteria were unclear and the intervention could not clearly be described as
psychological from the publication, then authors were contacted for more information to determine eligibility.
l We included ‘diabetes education’ as a comparator.
l We searched international conference abstracts from 2012–current. We also searched clinicaltrials.gov
for grey literature.
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Appendix 2 Search strategy in MEDLINE for
randomised controlled trials
MEDLINE (via OvidSP)
1. exp Diabetes Mellitus/
2. diabet$.ab,ti.
3. (DKA or IDDM).mp. or DMI.ab,ti. [mp=title, original title, abstract, name of substance word, subject
heading word]
4. (MODY or DM2 or NIDDM).mp. or IIDM.ti,ab. [mp=title, original title, abstract, name of substance
word, subject heading word]
5. insulin$ secret$ dysfunc$.ti,ab.
6. insulin$ resist$.ti,ab.
7. ((impaired glucose tolerance or glucose intoleran$ or insulin$ resist$) and (DM or DM2)).ti,ab.
8. insulin$ depend$.mp. or insulin?depend$.ti,ab. [mp=title, original title, abstract, name of substance
word, subject heading word]
9. (non insulin$ depend$ or nonisulin$ depend$ or nonisulin?depend).mp. or non insulin?depend$.ti,ab.
[mp=title, original title, abstract, name of substance word, subject heading word]
10. (("typ$ 1" or typ$ I) adj6 DM).ti,ab.
11. (("typ$ 2" or typ$ II) adj6 DM).ti,ab.
12. ((juvenil$ or child$ or keto$ or labil$ or brittl$ or earl$ onset) adj6 (DM or DM1)).ti,ab.
13. ((keto$ prone or autoimmun$ or auto immun$ or sudden onset) adj6 (DM or DM1)).ti,ab.
14. ((keto$ resist$ or nonketo$ or non keto$ or adult$ onset or matur$ onset or late$ onset or slow onset
or stabl$) adj6 (DM or DM2)).ti,ab.
15. exp Insulin Resistance/
16. (insulin$ defic$ adj6 (absolut$ or relativ$)).ti,ab.
17. metabolic$ syndrom$.ti,ab.
18. (syndrom$ X not (fragil$ X or X linked)).ti,ab.
19. (plurimetabolic$ syndrom$ or pluri metabolic$ syndrom$).ti,ab.
20. or/1-19
21. exp Psychotherapy/
22. exp Counseling/
23. exp Mood disorders/
24. exp Depression/
25. psycho$.mp
26. counsel$.mp
27. depression.mp
28. depressive.mp
29. (interpersonal adj5 therap$).mp
30. art therap$.mp
31. aversion therap$.mp
32. balint.mp
33. behavio?r adj5 (intervention or therap* or modific*)
34. cognitive adj5 (therap* or intervention or program* or train* or theory)
35. (family adj3 (intervention or treatment or counsel* or therap*)
36. colo?r therap$.mp.
37. crisis intervention.mp
38. dance therap$.mp
39. gestalt therap$.mp
40. music therap$.mp
41. milieu therap$.mp
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42. (assert$ adj5 training).mp
43. Narrative therap$.mp.
44. nondirective therap$.mp
45. (problem solving adj5 therap$).mp
46. (self control adj5 therap$).mp
47. person cent$.mp
48. client cent$.mp
49. psychodrama$.mp
50. paradoxical technique$.mp
51. play therap$.mp
52. rational emotive.mp
53. reality therap$.mp
54. role play$.mp
55. (relax$ adj5 training).mp
56. sociotherap$.mp
57. socioenvironmental.mp
58. supportive therap$.mp
59. transactional.mp
60. acceptance adj2 (commitment therap*)
61. coping skills training.mp.
62. exp Mindfulness/
63. motivation* adj2 (interview* or therap*)
64. multisystemic therapy
65. or/21-64
66. Randomized Controlled Trials as Topic/
67. randomized controlled trial/
68. Random Allocation/
69. Double Blind Method/
70. Single Blind Method/
71. clinical trial/
72. clinical trial, phase i.pt
73. clinical trial, phase ii.pt
74. clinical trial, phase iii.pt
75. clinical trial, phase iv.pt
76. controlled clinical trial.pt
77. randomized controlled trial.pt
78. multicenter study.pt
79. clinical trial.pt
80. exp Clinical Trials as topic/
81. (clinical adj25 trial$).tw
82. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$3 or mask$3)).tw
83. PLACEBOS/
84. placebo$.tw
85. randomly allocated.tw
86. (allocated adj2 random$).tw
87. or/66-86
88. case report.tw
89. letter/
90. historical article/
91. or/88-90
92. 87 NOT 91
93. 20 AND 65 AND 92
94. limit 93 to yr=“2003-Current”
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Appendix 3 Data extraction items for randomised
controlled trials
I tems for data extraction (conducted in Microsoft Excel):
l reference
l name of first author/trial name
l psychological intervention category
l publication characteristics –
¢ Digital Object Identifier (DOI)
¢ year of publication
¢ country of origin
¢ health-care setting
¢ language
¢ funding source
¢ study design
l patient characteristics –
¢ type of diabetes
¢ number of participants screened/assessed for eligibility
¢ number of participants excluded
¢ reasons participants were excluded
¢ number participants declined before randomisation
¢ intervention/control label
¢ number of participants randomised to group
¢ number of participants lost to follow-up in group
¢ reasons for loss to follow-up
¢ intervention/control label for age and duration
¢ baseline characteristics –
¢ age (mean, SD)
¢ duration of diabetes in group (years: mean, SD)
¢ sex (n, %)
¢ clinical subgroup information (treatment type, smoking status, weight/BMI)
¢ ethnicity group (n, %)
¢ socioeconomic setting type (e.g. individual’s or family’s income, education)
¢ complication status information
¢ receipt of diabetes education
l intervention characteristics –
¢ type of therapy
¢ number of therapy sessions
¢ duration of overall treatment
¢ duration of treatment session
¢ psychological theoretical framework or model
¢ specialty of facilitator
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¢ use of manual
¢ interventionist training
¢ format of delivery
¢ mode of delivery
¢ use of boost or maintenance sessions
l control characteristics –
¢ same as intervention characteristics, if applicable
l primary outcome characteristics –
¢ intervention
¢ comparison
¢ outcome measure
¢ time point of follow-up
¢ baseline intervention (n, mean, SD)
¢ baseline control (n, mean, SD)
¢ intervention follow-up (n, mean, SD)
¢ control follow-up (n, mean, SD)
l secondary outcome characteristics –
¢ same as primary outcome characteristics in addition to:
¢ type of secondary outcome, for example (1) changes in self-management behaviours or
(2) change in psychological functioning or (3) other.
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Appendix 4 Data extraction items for randomised
controlled trial non-English studies
I tems for data extraction (conducted in Microsoft Excel):
l reference
l year
l country of study
l total number of participants
l age (mean, SD) in intervention
l age (mean,SD) in control
l duration of diabetes (mean, SD) in intervention
l duration of diabetes (mean, SD) in control
l type of intervention
l duration of therapy in intervention
l number of sessions in intervention
l interventionist
l interventionist training
l type of control, for example usual care/diabetes education
l follow-up period
l HbA1c level at baseline in intervention (mean, SD)
l HbA1c level at baseline in control (mean, SD)
l HbA1c level at follow-up in intervention (mean, SD)
l HbA1c level at follow-up in control (mean, SD).
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Appendix 5 Psychological intervention, control
and interventionist categories
T2DM studies
Psychological intervention
category Psychological intervention condition
CBT l CBT106,114,116,125–127,131,135,140,155,160
l Self-management group110
l CBT+ DSMT + CST118
l Cognitive–behavioural pedometer-based group intervention119
l Minimal psychological intervention
l Psychoeducation147
l CBT-AD
l Mindfulness cognitive-based therapy104,197
l DIAMOS105
l MET+ CBT148
l TECNOB156
l Structured behavioural group192
Counselling l MI97,112,120,128,133,137,145,146,150,154,157,158,191,196
l Telephone support/coaching/counselling113,115,134,143
l Integrative health coaching117
l Culturally tailored diabetes self-care intervention121
l Family-based intervention123
l Group behavioural intervention124
l Mindfulness-based intervention132
l Intensive plus behavioural intervention142
l Health coaching149
l Minimal Psychological Intervention151
l DECIDE161
l Self-management intervention152
l Group-based counselling188
Collaborative care l Collaborative care195,214
l Sociocultural adapted collaborative care129
Creative therapy Music therapy136
Family therapy l Behavioural family systems therapy189
l Multisystemic therapy194
Control condition category Control condition
Usual care l Usual care104,106,110,113,115,117,119,121,123,124,126,127,129,131,132,134,135,137,142,143,145–152,154–158,189,191,195,214
l Usual care while on waiting list114,116,125,188,197
l Enhanced usual care140,161
Attention control l Diabetes education105,112,118,128,133,136,160,195,196
l Attention control120,192
l Telephone support194
Interventionist category Interventionist
Diabetes specialists l Diabetes nurses113,118,126,133,145,150,154,158,188
l CBT-trained nurse131
l Nurse practitioner120
l Primary care nurse127,137
l Diabetes educator128,192
l Diabetes researcher110
l Diabetes nurse and dietitian135
l Diabetes nurse and pharmacist146
l Clinicians (doctors, nurses and psychologists)149,191
l Primary care physicians129,195
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T2DM studies
Psychology professionals l Depression clinical specialist214
l Clinical psychologist106,112,124,156,197
l Health psychologist123
l Psychologist104,105,132,147,189
l Therapist97,140,194
l Psychotherapist and clinical nurse148
l Psychology assistant151
l Psychology researcher157
Other l Undergraduate psychologist115
l Counsellors114,125,143
l MSc-level coaches (in physical activity or clinical psychology or social work)117,119
l Medical assistant121
l Individuals with degree in physical activity134
l Music therapist136
l Lifestyle facilitator142
l Research assistants160
l Interventionist with degree in undergraduate or master's health education, psychology
or social work161
l Interventionist trained in MI152
l Peers196
T1DM adult studies
Psychological intervention
category Psychological intervention condition
CBT l CBT-based intervention (Amsberg et al.162; Petrak et al.106)
l MET+ CBT (Ismail et al.163)
l Cognitive–behavioural group training (Snoek et al.164)
l DIAMOS (Hermanns et al.105)
l Mindfulness cognitive-based therapy (van Son et al.104)
Counselling l Flexible guided self-determination (Zoffmann et al.,165 Zoffmann et al.166)
Control condition category Control condition
Usual care l Usual care (Ismail et al.,163 van Son et al.104)
l Usual care and antidepressants (Petrak et al.106)
l Waiting list control (Amsberg et al.,162 Zoffmann et al.,165 Zoffmann et al.166)
Attention control l BGAT (Snoek et al.164)
l Diabetes education (Hermanns et al.105)
Interventionist category Interventionist
Diabetes specialists l Diabetes specialist nurse and psychologist (Amsberg et al.162)
l Nurse (Ismail et al.,163 Zoffmann et al.,165 Zoffmann et al.166)
Non-diabetes specialist l Psychologist (Snoek et al.,164 Hermanns et al.,105 van Son et al.,104 Petrak et al.106)
T1DM adolescent studies
Psychological intervention
category Psychological intervention condition
CBT l CST (Grey et al.,171 Holmes et al.,185)
l CBT+ CST (Najmi et al.,177)
l The Best of Coping (Serlachius et al.184)
Counselling l MI (Channon et al.,168 Wang et al.172)
l Diabetes personal trainer intervention (Nansel et al.170)
l Positive affect (Jaser et al.179)
l Psychoeducation (Christie et al.181)
Family therapy l Multisystemic therapy (Ellis et al.169)
l Telehealth behaviour therapy (Lehmkuhl et al.173)
l Family behavioural intervention (Nansel et al.176)
l Care ambassador ultra (Katz et al.180)
l BFST-D (Harris et al.,182 Wysocki et al.186)
l Family intervention (Nansel et al.183)
l CST
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T1DM adolescent studies
Control condition category Control condition
Usual care l Usual care (Ellis et al.,169 Nansel et al.,176 Najmi et al.,177 Katz et al.,180 Christie et al.,181
Serlachius et al.184 and Wysocki et al.189)
l Waiting list (Lehmkuhl et al.173)
Attention control Diabetes education (Nansel et al.,170 Grey et al.,171 Wang et al.,172 Jaser et al.,179
Holmes et al.185)
Less intensive psychological
intervention
l Non-directive psychological support (Channon et al.168)
l BFST-D via Skype (Harris et al.182)
Interventionist category Interventionist
Diabetes specialists l Nurse (Channon et al.,168 Christie et al.181)
l Diabetes educators (Wang et al.172)
Psychology professionals l Therapist (Ellis et al.,169 Harris et al.,182 Wysocki et al.186)
l Mental health professional (Grey et al.171)
l Clinical psychologists (Lehmkuhl et al.173)
l Psychiatrists (Najmi et al.177)
l Health psychologist (Serlachius et al.184)
Other l Trained non-professional (Nansel et al.170)
l Health advisors (Nansel et al.176)
l Research assistant (Jaser et al.,179 Katz et al.,180 Nansel et al.183)
l Interventionist (Holmes et al.185)
T2DM and T2DM studies
Psychological intervention
category Psychological intervention condition
CBT l Group-based counselling (Karlsen et al.188)
l Structured behavioural group (Weinger et al.192)
l Mindfulness-based cognitive therapy (Schroevers et al.197)
Counselling l MI (Rosenbek Minet et al.,191 Safford et al.196)
Family therapy l Behavioural family systems therapy (Wysocki et al.189)
l Multisystemic therapy (Ellis et al.194)
Collaborative care l Collaborative care (Lin et al.195)
Control condition category Control condition
Usual care l Usual care (Wysocki et al.189, Rosenbek Minet et al.,191 Lin et al.195)
l Waiting list (Karlsen et al.,188 Schroevers et al.197)
Attention control l Group attention control (Weinger et al.192)
l Diabetes education (Safford et al.196)
Less intensive psychological
intervention
l Telephone support (Ellis et al.194)
Interventionist category Interventionist
Diabetes specialists l Nurse (Karlsen et al.188)
l Diabetes educators (Weinger et al.192)
Non-diabetes specialists l Psychologist (Wysocki et al.189 and Schroevers et al.197)
l Therapist (Ellis et al.194)
l Peers (Safford et al.196)
l Primary care physician (Rosenbek Minet et al.,191 Lin et al.195)
CBT-AD, cognitive–behavioural therapy for adherence and depression; CST, coping skills training; DECIDE, Decision-making
Education for Choices In Diabetes Everyday; DIAMOS, Diabetes Motivational Strengthening; DSMT, diabetes self-management
training MET, motivational enhancement therapy; TECNOB, TEChnology for Obesity.
DOI: 10.3310/hta24280 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 28
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Winkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
Appendix 6 Non-randomised controlled trial
search terms for non-randomised studies for MEDLINE
MEDLINE (via OvidSP)
Date range searched: January 2003 to July 2016.
Date searched 8 August 2016.
Search strategy
1. case-control studies/
2. retrospective studies/
3. cohort studies/
4. longitudinal studies/
5. follow-up studies/
6. prospective studies/
7. cohort.ti,ab.
8. longitudinal.ti,ab.
9. follow up.ti,ab.
10. followup.ti,ab.
11. prospective*.ti,ab.
12. retrospective*.ti,ab.
13. comparison group*.ti,ab.
14. control group*.ti,ab.
15. nonrandom*.ti,ab.
16. or/65-79
17. or/21-64
18. 20 and 80 and 81
19. limit 82 to yr=“2003 -Current“
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Appendix 7 Data extraction items for
non-randomised controlled trial studies
I tems for data extraction (conducted in Microsoft Excel):
l reference
l name of first author/trial name
l psychological intervention category
l publication characteristics –
¢ DOI
¢ Year of publication
¢ country of origin
¢ healthcare setting
¢ language
¢ funding source
¢ study design
l patient characteristics –
¢ type of diabetes
¢ number of participants screened/assessed for eligibility
¢ number of participants excluded
¢ reasons for participants excluded
¢ number participants declined before randomisation
¢ intervention/control label
¢ number of participants randomised to group
¢ number of participants lost to follow-up in group
¢ reasons for loss to follow-up
¢ intervention/control label for age and duration
¢ baseline characteristics –
¢ age (mean, SD)
¢ duration of diabetes in group (years: mean, SD)
¢ sex (n, %)
l intervention characteristics –
¢ type of therapy
¢ number of therapy sessions
¢ duration of overall treatment
¢ duration of treatment session
¢ psychological theoretical framework or model
¢ specialty of facilitator
¢ use of manual
¢ interventionist training
¢ format of delivery
¢ mode of delivery
¢ use of boost or maintenance sessions
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l control characteristics –
¢ same as intervention characteristics, if applicable
l outcome characteristics –
¢ intervention
¢ comparison
¢ outcome measure
¢ method of assessing outcome
¢ type of outcome: (1) HbA1c level, (2) change in psychological functioning, (3) change in
self-management behaviours, (4) other
¢ time point of follow-up
¢ findings
¢ limitations.
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Appendix 8 Mini posters of preliminary
findings of randomised controlled trial aggregate
meta-analysis for focus groups
The King’s College London logo has been reproduced with permission.
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Appendix 9 Additional tables and figures for the
glycated haemoglobin level aggregate meta-analysis
for adults with type 1 diabetes mellitus
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FIGURE 29 The RoB in studies of adults with T1DM.
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FIGURE 30 Funnel plot of publication bias in HbA1c level outcome for adults with T1DM.
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Appendix 10 Additional tables and figures
for the glycated haemoglobin level aggregate
meta-analysis for adolescents/children with
type 1 diabetes mellitus
Overall (I 2 = 77.3%; p = 0.000)
Subtotal (I 2 = 0.0%; p = 0.456)
Wang et al.172
Low RoB
Subtotal (I 2 = 89.2%; p = 0.000)
Grey et al.171
Najmi et al.177
Christie et al.181
Channon et al.168
Jaser et al.179
Husted et al.178
Lehmkuhl et al.173
Nansel et al.183
Serlachius et al.184
Robling et al.174
Harris et al.182
Katz et al.180
Sassmann et al.175
Nansel et al.170
Ellis et al.169
Graue et al.167
Nansel et al.176
Unclear RoB
0.00 (– 0.18 to 0.18)
– 0.05 (– 0.15 to 0.04)
4.56 (3.42 to 5.70)
0.35 (– 0.14 to 0.83)
0.18 (– 0.28 to 0.63)
– 0.06 (– 0.59 to 0.46)
0.13 (– 0.09 to 0.35)
– 0.42 (– 0.92 to 0.07)
0.23 (– 0.39 to 0.85)
– 0.09 (– 0.55 to 0.38)
– 0.33 (– 1.03 to 0.37)
– 0.02 (– 0.35 to 0.32)
– 0.20 (– 0.53 to 0.12)
0.00 (– 0.15 to 0.15)
– 0.13 (– 0.54 to 0.28)
0.07 (– 0.32 to 0.46)
– 0.49 (– 1.18 to 0.21)
– 0.23 (– 0.67 to 0.21)
– 0.12 (– 0.47 to 0.23)
– 0.29 (– 0.73 to 0.14)
– 0.05 (– 0.25 to 0.15)
100.00
Favours psychological intervention Favours control
60.23
1.96
39.77
5.49
4.92
7.39
5.17
4.23
5.39
3.72
6.47
6.58
7.85
5.82
6.02
3.77
5.63
6.37
5.65
7.55
– 2 – 1 0 1 2 3 4 5
Study SMD (95% CI) Weight (%)
FIGURE 31 Subgroup analysis by RoB for adolescent/children with T1DM. Weights are from random effects analysis.
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FIGURE 32 The RoB in studies of adolescents/children with T1DM.
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Overall (I 2 = 77.3%; p = 0.000)
Counselling
Graue et al.167
Channon et al.168
Nansel et al.170
Wang et al.172
Robling et al.174
Jaser et al.179
Christie et al.181
Husted et al.178
Subtotal (I 2 = 89.8%; p = 0.000)
Family therapy
Ellis et al.169
Lehmkuhl et al.173
Nansel et al.176
Katz et al.180
Harris et al.182
Nansel et al.183
Subtotal (I 2 = 0.0%; p = 0.936)
0.00 (– 0.18 to 0.18) 100.00
– 2
Favours psychological intervention Favours control
– 1 0 1 2 3 4 5 6
Study SMD (95% CI) Weight (%)
– 0.29 (– 0.73 to 0.14)
– 0.42 (– 0.92 to 0.07)
– 0.23 (– 0.67 to 0.21)
4.56 (3.42 to 5.70)
0.00 (– 0.15 to 0.15)
0.23 (– 0.39 to 0.85)
0.13 (– 0.09 to 0.35)
– 0.09 (– 0.55 to 0.38)
0.23 (– 0.17 to 0.63)
– 0.12 (– 0.47 to 0.23)
– 0.33 (– 1.03 to 0.37)
– 0.05 (– 0.25 to 0.15)
0.07 (– 0.32 to 0.46)
– 0.13 (– 0.54 to 0.28)
– 0.02 (– 0.35 to 0.32)
– 0.06 (– 0.19 to 0.07)
5.65
5.17
5.63
1.96
7.85
4.23
7.39
5.39
43.28
6.37
3.72
7.55
6.02
5.82
6.47
35.96
FIGURE 33 A subgroup meta-analysis of the SMD in HbA1c levels by psychological intervention category in the
psychological intervention groups compared with control groups in studies of adolescents/children with T1DM.
Weights are from random effects analysis.
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Overall (I 2 = 77.3%; p = 0.000)
Favours psychological intervention Favours control
Graue et al.167
Subtotal (I 2 = 0.0%; p = 0.861)
Harris et al.182
Katz et al.180
Psychology professional
Jaser et al.179
Sassmann et al.175
Serlachius et al.184
Diabetes specialist
Subtotal (I 2 = 94.0%; p = 0.000)
Channon et al.168
Other
Grey et al.171
Nansel et al.183
Christie et al.181
Subtotal (I 2 = 0.0%; p = 0.762)
Ellis et al.169
Husted et al.178
Wang et al.172
Najmi et al.177
Nansel et al.170
Robling et al.174
Nansel et al.176
Lehmkuhl et al.173
 0.00 (– 0.18 to 0.18)
– 0.29 (– 0.73 to 0.14)
– 0.02 (– 0.12 to 0.09)
– 0.13 (– 0.54 to 0.28)
0.07 (– 0.32 to 0.46)
0.23 (– 0.39 to 0.85)
– 0.49 (– 1.18 to 0.21)
– 0.20 (– 0.53 to 0.12)
0.57 (– 0.24 to 1.38)
– 0.42 (– 0.92 to 0.07)
0.18 (– 0.28 to 0.63)
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FIGURE 34 A subgroup meta-analysis of the SMD in HbA1c level by interventionist in the psychological intervention
groups compared with control groups in studies of adolescents/children with T1DM. Weights are from random
effects analysis.
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Appendix 11 Additional figures for glycated
haemoglobin level aggregate meta-analysis for adults
with type 2 diabetes mellitus
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FIGURE 35 The RoB in studies of adults with T2DM.
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FIGURE 36 Subgroup analysis by RoB for studies of adults with T2DM. Weights are from random-effects analysis.
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FIGURE 38 Subgroup meta-analysis of the SMD in HbA1c levels by psychological intervention category in
psychological intervention groups compared with control groups for studies of adults with T2DM. Weights are
from random-effects analysis.
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FIGURE 39 Subgroup meta-analysis of the SMD in HbA1c levels by interventionist in psychological intervention
groups compared with control groups for studies of adults with T2DM. Weights are from random-effects analysis.
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FIGURE 40 Subgroup meta-analysis of the SMD in HbA1c levels by primary outcome in psychological intervention
groups compared with control groups for studies of adults with T2DM. Weights are from random-effects analysis.
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Appendix 12 Additional figures for secondary
outcome aggregate meta-analysis for adults with
type 2 diabetes mellitus
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FIGURE 41 Funnel plot of publication bias for depression in studies of T2DM.
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FIGURE 42 Funnel plot of publication bias for QoL in studies of T2DM.
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FIGURE 43 Funnel plot of publication bias for BMI in studies of T2DM.
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FIGURE 44 Funnel plot of publication bias for SBP in studies of adults with T2DM.
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FIGURE 45 Funnel plot of publication bias for DBP in studies of adults with T2DM.
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FIGURE 46 Funnel plot of publication bias for general diet behaviour in studies of adults with T2DM.
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Appendix 13 Additional tables and figures for
the network meta-analyses
TABLE 26 Mean rank and SUCRA for studies of adults with T1DM, derived from ranking probabilities
Treatment Mean rank SUCRA Order of treatment
Usual care 3.9 0 4
CBT 2.0 0.7 3
Counselling 3.1 0.3 2
Attention control 1.1 1 1
Note
The lower the mean rank and the higher the SUCRA, the better the rank of the treatment. Order of treatment is final
approximate rank of treatment effect based on SUCRA.
TABLE 27 Mean rank and SUCRA, derived from ranking probabilities of studies of adults with T2DM
Treatment Mean rank SUCRA Order of treatment
Usual care 3.4 0.4 4
CBT 1.7 0.8 1.5
Counselling 1.9 0.8 1.5
Psychotherapy 3.2 0.5 3
Attention control 4.7 0.1 5
Note
The lower the mean rank and the higher the SUCRA, the better the rank of the treatment. Order of treatment is final
approximate rank of treatment effect based on SUCRA.
TABLE 28 Summary of all pairwise comparisons of treatment effects, assuming common heterogeneity estimate for
all treatment design comparisons, for studies of adults with T1DM
Treatment comparison b 95% CI SE z-value p-value
Usual care CBT –0.312 –0.499 to –0.126 0.095 –3.29 0.001
Usual care Counselling –0.121 –0.307 to 0.066 0.095 –1.27 0.21
Usual care Attention control –0.513 –0.848 to –0.177 0.1701 –3 0.003
Counselling CBT 0.192 –0.027 to 0.410 0.111 1.72 0.085
CBT Attention control –0.2 –0.479 to 0.078 0.142 –1.41 0.078
Counselling Attention control –0.392 –0.746 to –0.038 0.181 –2.17 0.03
SE, standard error.
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TABLE 29 Number of studies and arms included in the NMAs of studies of adolescents/children with T1DM
Treatment Studies (n) Studies (%) Arm Sample size (n)
CBT 4 11.1 T 167
Counselling 8 22.2 T 714
Family therapy 6 16.7 T 443
Usual care 11 30.6 C 1002
Attention control 5 13.9 C 183
Less intensive psychological intervention 2 5.7 C 74
Total 36 100 2583
C, arm was defined as control group in the original study; T, arm was defined as treatment arm in the original study.
CBT
CounsellingFamily therapy
Usual care
Attention control
Less intensive psychological
intervention
FIGURE 47 Network plots for all studies. Network plots of direct comparisons for the NMA of studies of
adolescents/children with T1DM. The width of the lines is proportional to the number of trials comparing each pair
of treatments and the size of each node is proportional to the number of studies testing that specific treatment.
It shows, roughly, how much information is available for each treatment and for each treatment comparison.
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FIGURE 48 Rankogram for all treatments. The plot shows the SUCRA curves for all treatments for adolescents/
children with T1DM. (a) Usual care; (b) CBT; (c) counselling; (d) family therapy; (e) attention control; and (f) less
intensive psychological intervention. For example, usual care has a very low probability of being among the best
treatments but a very high probability of being one of the worst.
TABLE 30 Mean rank and SUCRA derived from ranking probabilities of Figure 48 for adolescents/children with
T1DM
Treatment Mean rank SUCRA Order of treatment
Usual care 4.2 0.4 4
CBT 2.9 0.6 2
Counselling 4.5 0.3 5.5
Family therapy 3.4 0.5 3
Attention control 1.5 0.9 1
Less intensive psychological intervention 4.6 0.3 5.5
Note
The lower the mean rank and the higher the SUCRA, the better the rank of the treatment. Order of treatment is final
approximate rank of treatment effect based on SUCRA.
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TABLE 31 Mean rank and SUCRA derived from ranking probabilities for adolescents/children with T1DM
Treatment Mean rank SUCRA Order of treatment
Usual care 3.8 0.3 4
CBT 2.7 0.6 2.5
Counselling 4.2 0.2 5
Family therapy 2.9 0.5 2.5
Attention control 1.5 0.9 1
Note
The lower the mean rank and the higher the SUCRA, the better the rank of the treatment. Order of treatment is final
approximate rank of treatment effect based on SUCRA.
TABLE 32 Summary of pairwise comparisons of all treatments, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adolescents/children with T1DM
Treatment comparison b 95% CI SE z-value p-value
CBT Counselling 0.417 –0.628 to 1.462 0.533 0.78 0.43
CBT Family therapy 0.145 –0.946 to 1.236 0.557 0.26 0.8
CBT Usual care 0.329 –0.538 to 1.196 0.442 0.74 0.46
CBT Attention control –0.439 –1.525 to 0.648 0.554 –0.79 0.43
CBT Less intensive psychological intervention 0.549 –0.967 to 2.066 0.774 0.71 0.48
Counselling Family therapy –0.275 –1.194 to 0.645 0.469 –0.59 0.56
Counselling Usual care –0.09 –0.804 to 0.625 0.365 –0.25 0.81
Counselling Attention control –0.864 –1.732 to 0.005 0.443 –1.95 0.05
Counselling Less intensive psychological intervention 0.131 –1.137 to 1.399 0.647 0.2 0.84
Family therapy Usual care 0.184 –0.548 to 0.916 0.374 0.49 0.62
Family therapy Attention control –0.584 –1.598 to 0.431 0.518 –1.13 0.26
Family therapy Less intensive psychological intervention 0.404 –0.848 to 1.657 0.639 0.63 0.53
Usual care Attention control –0.768 –1.704 to 0.169 0.478 –1.61 0.11
Usual care Less intensive psychological intervention 0.22 –1.076 to 1.516 0.661 0.33 0.74
Attention control Less intensive psychological intervention 0.993 –0.449 to 2.435 0.736 1.35 0.18
SE, standard error.
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TABLE 33 Summary of pairwise comparisons of all treatments, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adolescents/children with T1DM
Treatment comparison b 95% CI SE z-value p-value
CBT Counselling 0.47 –0.649 to 1.59 0.571 0.82 0.41
CBT Family therapy 0.09 –1.088 to 1.267 0.601 0.15 0.88
CBT Usual care 0.329 –0.588 to 1.246 0.468 0.7 0.48
CBT Attention control –0.438 –1.587 to 0.711 0.586 –0.75 0.46
Counselling Family therapy –0.383 –1.439 to 0.672 0.538 –0.71 0.48
Counselling Usual care –0.143 –0.924 to 0.639 0.399 –0.36 0.72
Counselling Attention control –0.915 –1.835 to 0.005 0.469 –1.95 0.05
Family therapy Usual care 0.24 –0.565 to 1.044 0.41 0.58 0.56
Family therapy Attention control –0.528 –1.634 to 0.579 0.565 –0.93 0.35
Usual care Attention control –0.767 –1.757 to 0.222 0.505 –1.52 0.13
SE, standard error.
CBT
Counselling
PsychotherapyCreative therapy
Usual care
Attention control
Computerised material
Printed material Music relaxation CD
Family therapy
FIGURE 49 Network plots for all studies. Network plots of direct comparisons for the NMA for adults with T2DM.
The width of the lines is proportional to the number of trials comparing each pair of treatments and the size of
each node is proportional to the number of studies testing the specific treatment. It shows roughly how much
information is available for each treatment and for each treatment comparison.
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FIGURE 50 Rankogram for all treatments in studies of adults with T2DM. (a) Usual care; (b) CBT; (c) counselling;
(d) psychotherapy; (e) creative therapy; (f) attention control; (g) computerised material; (h) printed material;
(i) music relaxation CD; and (j) family therapy. The plot shows the SUCRA curves for all treatments. For example,
usual care has a very low probability of being among the best treatments, but a very high probability of being
one of the worst treatments.
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TABLE 34 The mean rank and SUCRA derived from ranking probabilities of Figure 55 for adults with T2DM
Treatment Mean rank SUCRA Order of treatment
Usual care 5.7 0.5 5.5
CBT 3.2 0.8 2
Counselling 3.6 0.7 3.5
Psychotherapy 5.3 0.5 5.5
Creative therapy 8.1 0.2 9.5
Attention control 7.8 0.2 9.5
Computerised material 4.0 0.7 3.5
Printed material 7.5 0.3 7.5
Music relaxation CD 2.2 0.9 1
Family therapy 7.6 0.3 7.5
CD, compact disc.
Note
The lower the mean rank and the higher the SUCRA, the better the rank of the treatment. Order of treatment is final
approximate rank of treatment effect based on SUCRA.
TABLE 35 Summary of pairwise comparisons of all treatment assuming common heterogeneity estimate for all
treatment design comparisons for adults with T2DM
Number Treatment comparison b 95% CI SE z-value p-value
1 CBT Counselling 0.046 –0.249 to 0.342 0.151 0.31 0.76
2 CBT Psychotherapy 0.222 –0.376 to 0.819 0.305 0.73 0.47
3 CBT Creative therapy 0.703 –0.263 to 1.67 0.493 1.43 0.15
4 CBT Usual care 0.213 –0.035 to 0.46 0.126 1.68 0.09
5 CBT Attention control 0.483 0.13 to 0.835 0.18 2.68 0.01
6 CBT Computerised material 0.057 –0.527 to 0.641 0.298 0.19 0.85
7 CBT Printed material 0.586 –0.38 to 1.551 0.493 1.19 0.23
8 CBT Music relaxation CD –0.349 –1.305 to 0.608 0.488 –0.71 0.48
9 CBT Family therapy 0.591 –0.329 to 1.511 0.469 1.26 0.21
10 Counselling Psychotherapy 0.175 –0.402 to 0.753 0.295 0.6 0.55
11 Counselling Creative therapy 0.657 –0.287 to 1.602 0.482 1.36 0.17
12 Counselling Usual care 0.166 –0.027 to 0.36 0.099 1.68 0.09
13 Counselling Attention control 0.436 0.15 to 0.723 0.146 2.98 0
14 Counselling Computerised material 0.01 –0.524 to 0.545 0.273 0.04 0.97
15 Counselling Printed material 0.54 –0.404 to 1.483 0.481 1.12 0.26
16 Counselling Music relaxation CD –0.395 –1.305 to 0.515 0.464 –0.85 0.4
17 Counselling Family therapy 0.545 –0.362 to 1.452 0.463 1.18 0.24
18 Psychotherapy Creative therapy 0.482 –0.616 to 1.58 0.56 0.86 0.39
19 Psychotherapy Usual care –0.009 –0.551 to 0.534 0.277 –0.03 0.98
20 Psychotherapy Attention control 0.261 –0.369 to 0.892 0.322 0.81 0.42
21 Psychotherapy Computerised material –0.165 –0.926 to 0.597 0.389 –0.42 0.67
22 Psychotherapy Printed material 0.365 –0.733 to 1.462 0.56 0.65 0.52
23 Psychotherapy Music relaxation CD –0.57 –1.647 to 0.506 0.549 –1.04 0.3
continued
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TABLE 35 Summary of pairwise comparisons of all treatment assuming common heterogeneity estimate for all
treatment design comparisons for adults with T2DM (continued )
Number Treatment comparison b 95% CI SE z-value p-value
24 Psychotherapy Family therapy 0.37 –0.669 to 1.409 0.53 0.7 0.49
25 Creative therapy Usual care –0.485 –1.435 to 0.465 0.485 –1 0.32
26 Creative therapy Attention control –0.215 –1.11 to 0.679 0.456 –0.47 0.64
27 Creative therapy Computerised material –0.641 –1.717 to 0.436 0.549 –1.17 0.24
28 Creative therapy Printed material –0.115 –1.011 to 0.781 0.457 –0.25 0.8
29 Creative therapy Music relaxation CD –1.046 –2.353 to 0.261 0.667 –1.57 0.12
30 Creative therapy Family therapy –0.106 –1.405 to 1.193 0.663 –0.16 0.87
31 Usual care Attention control 0.27 –0.051 to 0.591 0.164 1.65 0.1
32 Usual care Computerised material –0.156 –0.69 to 0.379 0.273 –0.57 0.57
33 Usual care Printed material 0.373 –0.581 to 1.328 0.487 0.77 0.44
34 Usual care Music relaxation CD –0.562 –1.492 to 0.369 0.475 –1.18 0.24
35 Usual care Family therapy 0.379 –0.507 to 1.265 0.452 0.84 0.4
36 Attention control Computerised material –0.426 –1.025 to 0.174 0.306 –1.39 0.16
37 Attention control Printed material 0.103 –0.796 to 1.002 0.459 0.23 0.82
38 Attention control Music relaxation CD –0.831 –1.785 to 0.123 0.487 –1.71 0.09
39 Attention control Family therapy 0.109 –0.834 to 1.051 0.481 0.23 0.82
40 Computerised material Printed material 0.529 –0.551 to 1.608 0.551 0.96 0.34
41 Computerised material Music relaxation CD –0.406 –1.46 to 0.648 0.538 –0.75 0.45
42 Computerised material Family therapy 0.534 –0.5 to 1.568 0.528 1.01 0.31
43 Printed material Music relaxation CD –0.93 –2.237 to 0.376 0.667 –1.4 0.16
44 Printed material Family therapy 0.01 –1.288 to 1.308 0.662 0.02 0.99
45 Music relaxation CD Family therapy 0.935 –0.346 to 2.215 0.653 1.43 0.15
CD, compact disc; SE, standard error.
TABLE 36 Summary of pairwise comparisons of all treatments, assuming a common heterogeneity estimate for all
treatment design comparisons, for studies of adults with T2DM
Number Treatment comparison b 95% CI SE z-value p-value
1 CBT Counselling 0.047 –0.253 to 0.347 0.153 0.31 0.76
2 CBT Psychotherapy 0.222 –0.384 to 0.828 0.309 0.72 0.47
3 CBT Usual care 0.213 –0.038 to 0.464 0.128 1.66 0.1
4 CBT Attention control 0.483 0.125 to 0.841 0.183 2.65 0.01
5 Counselling Psychotherapy 0.175 –0.411 to 0.76 0.299 0.58 0.56
6 Counselling Usual care 0.166 –0.031 to 0.362 0.1 1.66 0.1
7 Counselling Attention control 0.436 0.146 to 0.727 0.148 2.94 0
8 Psychotherapy Usual care –0.009 –0.559 to 0.542 0.281 –0.03 0.98
9 Psychotherapy Attention control 0.262 –0.378 to 0.901 0.326 0.8 0.42
10 Usual care Attention control 0.27 –0.056 to 0.596 0.166 1.63 0.1
SE, standard error.
Note
‘b’ is the SMD using TAU as the control group. The formulas for Hedges’ g in White and Thomas87 are used.
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Appendix 14 Additional tables and figures for
the individual patient data meta-analysis
TABLE 37 Study ID against reference for IPD studies
Reference ID
Studies of only adults with T1DM
Ismail K, Thomas SM, Maissi E, Chalder T, Schmidt U, Bartlett J, et al. Motivational enhancement
therapy with and without cognitive behavior therapy to treat type 1 diabetes: a randomized trial.
Ann Intern Med 2008;149:708–19163
ITM08
Snoek FJ, van der Ven NC, Twisk JW, Hogenelst MH, Tromp-Wever AM, van der Ploeg HM, Heine RJ.
Cognitive behavioural therapy (CBT) compared with blood glucose awareness training (BGAT) in poorly
controlled type 1 diabetic patients: long-term effects on HbA moderated by depression. A randomized
controlled trial. Diabet Med 2008;25:1337–42164
SVT08
Studies of adolescents/children with T1DM
Channon SJ, Huws-Thomas MV, Rollnick S, Hood K, Cannings-John RL, Rogers C, Gregory JW.
A multicenter randomized controlled trial of motivational interviewing in teenagers with diabetes.
Diabetes Care 2007;30:1390–5168
CHR07
Ellis DA, Templin T, Naar-King S, Frey MA, Cunningham PB, Podolski CL, Cakan N. Multisystemic
therapy for adolescents with poorly controlled type I diabetes: stability of treatment effects in a
randomized controlled trial. J Consult Clin Psychol 2007;75:168–74169
ETN07
Grey M, Whittemore R, Jaser S, Ambrosino J, Lindemann E, Liberti L, et al. Effects of coping skills
training in school-age children with type 1 diabetes. Res Nurs Health 2009;32:405–18171
GWJ09
Nansel TR, Iannotti RJ, Liu A. Clinic-integrated behavioral intervention for families of youth with type 1
diabetes: randomized clinical trial. Pediatrics 2012;129:e866–73176
NIL12 aka
FMOD
Jaser SS, Patel N, Rothman RL, Choi L, Whittemore R. Check it! A randomized pilot of a positive
psychology intervention to improve adherence in adolescents with type 1 diabetes. Diabetes Educ
2014;40:659–67179
JPR14
Nansel TR, Laffel LM, Haynie DL, Mehta SN, Lipsky LM, Volkening LK, et al. Improving dietary quality
in youth with type 1 diabetes: randomized clinical trial of a family-based behavioral intervention.
Int J Behav Nutr Phys Act 2015;12:58183
NLH15 aka
CHEF
Serlachius AS, Scratch SE, Northam EA, Frydenberg E, Lee KJ, Cameron FJ. A randomized controlled
trial of cognitive behaviour therapy to improve glycaemic control and psychosocial wellbeing in
adolescents with type 1 diabetes. J Health Psychol 2016;21:1157–69184
SSN16
Nansel TR, Iannotti RJ, Simons-Morton BG, Cox C, Plotnick LP, Clark LM, Zeitzoff L. Diabetes personal
trainer outcomes: short-term and 1-year outcomes of a diabetes personal trainer intervention among
youth with type 1 diabetes. Diabetes Care 2007;30:2471–7170
NIS07 aka DPT
study
Christie D, Thompson R, Sawtell M, Allen E, Cairns J, Smith F, et al. Structured, intensive education
maximising engagement, motivation and long-term change for children and young people with
diabetes: a cluster randomised controlled trial with integral process and economic evaluation – the
CASCADE study. Health Technol Assess 2014;18(20)181
CTS14
Studies of adults with T2DM
Chiu CJ, Hu YH, Wray LA, Beverley EA, Yang YC, Wu JS, Lu FH. Dissemination of evidence-base
minimal psychological intervention for diabetes management in Taiwan adults with type 2 diabetes.
Int J Clin Exp Med 2016;9:14489–98151
CHW16
D’Eramo Melkus G, Chyun D, Vorderstrasse A, Newlin K, Jefferson V, Langerman S. The effect of a
diabetes education, coping skills training, and care intervention on physiological and psychosocial
outcomes in black women with type 2 diabetes. Biol Res Nurs 2010;12:7–19118
ECV10
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TABLE 37 Study ID against reference for IPD studies (continued )
Reference ID
Keogh KM, Smith SM, White P, McGilloway S, Kelly A, Gibney J, O’Dowd T. Psychological family
intervention for poorly controlled type 2 diabetes. Am J Manag Care 2011;17:105–13123
KSW11
Hartmann M, Kopf S, Kircher C, Faude-Lang V, Djuric Z, Augstein F, et al. Sustained effects of a
mindfulness-based stress-reduction intervention in type 2 diabetic patients: design and first results
of a randomized controlled trial (the Heidelberger Diabetes and Stress-study). Diabetes Care
2012;35:945–7132
HKK12
Safren SA, Gonzalez JS, Wexler DJ, Psaros C, Delahanty LM, Blashill AJ, et al. A randomized controlled
trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with
uncontrolled type 2 diabetes. Diabetes Care 2014;37:625–33140
SGW14
Welschen LM, van Oppen P, Bot SD, Kostense PJ, Dekker JM, Nijpels G. Effects of a cognitive
behavioural treatment in patients with type 2 diabetes when added to managed care; a randomised
controlled trial. J Behav Med 2013;36:556–66135
WOB13
Eakin EG, Winkler EA, Dunstan DW, Healy GN, Owen N, Marshall AM, et al. Living well with diabetes:
24-month outcomes from a randomized trial of telephone-delivered weight loss and physical activity
intervention to improve glycemic control. Diabetes Care 2014;37:2177–85143
EWD14
Chlebowy DO, El-Mallakh P, Myers J, Kubiak N, Cloud R, Wall MP. Motivational interviewing to
improve diabetes outcomes in African Americans adults with diabetes. West J Nurs Res
2015;37:566–80145
CEM15
Kasteleyn MJ, Vos RC, Rijken M, Schellevis FG, Rutten GE. Effectiveness of tailored support for people
with type 2 diabetes after a first acute coronary event: a multicentre randomized controlled trial
(the Diacourse-ACE study). Diabet Med 2016;33:125–33150
KVR16
Griffin SJ, Simmons RK, Prevost AT, Williams KM, Hardeman W, Sutton S, et al. Multiple behaviour
change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus
randomised controlled trial. Diabetologia 2014;57:1308–19142
GSP14
Mandel SE, Davis BA, Secic M. Effects of music therapy and music-assisted relaxation and imagery on
health-related outcomes in diabetes education: a feasibility study. Diabetes Educ 2013;39:568–81136
MDS13
Jansink R, Braspenning J, Keizer E, van der Weijden T, Elwyn G, Grol R. No identifiable HbA1c or
lifestyle change after a comprehensive diabetes programme including motivational interviewing:
a cluster randomised trial. Scand J Prim Health Care 2013;31:119–27137
JBK13
Dale J, Caramlau I, Sturt J, Friede T, Walker R. Telephone peer-delivered intervention for diabetes
motivation and support: the telecare exploratory RCT. Patient Educ Couns 2009;75:91–8113
DCS09
Ell K, Katon W, Xie B, Lee PJ, Kapetanovic S, Guterman J, Chou CP. One-year postcollaborative
depression care trial outcomes among predominantly Hispanic diabetes safety net patients.
Gen Hosp Psychiatry 2011;33:436–42129
EKX11
Pibernik-Okanovic´ M, Hermanns N, Ajdukovic´ D, Kos J, Prasˇek M, Sˇekerija M, Lovrencˇic´ MV. Does
treatment of subsyndromal depression improve depression-related and diabetes-related outcomes?
A randomised controlled comparison of psychoeducation, physical exercise and enhanced treatment
as usual. Trials 2015;16:305147
PHA15
Studies of adults with a T1DM and T2DM population
Hermanns N, Schmitt A, Gahr A, Herder C, Nowotny B, Roden M, et al. The effect of a Diabetes-Specific
Cognitive Behavioral Treatment Program (DIAMOS) for patients with diabetes and subclinical depression:
results of a randomized controlled trial. Diabetes Care 2015;38:551–60105
HSG15
van Son J, Nyklícˇek I, Pop VJ, Blonk MC, Erdtsieck RJ, Pouwer F. Mindfulness-based cognitive therapy
for people with diabetes and emotional problems: long-term follow-up findings from the DiaMind
randomized controlled trial. J Psychosom Res 2014;77:81–4104
VNP14
Petrak F, Herpertz S, Albus C, Hermanns N, Hiemke C, Hiller W, et al. Cognitive behavioral therapy
versus sertraline in patients with depression and poorly controlled diabetes: the Diabetes and
Depression (DAD) study: a randomized controlled multicenter trial. Diabetes Care 2015;38:767–75106
PET15
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TABLE 38 Comparison of characteristics between all studies and studies included in the IPD meta-analysis
Variable Included in IPD All studies (n= 74)
Difference between
studies included in IPD
and all studies (p-value)
Population, mean (SD); range 160.03 (111.85); 40–478 202.62 (469.74), 22–3946 0.63
Location, n (%)
Asia 1 (3.45) 9 (12.16) 0.62
Australia 2 (6.90) 3 (4.05)
Europe (non-UK) 10 (34.48) 24 (32.43)
North America 5 (17.24) 19 (25.68)
South America 0 (0) 1 (1.35)
UK 5 (17.24) 8 (10.81)
USA 6 (20.69) 10 (13.51)
Year, range 2007–2016 2004–2016 0.45
Type of psychological intervention, n (%)
CBT 11 (37.93) 26 (35.14) 0.95
Counselling 13 (44.83) 37 (50)
Creative therapy 1 (3.45) 1 (1.35)
Family therapy 3 (10.34) 7 (9.46)
Psychotherapy 1 (3.45) 3 (4.05)
RoB assessment, n (%)
Low 18 (62.07) 37 (50) 0.48
Unclear 11 (37.03) 36 (48.65)
High 0 (0) 1 (1.35)
Overall effect
VNP14104
SVT08164
PET15106
ITM08163
HSG15105
EKX11129
S
tu
d
ie
s
– 4.0 – 3.5 – 3.0 – 2.5 – 2.0 – 1.5 – 1.0 – 0.5 0.5 1.0 1.50
Effect sizes and CIs (coefficients)
Favours psychological intervention Favours control
FIGURE 51 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c response at
follow-up for adults with T1DM. Effect sizes are unstandardized differences in mmol HbA1c at follow-up between
treatment and control arms after controlling for baseline HbA1c values (six study sites).
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Overall effect
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FIGURE 52 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c levels at follow-up
for adults with T1DM. Effect sizes are unstandardized differences in % HbA1c at follow-up between treatment and
control arms after controlling for baseline HbA1c values and age (six study sites).
NLH15183
NIS07170
NIL12176
JPR14179
GWJ09171
ETN07169
CTS14181
Overall effect
SSN16184
CHR07168
– .2.0 – 1.5 – 1.0 – 0.5 0.5 1.0 1.50
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FIGURE 53 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c levels at follow-up
for adolescents and children with T1DM. Effect sizes are unstandardized differences in % HbA1c at follow-up
between treatment and control arms after controlling for baseline HbA1c values.
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FIGURE 55 The HbA1c levels (%) at follow-up, adjusted for HbA1c baseline values for each treatment arm separately
for adults with T2DM.
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FIGURE 54 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c levels at follow-up
for adolescents and children with T1DM. Effect sizes are unstandardized differences in mmol HbA1c at follow-up
between treatment and control arms after controlling for baseline HbA1c values, age and duration of diabetes
(eight study sites).
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ML Overall (I 2 = 0.0%)
Favours psychological intervention Favours control
EWD14143
ECV10118
PHA15147
JBK13137
ETN07169
HKK12132
GSP14142
KSW11123
WOB13135
KVR16150
MDS13136
– 0.13 (– 0.23 to – 0.04)
– 0.09 (– 0.48 to 0.31)
– 0.49 (– 1.21 to 0.22)
0.18 (– 0.16 to 0.51)
– 0.09 (– 0.29 to 0.11)
– 2.49 (– 6.92 to 1.94)
– 0.23 (– 0.66 to 0.21)
0.03 (– 0.24 to 0.29)
– 0.40 (– 0.88 to 0.07)
0.01 (– 0.34 to 0.37)
– 0.06 (– 0.53 to 0.41)
0.02 (– 0.36 to 0.41)
100.00
17.99
3.24
8.96
20.33
0.96
7.10
15.02
6.96
8.82
4.62
6.00
– 6.92 0 6.92
Study ES (95% CI) Weight (ML ) (%)
FIGURE 57 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c response at
follow-up for adults with T2DM. Effect sizes are unstandardized differences in mmol HbA1c at follow-up between
treatment and control arms after controlling at an average baseline HbA1c values of 7.8% (19 study sites), age and
duration of illness.
ML Overall (I 2 = 0.0%)
PHA15147
SGW14140
EWD14143
HKK12132
CHW16151
EKX11129
PET15106
ETN07169
KVR16150
WOB13135
VNP14104
DCS09113
MDS13136
KSW11123
JBK13137
GSP14142
HSG15105
CEM15145
ECV10118
– 0.11 (– 0.19 to – 0.02)
0.18 (– 0.16 to 0.51)
– 0.82 (– 1.47 to – 0.18)
– 0.06 (– 0.44 to 0.32)
– 0.23 (– 0.66 to 0.21)
0.03 (– 0.36 to 0.43)
– 0.11 (– 0.69 to 0.46)
– 0.13 (– 0.94 to 0.67)
– 2.49 (– 6.92 to 1.94)
– 0.06 (– 0.53 to 0.41)
0.08 (– 0.26 to 0.41)
– 0.09 (– 0.68 to 0.50)
0.02 (– 0.40 to 0.43)
0.02 (– 0.36 to 0.39)
– 0.39 (– 0.86 to 0.08)
– 0.11 (– 0.30 to 0.09)
– 0.03 (– 0.20 to 0.15)
0.14 (– 0.74 to 1.02)
– 0.53 (– 2.57 to 1.51)
– 0.29 (– 0.95 to 0.38)
100.00
5.12
3.03
10.90
4.05
6.73
8.74
2.16
0.55
2.64
5.39
3.03
4.80
3.50
4.01
12.83
17.16
2.52
0.51
2.32
– 6.92
Favours psychological intervention Favours control
0 6.92
Study ES (95% CI) Weight (ML) (%)
FIGURE 56 The IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c response at
follow-up for adults with T2DM. Effect sizes are unstandardized differences in % HbA1c at follow-up between
treatment and control arms after controlling at an average baseline HbA1c values of 7.8% (19 study sites).
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ML Overall (I 2 = 0.0%)
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ECV10118
KVR16150
– 0.12 (– 0.22 to – 0.02)
– 0.40 (– 0.88 to 0.07)
0.18 (– 0.16 to 0.51)
0.02 (– 0.36 to 0.41)
0.03 (– 0.24 to 0.29)
0.01 (– 0.34 to 0.37)
– 0.09 (– 0.29 to 0.11)
– 0.09 (– 0.48 to 0.31)
– 0.23 (– 0.66 to 0.21)
– 0.49 (– 1.21 to 0.22)
– 0.06 (– 0.53 to 0.41)
100.00
7.03
9.05
6.05
15.17
8.91
20.53
18.16
7.17
3.27
4.66
– 1.21 0 1.21
Study ES (95% CI) Weight (ML) (%)
FIGURE 58 Sensitivity analyses: IPD meta-analysis comparing treatment arms with control arms in terms of HbA1c
response at follow-up for adults with T2DM without the Ellis et al.169 study. Effect sizes are unstandardized
differences in mmol HbA1c at follow-up between treatment and control arms after controlling at an average
baseline HbA1c values of 7.8% (19 study sites), age and duration of illness.
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Appendix 15 Additional tables for
non-randomised controlled trials
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TABLE 39 Risk of bias assessment: grading biases observed in seven domains for individual nRCT studies
Year, country, reference Confounding
Selection of
participants
Classification of
interventions
Deviations from
intended interventions
Missing
data
Measurement
of outcomes
Selection of
reported results
Overall
assessment
T2DM studies
2004, South Korea, Kim et al.233 Moderate Low Low NI NI Moderate Moderate NI
2007, South Korea, Song and
Kim234
Low Low Low NI NI Moderate Moderate NI
2009, Italy, Forlani et al.235 Serious Moderate Low Low NI Moderate Moderate Serious
2011, South Korea, Lee et al.236 Low Low Moderate Low NI Moderate Moderate Moderate
2013, Spain, Cervantes
Cuesta et al.237
Moderate Low Low NI NI Moderate Moderate NI
2014, Thailand,
Ounnapiruk et al.238
Low Low Low NI NI Moderate Moderate NI
2014, Taiwan, Wu et al.240 Critical Moderate Moderate NI NI Moderate Moderate Critical
T1DM studies
2003, USA, Ellis et al.229 Serious Serious Moderate Serious NI Serious Critical Critical
2003, Japan, Takii et al.226 Moderate Moderate Moderate NI NI Moderate Moderate NI
2006, Germany, Kubiak et al.228 Moderate Low Moderate NI NI Moderate Moderate NI
2006, Iran, Attari et al.227 Moderate Low Moderate NI NI Moderate Moderate NI
2010, Spain, García-Pérez et al.230 Moderate Low Low NI NI Moderate Moderate NI
2013, USA, Bitsko et al.231 Serious Low Low NI NI Moderate Moderate Serious
Studies including a T2DM and T1DM population
2009, USA, Harris et al.232 Critical Serious Low NI NI Moderate Moderate Critical
NI, no information.
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TABLE 40 Comparison of HbA1c levels between intervention and control groups in nRCT studies
Year, country, reference
Follow-up
period (months)
Intervention group Control group
p-valueBaseline Follow-up Baseline Follow-up
T2DM studies
2004, South Korea, Kim et al.233 Post intervention 7.84± 1.63 6.96± 1.19 7.78± 1.72 8.19± 2.07 0.02
2007, South Korea, Song and Kim234 3 9.4 ± 1.8 7.1 ± 1.2 9.0 ± 1.2 8.6± 71.3 0.001
2009, Italy, Forlani et al.235 48 7.4 ± 1.8 7.0 (2.3) 7.9 ± 1.9 7.5 (1.9) NR
2011, South Korea, Lee et al.236 6 7.95± 1.43 7.33± 1.22 7.42± 1.67 7.08± 1.79 NR
2013, Spain, Cervantes Cuesta et al.237 3 6.89± 1.16 6.38± 0.88 7.03± 1.20 6.97± 1.30 0.04
2014, Thailand, Ounnapiruk et al.238 3 8.17± 0.44 7.71± 0.28 7.99± 0.42 8.24± 0.41 0.292
2014, Taiwan, Wu et al.240 1 8.18± 1.76 7.79± 1.62 8.49± 1.99 8.60± 2.02 **
T1DM studies
2003, USA, Ellis et al.229 l Controlsa 1
and 2: 3
l Control 3: 2
l Control 4: 9
NR NR NR NR NR
2003, Japan, Takii et al.226 36 12.2± 1.7 NR 12.8± 2.9 NR NR
2006, Germany, Kubiak et al.228 6 6.8 ± 1.6 6.3 ± 0.9 6.8 ± 1.5 6.2± 1.3 0.67
2006, Iran, Attari et al.227 Post intervention 11.7± 2.9 8.5 ± 1.7 10.9± 2.1 10.3± 2.1 **
2010, Spain, García-Pérez et al.230 3 8.63± 1.75 9.19± 1.89 9.06± 1.37 9.42± 1.87 .646
2013, USA, Bitsko et al.231 12
10.40± 2.21 9.67 ± 2.19 8.65± 1.99 9.34± 1.79 0.459
Studies including a T2DM and T1DM population
2009, USA, Harris et al.232 Post intervention 11.4± 1.4 11.1± 1.4 11.1± 1.6 NR NR
**p < 0.001.
NR, not reported.
a Follow-period for individual cases.
Note
Data are means ± SD or median (interquartile range).
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TABLE 41 Comparison of psychological scores between intervention and control groups in nRCT studies
Year, country,
reference Psychological measures
Follow-up period
(months)
Intervention group Control group
p-valueBaseline Follow-up Baseline Follow-up
T2DM studies
2004, South Korea, Kim et al.233 Stages of Readiness Exercise Behavior
Scale
Psychological
intervention
3.41 ± 1.33 4.36± 0.66 3.22 ± 1.35 3.22± 1.38 0.001
2011, South Korea, Lee et al.236 Jalowiec Coping Scale 6
Affective-oriented 59.52± 9.98 58.45± 10.74 61.00 ± 9.65 61.71 ± 10.07 0.643
Problem-oriented 42.03± 10.50 43.41± 9.04 47.00 ± 10.12 46.18 ± 11.64 0.112
2014, Thailand, Ounnapiruk et al.238 Diabetes Management
Self-Efficacy Scale
3 28.86± 0.71 30.63± 0.51 28.96 ± 0.67 27.73 ± 0.63 0.001
2014, Taiwan, Wu et al.240 Perceived Therapeutic Efficacy Scale 1
Self-efficacy 75.22± 18.97 81.90± 15.65 75.09 ± 16.62 76.24 ± 16.00 **
Self-care 37.33± 14.20 56.20± 14.21 37.58 ± 12.33 48.55 ± 14.66 **
Depression, Anxiety and Stress Scale 16.51± 13.68 15.50± 14.29 16.49 ± 13.88 16.56 ± 13.95 **
WHO Well-Being Index 16.60± 5.65 17.17± 5.66 15.06 ± 5.17 15.42 ± 5.36 0.21
T1DM studies
2003, Japan, Takii et al.226 Eating Disorder Inventory l Intervention: 36
l Control: 24
102.3± 19.2 40.6± 32.6 78.7 ± 25.6 75.0± 23.8 NR
Self-Rating Depression Scale 52.8 ± 05.7 36.8± 13.4 49.9 ± 5.2 51.2± 4.0 NR
STAI 58.8 ± 05.7 44.1± 14.0 53.9 ± 4.6 57.9± 5.9 NR
2006, Germany, Kubiak et al.228 Zerssen-d-Scale (Depression) 6 7.9 ± 6.1 6.8± 6.1 6.5 ± 6.2 7.9 ± 6.8 0.09
STAI 36.5 ± 10.1 38.1± 11.5 36.2 ± 8.5 36.5± 10.5 0.83
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Year, country,
reference Psychological measures
Follow-up period
(months)
Intervention group Control group
p-valueBaseline Follow-up Baseline Follow-up
Control beliefs: IPC-D Q
Internal control 38.4 ± 7.0 38.2± 5.7 37.7 ± 6.0 38.7± 7.1 0.12
External control 23.1 ± 7.1 21.7± 8.2 22.5 ± 7.0 19.5± 7.4 0.26
Unpredictability 26.7 ± 7.7 28.1± 7.8 25.2 ± 8.1 24.4± 8.2 0.41
Luck and chance 7.9 ± 3.3 8.8± 4.3 7.8 ± 4.0 7.5 ± 3.4 0.43
Visual Analogue scales
Fear of hypoglycemia 6.0 ± 6.1 5.3± 3.9 5.1 ± 4.2 4.3 ± 3.7 0.83
Fear of diabetes complications 13.5 ± 2.5 8.2± 3.9 13.9 ± 1.6 9.8 ± 5.2 0.17
2006, Iran, Attari et al.227 Stress Management Questionnaire:
applied positive coping
Psychological
intervention
5.06 ± 2.75 8.13± 2.44 5.63 ± 2.97 5.8 ± 2.09 0.001
2010, Spain, García-Pérez et al.230 STAI (State) 3 35 (54) 28 (60) 20 (34) 10 (28) 0.347
STAI-C (Trait) 48 (43) 53 (71) 21 (51) 18 (41) 0.091
Studies including a T2DM and T1DM population
2009, USA, Harris et al.232 Diabetes Responsibility and Conflict
Scale
Psychological
intervention
Adolescents 30.7 ± 15.0 25.4± 12.8 NR 37.7± 12.3 **
Mothers 29.7 ± 15.0 23.9± 6.9 NR 37.6± 13.5 *
Fathers 27.1 ± 08.1 26.6± 7.6 NR 36.3± 11.2 Non-significant
Conflict Behaviour Questionnaire
Adolescents 06.1 ± 5.7 4.5± 4.5 NR 6.6 ± 5.5 *
Mothers 9.5 ± 4.7 5.1± 5.0 NR 7.3 ± 6.1 *
Fathers 9.9 ± 6.1 6.8± 7.2 NR 7.3 ± 6.3 *
IPC-D Q, diabetes-specific control beliefs questionnaire; STAI, State–Trait Anxiety Inventory.
Note
Data are means ± SD.
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Appendix 16 Technical appendices to the health
economic analysis
Technical appendix on details of baseline characteristics used for
modelling type 1 diabetes patients
TABLE 42 Distributions used to generate baseline characteristics for patients included in the T1DM simulation
What is needed Key
Transformations
applied for
sampling
Values used
SourceMean SD
Age Years None 40.9819 13.59232 DAFNE research database
Duration of
diabetes
Years None 16.92 13.31 National Diabetes Audit
Gender 0 = female, 1 = male 0.57 0.50006 National Diabetes Audit
(mean) DAFNE research
database (SD)
Smoker 1 = current smoker,
2 = former smoker,
3 = non-smoker
2.380388 0.780509 DAFNE research database
Systolic blood
pressure
mmHg LN 4.854137 0.132766 National Diabetes Audit
(mean) DAFNE research
database (SD)
LDL cholesterol mmol/l None 2.84 0.75 National Diabetes Audit
HDL cholesterol mmol/l LN 0.41996 0.278074 DAFNE research database
Total cholesterol mmol/l LN 1.507881 0.20003 DAFNE research database
Triglycerides mmol/l LN 0.032197 0.575833 DAFNE research database
Physical activity
Race 0 = white, 1 = Hispanic,
2 = black
0.1 0.369242 National Diabetes Audit
(mean) DAFNE research
database (SD)
Baseline insulin
costs
£ – –
Baseline diabetes-
related costs
£ – –
HbA1c level DCCT aligned LN (HbA1c) 2.151762 0.172024 National Diabetes Audit
(mean) DAFNE research
database (SD)
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TABLE 42 Distributions used to generate baseline characteristics for patients included in the T1DM simulation
(continued )
What is needed Key
Transformations
applied for
sampling
Values used
SourceMean SD
Nephropathy 1 = no comps/missing,
2 =microalbumuria,
3 =macroalbumuria,
4 = dialysis/transplant
1.103301 0.431909 DAFNE research database
Neuropathy 1 = no comps/missing,
2 = neuropathy or ulcers,
5 = reported amputation
(above or below the toe)
3 = amputation
(above or below toe)
1.055378 0.62177 DAFNE research database
Retinopathy 1 = no comps/missing,
2 = BDR, 3 = PDR,
4 = partially sighted/blind
1.339723 0.62177 DAFNE research database
Myocardial
infarction
1 = no comps/missing,
2 =myocardial infarction
1.014909 0.233451 DAFNE research database
Stroke 1 = no comps/missing,
2 = stroke
1.007455 0.121255 DAFNE research database
Heart failure 1 = no comps/missing,
2 = hear failure
1 NR DAFNE research database
Angina 1 = no comps/missing,
2 = angina
1.011715 0.107655 DAFNE research database
DCCT, Diabetes Control and Complications Trial; NR, not reported.
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TABLE 43 Correlation matrix from the DFANE research database used in conjunction with Table 42 to generate characteristics for patients included in the T1DM simulation
Characteristic Age Duration Gender Smoke
ldl_mol_
result eth neph neuro ret
Myocardial
infarction Stroke Angina l_A1c l_SBP l_HDL l_tri l_chol
Age 1 0.461557 0.077086 –0.05265 –0.20529 –0.05886 0.064699 0.127438 0.166778 0.125375 0.06462 0.160945 –0.0713 0.316724 0.110877 –0.02584 –0.13275
Duration 0.461557 1 0.002752 0.066821 –0.11464 –0.02671 0.1989 0.187423 0.441926 0.151865 0.106954 0.169587 0.000766 0.258778 0.121674 –0.08435 –0.08116
Gender 0.077086 0.002752 1 –0.0821 –0.04005 0.05245 0.014266 0.000739 0.062288 0.033366 0.023498 0.047723 –0.07077 0.091767 –0.31077 0.081835 –0.17903
Smoke –0.05265 0.066821 –0.0821 1 –0.0406 0.02119 –0.03963 –0.04292 –0.03751 0.015813 –0.09482 0.023793 –0.17369 0.043068 0.088948 –0.13688 –0.03202
ldl_mol_result –0.20529 –0.11464 –0.04005 –0.0406 1 –0.00499 0.029985 –0.0176 –0.05926 –0.04299 0.005286 –0.04058 0.138707 –0.06789 –0.12822 0.21733 0.816337
eth –0.05886 –0.02671 0.05245 0.02119 –0.00499 1 0.024462 0.018193 –0.00289 –0.02692 0.06937 –0.02552 0.137036 –0.02343 –0.10038 0.064053 –0.03019
neph 0.064699 0.1989 0.014266 –0.03963 0.029985 0.024462 1 0.264598 0.260778 0.089258 0.021153 –0.02767 0.046666 0.104641 0.017395 0.070919 0.054139
neuro 0.127438 0.187423 0.000739 –0.04292 –0.0176 0.018193 0.264598 1 0.267284 0.079597 0.056058 0.029498 0.127995 0.100522 0.044187 –0.00618 0.012525
ret 0.166778 0.441926 0.062288 –0.03751 –0.05926 –0.00289 0.260778 0.267284 1 0.134453 0.037145 0.105935 0.107738 0.107083 –0.05104 0.057722 –0.0549
Myocardial
infarction
0.125375 0.151865 0.033366 0.015813 –0.04299 –0.02692 0.089258 0.079597 0.134453 1 0.131752 0.519815 0.023971 0.009747 –0.03703 0.014236 –0.0947
Stroke 0.06462 0.106954 0.023498 –0.09482 0.005286 0.06937 0.021153 0.056058 0.037145 0.131752 1 –0.01078 0.11291 0.002222 0.020342 –0.00582 0.0119
Angina 0.160945 0.169587 0.047723 0.023793 –0.04058 –0.02552 –0.02767 0.029498 0.105935 0.519815 –0.01078 1 –0.00576 0.121203 –0.11386 0.062528 –0.10244
l_A1c –0.0713 0.000766 –0.07077 –0.17369 0.138707 0.137036 0.046666 0.127995 0.107738 0.023971 0.11291 –0.00576 1 0.041214 –0.06577 0.245816 0.148099
l_SBP 0.316724 0.258778 0.091767 0.043068 –0.06789 –0.02343 0.104641 0.100522 0.107083 0.009747 0.002222 0.121203 0.041214 1 0.002022 0.142123 –0.01014
l_HDL 0.110877 0.121674 –0.31077 0.088948 –0.12822 –0.10038 0.017395 0.044187 –0.05104 –0.03703 0.020342 –0.11386 –0.06577 0.002022 1 –0.32514 0.282313
l_tri –0.02584 –0.08435 0.081835 –0.13688 0.21733 0.064053 0.070919 –0.00618 0.057722 0.014236 –0.00582 0.062528 0.245816 0.142123 –0.32514 1 0.29572
l_chol –0.13275 –0.08116 –0.17903 –0.03202 0.816337 –0.03019 0.054139 0.012525 –0.0549 –0.0947 0.0119 –0.10244 0.148099 –0.01014 0.282313 0.29572 1
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TABLE 44 The costs (£) used in the economic model, part a. Seemingly unrelated regression functions for estimated
costs in year 1 and ongoing based on REPOSE trial data (Multivariate normal distributionsa)
Annual cost of
insulin and MDI
consumables
(year 1)
Annual cost of
insulin and MDI
consumables
(ongoing)
Annual cost of
DRC (year 1)
Annual
cost of DRC
(ongoing) Source
Multiplier for the
baseline DRC cost (β1)
b b
–0.11 0.03 Heller et al.245
Multiplier for the
baseline insulin cost (β2)
–0.99 –1.07 b b
Multiplier for the
baseline HbA1c
(DCCT % scale) (β3)
–5.19 –13.10 –22.15 –12.42
Constant (β0) 379.14 303.60 472.43 179.73
DCCT, Diabetes Control and Complications Trial; MDI, multiple daily injections.
a The variance–covariance matrices used to parameterise the multivariate normal distribution are provided in the
supplementary material B in Pollard et al.244
b This value was not included as a covariate in the regression formula and is taken to be a zero value in the total
cost formula.
Note
The cost for each total cost is calculated using the following formula:
Total cost = β0+ β1 × Individual’s baseline diabetes-related contact cost + β2 × Individual’s baseline insulin
cost + β3 × Individual’s baseline HbA1c (DCCT % scale) + β4 × Individual’s treatment at the start of the year (1 = pump,
0 =MDI)+ β5 × (1 = switched from pump to MDI, 0 = did not switch from pump to MDI)+ β6 × (1 = switched from MDI to
pump, 0 = did not switch from MDI to pump).
TABLE 45 The costs (£) used in the economic model, part c. Costs of adverse events, comorbidities and
complications; gamma distributions
Health state
Mean
cost (£) SE Source Health state
Mean
cost (£) SE Source
Adverse events
Hypoglycaemia 191 19 Heller et al.242 DKA 2091 197 Dhatariya
et al.301
Nephropathy
Ongoing yearly cost
of microalbuminuria
36 4 BNF265 and
McEwan
et al.302
Ongoing yearly cost of
microalbuminuria –
ongoing
36 4 BNF265 and
McEwan
et al.302
Ongoing yearly cost
of ESRD
24,983 2498 NHS reference
costs303
Death due to ESRD 0 0 Assumed
equal to Zero
Neuropathy
Clinically confirmed
neuropathy
277 28 Currie et al.304 Clinical neuropathy 277 28 Currie
et al.304
Diabetic foot
syndrome
2912 291 NHS Reference
costs303
PAD with amputation
(year 1)
7383 738 NHS Reference
costs303
Ongoing yearly cost
of PAD with
amputation
449 45 McEwan
et al.302
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TABLE 45 The costs (£) used in the economic model, part c. Costs of adverse events, comorbidities and
complications; gamma distributions (continued )
Health state
Mean
cost (£) SE Source Health state
Mean
cost (£) SE Source
Retinopathy
Background
retinopathy
148 15 McEwan
et al.302
Proliferative retinopathy 676 68 McEwan
et al.302
Macular oedema
(year 1)
5726 573 NICE,305 BNF265 Macular oedema
(year 2)
3432 343 NICE,305 BNF265
Macular oedema
(year 3)
2574 257 NICE,305 BNF265 Macular oedema
(ongoing)
280 28 NICE,305 BNF265
Blindness (year 1) 2227 223 Alva et al.306 Blindness (ongoing) 207 21 Alva et al.306
Cardiovascular
First myocardial
infarction (year 1)
6565 657 Alva et al.306 Second myocardial
infarction (year 1)
6565 657 Alva et al.306
Final myocardial
infarction (year 1)
6565 657 Alva et al.306 Ongoing yearly cost of
a myocardial infarction
862 86 Alva et al.306
Fatal myocardial
infarction
1098 110 Alva et al.306 Heart failure (year 1) 3286 329 Alva et al.306
Heart failure
(ongoing)
1504 150 Alva et al.306 Fatal heart failure 3286 329 Alva et al.306
First stroke (year 1) 7132 714 Alva et al.306 Second stroke 7132 713 Alva et al.306
Fatal stroke 3613 361 Alva et al.306 First stroke (ongoing) 920 92 Alva et al.306
Angina (year 1) 9965 997 Alva et al.306 Angina (ongoing) 870 87 Alva et al.306
BNF, British National Formulary; ESRD, end-stage renal disease; PAD, peripheral arterial disease; SE, standard error.
TABLE 46 The utilities used in the economic model
Health state for event Utility SE
Beta distribution
SourceAlpha Beta
Baseline utility value
Male with type 1 diabetes and no complications 0.866 0.010 947.79 146.90 Peasgood et al.250
Disutility SE
Gamma distribution
SourceAlpha Beta
Complications or covariates
Female with type 1 diabetes and no complications –0.0236 0.008 8.70 0.003 Peasgood et al.250
Age decrement (per 10 years) –0.0214 0.003 50.88 0.0004 Peasgood et al.250
Adverse eventsa
Severe hypoglycaemia –0.002 –0.002 1 0.002 Peasgood et al.250
DKA –0.0091 –0.01 0.83 0.01 Peasgood et al.250
Nephropathy
Microalbuminuria 0 Assumption
Microalbuminuria –0.017 0.01 2.89 0.01 Coffey et al.249
ESRD –0.078 0.026 9 0.01 Coffey et al.249
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Technical appendix on methods to model severe hypoglycaemia and
diabetic ketoacidosis in people with type 1 diabetes
Data on the incidence and severe hypoglycaemia and DKA was obtained from analyses of the DAFNE
research database.242 This source was used for three reasons: first, it had the largest sample size for this
data; second, it was not clinically expected that the inclusion of a bolus advisor to a DAFNE course would
affect the incidence of these two serious adverse events; and third, it was expected that the REPOSE trial
exclusion of people immediately eligible for a pump would have lowered the incidence of these two events
compared with the population who normally receive DAFNE.
TABLE 46 The utilities used in the economic model (continued )
Health state for event Utility SE
Beta distribution
SourceAlpha Beta
Neuropathy
Clinical neuropathy –0.055 0.01 30.25 0.002 Coffey et al.249
Clinically confirmed neuropathy –0.055 0.01 30.25 0.002 Coffey et al.249
Diabetic foot syndrome –0.1042 –0.119 0.77 0.14 Peasgood et al.250
PAD with amputation –0.1172 –0.055 4.54 0.03 Peasgood et al.250
Retinopathy
Background retinopathy –0.0544 –0.023 5.59 0.01 Peasgood et al.250
Proliferative retinopathy –0.0288 –0.026 1.23 0.02 Peasgood et al.250
Blindness –0.208 0.013 256 0.001 Coffey et al.249
Cardiovascular
Myocardial infarction (first year)a –0.065 0.03 4.69 0.01 Alva et al.247
Myocardial infarction (subsequent years) –0.057 0.03 3.61 0.02 Alva et al.247
Heart failure –0.101 0.032 9.96 0.010 Alva et al.247
Stroke –0.165 0.035 22.22 0.007 Alva et al.247
Anginab –0.09 0.018 25 0.004 Clarke et al.248
ESRD, end stage renal disease; PAD, peripheral arterial disease; SE, standard error.
a These disutilites are applied transiently to the number of these events in each year.
b Value is presented in Table 5 as ischaemic heart disease.
TABLE 47 The results of the negative binomial regression fitted to the DAFNE research database to predict the
incidence of DKA
Parameters Coefficient SE 95% CI Relative risk 95% CI Source
Constant –7.601 1.2041 –9.961 to –5.241 – – Re-analysis of
data used in Heller
et al.242 and
Thokala et al.246
DAFNE receipt
(before = 0/
after = 1)
–0.943 0.3443 –1.618 to –0.268 0.006 0.198 to 0.765
HbA1c (DCCT
aligned)
0.563 0.1235 0.320 to 0.805 1.755 1.376 to 2.236
Overdispersion
parameter
6.974 N/A
DCCT, Diabetes Control and Complications Trial; N/A, not applicable; SE, standard error.
Note
The covariance matrix required to sample the coefficients from a multivariate distribution is given in Table 48.
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Risk of severe hypoglycaemia
How to sample from these negative binomial regressions
The number of events was directly sampled for each individual in the model. An example of how to
estimate the number of severe hypoglycaemic events that occur in 1 year for a person with a HbA1c level
of 10% and post DAFNE using the central estimates of the coefficients is given below.
l The fitted value (FV) of the regression coefficients was estimated: (FV = 0.912 + –1.288 + –0.131 × 10).
l The mean number of events for this individual (µ) was calculated using the following formula: µ = eFV.
l A parameter of the negative binomial distribution (p) was calculated using the following
formula: p = 1 – [1 / (8.525 + 1 / µ)].
l A parameter of the negative binomial distribution (r) was calculated using the following
formula: r = [µ × (1 – p)] / p.
l A random sample (λ) from the following gamma distribution (using a shape and scale parameterisation)
was taken: λ ∼ gamma [r, p/(1 – p)].
l A random sample for the number of predicted events (N) was taken from the following Poisson
distribution: N ∼ Poisson(λ).
l This process was applied in the model in each year that each individual was run through the model.
l In each PSA run, the coefficients of the negative binomial regression were sampled from a multivariate
normal distribution.
TABLE 48 Covariance matrix for the negative binomial data fitted to estimate DKA
Parameters Intercept (After DAFNE= 1, otherwise= 0) HbA1c
Intercept 1.20397 0.19004 –0.12386
(After DAFNE = 1, otherwise = 0) 0.19004 0.12308 –0.02408
HbA1c –0.12386 –0.02408 0.01318
TABLE 49 The results of the negative binomial regression fitted to the DAFNE research database
Parameters Coefficient SE 95% CI Relative risk 95% CI Source
Constant 0.912 0.5961 –0.257 to 2.080 – – Re-analysis of data
used in Heller et al.
(1) & Thokala
et al.246 (7)
DAFNE
(before = 0/
after = 1)
–1.288 0.1487 –1.580 to –0.977 0.275 0.208 to 0.363
HbA1c (DCCT
aligned)
–0.131 0.0689 –0.266 to 0.004 0.876 0.772 to 0.994
Overdispersion
parameter
8.525 N/A
DCCT, Diabetes Control and Complications Trial; N/A, not applicable; SE, standard error.
TABLE 50 Covariance matrix for the negative binomial data fitted to estimate severe hypoglycaemia
Parameters Intercept (After DAFNE= 1, otherwise= 0) HbA1c
Intercept 0.35534 –0.02779 –0.04043
(After DAFNE = 1, otherwise = 0) –0.02779 0.02212 0.00195
HbA1c –0.04043 0.00195 0.00475
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It should be noted that the formulae for p and r depend on the parameterisation of the variance in the
negative binomial regression that an analyst is using. These formulae are valid for SPSS; the formulae may
be different if other statistical software is used to fit the negative binomial regression.
Technical appendix on Sheffield Type 2 Diabetes Prevention Model
adapted to this study
Whitehall II statistical model of metabolic trajectories
The metabolic trajectories used in the model are derived from statistical analysis of the longitudinal
Whitehall II cohort.258 The parameters derived from this model are described in Tables 51–53.
TABLE 51 Coefficient estimates for metabolic risk factor parallel growth models
Parameters Parameter description Estimated mean SE p-value
BMI intercept
α10 Population mean BMI intercept 2.2521 0.045 < 0.001
γ10 Age at baseline coefficient for BMI intercept 0.0056 0.001 < 0.001
Sex coefficient for BMI intercept –0.0311 0.012 0.009
Family history of CVD coefficient for BMI intercept –0.0079 0.012 0.515
υ10 Random error term for BMI intercept 0.1165 0.003 < 0.001
BMI linear slope
α11 Population mean BMI linear slope 0.6409 0.042 < 0.001
γ11 Age at baseline coefficient for BMI linear slope –0.0084 0.001 < 0.001
Sex coefficient for BMI linear slope –0.0285 0.011 0.009
Family history of CVD coefficient for BMI linear slope –0.0155 0.010 0.117
υ11 Random error term for BMI linear slope 0.0222 < 0.001 < 0.001
BMI quadratic slope
α12 Population mean BMI quadratic slope –0.2007 0.023 < 0.001
γ12 Age at baseline coefficient for quadratic slope 0.0026 < 0.001 < 0.001
Sex coefficient for quadratic slope 0.0089 0.006 0.147
Family history of CVD coefficient for quadratic slope 0.0104 0.006 0.061
ϵ1 Random error term for BMI 0.0104 < 0.001 < 0.001
Glycaemic intercept
α20 Population mean glycaemic intercept 0 NA NA
γ20 Smoker coefficient for glycaemic intercept –0.1388 0.029 < 0.001
τ20 Association between BMI intercept and glycaemic intercept 0.2620 0.024 < 0.001
υ20 Random error term for glycaemic intercept 0.0851 0.008 < 0.001
Glycaemic linear slope
α21 Population mean glycaemic linear slope –0.4255 0.071 < 0.001
γ21 Sex coefficient for glycaemic linear slope 0.1486 0.045 0.001
Ethnicity coefficient for glycaemic linear slope –0.0218 0.081 0.786
Family history of T2DM coefficient for glycaemic linear slope –0.0512 0.054 0.345
Smoker coefficient for glycaemic linear slope 0.1796 0.066 0.007
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TABLE 51 Coefficient estimates for metabolic risk factor parallel growth models (continued )
Parameters Parameter description Estimated mean SE p-value
τ21 Association between BMI intercept and glycaemic linear slope 0.0821 0.024 0.001
τ22 Association between BMI linear slope and glycaemic linear slope 0.1984 0.073 0.007
υ21 Random error term for glycaemic linear slope 0.0222 0.011 0.053
Glycaemic quadratic slope
α22 Population mean glycaemic quadratic slope 0.1094 0.025 < 0.001
γ22 Sex coefficient for glycaemic quadratic slope –0.0855 0.027 0.002
Ethnicity coefficient for glycaemic quadratic slope 0.0899 0.049 0.067
Family history of T2DM coefficient for glycaemic quadratic slope 0.0633 0.033 0.052
Smoker coefficient for glycaemic quadratic slope –0.0390 0.040 0.330
υ22 Random error term for glycaemic quadratic slope 0.0107 0.003 0.002
ϵ2 Glycaemic measurement error 0.0707 0.005 < 0.001
SBP intercept
α30 Population mean SBP intercept 0.6934 0.021 < 0.001
γ30 Age at baseline coefficient for SBP intercept 0.0043 < 0.001 < 0.001
Sex coefficient for SBP intercept 0.0380 0.004 < 0.001
Smoking coefficient for SBP intercept –0.0243 0.006 < 0.001
Ethnicity coefficient for SBP intercept 0.0078 0.007 0.300
Family history of CVD coefficient for SBP intercept 0.0061 0.004 0.160
τ31 Association between BMI intercept and SBP intercept 0.1080 0.006 < 0.001
υ30 Random error term for SBP intercept 0.0085 0.00 < 0.001
SBP linear slope
α31 Population mean SBP linear slope –0.0227 0.021 0.278
γ31 Age at baseline coefficient for SBP linear slope 0.0024 < 0.001 < 0.001
Sex coefficient for SBP linear slope –0.0004 0.004 0.927
Smoking coefficient for SBP linear slope 0.0205 0.005 < 0.001
Ethnicity coefficient for SBP linear slope 0.0224 0.007 0.001
Family history of CVD coefficient for SBP linear slope –0.0013 0.004 0.748
τ31 Association between BMI intercept and SBP linear slope –0.0396 0.006 < 0.001
Association between BMI linear slope and SBP linear slope 0.2325 0.019 < 0.001
υ31 Random error term for SBP linear slope 0.0024 < 0.001 < 0.001
ϵ3 SBP measurement error variance 0.0093 < 0.001 < 0.001
TC intercept
α40 Population mean TC intercept 2.9956 0.176 < 0.001
γ40 Age at baseline coefficient for TC intercept 0.0456 0.003 < 0.001
Sex coefficient for TC intercept 0.0660 0.036 0.070
τ40 Association between BMI intercept and TC intercept 0.4459 0.049 < 0.001
υ40 Random error term for TC intercept 0.8960 0.025 < 0.001
continued
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TABLE 51 Coefficient estimates for metabolic risk factor parallel growth models (continued )
Parameters Parameter description Estimated mean SE p-value
TC linear slope
α41 Population mean TC linear slope 2.1216 0.128 < 0.001
γ41 Age at baseline coefficient for TC linear slope –0.0316 0.002 < 0.001
Sex coefficient for TC linear slope –0.2677 0.026 < 0.001
τ41 Association between BMI intercept and TC linear slope –0.4808 0.035 < 0.001
τ42 Association between BMI linear slope and TC linear slope 0.9802 0.108 < 0.001
υ41 Random error term for TC linear slope 0.1583 0.011 < 0.001
ϵ4 TC measurement error variance 0.3426 0.006 < 0.001
HDL intercept
α50 Population mean HDL intercept 2.4124 0.054 < 0.001
γ50 Age at baseline coefficient for HDL intercept 0.0032 0.011 < 0.001
Sex coefficient for HDL intercept –0.3710 0.001 < 0.001
τ51 Association between BMI intercept and HDL intercept –0.3514 0.015 < 0.001
υ50 Random error term for HDL intercept 0.0827 –0.040 < 0.001
HDL linear slope
α51 Population mean HDL linear slope 0.1241 0.034 < 0.001
γ51 Age at baseline coefficient for HDL linear slope 0.0020 0.001 < 0.001
Sex coefficient for HDL linear slope 0.0041 0.007 0.558
τ51 Association between BMI intercept and HDL linear slope –0.0400 0.010 < 0.001
υ51 Random error term for HDL linear slope 0.0090 0.001 < 0.001
ϵ5 HDL measurement error variance 0.0333 0.001 < 0.001
HDL, high-density lipoprotein; SE, standard error; TC, total cholesterol.
TABLE 52 Coefficient estimates for latent glycaemic measurement model
Parameters Parameter description Estimated mean SE p-value
μ0 FPG intercept 4.2903 0.089 < 0.001
θ01 Glycaemic factor to FPG 1 NA NA
θ02 Age to FPG 0.0031 0.001 0.022
θ03 Sex to FPG 0.2129 0.021 < 0.001
θ04 Ethnicity to FPG 0.0100 0.037 0.786
θ05 Family history of diabetes to FPG 0.1168 0.025 < 0.001
ϵ0 FPG measurement error variance 0.1649 0.007 < 0.001
μ1 Two-hour glucose intercept 0.5707 0.223 0.011
θ11 Glycaemic factor to 2-hour glucose 2.4384 0.078 < 0.001
θ12 Age to 2-hour glucose 0.0716 0.003 < 0.001
θ13 Sex to 2-hour glucose –0.1411 0.058 0.014
θ14 Ethnicity to 2-hour glucose 0.3047 0.100 0.002
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Glycated haemoglobin trajectory in individuals diagnosed with type 2 diabetes mellitus
The input parameters for the initial reduction in HbA1c level and long-term trend in HbA1c level following
diagnosis, derived from analysis of the UKPDS outcomes model, are reported in Tables 54 and 55.
TABLE 52 Coefficient estimates for latent glycaemic measurement model (continued )
Parameters Parameter description Estimated mean SE p-value
θ15 Family history of diabetes to 2-hour glucose 0.3496 0.068 < 0.001
ϵ1 2-hour measurement error variance 2.3679 0.054 < 0.001
μ2 HbA1c intercept 4.4769 0.073 < 0.001
θ21 Glycaemic factor to HbA1c 0.5074 0.016 < 0.001
θ22 Age to HbA1c 0.0101 0.001 < 0.001
θ23 Sex to HbA1c –0.0457 0.001 < 0.001
θ24 Ethnicity to HbA1c 0.1854 0.030 < 0.001
θ25 Family history of diabetes to HbA1c 0.0563 0.020 0.004
ϵ2 HbA1c measurement error variance 0.1166 0.003 < 0.001
FPG, fasting plasma glucose; SE, standard error.
TABLE 53 Covariance matrix Ω for individual random error
Parameters υ10 υ11 υ20 υ21 υ22 υ30 υ31 υ40 υ41 υ50 υ51
υ10 0.1165
υ11 0.0095 0.0131
υ20 < 0.0010 < 0.0010 0.0851
υ21 < 0.0010 < 0.0010 0.0222 0.0209
υ22 < 0.0010 < 0.0010 < 0.0010 < 0.0010 0.0107
υ30 < 0.0010 < 0.0010 0.0080 < 0.0010 < 0.0010 0.0085
υ31 < 0.0010 < 0.0010 < 0.0010 0.0018 < 0.0010 < 0.0017 0.0024
υ40 < 0.0010 < 0.0010 0.0324 < 0.0010 < 0.0010 0.0031 < 0.0010 0.8960
υ41 < 0.0010 < 0.0010 < 0.0010 < 0.0012 < 0.0010 < 0.0010 0.0066 –0.2229 0.1583
υ50 < 0.0010 < 0.0010 –0.0118 < 0.0010 < 0.0010 0.0010 < 0.0010 0.0273 < 0.0010 0.0827
υ51 < 0.0010 < 0.0010 < 0.0010 –0.0059 < 0.0010 < 0.0010 0.0020 < 0.0010 0.0159 0.0061 0.0090
TABLE 54 Estimated change in HbA1c level in the first year following diabetes diagnosis
Parameters Distribution Parameter 1 Parameter 2 Central estimate
Change in HbA1c intercept Normal –2.9465 0.0444513 –2.9465
HbA1c at baseline Normal 0.5184 0.4521958 0.5184
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Microvascular complications
The parameter distributions for the risk models for foot ulcer, blindness, renal failure, first amputation and
second amputation are reported in Table 56. Parameters for renal failure were based on the UKPDS
Outcomes Model 1,261 whereas parameters for other microvascular complications were based on the
UKPDS Outcomes Model 2.262
Cancer
The parameter distributions for the incidence and hazard ratios for breast cancer and colorectal cancer are
reported in Table 57.
The parameter distributions for breast and colorectal cancer mortality are reported in Table 58.
TABLE 55 Estimated change in HbA1c level following diabetes diagnosis over the long term
Parameter description Distribution Parameter 1 Parameter 2 Central estimate
Longitudinal HbA1c for diabetes
intercept
Normal –0.024 0.017 –0.024
Longitudinal HbA1c for diabetes log
(time since diagnosis)
Normal 0.144 0.009 0.144
Longitudinal HbA1c for diabetes
second year
Normal –0.333 0.05 –0.333
Longitudinal HbA1c for diabetes lag
HbA1c
Normal 0.759 0.004 0.759
Longitudinal HbA1c for diabetes
HbA1c at diagnosis
Normal 0.085 0.004 0.0896
TABLE 56 Input parameters for microvascular complications
Parameter description Distribution Parameter 1 Parameter 2 Central estimate
Renal failure baseline hazard Normal –10.016 0.939 –10.016
Renal failure Weibull shape Normal 1.865 1.4352 1.865
Renal failure SBP Normal 0.404 0.106 0.404
Renal failure blindness Normal 2.082 0.551 2.082
Foot ulcer baseline hazard Normal –11.295 1.13 –11.295
Foot ulcer age at diagnosis Normal 0.043 0.014 0.043
Foot ulcer female Normal –0.962 0.255 –0.962
Foot ulcer BMI Normal 0.053 0.019 0.053
Foot ulcer HbA1c Normal 0.16 0.056 0.16
Foot ulcer PVD Normal 0.968 0.258 0.968
Amputation baseline hazard Normal –14.844 1.205 –14.844
Amputation age at diagnosis Normal 0.023 0.011 0.023
Amputation female Normal –0.445 0.189 –0.445
Amputation atrial fibrillation Normal 1.088 0.398 1.088
Amputation HbA1c Normal 0.248 0.042 0.248
Amputation HDL Normal –0.059 0.032 –0.059
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TABLE 56 Input parameters for microvascular complications (continued )
Parameter description Distribution Parameter 1 Parameter 2 Central estimate
Amputation heart rate Normal 0.098 0.05 0.098
Amputation MMALB Normal 0.602 0.18 0.602
Amputation PVD Normal 1.01 0.189 1.01
Amputation white blood count Normal 0.04 0.017 0.04
Amputation stroke Normal 1.299 0.245 1.299
Amputation shape Normal 2.067 0.193 2.067
Amputation with ulcer lambda Normal –0.881 0139 –0.881
Amputation with ulcer age at
diagnosis
Normal –0.065 0.027 –0.065
Amputation with ulcer PVD Normal 1.769 0.449 1.769
Second amputation baseline hazard Normal –3.455 0.565 –3.455
Second amputation HbA1c Normal 0.127 0.06 0.127
Blindness baseline hazard Normal –10.6774 0.759 –10.6774
Blindness age at diagnosis Normal 0.047 0.009 0.047
Blindness HbA1c Normal 0.171 0.032 0.171
Blindness heart rate Normal 0.08 0.039 0.08
Blindness SBP Normal 0.068 0.032 0.068
Blindness white blood cells Normal 0.052 0.019 0.052
Blindness CHF Normal 0.841 0.287 0.841
Blindness IHD Normal 0.61 0.208 0.61
CHF, chronic heart failure; HDL, high-density lipoprotein; IHD, ischaemic heart disease; MMALB, micro-/macro-albuminuria
PVD, peripheral vascular disease.
TABLE 57 Input parameters for breast cancer and colorectal cancer risk models
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source
Colorectal cancer men Normal 0.0011 0.0001 0.0011 Pischon et al.307
Colorectal cancer women Normal 0.0005 0.0000 0.0005 Pischon et al.307
Breast cancer pre
menopause
Normal 0.0010 0.0001 0.0010 Lahmann et al.308
Breast cancer post
menopause
Normal 0.0028 0.0002 0.0028 Lahmann et al.308
Colorectal cancer BMI
relative risk for men
Lognormal 0.1906 0.0111 1.21 Renehan et al.309
Colorectal cancer BMI
relative risk for women
Lognormal 0.0392 0.0151 1.04 Renehan et al.309
Breast cancer BMI relative
risk for pre menopause
Lognormal –0.1165 0.0251 0.89 Renehan et al.309
Breast cancer BMI relative
risk for post menopause
Lognormal 0.0862 0.0205 1.09 Renehan et al.309
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Osteoarthritis
The parameter distributions for the incidence and hazard ratios for osteoarthritis are reported in Table 59.
Depression
The parameter distributions for the incidence and hazard ratios for depression are reported in Table 60.
Utilities
The parameter distributions used to estimate health state utilities in the model are reported in Table 61.
Unit health-care costs
The parameter distributions used to estimate health state utilities in the model are reported in Table 62.
TABLE 58 Input parameters for breast cancer and colorectal cancer mortality
Parameter description Distribution Parameter 1 Parameter 2 Central estimate
Breast cancer 5-year survival Beta 439.69 2354.44 0.157
Colorectal cancer 5-year survival Beta 1457.56 1806.35 0.447
TABLE 59 Input parameters for the osteoarthritis risk model
Parameter description Distribution Parameter 1 Parameter 2 Central estimate
Osteoarthritis incidence Normal 0.0053 0.0000004 0.0053
Osteoarthritis relative risk of diabetes mellitus Lognormal 0.723 0.317 2.06
Osteoarthritis relative risk of BMI Lognormal 0.073 0.026 1.076
Note
The parameters in this table have been sourced from Schett et al.310
TABLE 60 Input parameters for the depression risk model
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source
Odds of depression Beta 336 8803 0.0397 Golden et al.311
Odds ratio for diabetes Lognormal 0.4187 0.1483 1.52 Golden et al.311
Odds ratio for stroke Lognormal 1.8406 0.5826 6.3 Whyte et al.312
TABLE 61 Utility input parameters
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source
Renal/ulcer baseline utility Normal 0.689 0.014 0.689 Coffey et al.249
Renal dialysis Normal –0.078 0.026 –0.078 Coffey et al.249
Foot ulcer Normal –0.099 0.013 –0.099 Coffey et al.249
Amputation/heart failure
baseline utility
Normal 0.807 0.005 0.807 Hayes et al.262
Heart failure Normal –0.101 0.032 –0.101 Hayes et al.262
Amputation Normal –0.172 0.045 –0.172 Hayes et al.262
Stable angina
multiplicative factor
decrement
Normal 0.801 0.038 0.801 Ward et al.313
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TABLE 61 Utility input parameters (continued )
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source
Unstable angina
multiplicative factor
decrement
Normal 0.77 0.038 0.77 Ward et al.313
Myocardial infarction
multiplicative factor
decrement
Normal 0.76 0.018 0.76 Ward et al.313
Stroke multiplicative
factor decrement
Normal 0.629 0.04 0.629 Ward et al.313
Cancer baseline utility Normal 0.8 0.0026 0.8 Yabroff et al.314
Cancer decrement Normal –0.06 0.008 –0.06 Yabroff et al.314
Osteoarthritis utility Normal 0.69 0.069 0.69 Black et al.315
Depression baseline utility Normal 0.48 0.048 0.48 Benedict et al.316
Depression remitters Normal 0.31 0.031 0.31 Benedict et al.316
Depression responders Normal 0.20 0.020 0.20 Benedict et al.316
Depression
non-responders
Normal 0.070 0.007 0.070 Benedict et al.316
Depression drop-outs Normal 0.050 0.005 0.050 Benedict et al.316
Age utility decrement Normal –0.004 0.0001 –0.004 Ward et al.313
TABLE 62 Cost input parameters
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source/reference
Diabetes costs
Insulin (annual cost) Gamma 3.367 408.6 £1375.72 Poole et al.317
Metformin (annual cost) Constant NA NA £28.24 Curtis318
Sitagliptin (annual cost) Constant NA NA £433.77 Curtis318
Nurse appointment
(advanced)
Gamma 100 0.26 £25.52 Curtis318
Health-care assistant
appointment
Gamma 100 0.03 £3.40 Curtis318
Eye screening Gamma 15.3664 1.58219 £24.31 Burr et al.319
HbA1c test Gamma 100 0.03 £3.00 NHS Reference
Costs320
Lipids test Gamma 100 0.01 £1.00 NHS Reference
Costs320
Liver function test Gamma 100 0.03 £3.13 NHS Reference
Costs320
Vitamin B12 test Gamma 100 0.03 £3.13 NHS Reference
Costs320
Nicotine replacement
therapy
Gamma 100 1.03 £103.00 Curtis318
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TABLE 62 Cost input parameters (continued )
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source/reference
CVD costs
Unstable angina hospital
admission
Gamma 100 12.75591 £1275.59 Ara et al.321
Revascularisation in
hospital
Gamma 100 60.36846 £6036.85 Ara et al.321
Myocardial infarction
hospital admission
Gamma 100 15.54896 £1554.90 Ara et al.321
First outpatient
appointment
Gamma 100 1.653571 £165.36 Ara et al.321
Subsequent outpatient
appointments
Gamma 100 1.100574 £110.06 Ara et al.321
Fatal coronary heart
disease
Gamma 100 7.125001 £712.50 Palmer et al.322
Fatal stroke Gamma 100 44.42562 £4442.56 Youman et al.323
First year stroke Gamma 100 126.77 £12676.60 Luengo-Fernandez
et al.324
Subsequent year stroke Gamma 100 17.399 £1739.91 Luengo-Fernandez
et al.324
Transient ischaemic attack Gamma 100 27.226 £2722.65 Luengo-Fernandez
et al.324
Glyceryl Trinitrate Spray
(Glytrin spray; Aspire
Pharma Ltd, Petersfield, UK)
Constant NA NA £12.61 Ara et al.321
Isosorbide mononitrate Constant NA NA £13.54 Ara et al.321
Verapamil Constant NA NA £50.57 Ara et al.321
(Tenormin®; AstraZeneca
plc, Cambridge, UK)
Constant NA NA £36.42 Ara et al.321
Aspirin Constant NA NA £8.01 Ara et al.321
Ramipril Constant NA NA £90.45 Ara et al.321
ARB Constant NA NA £253.28 Ara et al.321
Clopidogrel Constant NA NA £554.41 Ara et al.321
Chronic heart failure
year 1 inpatient
Gamma 17.08787 197.607 £3376.68 Alva et al.247
Chronic heart failure
year 1 non inpatient
Gamma 50.13476 20.66365 £1035.97 Alva et al.247
Chronic heart failure
subsequent years
inpatient
Gamma 23.46525 66.42644 £1558.71 Alva et al.247
Chronic heart failure
subsequent years non
inpatient
Gamma 109.7982 9.377373 £1029.62 Alva et al.247
Microvascular costs
Blindness year 1 inpatient Gamma 7.982428 179.6254 £1433.85 Alva et al.247
Blindness year 1
non-inpatient
Gamma 14.79887 127.9935 £1894.16 Alva et al.247
Blindness subsequent
years inpatient
Gamma 41.39524 11.58007 £479.36 Alva et al.247
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TABLE 62 Cost input parameters (continued )
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source/reference
Blindness subsequent
years non-inpatient
Gamma 79.72506 9.795462 £780.94 Alva et al.247
Amputation year 1
inpatient
Gamma 35.73274 282.6952 £10101.48 Alva et al.247
Amputation year 1
outpatient
Gamma 16.81661 169.8352 £2856.05 Alva et al.247
Amputation subsequent
years inpatient
Gamma 23.02322 82.36361 £1896.28 Alva et al.247
Amputation subsequent
years outpatient
Gamma 57.06248 29.87502 £1704.74 Alva et al.247
Renal haemodialysis Gamma 100 420.49 £42,049.00 Baboolal et al.325
Renal automated
peritoneal dialysis
Gamma 100 272.1714 £27,217.14 Baboolal et al.325
Renal ambulatory
peritoneal dialysis
Gamma 100 197.4225 £19,742.25 Baboolal et al.325
Renal transplant Gamma 100 236.5973 £23,659.73 Organ Donation326
Immunosuppressants Gamma 100 69.58745 £6958.75 Organ Donation326
Foot ulcer not infected Gamma 100 1.677526 £167.75 Gordois et al.327
Foot ulcer with cellulitis Gamma 100 4.431003 £443.10 Gordois et al.327
Foot ulcer with
osteomyelitis
Gamma 100 8.215817 £821.58 Gordois et al.327
Other disease costs
Breast cancer Gamma 100 138.1811 £13,818.11 Madan et al.328
Colorectal cancer Dukes A Gamma 100 100.9135 £10,091.35 Tappenden et al.329
Colorectal cancer Dukes B Gamma 100 173.1532 £17,315.32 Tappenden et al.329
Colorectal cancer Dukes C Gamma 100 265.5026 £26,550.26 Tappenden et al.329
Colorectal cancer Dukes D Gamma 100 166.2553 £16,625.53 Tappenden et al.329
Osteoarthritis Gamma 100 9.616886 £961.69 Oxford Economics330
Depression – Practice
nurse surgery
Gamma 100 0.090154 £9.02 Chalder et al.331
Depression – Practice
nurse home
Gamma 100 0.270463 27.05 Chalder et al.331
Depression – Practice
nurse telephone
Gamma 100 0.090154 9.02 Chalder et al.331
Depression – health visitor Gamma 100 0.387834 38.78 Chalder et al.331
Depression – district nurse Gamma 100 0.377628 37.76 Chalder et al.331
Depression – other nurse Gamma 100 0.090154 9.02 Chalder et al.331
Depression – health-care
assistant phlebotomist
Gamma 100 0.034021 3.40 Chalder et al.331
Depression – other
primary care
Gamma 100 0.255154 25.52 Chalder et al.331
Depression – out of hours Gamma 100 0.268661 26.87 Chalder et al.331
Depression – NHS Direct Gamma 100 0.25295 25.30 Chalder et al.331
Depression – walk-in centre Gamma 100 0.388316 38.83 Chalder et al.331
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Technical appendix on network meta-analysis results used in
cost-effectiveness modelling
Adults with type 1 diabetes mellitus
Adults with type 2 diabetes mellitus
TABLE 62 Cost input parameters (continued )
Parameter description Distribution Parameter 1 Parameter 2 Central estimate Source/reference
Depression – prescribed
medicines
Gamma 100 0.096144 9.61 Chalder et al.331
Depression – secondary
care
Gamma 100 0.81 81.00 Chalder et al.331
Diagnosis and other costs
GP appointment Gamma 100 0.47 £46.95 Chalder et al.331
Diabetes diagnosis Gamma 100 0.12 £14.81 NHS Reference
Costs320
Hypertension diagnosis Gamma 100 0.57 £56.51 NICE332
Antihypertensives Gamma 100 1.96 £195.94
Simvastatin Constant NA NA £26.59
ARB, angiotensin II receptor blockers; GP, general practitioner; NA, not applicable.
TABLE 63 Variance–covariance matrix for HbA1c treatment effects in year 1, for adults with T1DM
_y_A: _y_B: _y_D: tau:
_cons _cons _cons _cons
_y_A:_cons 0.00902538
_y_B:_cons 0.00283336 0.0090491
_y_D:_cons 0.0090252 0.0028333 0.02923929
tau:_cons 1.174 × 109 1.189 × 109 1.479 × 109 0.00995378
A, CBT; B, counselling; C (reference): usual care; D, attention control.
TABLE 64 Variance–covariance matrix for HbA1c treatment effects in year 1, for adults with T2DM
_y_A: _y_B: _y_C: _y_E: tau:
_cons _cons _cons _cons _cons
_y_A:_cons 0.01642376
_y_B:_cons 0.00152833 0.01004061
_y_C:_cons 4.068 × 10–6 3.676 × 10–6 .0791886
_y_E:_cons 0.00537357 0.00783819 2.476 × 10–6 0.02765208
tau:_cons –0.00016284 –0.00014717 –0.00008289 –0.00009913 0.00331815
A, CBT; B, counselling; C, psychotherapy; D (reference), usual care; E attention control.
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Adults with type 1 diabetes mellitus: dispersion parameters
See appendix 22 of supplementary materials B in Pollard et al.244 to obtain the covariance matrix for
these coefficients.
Technical appendix on longer-term (post 1 year) duration of treatment
effect for psychological interventions
Technical appendix on costing psychological interventions
Purpose of this section
This section details the assumptions made in estimating the cost of the different types of psychological
interventions for adults with T1DM and people with T2DM. Values used in the costing are underlined.
Adults with type 1 diabetes mellitus
This section highlights the different components of intervention resource use and cost associated with the
different types of psychological interventions delivered to adults with T1DM. These are broadly split into
two categories: those types of resource use/cost that are assumed to be the same across interventions and
those that are different. The following categories are assumed to be the same across interventions: the
interventionists, the session-related non-contact time (either as a ratio of contact time or an absolute value),
TABLE 65 Dispersion parameters used for individual heterogeneity in HbA1c year 1 effect for adults with T2DM
HbA1c at 1 year (beta scale) Coefficient SE t p> t 95% CI
Dispersion parameter (phi), using a natural logarithm link function
Baseline HbA1c (beta scale) –2.996862 0.9980645 –3 0.003 –4.954 to –1.040
Constant 4.912 0.332 14.79 0 4.261 to 5.563
SE, standard error.
TABLE 66 Joint distribution for 1-year fall and longer-term trajectory in HbA1c levels for T1DM: CBT versus usual care
Mean and SEs from the Ridge et al.251 analysis Mean SE Covariance matrix
Initial fall –0.46 0.178575 0.031888927 –0.01613
Trajectory 0.062145 0.116901 –0.016134413 0.013666
SE, standard error.
TABLE 67 Joint distribution for 1-year fall and longer-term trajectory in HbA1c levels for T1DM: counselling versus
usual care
Mean and SEs from the Ridge et al.251 analysis Mean SE Covariance matrix
Initial fall –0.19 0.178575 0.030984323 –0.01489
Trajectory –0.02707 0.14901 –0.014886507 0.022204
SE, standard error.
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the cost of consumables and the training costs. The following categories are assumed to be different: the
split between individual and group sessions, the average number of people in a group session, the number
of sessions and the duration of each session. These are all dealt with in the following sections.
Resources that are the same across the different psychological interventions
Interventionists
Table 68 shows the different interventionists who delivered psychological interventions for people with
T1DM and associated UK full economic costs (from the PSSRU Unit Costs of Health and Social Care 2016333).
We have assumed that the person delivering the intervention is a band 7 nurse. The full economic cost of
staff time will be £53 per hour worked, as most studies used nurses rather than psychologists for
psychological interventions for people with T1DM.
Q1 – Is a band 7 nurse an appropriate interventionist, if a psychological intervention were to be
implemented for adults with T1DM in the UK?
Session-related non-contact time
The number of hours spent on course administration was reported in only one study (ADaPT);251 it was
0.25 hours per session. As this is only one study, there are some concerns of the applicability of this, more
generally, to psychological interventions in a UK setting. Therefore, the proportion of non-contact time to
contact time will be based on the ratio of direct to indirect contacts reported for band 7 hospital nurses
in the PSSRU.333 This is for every hour of face-to-face contact, there is 1.44 hours of indirect time. This was
chosen as it is based on a nationally representative ratio of non-contact to contact time for this grade of
nurse in the UK.
Q2 – Are you aware of any other information which gives information on the non-contact time associated
with delivering a psychological intervention to adults with T1DM?
Q3 – Does the ratio of 1.44 non-contact hours per hour of contact capture all non-contact time spent
delivering the session (e.g. administration, rearranging session times)? If not, what alternative assumption
do you think that we should make?
TABLE 68 The staff member who delivered psychological interventions to adults with T1DM in the systematic
review and the associated costs per hour of staff time in the UK
Interventionist
Number of
studies Typical NHS band (PSSRU) Cost (£) per hour (PSSRU)
Nurse/dietitian/educator 4 Band 6 (nurse specialist) 44 (excluding standard non-patient
contact)
Band 7 (nurse advanced) 53 (excluding standard non-patient
contact)
Band 8a (modern matron) 62
Psychologist 2 Band 7 (clinical psychologist) 52
Band 8a–b (clinical psychologist
principle)
62
Band 8d–9 (clinical psychologist
consultant)
Not stated
Nurse and psychologist 1 Combination of the two above categories
Nurse or psychologist 1 Combination of the two above categories
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Consumable cost per session
Only one study reported the cost of consumables per session (ADaPT); this was £0.72 in 2005–06 prices.
After inflating these to 2015–16 prices using the Hospital and Community Health Service (HCHS) pay and
prices index,333 this gives a consumable cost per session of £0.89.
Q4 – Are you aware of any other studies that give a cost of consumables spent delivering psychological
interventions in T1DM adults?
Training duration
The mean duration of training for interventionists to deliver a group session across all psychological
interventions for adults with T1DM was 40 hours of contact time. The mean duration of training for
individual sessions was 30 hours of contact time.
We will assume that both sessions were delivered by a band 8 clinical psychologist (£62 per hour) to band
7 nurses. We will assume that the training session is delivered to, on average, 15 nurses at the same time.
This is based on the DAFNE activity report from 2014–15 in which 46 educators were trained in three
courses (DAFNE programme activity, 1 April 2014–31 March 2015). Furthermore, based on the costings
conducted for DAFNE, we will assume that each site will train three trainees, and that there will be a
10% depletion of staff per year (DAFNE fact sheet 6). The yearly costs of training were calculated assuming
a 10-year lifespan and a depreciation rate of 3.5%.
A breakdown of the costs of training staff to deliver psychological interventions is presented in Table 69.
Q5 – Is a band 8 clinical psychologist an appropriate grade for the average person likely to deliver training
sessions for psychological interventions?
Q6 – Is DAFNE an appropriate source for the duration of training effect and the number of trainees per session?
Q7 – If not, what data/values should be used instead to estimate the training costs of delivering
psychological interventions?
Resource use specific to the different psychological interventions
The resource use specific to the different psychological interventions are presented in Table 70. The mean
number of sessions, the mean time spent delivering sessions and the average number of people receiving
an intervention in each session were obtained from a sample size-weighted average of the data reported
in the studies in the systematic review.
TABLE 69 The staff member who delivered psychological interventions to adults with T1DM in the systematic
review and the associated costs per hour of staff time in the UK
Breakdown of training costs per recipient of
psychological interventions
Course cost
Individual Group
a) Trainer £1860 £2480
b) Cost per trainee (a / 15.3) £121.30 £161.74
c) Cost of trainee time £1590 £2120
d) Cost for three trainees [(b + c) × 3] £5133.91 £6845.22
e) Annuity factora 8.32 8.32
f) Cost per year (d / e) £617.31 £823.08
g) Cost per recipient of psychological intervention (f / 48) £12.86 £17.15
a 3.5% depreciation and a 10-year duration.
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The cost of delivering a CBT intervention is £657 per participant and the cost of delivering a counselling
intervention is £580 per participant.
Usual care
Whenever data on usual care were presented in the studies included in the systematic review, it was either an
enhancement to usual care or the contacts were related to protocol requirements (e.g. collection of blood
samples at baseline). Therefore, it was assumed that there were no additional costs associated with usual care.
Type 2 diabetes mellitus
Resources that are the same across the different psychological interventions
This section highlights the different components of intervention resource use and cost associated with
the different types of interventions. These are broadly split into two categories: those types of resource
use/cost that are assumed to be the same across interventions and those that are different. The following
categories are assumed to be the same across interventions: the interventionists, the session-related
non-contact time (either as a ratio of contact time or an absolute value), the cost of consumables and
the training costs. The following categories are assumed to be different: the split between individual and
group sessions, the average number of people in a group session, the number of sessions and the duration
of each session. These are all dealt with in turn in the following sections.
TABLE 70 The cost of delivering CBT and counselling to adults with T1DM
Breakdown of training costs per recipient of
psychological interventions CBT Counselling
a) Proportion of the intervention that is delivered to a group 71.1% 27.8%
Mean number of sessions
b.1) Individual 9.2 7
b.2) Group 7 9.6
Mean time spent delivering sessions (hours)
c.1) Individual 0.9 0.9
c.2) Group 2.2 2.3
Average number of people receiving an intervention per session
d.1) Individual 1 1
d.2) Group 6.6 6.2
Direct costs
e.1) Direct cost of an individual session [(b.1 × c.1 × £53) / d.1] £433 £336
e.2) Direct cost of a group session [(b.2 × c.2 × £53) / d.2] £133 £186
Average cost of the intervention [a*e.1 +(1-a)*e.2] £219.86 £294.01
Indirect cost of nurse time for the session £65.96 £55.90
Transcription of the sessions £21.74 £27.64
Supervision costs
Direct £279.00 £85.31
Indirect £52.34 £115.87
Training cost per participant £18.26 £16.15
Capital costs of running the course (tape recorder) £0.07 £0.07
Total cost £657 £580
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TABLE 71 Detailed parameters for final costing of psychological interventions for T1DM
Item Value Notes Source
Cost per hour of interventionist time £53 Band 7 nurse Unit Costs of Health and Social
Care 2016333
Cost per hour of trainer time £62 Band 8a clinical
psychologist
Unit Costs of Health and Social
Care 2016333
Cost per hour of supervisor time £62 Band 8a clinical
psychologist
Unit Costs of Health and Social
Care 2016333
HCHS pay and prices 2011/12 282.5 Unit Costs of Health and Social
Care 2016333
HCHS pay and prices 2015/16 297 Unit Costs of Health and Social
Care 2016333
Transcription costs £0.80 2011/12 prices Ismail et al.300
Number of people delivered to per year 48 DAFNE334
CBT
Proportion of the interventions that are
delivered to a group
71.1% Systematic review of this study
Individual sessions
Number of sessions 9.197452229 Systematic review of this study
Mean time spent delivering sessions 0.88761175 Systematic review of this study
Average number of people receiving an
intervention
1 Definition
Group sessions
Number of sessions 7.487046632 Systematic review of this study
Mean time spent delivering sessions 2.221631206 Systematic review of this study
Average number of people receiving an
intervention
6.613475177 Systematic review of this study
Hours of non-contact time per hour of
contact time
0.3 ADaPT251
Counselling
Proportion of the interventions that are
delivered to a group
27.8%
Individual sessions
Number of sessions 7 Systematic review of this study
Mean time spent delivering sessions 0.904761905 Systematic review of this study
Average number of people receiving an
intervention
1 Definition
Group sessions
Number of sessions 9.615384615 Systematic review of this study
Mean time spent delivering sessions 2.269230769 Systematic review of this study
Average number of people receiving an
intervention
6.230769231 Systematic review of this study
Hours of non-contact time per hour of
contact time
0.2 ADaPT251
continued
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TABLE 71 Detailed parameters for final costing of psychological interventions for T1DM (continued )
Item Value Notes Source
Training
Number of people trained at once 5.5 Ismail et al.300
Depletion of staff trained per year 10% DAFNE334
Depreciation rate 3.50% NICE methods guide335
Capital costs
Room hire £3.10 per hour, 2011/12
prices
Ismail et al.300
Video camera £19.99 2011/12 prices
Costs per person
Handbook £11.94 2011/12 prices Ismail et al.300
Slides £7.20 2011/12 prices Ismail et al.300
Individual sessions
Time of training sessions 30 Systematic review of this study
Group sessions
Time of training sessions 40 Systematic review of this study
Supervision
Capital costs
Audio-recorder 24.99 2011/12 prices Ismail et al.300
Lifespan of technology 5 years Ismail et al.300
Staff costs
Counselling
Supervision time per session 0.140666667 per hour of contact ADaPT251
Therapist non-contact 0.25 per hour of contact ADaPT251
Supervisor non-contact 0.140666667 per hour of contact ADaPT251
CBT
Supervision time per session – senior 0.033166667 per hour of contact ADaPT251
Supervisor non-contact – senior 0.01153845 per hour of contact ADaPT251
Supervision time per session – non-senior 0.551666667 per hour of contact ADaPT251
Supervisor non-contact – non-senior 0.19196155 per hour of contact ADaPT251
Therapist non-contact 0.25 per hour of contact ADaPT251
Intermediate calculations
Average contact time per person
CBT
Group 2.515085638 ADaPT251
Individual 8.163766666 ADaPT251
Average 4.148313854 ADaPT251
Counselling
Group 2.515085638
Individual 6.333333333
Average 5.273463866
Transcription costs applied to % of sessions 10%
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TABLE 72 Summary of T1DM intervention costs
Item Individual Group
Training costs (£)
Trainer time 1860 2480
Room hire 93 124
Video recording 21.02 21.02
Sum 1974 2625
Per participant 359 477
Cost of participant time 1590 2120
Cost of handbooks 13 13
Cost of slide printouts 8 8
Cost for number of trainees 5907.10 7852.19
Annuity factor 8.32 8.32
Cost per annum 710.28 944.16
Cost per recipient of a psychological intervention 14.80 19.67
Capital costs
Tape recorder £26.27
Assumed lifespan (years) 5
Depreciation rate 3.50%
Annuity factor 8.32
Cost per year £3.16
Cost per psychological intervention recipient £0.07
Intervention costs
CBT (£)
Direct costs of staff time to deliver the session
Individual 432.68
Group 133.30
Average 219.86
Indirect cost of nurse time for the session 65.96
Transcription of the sessions 21.74
Supervision costs
Direct 279.00
Indirect 52.34
Training cost per participant 18.26
Capital costs of running the course (tape recorder) 0.07
Total cost 657
Cost per session for comparison with Ismail et al.252 82.34
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Interventionists
Assume that the interventionist is a band 7 (regardless of type). We will cost this as £53 per hour worked,
as most studies used nurses for psychological interventions for people with T2DM.
TABLE 72 Summary of T1DM intervention costs (continued )
Item Individual Group
Counselling (£)
Direct costs of staff time to deliver the session
Individual 335.67
Group 133.29
Average 279.49
Indirect cost of nurse time for the session 55.90
Transcription of the sessions 27.64
Supervision costs
Direct 85.31
Indirect 115.87
Training cost per participant 16.15
Capital costs of running the course (tape recorder) 0.07
Total cost 580
Cost per session for comparison with Ismail et al.252 72.72
TABLE 73 The staff members who delivered psychological interventions to people with T2DM in the systematic
review and the associated costs per hour of staff time in the UK
Interventionist
Number
of studies Typical NHS band (PSSRU) Cost per hour (PSSRU)
Nurse/dietitian/educator 23 Band 6 (nurse specialist) £44 (excluding standard
non-patient contact)
Band 7 (nurse advanced) £53 (excluding standard
non-patient contact)
Band 8a (modern matron) £62
Psychologist/psychotherapist 12 Band 7 (clinical psychologist) £52
Band 8a–b (clinical psychologist principle) £62
Band 8d–9 (clinical psychologist consultant) Not stated
Counsellor 1 Band 5 counsellor (entry level) £32
Band 6 counsellor £42
Band 7 counsellor (specialist) £52
Band 8a–c counsellor consultant £62–74
Music therapists 1 Band 6 £42
Pharmacist 1 Band 6 pharmacist £42
Band 7 pharmacist specialist £52
Band 8a–b pharmacist advanced £62–74
Band 8b–d pharmacist consultant Not stated
General practitioner/
community doctor
2 £3.90 per minute (direct staff
care costs and with qualifications)
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Q8 – Is a band 7 interventionist (either a nurse or clinical psychologist) appropriate, if a psychological
intervention were to be implemented in the UK for people with T2DM?
Session-related non-contact time
The number of hours spent on course administration was reported in only one study (Walker336); it was
10 minutes per 1- hour session. As this is only one study and it has been conducted in the US health-care
setting, there are some concerns of the applicability of this, more generally, to psychological interventions
in a UK setting. The proportion of non-contact time to contact time will be based on the ratio of direct to
indirect contacts reported for band 7 hospital nurses in the PSSRU. This is for every hour of face-to-face
contact; there are 1.44 hours of indirect time.
Q9 – Are you aware of any other information that gives the session-related non-contact time for
health-care professionals in the field of diabetes?
Q10 – Does the ratio of 1.44 non-contact hours per hour of contact capture all non-contact time spent
delivering the session (e.g. administration, rearranging session times)?
Consumable cost per session
Only one study reported the cost of consumables per session (Walker336), this was US$650 across 154
sessions (US$4.22 per session) in 2010–11 prices. This gives a cost of £3.18 per session after converting
the cost to Great British pounds using the Organisation for Economic Co-operation and Development
(OECD) purchasing power parity rates and inflating to 2015–16 prices using the HCHS pay and prices
index.
Q11 – Are you aware of any other studies that give a cost of consumables spent delivering psychological
interventions for people with T2DM?
Training duration
The mean duration of training for individual sessions was 30.63 hours of contact time. No studies that
used a group session reported the training duration, so it was assumed that the time taken to train
health-care professionals to deliver a psychological intervention was also 30.63 hours.
We will assume that both sessions were delivered by a band 8 clinical psychologist (£62 per hour) to band
7 nurses. Based on the economic analysis of the DESMOND (Diabetes Education and Self Management for
Ongoing and Newly Diagnosed) structured education course for people with T2DM (Gillett et al.337), it was
assumed that:
l the training session is delivered to, on average, 13 interventionists at the same time
l three interventionists per site will be trained for the course
l training will be valid for 3 years
l Each trained educator will conduct, on average, 18.7 (56/3) interventions per year.
Q12 – Is a band 8 clinical psychologist an appropriate grade for the average person likely to deliver training
sessions for psychological interventions?
Q13 – Is DESMOND an appropriate source for the duration of training effect and the number of trainees
per session?
Q14 – Would DAFNE be a more appropriate source of evidence for the duration of training effect and
the number of trainees per session? (10-year effect of training, three trainees per site, trainees would see
48 people per annum.)
Q15 – If neither of these data sources are appropriate, what data/values should be used instead?
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Interventions
The cost of the staff time for delivering the intervention (both direct and indirect) was recalculated for
the studies based on the classification in the NMA. The three categories of intervention for people with
T2DM were CBT, counselling and psychotherapy. Only weighted averages between individual and group
interventions were used to estimate the cost of each of the intervention categories. The results of these
analyses are presented in Table 75.
TABLE 74 The staff member who delivered psychological interventions to people with T2DM in the systematic
review and the associated costs per hour of staff time in the UK
Course cost Individual Group
a) Trainer £2065.32 £2065.32
b) Cost per trainee (a / 13) £158.87 £158.87
c) Cost of trainee time £1765.51 £1765.51
d) Cost for three trainees [(b + c) × 3] £5296.53 £5296.53
e) Annuity factora 2.80 2.80
f) Cost per year (d / e) £1890.51 £1890.51
g) Cost per recipient of psychological intervention (f / 18.7) £101.28 £101.28
a 3.5% depreciation and a 3-year duration.
TABLE 75 The cost of delivering CBT, counselling and psychotherapy to people with T2DM
CBT Counselling
a) Proportion of the interventions that is delivered to a group 72.0% 5.5%
Mean number of sessions
b.1) Individual 14.9 11.0
b.2) Group 7.3 5.9
Mean time spent delivering sessions (hours)
c.1) Individual 0.6 0.8
c.2) Group 1.6 2.2
Average number of people receiving an intervention per session
d.1) Individual 1 1
d.2) Group 7.1 8.5
Direct costs
e.1) Direct cost of an individual session [(b.1*c.1*£53)/d.1] £444.07 £466.17
e.2) Direct cost of an group session [(b.2*c.2*£53)/d.2] £87.66 £80.74
Average cost of the intervention [a × e.1 + (1 – a) × e.2] £187.29 £444.79
Other costs
Indirect cost of nurse time for the session £56.19 £88.96
Transcription of the sessions £18.52 £43.98
Supervision costs
Direct £237.66 £136
Indirect £91.41 £184
Training cost per participant £42.07 £42.07
Capital costs of running the course (tape recorder) £0.07 £0.07
Total cost £633 £940
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The cost of delivering a CBT intervention is £633 per participant; the cost of delivering a counselling
intervention is £940 per participant.
Usual care
Whenever data on usual care were presented in the studies included in the systematic review, they were
either an enhancement to usual care or the contacts were related to protocol requirements (e.g. collection
of blood samples at baseline). Therefore, it was assumed that there were no additional costs associated
with usual care.
TABLE 76 Detailed parameters for final costing of psychological interventions for T2DM
Item Value Notes Source
Cost per hour of interventionist time £53 Band 7 nurse Unit Costs of Health and Social Care 2016333
Cost per hour of trainer time £62 Band 8a clinical psychologist Unit Costs of Health and Social Care 2016333
Cost per hour of supervisor time £62 Band 8a clinical psychologist Unit Costs of Health and Social Care 2016333
HCHS Pay and prices 2011/12 £282.5 Unit Costs of Health and Social Care 2016333
HCHS Pay and prices 2015/16 £297 Unit Costs of Health and Social Care 2016333
Transcription costs £0.80 2011/12 prices Ismail et al.300
Number of people delivered to
per year
48 DAFNE334
CBT
Proportion of the interventions that
are delivered to a group
72.0% SR
Individual sessions
Number of sessions 14.94 Systematic review of this study
Mean time spent delivering
sessions (hours)
0.561 Systematic review of this study
Average number of people
receiving an intervention
1 Definition
Group sessions
Number of sessions 7.35 Systematic review of this study
Mean time spent delivering
sessions (hours)
1.591 Systematic review of this study
Average number of people
receiving an intervention
7.071 Definition
Hours of non-contact time per hour
of contact time
0.3 ADaPT251
Counselling
Proportion of the interventions that
are delivered to a group
5.5% Systematic review of this study
Individual sessions
Number of sessions 10.99 Systematic review of this study
Mean time spent delivering
sessions (hours)
0.8 Systematic review of this study
Average number of people
receiving an intervention
1 Definition
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TABLE 76 Detailed parameters for final costing of psychological interventions for T2DM (continued )
Item Value Notes Source
Group sessions
Number of sessions 5.885 Systematic review of this study
Mean time spent delivering
sessions (hours)
2.191 Systematic review of this study
Average number of people
receiving an intervention
8.465 Definition
Hours of non-contact time per hour
of contact time
0.2 ADaPT251
Psychotherapy
Proportion of the interventions that
are delivered to a group
0.0%
Individual sessions
Number of sessions 12
Mean time spent delivering
sessions (hours)
0.5
Average number of people
receiving an intervention
1
Group sessions
Number of sessions –
Mean time spent delivering
sessions (hours)
–
Average number of people
receiving an intervention
–
Hours of non-contact time per hour
of contact time
0.2 Assumed it is closer to
counselling than CBT (as a
result of the proportion of
events that are individual
sessions)
ADaPT251
Training
Time spent training nurses (hours) 33.31
Cost per hour of trainer time £62 PSSRU
Cost per hour of interventionist time £53 PSSRU
Duration of training (hours) 10 Assumed same as type 1
Number of people in a training
session
13 Gillett et al.337
Number of nurses per centre 3 Gillett et al.337
Depreciation rate 0.035% NICE methods guide335
Number of people trained at once 5.5 Ismail et al.300
Number of people receiving a
psychological intervention per year
18.7 Gillett et al.337
Capital costs
Room hire £3.1 Per hour, 2011/12 prices Ismail et al.300
Video camera £19.99 2011/12 prices
Costs per person
Handbook £11.94 2011/12 prices Ismail et al.300
Slides £7.2 2011/12 prices Ismail et al.300
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TABLE 76 Detailed parameters for final costing of psychological interventions for T2DM (continued )
Item Value Notes Source
Intermediate calcs
Average contact time per person (hours)
CBT
Group 1.654
Individual 8.379
Average 3.534
Counselling
Group 1.523
Individual 8.796
Average 8.392
TABLE 77 Summary of T2DM intervention costs
Item Cost (£)
Training costs
Trainer time 2065
Room hire 98.22
Video-recording 21.02
Sum 2185
Per participant 397.19
Cost of participant time 1765.51
Cost of handbooks 11.36
Cost of slide print outs 6.85
Cost for number of trainees 6542.73
Annuity factor 8.32
Cost per annum 786.71
Cost per recipient of a psychological intervention 42.07
CBT
Direct costs of staff time to deliver the session
Average 187.29
Indirect cost of nurse time for the session 56.19
Transcription of the sessions 18.52
Supervision costs
Direct 237.66
Indirect 91.41
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TABLE 77 Summary of T2DM intervention costs (continued )
Item Cost (£)
Training cost per participant 42.07
Capital costs of running the course (tape recorder) 0.07
Total cost 633
Counselling
Direct costs of staff time to deliver the session
Average 445
Indirect cost of nurse time for the session 88.96
Transcription of the sessions 43.98
Supervision costs
Direct 136
Indirect 184
Training cost per participant 42.07
Capital costs of running the course (tape recorder) 0.07
Total cost 940
Psychotherapy
Direct costs of staff time to deliver the session
Average 318
Indirect cost of nurse time for the session 63.6
Transcription of the sessions 31.44
Supervision costs
Direct 97.06
Indirect 131.828
Training cost per participant 42.07
Capital costs of running the course (tape recorder) 0.07
Total cost 684
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